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Thesis summary 
Epidemiological and clinical studies demonstrate a high degree of comorbidity 
between bipolar disorder (BD) and migraine. A relationship between BD and epilepsy is 
also suggested, with both disorders displaying phenotypically similar symptom profiles. 
The overall aim of this thesis was to further explore the relationship between BD and 
the neurological conditions of migraine, and epilepsy, within a large, well-characterised 
sample of individuals with BD.  
Data were utilised from the Bipolar Disorder Research Network (BDRN); a large 
(n>6000) UK sample of individuals with a diagnosis of BD. Lifetime history of migraine 
and epilepsy were assessed within BDRN using questionnaire and telephone interview 
methods.  
Migraine was highly prevalent within the bipolar sample and was found to 
disproportionately affect those with bipolar II disorder. Bipolar subjects with comorbid 
migraine experienced a relatively distinct illness profile, with a multivariate model 
revealing migraine comorbidity to be characterised by an increased risk of suicide 
attempt and anxiety disorder. Further analysis of the migraine phenotype revealed that 
observed differences in the clinical presentation of BD associated with migraine were 
largely associated with the migraine with aura subtype. A high rate of self-reported 
epilepsy was identified within the bipolar sample and group differences were revealed 
in the clinical course of the bipolar illness according to the presence of self-reported 
epilepsy. Multivariate analysis revealed an independent association of a history of 
suicide attempt with self-reported epilepsy within BD.  
Findings from this thesis highlight the importance of identifying migraine and epilepsy 
within BD, and that their recognition and treatment may have a beneficial impact on 
the course of illness and outcome in BD. This thesis also suggests that these 
comorbidities may represent a clinically useful subgroup characterised by specific 
clinical features, and may provide an opportunity for subcategorising for future 
aetiological studies, potentially facilitating the identification of shared 
pathophysiological mechanisms. 
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Chapter 1 
Introduction 
 
Reported in part by Knott, Forty, Craddock & Thomas, 2015 
 
Within this introductory chapter I will begin by providing an overview of bipolar 
disorder (BD) in terms of its classification, epidemiology and course of illness, and 
treatment and management of the disorder. I will also summarise what is known about 
the pathophysiology of the disorder before discussing the role and importance of co-
occurring conditions within BD. The second section of this chapter will introduce the 
neurological condition of migraine and outline the evidence for overlap between 
migraine and BD. Next, the chapter will provide an overview of epilepsy; the second 
neurological disorder of interest within this thesis, before summarising the evidence 
suggesting a potential overlap between epilepsy and BD. The final section of this 
chapter will describe the aims and outline of the current thesis.  
 
1.1   Introduction to bipolar disorder 
Bipolar disorder (BD) is a common, enduring, and severe mental illness characterised 
by pathological disturbances in mood, ranging from extreme elation, known as mania, 
to severe depression. Such mood episodes are associated with a number of cognitive, 
physical and behavioural symptoms and the breadth of symptoms experienced within 
BD may also extend to include psychotic features, such as delusions or hallucinations.  
Bipolar disorder (BD) is associated with high levels of functional impairment, 
morbidity and mortality. It is generally understood that BD is a chronic disorder, 
typified by periods of remission and relapse. As such, mood episodes are said to be 
separated by periods of recovery. However, the high rate of recurrence places 
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significant burden on both the individual sufferer and wider society. In addition, there 
is evidence to suggest that many patients with BD experience a continuation of 
residual, sub-syndromal symptoms after resolution of a major affective episode, 
acting to further perpetuate this burden (Judd et al., 2016).  
The chronic nature of BD, together with its relatively young age of onset, contribute 
to BD being ranked one of the top ten leading causes of disability worldwide among 
adults by the World Health Organization (Ayuso-Mateos, 2006; Murray and Lopez, 
1996). In 1991, a US study revealed the total annual costs associated with BD to be 
$US45 billion (Wyatt and Henter, 1995). Whilst this figure included significant direct 
costs attributable to the treatment and management of BD, these comprised of less 
than 20% of the total cost. Rather, the real burden lay within indirect costs associated 
with the disorder, such as loss of productivity due to impairments in functioning and 
premature mortality. Das Gupta and Guest (2002) estimated the annual UK costs of 
BD to be £2 billion at 1999/2000 prices, based on 297 000 people with the disorder. 
Similar to Wyatt and Henter (1995), much of this cost (86%) was attributed to indirect 
costs. Unfortunately, despite improvements in BD treatment and psychosocial 
interventions, it is thought that these costs are likely to be even larger today.  
 
1.1.1 Origins and classification  
The modern concept of bipolar disorder (BD) originated in the 19th century, with the 
writings of Jules Baillarger (1809-1890) and Jean-Pierre Falret (1794-180). In 1854, 
Baillarger and Falret, both students of the French psychiatrist Jean-Étienne-
Dominique Esquirol, independently described a disorder in which mania, depression 
and symptom-free periods occurred within regular cycles. In his description of the 
disorder, Baillarger coined the term folie à double forme (‘dual-form insanity’), with 
Falret referring to folie circulaire (‘circular insanity’) (Healy, 2008). In addition, in 1882, 
German psychiatrist Karl Kahlbaum described cyclothymia; a specified mood disorder 
from which patients could recover (Healy, 2008). 
Using Kalhbaum’s concept of cyclothymia, Emil Kraepelin brought affective 
syndromes together and first introduced the term ‘manic-depressive’ to the field of 
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psychiatry in the early 20th century. Kraepelin distinguished this unitary concept of 
mood disorder from dementia praecox (what is now commonly known as 
schizophrenia), based on a family history of mood disorder, an episodic nature, and a 
relatively benign illness course (Kraepelin, 1921). Kraepelin’s distinction between the 
two disorders produced a concept that formed the basis for the understanding of 
psychiatric illness for over a century and continues to shape the World Health 
Organisation’s International Classification of Disease (ICD), and the American 
Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM) 
classifications to this day.  
In 1959, Karl Leonhard proposed the sub-classification of affective disorders into 
unipolar depression and bipolar illness (Leonhard, 1959), following his observation 
that manic-depressive patients with a history of mania had a higher incidence of mania 
in their families, when compared to those with recurrent depression only. This 
distinction proved a revolutionary development and was adopted by the American 
Classification Diagnostic Statistical Manual of Mental Disorders-III (DSM-III) in 1980. 
By the mid-1990’s, the term bipolar disorder had almost completely replaced manic-
depressive Illness, which was largely attributed to the wide-spread use of the term 
bipolar disorder outside of America with the International Classification of Disease-10 
(ICD-10). 
Current formal diagnostic classifications continue to follow the bipolar-unipolar 
dichotomy established by Leonhard. Psychiatric disorders are classified by two major 
nosological systems; the Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition (DSM5; American Psychiatric Association, 2013), and the International 
Classification of Diseases (ICD-10; World Health Organisation, 1992). Within the 
framework of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM5; American Psychiatric Association, 2013), bipolar disorder is defined by the 
presence of at least one episode of mania, which may or may not be accompanied by 
one or more episodes of depression. The main distinction within bipolar disorder is 
made between bipolar I disorder (BDI) and bipolar II disorder (BDII). A diagnosis of BDI 
requires at least one or more manic episodes, whereas BDII is characterized by the 
presence of at least one episode of major depression, and one hypomanic episode.  
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Mania is defined by the DSM5 (American Psychiatric Association, 2013) as a distinct 
period during which patients experience abnormally and persistently raised, 
expansive, or irritable mood, as well as notably persistent goal-directed activity. A 
manic episode must last for at least seven days, or less if hospitalization is required, 
and must have caused marked impairment to the individual’s functioning. Mood 
disturbance experienced within a manic episode must be accompanied by at least 
three additional symptoms from a list that includes: inflated-self-esteem or 
grandiosity; flight of ideas; distractibility; pressure of speech; reduced need for sleep; 
increased involvement in goal-directed activity or psychomotor agitation; and 
excessive involvement in pleasurable activities with a high risk for damaging 
consequences. A hypomanic episode is defined as being less severe than mania. The 
minimum duration criterion for hypomanic episodes is shorter (at least four days) and 
although there is a clinically significant elevation of mood, the disturbance is not 
severe enough to cause the degree of impairment seen within mania, or to require 
hospitalization. The characteristic feature of a major depressive episode is a period of 
at least two weeks during which there is depressed mood, or a loss of interest or 
pleasure in almost all activities. To meet the DSM5 criteria for major depression, the 
patient must experience at least four additional symptoms from a list that includes: 
changes in appetite or weight; sleep and psychomotor activity; decreased energy; 
difficulty with thinking, concentrating or decision-making; feelings of worthlessness 
or guilt; recurrent thoughts of death or suicidal ideation, plans or attempts. Finally, a 
mixed episode is characterized by a period of at least one week in which the criteria 
are met for both manic and major depressive episodes.   
 
Within their description of bipolar disorder, DSM5 (American Psychiatric Association, 
2013) also define cyclothymia, and bipolar disorder not otherwise specified (BPNOS). 
Cyclothymia is a chronic disorder, requiring more than two years of fluctuating mood 
disturbance, whereby the patient experiences numerous periods with hypomanic 
symptoms and periods with depressed symptoms that do not meet criteria for major 
depressive disorder. BPNOS is diagnosed when the patient experiences bipolar 
features that do not meet criteria for formal disorder.  
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Whilst the DSM and ICD classification systems are considered to be largely similar, 
there does exist some heterogeneity between the two in the criteria for BD. These 
differences are mainly focused around the number of episodes required for a diagnosis 
and the distinction between the two major subtypes, bipolar I (BDI) and II (BDII) 
disorders. According to the tenth revision of the International Classification of 
Diseases (ICD-10), a diagnosis of BD requires two discrete mood episodes, at least one 
of which must be manic in polarity. In contrast, within DSM5, a diagnosis of BD can be 
made following a single episode of mania. In addition, within ICD-10, BDII is not 
recognized as a separate entity, but rather describes a single category of ‘bipolar 
affective disorder’ where mania is distinguished from hypomania, on the basis of 
severity. 
  
Inherent within both systems is the description of diagnostic categories based on 
clinical symptomatology, rather than underlying etiological factors. Advances in  
understanding of the underlying pathogenic mechanisms and genetic susceptibility 
for major psychiatric disorders, including BD (discussed later in this chapter), suggest 
that we should be moving away from current descriptive categories, to entities or 
dimensions that are based on the underlying workings of the brain (Craddock and 
Owen, 2010). 
 
The clinical manifestations of bipolar disorder are diverse and over recent times, there 
has been an increasing recognition of a spectrum of bipolar disorders. Such a notion 
conceptualizes a continuum of affective pathology, ranging from severe mood 
disturbance observed within BDI, to ‘softer’ forms of mood variation, including 
recurrent depression accompanied by a hyperthymic temperament and a family 
history of bipolar disorder, and recurrent depression with antidepressant-induced 
mania (Akiskal et al., 2000).  
 
A further topic of contention when considering a spectrum of affective illness concerns 
the classification of schizoaffective illness within that continuum. As already 
mentioned, within acute, severe episodes of mania, patients can exhibit classic signs 
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of schizophrenia, including thought disorder, delusions and hallucinations. 
Schizoaffective illness is considered when an individual experiences psychotic 
symptoms together with affective disturbance, and can be difficult to distinguish from 
very severe forms of BD. The diagnosis of schizoaffective disorder itself has been ever-
changing in the different editions of the Diagnostic and Statistical Manual (DSM) and 
its diagnosis remains controversial because of poor diagnostic reliability, weak validity 
and its overuse within clinical practice (Malaspina et al., 2013). Diagnostic criteria for 
schizoaffective disorder were first introduced within the fourth edition of the DSM 
(DSM-IV; American Psychiatric Association, 2000) and was continued within the most 
recent edition of the DSM (DSM5; American Psychiatric Association, 2013). The DSM 
states that the diagnosis should be made when an individual experiences at least one 
episode where psychotic symptoms dominate the clinical picture, with fleeting mood 
symptoms, or when psychotic symptoms persist for more than two weeks without 
affective symptoms. DSM further specifies schizoaffective, bipolar type (for those 
experiencing a current or previous manic syndrome) and schizoaffective, depressed 
type (for those with no current or previous manic syndrome).  
 
Uncertainty and disagreement continue over whether schizoaffective illness is a 
separate disorder, a subtype of affective disorder, or a subtype of schizophrenia. Some 
investigators postulate that the position schizoaffective illness plays on the 
schizophrenia-affective spectrum, may depend on the type (bipolar or depressed type) 
that is being considered. Family studies have shown increased risks for schizoaffective 
disorder in the relatives of probands with bipolar disorder, and for probands with 
schizophrenia (Laursen et al., 2005), suggesting that schizoaffective disorder may 
constitute a subtype for either disorder.  
 
1.1.2 Epidemiology and course of illness  
The lifetime prevalence of strictly defined bipolar I disorder (BDI) within the general 
population is reported to be approximately 1% (Merikangas et al., 2007; Merikangas et 
al., 2011; Pini et al., 2005; Waraich et al., 2004). Estimates of the lifetime prevalence of 
bipolar II disorder (BDII) range from 0.5% to 3% (Oliver and Simmons, 1985; 
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Stefánsson et al., 1991; Weissman and Myers, 1978). Moreover, when a wider range of 
bipolar spectrum disorders were considered, prevalence estimates have been reported 
to increase to approximately 6% (Pini et al., 2005). Evidence suggests that there exists 
an equal gender ratio in the prevalence of bipolar disorder (Lloyd et al., 2005; Smith 
and Weissman, 1992; Wells et al., 2006). While this does appear to be true for BDI, 
studies have repeatedly reported that BDII is more common in females than males 
(Baldasanno et al., 2005; Cassano et al., 1992; Di Florio and Jones, 2010).  
 
There is general agreement that the age of onset of BD is early, usually occurring in 
adolescence and young adulthood. The peak age at onset of the first symptoms of BD 
is estimated to be between 15 and 19 years (Weissman et al., 1996). It was reported by 
Mantere et al. (2004) that bipolar patients report an average delay of 8 years from first 
experience of mood symptoms to receiving a formal diagnosis. A delay in diagnosis 
subsequently means a delay in appropriate treatment, and as such can lead to a worse 
prognosis (Angst and Cassano, 2005). Conversely, early detection and treatment of BD 
can reduce the risk of serious events, such as suicide, a finding that is particularly 
important given that between 25-50% of patients with BD will attempt suicide at least 
once in their lifetime (Goodwin and Jamison, 1990; Hawton et al., 2005; Jamison, 2000; 
Valtonen et al., 2006).  
 
Whilst the peak onset of BD occurs in early adulthood, a minority of patients may 
develop the disorder within their adolescent or even childhood years, although there 
is controversy surrounding the diagnosis and treatment of BD in children (Parens and 
Johnston, 2010). Such an early onset of BD (particularly childhood onset) has been 
associated with long delay to first treatment, a greater number of lifetime mood 
episodes, higher rate of comorbid conditions, more severe manic and depressive 
episodes and fewer days spent well (Leverich et al., 2007). 
The rate of recurrence in BD is high, and more than 90% of individuals who experience 
a first manic episode will have future episodes. The frequency of mood episodes in 
bipolar patients is highly variable. Some patients will experience discrete episodes, 
occurring perhaps no more than once a year and will make a full recovery in-between. 
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Other patients may experience a far greater number of episodes and some may fail to 
fully recover in-between episodes. An individual is said to suffer from a ‘rapid cycling’ 
illness course if they experience four or more distinct episodes of mania or depression 
over a 12-month period. However, this criterion is deemed to be arbitrary. Data on the 
prevalence of rapid cycling in patients with BD is inconsistent. A meta-analysis 
conducted by Kupka et al. (2003) including data from 1972-2002, noted a range 
between 12-25%, with an overall prevalence of 16.3%. Kupka et al. (2003) also reported 
rapid cycling to be significantly more prevalent in women than in men. Although a 
wealth of previous studies have suggested a relationship between rapid cycling and 
female gender (Bauer et al., 1994; Coryell et al., 1992; Tondo and Baldessarini, 1998), 
a more recent large, prospective study reported an almost equal prevalence of a rapid 
cycling illness pattern in men and women (Schneck et al., 2008).  
When compared to the general population, individuals with BD are found to have a 
significantly increased risk of premature mortality. A national cohort study of 
6,587,036 Swedish adults (including 6,618 individuals with BD), found that both men 
and women with BD died prematurely from multiple causes, including cardiovascular 
disease, diabetes mellitus, chronic obstructive pulmonary disorder and suicide (Crump 
et al., 2013).  The excess deaths associated with BD have also been associated with 
unnatural causes such as suicide, a leading cause of death among individuals with BD. 
As noted above, between 25%-50% of patients with BD will attempt suicide at least 
once in their lifetime (Goodwin and Jamison, 1990; Hawton et al., 2005; Jamison, 2000; 
Valtonen et al., 2006). Suicide has also been reported to be the leading single cause of 
excess mortality in BD, with suicide mortality rates reported as being 15-fold high than 
that in the general population (Harris and Barraclough, 1997). A recent review of the 
risk factors for suicidal behavior indicated that a: younger age of bipolar onset; history 
of past suicidal behavior; family history of suicidal behavior;  predominantly depressive 
illness course; comorbid alcohol and substance misuse disorders; and comorbid 
borderline personality disorder, were all associated with increased suicidality 
(Latalova et al., 2014).  
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1.1.3 Treatment and management 
Treatment of bipolar disorder (BD) is concerned with the acute management of mood 
episodes and symptoms, as well as the prevention of future episodes and ensuring 
optimal functionality. Whilst much of the treatment for BD is pharmacologic in nature, 
the combination of psychological and lifestyle approaches with medication is essential 
for the long-term management of the disorder. Within the UK, the National Institute 
for Health and Care Excellence (NICE) produce evidence-based treatment 
recommendations to act as guidelines for the National Health Service (NHS), which 
recommend a range of both pharmacological and non-pharmacological approaches 
for the management of bipolar disorder (NICE, 2014; 
https://www.nice.org.uk/guidance/cg185).  
The goal of treatment for BD is to regulate both depressive and manic states, which is 
often achieved through the use of a mood stabilizer. Mood stabilisers can also be used 
in the long-term treatment of BD, acting as a preventative measure to reduce risk of 
future mood episodes. Lithium was introduced by John Cade in 1949 and was the first 
mood stabilizer to alleviate acute manic and depressive episodes and remains the best 
established maintenance drug for the prevention of subsequent episodes, as 
highlighted by a recent meta-analysis (Miura et al., 2014). Moreover, lithium is the only 
known pharmacological agent to be effective in reducing the rate of suicide in the 
long-term treatment of patients with BD. Evidence from a recent systematic review of 
48 randomized controlled trials (6674 participants) confirmed the anti-suicidal effect 
of lithium in people with mood disorders (Cipriani et al., 2013).  
Several anticonvulsive medications (drugs used in the treatment of epileptic seizures), 
such as valproic acid, carbamazepine and lamotrigine, are also known to be effective 
mood stabilisers. They can be used in the primary treatment of BD however evidence 
suggests a greater efficacy for their anti-manic and prophylactic ability over their anti-
depressive properties. Among the anticonvulsants, maintenance of BD is particularly 
well-established for valproic acid, which has been used in the prophylactic treatment 
of BD in Europe since 1966 (Lambert et al., 1966). Valproate is still frequently used in 
clinical practice (Geddes and Miklowitz, 2013), however evidence suggests that 
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combination with lithium is more effective than treatment with valproate 
monotherapy (Geddes et al., 2010).  
Atypical antipsychotics such as olanzapine, aripiprazole, quetiapine and risperidone, 
are also known to play an increasing role in the treatment of BD. They are particularly 
helpful in instances where lithium or anticonvulsants alone may be ineffective, such as 
the treatment of agitation and psychotic symptoms that occur within severe mood 
episodes. Where monotherapy fails to sufficiently reduce symptoms, a combination of 
mood stabilisers and/or antipsychotics is the next recommended line of treatment. If 
symptoms of depression cannot be managed by mood stabilisers and antipsychotic 
medication alone, then an antidepressant can be added, however the role of 
antidepressants in the treatment of bipolar depression remains controversial, given 
the risk of a rapid switch to mania, or the triggering of a rapid cycling illness course. It 
has been noted, however, that selective serotonin reuptake inhibitors (SSRIs) may 
pose less of a risk for inducing mood switches than tricyclic antidepressants (Salvadore 
et al., 2010).  
Although pharmacotherapy is the mainstay of treatment for BD, many people do not 
respond fully to medication and continue to experience sub-syndromal, inter-episode 
symptoms (Keck et al., 1998). For example, it has been noted that up to a third of 
patients with BD do not respond to treatments in naturalistic studies (Geddes and 
Miklowitz, 2013). Electro-convulsive therapy (ECT) is among the non-pharmacological 
treatments for BD that has a documented positive effect on severe episodes of both 
depressive and manic polarities in patients (Dierckx et al., 2012; Medda et al., 2009) 
and is particularly useful for treatment resistant BD (Gitlin, 2006). 
Non-adherence to drug treatment among bipolar patients is also a problem, with non-
adherence rates of up to 60% following acute episodes (Strakowski et al., 1998).  A lack 
of awareness or insight into their disorder is considered a major source of non-
adherence among bipolar patients (Colom et al., 2005). Adverse side effects of 
medication, particularly weight gain and sedation (Velligan et al., 2009); comorbid 
alcohol dependence, youth, greater number of affective symptoms and a recent manic 
or hypomanic episode (Baldessarini et al., 2008) and have also been cited as important 
factors associated with non-adherence. Treatment non-adherence can have serious 
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clinical and economic consequences; therefore, non-pharmacological approaches 
adjunctive to medication are essential in ensuring optimal outcomes for patients with 
BD.  
A number of psychosocial interventions have been established for the treatment of BD 
which broadly fall into five categories: psychoeducation, integrated treatments, 
family-based therapy, cognitive behavioural therapy, and interpersonal and social 
rhythm therapy (Castle et al., 2009). Psychosocial therapies look to improve the self-
management of the disorder and common objectives include: increasing acceptance 
of the illness, improving drug adherence, identifying triggers and early warning signs, 
enhancing communication and relationships, and stabilizing sleep cycles and daily 
routines (Geddes and Miklowitz, 2013). The role of self-management is an important 
theme in psychosocial therapy, encouraging patients to take increased responsibility 
for their health through learning about the illness itself and developing the skills to 
recognise and control symptoms.  
 
1.1.4 Overview of pathophysiological mechanisms 
Early biological theories concerning the pathophysiology of bipolar disorder (BD), 
focused on the dysfunction of several neurotransmitter systems. Such studies have 
implicated abnormalities in monaminergic systems such as, dopaminergic, 
noradrenergic and serotonergic systems, with much of this research driven by the 
discovery of effective pharmacologic treatments for depression and mania that were 
shown to alter central amine function in animals (Goodwin and Jamison, 2007). There 
has also been some evidence for reduced GABAergic activity from post-mortem 
studies (Benes and Berretta, 2001; Knable et al., 2004; Torrey et al., 2005). Moreover, 
altered platelet GABA and glutamate uptake was found to be correlated with severity 
of depression and mania, respectively (Daniele et al., 2012). Despite evidence 
suggesting the involvement of these circuits, the precise pathophysiology of BD is yet 
to be identified. In addition, abnormalities of endocrine function, including the 
hypothalamic-pituitary-axis (HPA), have been reported in patients with mood 
disorders. For example, there is consistent evidence for elevated cortisol and 
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corticotrophin releasing hormone (CRH) levels, as well as hypofunction of the 
glucocorticoid receptor (GR) in patients with major depression (Zunszain et al., 2011). 
Moreover, it is hypothesised that manic episodes may be preceded by increased 
adrenocorticotropic hormone (ACTH) and cortisol levels, leading to cognitive and 
functional impairments (Daban et al., 2005).  
Neurophysical abnormalities have also been implicated in BD, for example in the 
anterior cingulate, hippocampus and amygdala, all of which are involved in the 
regulation of mood and cognition in humans (Drevets et al., 2008). However, because 
of limitations in sample sizes and cross-sectional study designs, as well as possible 
confounding by clinical status and medication effects, it is unknown whether the 
structural brain changes reported are a result of abnormal development, the disease 
process itself, or consequences of drug exposure.  
Although our understanding of the underlying pathogenesis of BD is limited, a strong 
body of evidence suggests a substantial contribution of genetic factors in the 
susceptibility to the disorder. Classic genetic epidemiology in the form of family, twin 
and adoption studies over the past several decades have provided a wealth of evidence 
suggesting that BD is a highly heritable disorder. For example, family studies have 
demonstrated that BD has a tendency to run in families and a meta-analysis of family 
studies based on more than 6000 first-degree relatives of bipolar probands revealed a 
weighted summary morbid risk estimate for BD of 8.7% (Smoller and Finn, 2003). 
Moreover, in a classic family study by Gershon et al. (1982), first-degree relatives of 
probands with bipolar I disorder (BDI) had similar risks of BDI (4.5%) and bipolar II 
disorder (BDII) (4.1%), compared to relatives of controls. They also reported that 
relatives of probands with BDII had increased rates of both BDI (2.6%) and BDII (4.5%).  
Evidence from twin studies suggests that the familial aggregation demonstrated by 
family studies is largely due to genetic factors. Twin studies compare concordance 
rates of a disorder between monozygotic (MZ) twins, who are genetically identical, 
with dizygotic twins (DZ), who share approximately half of their genetic material in 
common. Assuming an equal shared environment (including environmental risk 
factors for bipolar disorder), any reported differences in the concordance rates for BD 
between MZ and DZ twin pairs are likely due to the genetic similarity of MZ over DZ 
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twins. Studies have consistently demonstrated significantly increased concordance 
rates in MZ compared with DZ twins (Allen et al., 1974; Bertelsen et al., 1977; Cardno 
et al., 1999; Kendler et al., 1993; Kringlen, 1967; Torgersen, 1986), thus implicating the 
role of a genetic component in susceptibility to BD. For example, a study by McGuffin 
et al. (2003) involving 30 monozygotic and 37 dizygotic twin pairs reported a 
probandwise concordance rate of 67% in MZ twins compared to 19% in DZ twins. Data 
from twin studies allows for the calculation of heritability: (concordance rate in MZ 
twins – concordance rate in DZ twins) divided by (100 – concordance rate in DZ twins) 
(Goodwin and Jamison, 2007). Heritability for BD is estimated to be between 60-85% 
(Smoller and Finn, 2003). Therefore, whilst it is well established that genetic factors 
are important in the aetiology of BD, given that heritability estimates do not reach 
100%, this suggests that environmental factors may play an important role in 
contributing to disease susceptibility. For example, the literature is fairly consistent in 
suggesting that individuals with BD experience increased stressful events prior to 
onset or subsequent episodes of their disorder (Hosang et al., 2010; Johnson and 
Roberts, 1995). In addition, it has been shown that adverse childhood life events may 
increase susceptibility to onset of BD (Fisher and Hosang, 2010) and that early parental 
loss in particular may be associated with an increased risk for BD in later life (Tsuchiya 
et al., 2005).  
 
Adoption studies can help to separate the genetic and environmental contributions in 
the aetiology of a disorder by comparing rates of the disorder in question between 
offspring of a set of biological parents raised from infancy by unrelated foster parents. 
Understandably, because of the logistical difficulty in the availability and recruitment 
of such subjects, only two adoption studies of BD can be found in the literature 
(Mendlewicz and Rainer, 1977; Wender et al., 1986). Both studies found a greater risk 
of affective disorder in the bipolar parents of bipolar adoptive relatives, however this 
was not found to be significantly increased in the study conducted by Wender and 
colleagues. It is argued that this may be explained by the small sample size involved 
(based on 10 bipolar probands) likely resulting in a lack of statistical power.  
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The genetic aetiology of BD is complex, and therefore rather than following a 
Mendelian mode of inheritance, it is posited that many risk variants, each conferring a 
small risk, interact to increase risk of the disorder (Craddock and Jones, 1999). Thus, 
over the past two decades research has focused on identifying susceptibility genes 
that confer risk for BD. Initial efforts to identify variants associated with BD were made 
through the use of linkage studies. Linkage studies examine genetic markers spread 
across the genome to determine chromosomal regions that harbor susceptibility 
genes, by examining those markers that are co-inherited with disease within biological 
family members (with more than one affected member). Linkage studies require no 
prior knowledge of disease pathophysiology, and so were an attractive early method 
for the study of BD (and psychiatric illness more widely), given the relatively poor 
understanding of pathogenesis.  
Results from a meta-analysis of seven published genome scans for BD identified 
susceptibility loci on 13q and 22q (Badner and Gershon, 2002). Following this, a meta-
analysis of 18 studies conducted by Segurado et al., (2003) did not find genome-wide 
significant evidence for linkage, however, they did find modest support for regions on 
chromosomes; 9p22.3–21.1, 10q11.21–22.1, 14q24.1–32.12 and regions of 
chromosome 18. In 2004, Middleton et al., identified evidence for genome-wide 
significant linkage for BD in the region of 6q21-25, a region which has received 
genome-wide suggestive signals in three further independent samples (Dick et al., 
2003; Ewald et al., 2002; Lambert et al., 2005). Moreover, this region again showed 
genome-wide significance in a collaborative analysis of 11 bipolar linkage studies 
(McQueen et al., 2005).  Although several susceptibility regions have been implicated, 
the limited success of linkage studies to accurately and consistently identify risk loci 
for BD suggests that genes that confer a relatively large effect on disease risk are not 
major contributors to the genetic aetiology of BD. Following the limited success of 
linkage studies, focus shifted to the search for susceptibility genes according to the 
‘common disease-common variant’ (CDCV) model, in which several common variants 
are thought to confer a small risk and interact to give rise to the disorder (Barnett and 
Smoller, 2009).  
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In a candidate gene approach, early association studies focused on serotonin, 
dopamine, and noradrenaline neurotransmitter systems, based on their involvement 
in the pharmacological treatment of BD.  Several studies investigated genes encoding 
monoamine oxidase A (MAOA) (Preisig et al., 2000), catechol-O-methyltransferase 
(COMT) (Jones and Craddock 2001), and the serotonin transporter (5HTT) (Anguelova 
et al., 2003; Lasky-Su et al., 2005). However, none provided robust support for any of 
these genes. Genes involved in circadian rhythms have also been a focus of candidate 
association studies, based on the suggestion that abnormalities of circadian rhythms 
underlie certain aspects of BD (Harvey, 2008). For example, it has long been known 
that deprivation of sleep can have both antidepressant qualities (Wehr et al., 1982), 
and mania-inducing effects (Colombo et al., 1999). Such efforts have yielded 
inconsistent findings (Benedetti et al., 2003; Mansour et al., 2006; Serretti et al., 2005; 
Shi et al., 2008) and none have been reliably established as susceptibility genes for BD. 
A number of studies have also assessed the potential involvement of schizophrenia 
risk genes in BD, given the clinical and proposed genetic overlap between the two 
disorders. Initial research provided evidence for the involvement of a number of 
schizophrenia implicated genes in BD, including; disrupted in schizophrenia 1 (DISC 1), 
d-amino acid oxidase activator (DAOA, aka G72), neuregulin1 (NRG1), and brain-
derived neurotrophic factor (BDNF) (Craddock et al., 2006), supporting the hypothesis 
of an overlap in genetic susceptibility between the two disorders.  
 
It is perhaps the case that the limited success of candidate gene approaches reflects 
our inadequate understanding of the mechanisms underlying major psychiatric 
disorders, resulting in poorly informed candidate choices. The relatively disappointing 
findings from the candidate gene studies, together with major statistical and 
technological advances, led the way for more hypothesis-free approaches.   
 
Genome-wide association studies (GWAS) allow for the simultaneous analysis of 
genetic variation across the genome, by assaying hundreds of thousands of genetic 
markers (single nucleotide polymorphisms, or SNPs) across groups of cases and 
controls, thus providing an unbiased approach to identifying potential disease 
associated variation (Corvin et al., 2010). Given the large number of statistical tests 
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performed in GWAS, this does pose a statistical challenge with regards to multiple 
testing, and as such a 5x10-8 threshold for significance is adopted (analogous to a 
Bonferroni correction of a 0.05 Type 1 error level for 1,000,000 independent tests). 
Because of the stringent significance threshold enforced, large numbers of cases and 
controls are required in order to achieve adequate statistical power to detect the small 
genetic effect sizes typical for human GWAS studies (Corvin et al., 2010). Since the 
arrival of the GWAS era, the field of bipolar genetics has flourished and has seen the 
identification of a number of significant risk variants for the disorder, some of which 
have been robustly replicated.   
 
The first published GWAS for BD involved 1233 cases and 1439 controls (Baum et al., 
2008). Using pooled genotyping they reported a genome-wide significant association 
with DGKH, an association that has not since been replicated within later larger 
studies. During that same year, the Welcome Trust Case Control Consortium (WTCCC) 
published results of a GWAS looking to identify genetic variation associated with 7 
different diseases, one of which was bipolar disorder. Although they did not report any 
genome-wide significant findings, a region at chromosome 16 showed a strong 
association with BD. Within a second consortium driven GWAS based on 1461 cases 
and 2008 controls Sklar et al. (2008) found the strongest signal for a SNP in MY05B 
(p=1.66x10-7). Within the largest collaborative effort at the time, Ferreira et al. (2008), 
reported results from a meta-analysis of the STEP-UCL and WTCCC GWAS studies, 
comprising of 4,387 cases and 6,209 controls. The result was a defining moment in the 
field, identifying ANK3 (ankyrin3) and CACNA1C (alpha 1C subunit of the L-type 
voltage-gated calcium channel) as BD candidate genes. ANK3 and CACNA1C have 
been replicated in a number of studies (Lee et al., 2011; Schulze et al., 2009; Scott et 
al., 2009; Sklar et al., 2008; Smith et al., 2009). Both CACNA1C and ANK3 encode 
proteins that influence neuronal excitability through ion channel function, therefore 
raising the possibility that bipolar disorder may partly result from channelopathies.  
 
In 2008, the Psychiatric GWAS Consortium (PGC) was established in order to facilitate 
high levels of data-sharing and coordinated analysis on an international level. The 
Psychiatric GWAS Consortium Bipolar Disorder Working Group (PGC-BD) reported on 
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a combined GWAS of 11,974 cases and 51,792 controls, making this the largest meta-
analysis of BD GWAS to date (Psychiatric GWAS Consortium Bipolar Disorder Working 
Group, 2011). The primary analysis of 4,496 cases and 42,422 controls identified two 
SNPs surpassing genome-wide significance in ANK3 and SYNE1. When the primary 
dataset was combined with a further replication sample, these results fell just below 
genome-wide significance within a meta-analysis, however, an association was 
confirmed for CACNA1C and new evidence was provided for ODZ4. In addition, when 
a GWAS combining data from five psychiatric disorders (BD, schizophrenia, major 
depressive disorder, autism spectrum disorder, and attention deficit-hyperactivity 
disorder) was performed, four SNPs with genome-wide significance were identified 
(Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013). Of these, two 
were within voltage-gated calcium channel subunits, CACNA1C and CACNB2. When 
top SNPs previously identified from bipolar GWAS (CACNA1C, ANK3, ODZ4, and 
SYNE1) were assessed for their role in other disorders, all except CACNA1C were found 
to be relatively specific to BD.  
 
More recently, evidence from a further meta-analysis involving 7,773 cases and 9,883 
controls, identified a significant GWAS signal near TRANK1, a gene which encodes a 
protein that has shown responsiveness to valproic acid (Chen et al., 2013). Moreover, 
combining new sets of 2,266 cases and 5,028 controls, and the previously reported 
PCG-BD dataset (7,481 cases and 9,250 controls), Mühleisen et al. (2014), reported 56 
SNPs reaching genome-wide significance at five genomic loci. Among these were the 
previously identified ANK3, ODZ4 and TRANK1 as well as two newly implicated loci, 
ADCY2 at 5p15.31 (linked to a common pathway for a number of neurotransmitter 
systems) and another at 6q16.1 where no specific gene was identified. At the time of 
writing, analyses were underway in a sample approaching 20, 000 probands with BD, 
however results were not yet published.   
 
Whilst GWAS have generated major breakthroughs in our understanding of the 
genetics of BD, and have shown that BD is a highly polygenic disorder, the majority of 
the genetic risk is yet to be explained. As already explained, GWAS operate on the 
‘common disease-common variant’ model and therefore are designed only to detect 
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the effects of common SNPs. There is some evidence to suggest the role of rare, copy 
number variants in BD (Zhang et al., 2009), however, this has not been supported by 
others (Grozeva et al., 2010). Moreover, it has been suggested that the pathogenicity 
of these variants may be lower in BD than for schizophrenia (Georgieva et al., 2014). 
Given the dramatic drop in the cost of DNA sequencing over recent years, it is hoped 
that this will help to further elucidate the role of rare genetic variants in influencing 
susceptibility to BD.  
 
1.1.5 Comorbidity 
Comorbidity is broadly defined as the co-occurrence of two disorders within the same 
person (Feinstein, 1970; Scher et al., 2005). Within individuals with bipolar disorder 
(BD), comorbidity is common and is most likely the rule rather than the exception.  The 
relevance of comorbid conditions is related to their impact, or potential impact, on the 
clinical course, outcome, choice of treatment, and management of the index disorder. 
If we consider the long-lasting, chronic course of bipolar disorder, the management of 
complex comorbid conditions must constitute an important and fundamental part of 
individualized treatment.  
Studies have consistently reported a high rate of psychiatric and non-psychiatric 
comorbidity in BD. In a Stanley Foundation Bipolar Treatment Outcome Network 
study of 288 patients with bipolar disorder, 65% were found to meet DSM-IV criteria 
for at least one other psychiatric comorbidity, 42% had two or more, and 24% were 
reported to have three or more co-existing psychiatric disorders (McElroy et al., 2001). 
Comorbid conditions can further complicate the bipolar illness and may influence the 
course of illness and lead to poorer outcomes and prognosis. For example, Vieta et al. 
(2001)  found that within a sample of 129 patients with bipolar I disorder, presence of 
psychiatric comorbidity was associated with a greater number of mixed features and 
depressive episodes, a greater rate of suicidal ideation and higher number of suicide 
attempts, and poorer social functioning and treatment compliance.  
Comorbid anxiety and substance misuse disorders are among the most common 
psychiatric disorders in BD. Within the Systematic Treatment Enhancement Program 
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for Bipolar Disorder (STEP-BD), the lifetime and current prevalence of anxiety 
disorders was reported at 51.2% and 30.5%, respectively (Simon et al., 2004). In a 
further study, Simon et al. (2007) reported that anxiety disorder comorbidity (and 
generalized anxiety disorder in particular), was associated with increased risk for 
suicidal ideation and behavior in patients with BD. Additionally, in an epidemiological 
survey of 42,000 respondents in the US, mania and hypomania were 14 times more 
likely to have drug dependence, and 6 times more likely to have experienced alcohol 
dependence in the preceding 12 month period (Grant et al., 2004). Further 
epidemiological studies have reported that lifetime presence of alcohol use disorders 
are present among 46-58% of bipolar I disorder patients, and 19-39% of bipolar II 
disorder patients (Grant et al., 2005; Merikangas et al., 2007; Regier et al., 1990a).  
Moreover, general medical conditions have been found to differentially effect 
individuals with BD (Kilbourne et al., 2004). Historically, the increased rate of medical 
illness observed in those with major psychiatric disorders was thought to be a 
consequence of pharmacologic treatment and unhealthy lifestyle choices. In 
particular, antipsychotics, antidepressants and mood stabilizers were shown to be 
associated with an increased risk of metabolic syndromes, such as diabetes and 
cardiovascular disease (Masand and Gupta, 2002; Nemeroff, 2003). However, a recent 
study by Khan et al. (2013) suggested that mortality risk was not increased in 
psychiatric patients that were exposed to psychotropic agents.  
In a Canadian, cross-sectional population-based study, McIntyre, et al. (2006a), 
reported that: chronic fatigue syndrome; migraine; asthma; hypertension; and gastric 
ulcer were all significantly increased in those with BD. Furthermore, they observed 
that presence of comorbid conditions was associated with a more severe course of BD, 
worse functional outcomes and increased use of medical services. Similarly, in a UK 
study looking to assess the rate of physical illness in a large, well-defined sample of 
patients with a diagnosis of BD, Forty et al. (2014) reported higher rates of a number 
of physical health conditions when compared to control subjects. These included: 
asthma; diabetes type I and II; epilepsy; kidney disease; gastric ulcers; migraine; 
rheumatoid arthritis; stroke; and kidney disease. In addition, the authors reported that 
illness burden (defined as a history of three or more medical illnesses), was associated 
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with a lifetime history of anxiety, a rapid cycling illness pattern, suicide attempt, and 
an acute onset of mood episodes, when controlling for other associated factors.  
It is currently unknown whether medical disorders and BD naturally occur together, 
whether they are a consequence of treatment or lifetime factors, or a combination of 
both. However, given the postulated detrimental impact on the course and prognosis 
of the bipolar illness, it is essential that we gain a better understanding of their 
relationship and that an awareness of comorbidity and its complications are 
considered in the management of BD as a means of improving patient outcomes. This 
is particularly important given that there is evidence to suggest that although 
individuals with major psychiatric illness appear to be differentially affected by 
multiple medical comorbidities, such patients receive less screening and fewer 
preventative interventions (Smith et al., 2013).  
The specific relationship and potential overlap between BD with i) migraine, and ii) 
epilepsy will be discussed further within upcoming sections of this chapter.  
 
1.1.6 Reducing heterogeneity in bipolar disorder 
Bipolar disorder (BD) is an overwhelmingly heterogeneous disorder in terms of its 
clinical presentation, comorbidity, and pathogenesis. There exists a fundamental need 
to identify more meaningful subgroups within BD that may differ in clinical expression 
and outcome. Identification of such subgroups may provide clinical benefits, 
potentially facilitating more effective, targeted treatment and management options. 
Moreover, it is possible that clinical homogeneity reflects pathophysiological 
homogeneity, thus making these subgroups a potential useful focus for studies 
investigating the aetiology of BD.  
There have been a number of attempts to reduce the heterogeneity in BD by 
identifying potential sub-phenotypes that may be more likely to share some common 
clinical and aetiological basis. These have included: polarity of onset of BD (Forty et al. 
2009a); comorbid anxiety disorders, including panic disorder (Forty et al. 2009b); age 
at onset (Hamshere et al., 2009); and puerperal psychosis (Jones and Craddock, 2001; 
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Jones and Craddock, 2002). Moreover, lithium responsiveness has also been proposed 
as a genetically valid subtype of BD (Turecki et al., 2001).  
It is proposed that comorbid conditions within BD may offer a further opportunity to 
increase homogeneity of the disorder. Specifically, this thesis will explore the 
relationship between BD and the neurological conditions of migraine, and epilepsy, as 
a means of distinguishing more homogenous subgroups of patients with BD. 
Subsequent sections within this introductory chapter (Section 1.2 and 1.3) will 
introduce the topics of migraine and epilepsy, as well as reviewing the evidence for 
overlap between these disorders and BD.  
 
1.2    Introduction to migraine  
Migraine is a chronic, paroxysmal neurological condition, characterised by severe, 
recurrent and stereotyped headaches. Migraine has a devastating effect on well-being 
and general functioning, which often lingers following the acute attack and is rated by 
the World Health Organisation (WHO) as being among the most disabling chronic 
disorders (Menken et al., 2000). Furthermore, migraine is estimated to be the most 
costly neurological disorder in Europe (Andlin-Sobocki et al., 2005). Migraine is among 
the most under-diagnosed and under-treated neurological conditions, with more than 
half of migraine sufferers not seeking medical care for their headaches (Lipton et al. 
2002). For those seeking medical care, the majority of health care for migraine 
patients is provided in the primary care setting, with only 10-15% of migraineurs seen 
by neurologists and 4% seen by headache specialists (Lipton et al., 2002).  
In 1988, the Headache Classification Committee of the International Headache 
Society (IHS), published the first internationally accepted headache classification 
system; The International Classification of Headache Disorders (ICHD), 1st Edition. This 
classification system allowed for the standardisation of headache diagnosis and 
although imperfect, these criteria are utilised by researchers and clinicians alike to aid 
headache disorder diagnosis. The criteria were revised in 2004 (ICHD-II; Headache 
Classification Subcommittee of the International Headache Society, 2004) to offer 
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increased clarity for headache diagnosis by building on the successes of the first 
edition. Within the classification system (ICHD-II), headaches are differentiated into 
primary and secondary categories (see Table 1.1), where secondary headache 
disorders are described as those having an identifiable underlying cause such as a brain 
tumour or infection. In contrast ‘primary’ refers to a lack of clear underlying causative 
pathology, trauma or systemic disease. Primary headaches are the most common of 
the headache disorders and the classification for primary headache is split into four 
sections: migraine, tension-type headache, cluster headache and other trigeminal 
autonomic cephalalgias, and other primary headaches.  
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Table 1.1 International Headache Society classification of primary and secondary 
headache disorders (ICHD-II; Headache Classification Subcommittee of the 
International Headache Society, 2004) 
The Primary Headaches 
1. Migraine 
2. Tension-type headache 
3. Cluster headache and other trigeminal autonomic cephalalgias 
4. Other primary headaches 
The Secondary headaches 
5. Headache attributed to head and/or neck trauma 
6. Headache attributed to cranial or cervical vascular disorder 
7. Headache attributed to non-vascular intracranial disorder 
8. Headache attributed to a substance or its withdrawal 
9. Headache attributed to infection 
10. Headache attributed to disorder of homoeostasis 
11. Headache or facial pain attributed to disorder of cranium, neck, eyes, ears, 
nose, sinuses, teeth, mouth or other facial or cranial structures 
12. Headache attributed to psychiatric disorder 
 
Migraine is considered the most burdensome of the primary headache disorders, with 
considerable impact on both the sufferer and wider society, thus rendering migraine 
an important public health issue.  ICHD-II distinguishes two main types of attack: 
migraine without aura (MoA), previously referred to as ‘common migraine’ and 
migraine with aura (MA), also known as ‘classic migraine’. Migraine without aura 
(MoA) is a clinical syndrome characterised by headache with specific features and 
associated symptoms. Within an attack of MoA, individuals experience head pain that 
is: throbbing; unilateral; aggravated by movement; and is severe enough to inhibit or 
prohibit daily activity. Moreover, migraine without aura (MoA) is associated with 
nausea, and/or photophobia and phonophobia.  
Migraine with aura (MA) is characterised, primarily, by focal neurological aura 
consisting of fully reversible visual, sensory or language symptoms that either precede 
or accompany the headache attack and occurs in approximately a third of migraine 
patients. Visual symptoms can include both positive (i.e. flickering lights, spots or 
lines) and/or negative features (loss of vision). Similarly, sensory aura can manifest as 
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positive symptoms in the form of pins and needles, and negative symptoms in the 
form of numbness. Those experiencing aphasic symptoms may have difficulty thinking 
logically, finding words or making sentences and suffering from slurred speech. These 
symptoms are classically transient; their onset is gradual and they persist for no longer 
than one hour. However, on rare occasions they may persist for days or months. There 
may also be a symptom-free period of up to one hour before the contralateral 
headache pain commences. Within MA, individuals may experience more severe 
neurological symptoms, including hemiparesis. When such motor weakness is 
experienced as part of the aura spectrum, this is referred to as hemiplegic migraine, of 
which there are recognised familial and sporadic forms. 
In 1996, Russell and Olesen reported a nosological analysis of migraine aura as 
experienced by 163 patients drawn from a general population sample of 4000 Danish 
citizens. They observed visual aura to be, overwhelmingly, the most common aura 
symptom (occurring in 99% of cases), followed by sensory (31%) and aphasic (18%) 
and motor auras (6%). Tables 1.2 and 1.3 summarise ICHD-II criteria for MoA and MA. 
There is much debate as to whether MA and MoA are part of the same disorder or 
whether they should be considered as two separate disorders. A common argument 
for the hypothesis of a single disorder comes from the observation that both types of 
attack can occur within the same individual; for example, 13% of migraineurs are 
reported to have attacks of both MoA and MA (Launer et al., 1999). Moreover, the 
finding that MA and MoA are frequently found within the same family (Ophoff et al., 
1994) is often cited as evidence of a shared aetiology between the subtypes. This was 
supported by Nyholt et al., (2004) who did not find evidence of an aetiological 
distinction between MA and MoA using latent class analysis to study migraine 
symptomatology in an Australian twin population (n=6,265). In contrast, reports of 
clinical differences between the two forms in terms of; duration of the attack, age at 
onset and resolution, and the frequency and pattern of attacks (Manzoni and Torelli, 
2008), argue for the separation of migraine with and without aura. Moreover, Russell 
and Olesen, (1995) revealed differences in familial patterns of MA and MoA, 
identifying a greater genetic component for MA and thus providing support for a 
distinct pathogenic basis.  
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Table 1.2 Migraine without aura (MoA) criteria defined by the International 
Headache Society (ICHD-II; Headache Classification Subcommittee of the 
International Headache Society, 2004) 
Migraine without aura (MoA) 
A. At least five attacks fulfilling B-D 
B. Attacks lasting 4-72 hours (untreated or unsuccessfully treated) 
C. At least two of the following four characteristics: 
 1. Unilateral location 
 2. Pulsating quality 
 3. Moderate or severe pain intensity 
 4. Aggravation by or causing avoidance of routine physical activity (e.g.  
                 walking or climbing stairs) 
D. During headache accompanied by at least one of the following: 
 1. Nausea and/or vomiting 
 2. Photophobia and phonophobia 
E. Not attributed to another disorder 
 
 
Table 1.3 Migraine with aura (MA) criteria defined by the International Headache 
Society (ICHD-II; Headache Classification Subcommittee of the International 
Headache Society, 2004) 
Migraine with aura (MA) 
A. At least two attacks fulfilling criteria B-D 
B. Aura consisting of at least one of the following, but no motor weakness: 
1. Fully reversible visual symptoms, including positive features (e.g., 
flickering lights, spots or lines) and/or negative features (e.g., loss of vision) 
2. Fully reversible sensory symptoms, including positive features (e.g., pins 
and needles) and/or negative features (e.g., numbness) 
 3. Fully reversible dysphasic speech disturbances 
C. At least two of the following: 
 1. Homonymous visual symptoms and/or unilateral sensory symptoms 
 2. At least one aura symptom develops gradually over ≥ 5 min and/or   
                different aura symptoms occur in succession ≥ 5 min 
 3. Each symptom lasts ≥ 5 and ≤ 60 min 
D. Headache fulfilling criteria B-D for migraine without aura begins during the aura 
or follows the aura within 60 min  
E. Not attributed to another disorder 
 
It is possible for many headache sufferers to experience migraine-like headaches that 
do not necessarily meet strict IHS criteria for migraine with or without aura (Russell 
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and Olesen, 1996). The first edition of the IHS classification (ICHD-I) acknowledged 
this occurrence of headache attack, coining the term ‘migrainous disorder’; a 
syndrome categorised by all but one of the full migraine diagnostic criteria. Once 
published, this category was met with criticism from clinicians, who believed such 
patients should be considered as genuine migraine sufferers. Later research by (Michel 
et al., 1993) revealed that although the IHS criteria for migraine had excellent 
specificity, sensitivity was low (<50%), thus indicating that the diagnostic criteria for 
migraine may perhaps be too restrictive. In similar vein, Rains et al. (2001) reported 
that of patients presenting to an outpatient headache clinic, 36% were given a 
diagnosis of ‘migrainous disorder’. The validity of this category was questioned due to 
its exclusion of patients presenting with a symptom pattern so close to that of 
migraine from the diagnosis of migraine. In light of this criticism, the second edition of 
the International Classification of Headache Disorders (ICHD-II; Headache 
Classification Subcommittee of the International Headache Society, 2004) 
acknowledged this category of headache sufferers as being an integral part of 
migraine, introducing the new subtype of ‘probable migraine’.  
 
The American Migraine Prevalence and Prevention study (AMPP) (Silberstein et al., 
2007) reported probable migraine to be a frequent, undertreated and disabling 
condition with an epidemiologic profile similar to that of strict migraine. Moreover, 
Henry et al. (2002) found probable migraine to be more prevalent than strict migraine 
in a French population study of 10,585 subjects aged 15 years and older (9.1% vs. 7.9%, 
respectively). Lantéri-Minet et al. (2005) noted the criterion most frequently missing 
in patients with probable migraine was typical headache duration (4–72 h), with the 
majority of patients having shorter average headache duration.  
Knowledge of migraine epidemiology has increased dramatically over the past two 
decades, with much of this said to have been driven by the emergence of standardised 
diagnostic criteria for migraine, the International Headache Society (IHS) classification 
of 1988 (ICHD-I; Headache Classification Committee of the International Headache 
Society, 1988) and 2004 (ICHD-II; Headache Classification Subcommittee of the 
International Headache Society, 2004). There currently exists no objective marker or 
diagnostic test for migraine, thus the epidemiological study of migraine has relied 
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heavily on case definition of migraine. A meta-analysis of 24 studies, only five of which 
employed IHS classification criteria (ICHD-I; Headache Classification Committee of 
the International Headache Society, 1988), revealed that case definition accounted for 
the largest portion of variation in migraine prevalence among studies (36%), followed 
by gender distribution of the study sample (14.5%) (Stewart et al., 1995). A second 
meta-analysis attempted to eliminate two of the largest sources of variation by 
including 18 population-based studies, all of which had utilised IHS criteria and by 
conducting separate meta-analyses for men and women (Scher et al., 1999). Following 
standardisation of case definition, a substantial proportion of variation in prevalence 
was explained by very few factors, such as age and geographic location of the study 
population. Some of the variation, however, remained unexplained with the authors 
postulating that socioeconomic status, cultural differences in symptom reporting or 
other unmeasured factors may explain part of the residual variance in migraine 
prevalence. Thus, introduction and adoption of IHS classification for migraine has 
helped to clarify our understanding of the scope of the public health problem posed by 
migraine.  
The American Migraine Study conducted in 1989 (Stewart et al., 1992) and the 
American Migraine Study II conducted in 1999 (Lipton et al., 2001) looked to describe 
the prevalence, sociodemographic profile, and burden of migraine in the United 
States. Another key objective of the AMS II was to make comparisons with the first 
study to assess changes in the epidemiology of migraine over time. Within the AMS II, 
a validated, self-report questionnaire was disseminated to 20, 000 households to 
identify IHS-based migraine in individuals aged 12 years and above. Of 43,527 eligible 
individuals, 29,727 responded to the questionnaire, providing a response rate of 
68.3%. The 1-year prevalence of migraine in the United States was reported to be 13%; 
18.2% in females and 6.5% in males and it was noted that 23% of respondent 
households had at least one member with migraine. These estimates were very similar 
to the 11.7%, 17.6% and 5.7% (respectively) results reported in the original and 
methodologically identical American Migraine Study, conducted ten years previously. 
Such findings suggested that within the United States, migraine prevalence had 
remained stable over time. This finding was in contrast to the results of the National 
Health Interview Survey data that reported a 60% increase in migraine prevalence in 
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the United States between 1980 and 1989 (Lipton et al., 2001). However, the measure 
of self-reported migraine within the survey data was not validated against IHS 
diagnostic criteria. Rather, migraine was defined by asking the following; “During the 
past 12 months, did anyone in the family have a migraine headache?” Thus, using this 
case definition, the increase in proposed prevalence of migraine may in fact be 
reflecting changes in the awareness of migraine over time.  
Interestingly and reassuringly, the rate of migraine sufferers that had received a 
medical diagnosis of migraine had increased from 38% in 1989 to 48% in 1999. Despite 
these improvements, it is notable that approximately half of migraine sufferers never 
receive a diagnosis of migraine (Lipton et al., 2001). Such findings may be explained 
by the proportion of migraine sufferers seeking medical care for their headaches. In 
the original American Migraine Study, 16% of migraineurs were currently visiting a 
physician for headache, 50% had previously seen a physician but had lapsed from care 
and 34% had never seen a physician for headache. When the study was repeated in 
1999, they found that the percentage of individuals currently seeing a physician had 
tripled to 47%, the percentage of those who had lapsed from care had declined by 
more than half to 21%, and the percentage of those who had never visited a physician 
had remained approximately the same at 32%. The increase in the rate of migraine 
sufferers currently seeking medical care is encouraging. However, with figures from 
the most recent study suggesting that more than half of sufferers are not seeking care 
(21% of those who had lapsed and 32% of those never seeking care), it is clear that 
migraine remains under-diagnosed and under-treated. 
Migraine prevalence in European populations has also been reported. As part of the 
Eurolight project; a project supported by the EC Public Health Executive Agency, 
Stovner and Andree (2010) aimed to provide an update on headache epidemiology as 
a preparation for the multinational European study on the prevalence and burden of 
headache. Across 33 studies of migraine prevalence in selected European countries 
(Austria, France, Germany, Italy, Lithuania, Netherlands, Spain, UK, Ireland and 
Luxembourg), the mean prevalence of current (in the last year or less) migraine among 
170,000 adults was 14.7% (8% in men and 17.6% in females), similar to the 1-year 
prevalence rates reported in the American Migraine Studies. Additionally, Steiner et 
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al. (2003) reported estimates of 1-year prevalence of migraine in the UK by surveying 
a representative sample of the population of mainland England. Steiner and 
colleagues conducted a telephone survey of a random sample (n=4007) of those aged 
16-65 years using a previously validated diagnostic interview. They revealed a 
response rate of 76.5% and reported an overall 1-year prevalence rate of migraine of 
7.6% for males and 18.3% of females.  
Migraine prevalence follows an inverted-U curve with increasing age, commonly 
arising during adolescence and young adulthood. Prevalence peaks in mid-life and 
declines thereafter (Lipton et al., 1999). Overall, prevalence is highest between the 
ages of 25-55 years, the peak years of economic productivity, which may explain the 
significant socioeconomic impact of migraine. The gap between peak incidence of 
migraine in adolescence and peak prevalence in middle life highlights the long 
duration of the condition.  
 
Women are particularly prone to migraine headaches, with a sex ratio for lifetime 
migraine being two to threefold greater among women, a finding consistent across 
countries (Low et al., 2007). However, the lifetime pattern of sex differences in 
migraine does appear to vary with age. Prior to puberty, prevalence of migraine in 
males is found to be equal to or greater than that reported in females. During and 
following adolescence, however, prevalence and incidence of migraine increases more 
rapidly among women. This increased prevalence continues until its peak in the 
fortieth and fiftieth decades and subsequently declines thereafter. The female 
preponderance of migraine has previously been explained, in part, by hormonal 
changes and more specifically, with falling levels or withdrawal of oestrogen (Lichten 
et al., 1996; Whitty et al., 1966).  
Research has suggested that migraine is associated with various psychiatric 
conditions, including BD, major depression and anxiety spectrum disorders (Antonaci 
et al., 2011). For example, a large UK study conducted by Samaan et al. (2009), looked 
to compare the rate of IHS-defined migraine between 1259 individuals with recurrent 
depression and 851 psychiatrically healthy controls, and found migraine to be more 
prevalent in cases than in controls (15% vs. 5.1%, respectively). Moreover, Baptista et 
al. (2012) looked to describe the prevalence of migraine in a clinical sample of 
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psychiatric patients compared to the general population of Venezuela. The authors 
reported an increased rate of migraine within a clinical sample of individuals with 
depression and dysthymia (n=82) (24.5%), and BD (n=191) (15.7%), compared to the 
general population (n=516) (14.9%). Baptista et al., (2012) also reported that the rate 
of migraine in a sample of 132 participants with schizophrenia was significantly lower 
than that reported in the general population (8.3% vs. 14.9%, p=.008). Rates of IHS-
defined migraine were reported to be even higher in a clinical sample of 62 inpatients 
with major affective disorders in a study conducted by Fasmer (2001), who reported 
migraine to be common in both those with unipolar depression (46%) and BD (44%). 
In addition, within their large study exploring the rates of a number of medical illnesses 
in patients with BD (n=1720), major depressive disorder (n=1737) and psychiatrically 
healthy controls (n=1340), Forty et al. (2014) reported increased rates of migraine in 
those with BD (23.7%) and major depression (21.9%) compared to controls (16.5%). 
Whilst these increased rates were found to be significantly increased in the BD group 
only, migraine was noted as being the most prevalent medical condition in those with 
major depressive disorder.  
The risk of suicide may also be increased in individuals with migraine (Arciniegas and 
Anderson, 2002; Breslau, 1992). The presence of psychiatric comorbidity in migraine 
patients has been identified as a risk factor for the transformation of migraine into a 
chronic form (Lipton, 2009). Moreover, migraine with psychiatric comorbidity is 
associated with increased use of healthcare resources. Therefore, identifying these 
comorbidities may result in improved patient management and provide the 
opportunity for individualized treatment targeted at both conditions. The next section 
of this chapter will explore both the clinical and aetiological evidence for overlap 
between migraine and BD.  
 
1.2.1 Evidence of overlap between migraine and bipolar disorder  
1.2.1.1 Clinical and epidemiological studies 
As discussed above, an association between migraine and affective disorder has long 
been recognised, with a wealth of clinical and genetic studies supporting a 
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bidirectional association between unipolar depression and migraine (Bruti et al., 2012). 
Although much of the research within this field traditionally focused on the study of 
unipolar depression, there has been an emerging body of evidence suggesting that 
individuals with bipolar disorder (BD) may also be disproportionately affected by 
migraine.  
In a cross-sectional study involving 62 Norwegian outpatients, Fasmer (2001) looked 
to investigate the prevalence of migraine (diagnosed according to International 
Headache Society criteria) in patients with major affective disorders. Migraine was 
found to be common in both those with major depressive disorder (MDD) (46%), and 
BD (44%). Moreover, within patients with BD, rates of migraine were found to be 
significantly increased in those with bipolar II disorder (BDII) compared to those with 
bipolar I disorder (BDI) (77% vs. 14%, respectively). Whilst rates of migraine were found 
to be similar amongst those with MDD and BD, a later study by Dilsaver et al. (2009) 
in a group of Latino adults with affective disorders (87 with BD and 123 with MDD) 
revealed that patients with BD were 2.9 times more likely to have migraine than those 
with MDD, suggesting that migraine may be more strongly associated with bipolarity. 
In that same year, Dilsaver et al. (2009) reported that a family history of BD (and not 
MDD) was associated with an increased risk of having migraine headaches, regardless 
of the patient’s diagnosis of BD or MDD.  
A number of studies have reported prevalence rates of migraine among individuals 
with BD to be approximately 25%. For example, Mahmood et al. (1999) reported a 
lifetime prevalence of International Headache Society (IHS)-defined migraine of 
25.9% (27% among BD women, 25% among BD men), based on their clinical sample 
of 117 bipolar patients attending a psychiatric outpatient unit. It is important to note, 
however, the 69% response rate of their mail in questionnaire. Whilst this is considered 
an excellent response rate within a psychiatric population, it is possible that a response 
bias exists potentially leading to an over or under-estimation of migraine prevalence. 
However, it is important to note that similar rates of migraine were also observed 
within Ortiz et al's. (2010) community-based study of 323 individuals with BD. They 
described a migraine prevalence of 24.5%, and found a higher prevalence of migraine 
among those with BDII compared to those with BDI (34.8% vs. 19.1%, p=.003). 
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Moreover, they reported that of the 79 subjects with comorbid migraine, 73% had 
migraine with aura (n=58, 17.9% of total sample), two times higher than that reported 
in the general population (Russell and Olesen, 1996).  
Using data derived from the Canadian Community Health Survey, McIntyre et al. 
(2006b) identified 2.4% of the sample as screening positively for BD, and of these, 
24.8% had received a diagnosis of migraine from a physician. Moreover, this was found 
to be significantly higher than the 10.3% of physician-diagnosed migraine observed in 
the general population. The sex-specific prevalence for bipolar subjects was 14.9% for 
males and 34.7% for females; more than twice that of the rate of physician-diagnosed 
migraine among males and females without BD (5.8% and 14.7%, respectively. Using 
data drawn from the Bipolar Disorder Research Network (BDRN); the same participant 
cohort that is reported on in the current thesis, Forty et al. (2014) also explored the 
rate of doctor or health professional-diagnosed migraine within their study of general 
medical comorbidity within BD. Forty and colleagues reported a migraine prevalence 
of 23.7% which was statistically significantly higher than the 16.5% prevalence 
identified within a control group. The reliance on a doctor diagnosis for the 
identification of migraine in the above two studies may have resulted in an 
underestimation of migraine, given that, as already discussed, more than half of 
migraine suffers do not seek medical care for their headaches.  
Low et al. (2003) reported one of the highest rates of migraine within a sample of 108 
individuals with BD, identifying a lifetime prevalence of 39.8%, with an overall 
migraine rate of 64.7% in a subgroup of patients with BDII (11 of 17).  However, it is 
important to note that this finding was based on a clinical sample, where subjects were 
currently receiving treatment in an outpatient psychiatric unit, and so may not be 
generalizable to community settings. Moreover, the clinical population sampled 
within this study may have given rise to inflated rates of migraine due to the increased 
risk of Berkson’s bias, whereby individuals reporting a diagnosis of one disorder are 
more likely to report a diagnosis of (or be diagnosed with) other disorders because of 
their more frequent contact with health professionals (Berkson, 1946). In addition, the 
overrepresentation of women in the sample (67.6%), and the fact that the mean age 
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of the sample matched the peak age of migraine noted with within the general 
population (approximately 40 years), may explain the high rate of migraine reported.  
A recent meta-analysis pooling data from 14 studies, encompassing 3976 individuals 
with BD (mean age 35.5 years, SD 7.6, 71% female), established an overall prevalence 
of migraine of 34.8% (95%CI: 25.54–44.69) (Fornaro and Stubbs 2015). Moreover, as 
suggested by the literature, the meta-analysis corroborated the finding that 
individuals with BDII may be particularly susceptible to migraine, reporting a higher 
prevalence of migraine among those with BDII (54.17%, 95% CI: 31.52–75.95) 
compared to BDI (32.7%, 95% CI: 18.16–49.19, p<.0001). However, Fornaro and Stubbs 
(2015) made a point of emphasizing the inconsistency across studies in their definition 
of BDII, with some broadening the criteria to include those with affective 
temperaments. The meta-analytic study also established higher rates of migraine in 
BD within studies identifying migraine using standardised criteria (e.g. International 
Headache Society) compared to non-standardised criteria/self-report measures 
(47.9% vs. 20%, p=.0001), emphasizing the importance of using recognised criteria in 
order to maximise sensitivity.  
Studies have also revealed differences in the clinical course of the bipolar illness in BD 
patients according to the presence or absence of migraine. A summary of key studies 
exploring the impact of migraine in a bipolar sample can be found in Table 1.4. Within 
Mahmood et al's. (1999) study, mentioned above, an association was found for an 
earlier onset of BD and comorbidity with migraine. An earlier age of onset has been 
associated with a more severe course and poor outcomes in BD (Post et al., 2010), 
suggesting that comorbid migraine in BD may be associated with a more severe illness 
course.  A younger age of onset of BD with comorbid migraine was also reported by 
McIntyre et al. (2006b), however, this finding was true for bipolar males only. Within 
this study, bipolar males were also more likely to have a higher lifetime prevalence of 
comorbid anxiety disorders, and to utilize primary and mental health services. When 
bipolar females with migraine were compared to bipolar females without migraine, 
they were not found to significantly differ on these variables however they did 
experience more comorbid medical disorders, and were more likely to require help 
with personal or instrumental activities of daily living. The sex-specific implications of 
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the BD-migraine comorbidity identified in this study suggest more serious 
implications for males with BD than females.  
Within their 2003 study of the sociodemographic and clinical characteristics 
associated with migraine in BD, Low et al. (2003) found that bipolar subjects with 
migraine: were younger; were more educated; were more likely to be employed or 
studying; had fewer psychiatric admissions; and were more likely to have a family 
history of migraine, and psychiatric disorders. Low et al. (2003) also reported that 
bipolar subjects with comorbid migraine were more likely to have had an index episode 
of depression and to have been treated with an antidepressant. These findings, 
combined with the previously mentioned higher rate of migraine among subjects with 
BDII in this study, suggest that bipolar subjects with comorbid migraine may be more 
vulnerable to the ‘depressions’ of bipolarity. This hypothesis is further supported by a 
more recent study by Brietzke et al. (2012b) who found that in a group of 339 subjects 
with bipolar disorder, those with comorbid migraine experienced more mood 
episodes, particularly those of depressive polarity.  
In an attempt to identify factors and outcomes associated with migraine in BD, 
Saunders et al. (2014) explored clinical correlates associated with self-reported doctor-
diagnosed migraine in 412 individuals with BD. Female sex increased the odds of 
migraine (OR: 3.5, 95% CI: 2.1-5.8), as did a BDII diagnosis (OR: 2.1, 95% CI: 1.2-3.6), 
and a history of mixed symptoms (OR: 2.0, 95% CI: 1.3-3.0). Comorbid migraine was 
also correlated with a greater number of episodes of depression reported at baseline 
(r=0.26, p<.001). Psychosocial factors including emotional and sexual abuse were also 
found to be correlated with migraine in the bipolar sample. Saunders et al. (2014) 
identified gender differences in the clinical correlates of migraine in BD. They reported 
that in bipolar men, comorbid migraine was associated with; BDII (OR: 4.2, 95% CI: 
1.4-12.4), rapid cycling (OR: 3.5, 95% CI: 1.4-8.8), and more depressive symptoms 
(r=0.29, p=.02). Conversely, these associations were not observed in bipolar women 
with comorbid migraine.  
In another study based on a sample of individuals from the Bipolar Disorder Research 
Network (BDRN), Gordon-Smith et al. (2015), also identified rapid cycling as a feature 
of BD and comorbid migraine, supporting the finding observed in males only in the 
35 | P a g e  
 
above study (Saunders et al., 2004). In their large study of 1488 individuals with BD, 
Gordon-Smith et al. (2015) reported that those with comorbid migraine (n=375) were 
nearly twice as likely to have a rapid cycling illness course. In addition, authors 
reported that being female (OR: 2.099, 95% CI: 1.254-3.515, p=0.005), having a rapid 
cycling illness course (OR: 1.888, 95% CI: 1.251-2.848, p=0.002), and a history of panic 
attacks (OR: 1.842, 95% CI: 1.221-2.779 p=0.004) best predicted the presence of 
comorbid migraine in a multivariate model.  
In the study by Ortiz et al. (2010) introduced above, the authors looked to further 
evaluate the relationship between migraine and psychiatric disorders by conducting 
two studies. The first examined clinical and demographic characteristics of BD 
patients with respect to their migraine status, with the second exploring psychiatric 
correlates in a sample of migraine patients. The first study included 323 subjects with 
BD (n=204 with BDI; n=92 with BDII; and n=27 with bipolar spectrum disorders; bipolar 
not otherwise specified, or schizoaffective disorder bipolar type). Migraine 
comorbidity within BD was associated with higher rates of suicidal behavior, social 
phobia, panic disorder and generalized anxiety disorder. Within their second study of 
102 individuals with migraine, Ortiz et al. (2010) identified a 34.4% prevalence of 
current psychiatric diagnosis, increasing to 73.5% for lifetime psychiatric diagnosis. A 
wide range of psychopathology was reported by migraine sufferers, particularly mood 
and anxiety disorders. The authors described an increased frequency in the lifetime 
prevalence of BD in migraine subjects compared to that reported in the general 
population (7.8% for BDII, and 4.9% for BDI). Given that increased rates of migraine 
are reported in BD, and that there is evidence to suggest that rates of BD are increased 
in individuals with migraine, this suggests the potential for a bidirectional relationship 
between migraine and BD, which raises the possibility of a common predisposition to 
both disorders. Moreover, this study also commented on the temporal relationship 
between migraine and psychiatric disorders, noting that a diagnosis of migraine 
preceded psychiatric diagnosis in 78.6% of cases (n=59), whereas a prior psychiatric 
diagnosis was found in only 14.6%, with the remaining 6.7% of diagnoses made within 
the same year.  
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In a large Canadian nationally representative (n=26,984) population-based study, 
Nguyen and Low (2012) examined the association of migraine with different 
combinations of mood episodes (manic episodes alone; depressive episodes alone; 
manic and depressive episodes; controls with no lifetime history of mood episodes), 
as well as exploring sociodemographic and clinical correlates of migraine for each 
migraine–mood episode combination. Compared to the control group who had no 
history of mood episodes, the adjusted odds ratio of having migraine was 2.0 (95% CI 
= 1.4–2.8) for manic episodes alone, 1.9 (95% CI = 1.6–2.1) for depressive episodes 
alone, and 3.0 (95% CI = 2.3–3.9) for subjects with both manic and depressive episodes. 
Moreover, when compared to those subjects with; i) manic episodes alone, and ii) 
depressive episodes alone, the odds of having migraine were significantly increased in 
subjects with both manic and depressive episodes (OR 1.5 vs. manic episodes alone; 
1.8 vs. depressive episodes alone). When focusing on the clinical correlates associated 
with migraine within each mood combination, migraine comorbidity was associated 
with an earlier age of onset of psychiatric illness in subjects with both manic and 
depressive episodes, whereas in those with either manic or depressive episodes alone, 
migraine comorbidity was associated with increased suicidality and anxiety. Such 
differences in the clinical correlates associated with migraine emphasize the 
importance of considering the specific mood episodes experienced when examining 
this comorbid relationship.  
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Table 1.4 Summary of key clinical studies exploring the relationship between comorbid migraine and bipolar disorder 
Study Aims Sample size and 
study design 
Main results Conclusions Limitations 
Mahmood et 
al. (1999) 
To estimate the 
prevalence of 
migraine in people 
suffering from 
bipolar disorder 
(BD) 
Cross-sectional.  
Self-report 
questionnaire 
incorporating IHS 
criteria for migraine 
mailed to 117 
individuals with 
bipolar disorder 
attending a 
psychiatric hospital.  
21 (25.9%) of BD patients met 
IHS criteria for migraine (27% in 
BD women and 25% in BD 
men). 
  
57% (12/21)) of BD patients with 
migraine had their first mood 
episode before the age of 25 
years compared to 36% (16/44) 
of BD patients without 
migraine.  
 
Migraine is increased 
in patients with BD 
compared to those 
within the general 
population and may 
indicate a more 
severe variant of BD.  
Unrepresentative 
clinical sample.  
 
Relatively small 
sample size.  
 
69% response rate, 
therefore there is a 
possibility a 
response bias 
exists.  
 
Self-report 
measure of 
migraine. 
McIntyre et al. 
(2006b) 
To report on the 
prevalence of 
comorbid migraine 
in BD and examine 
the implications for 
bipolar age of 
onset, psychiatric 
comorbidity, 
illness course, 
Cross-sectional, 
population-based 
survey from the 
Canadian 
Community 
Health Survey – 
Mental Health and 
Well-Being (CCHS) 
(n=36,984). 
2.4% of the sample met criteria 
for bipolar I disorder. 
 
Migraine prevalence was 
significantly greater in those 
with BD compared to those in 
the general population (24.8% 
vs. 10.3%). The sex-specific 
prevalence of comorbid 
Migraine 
differentially affects 
people with BD in 
the general 
population and may 
have more serious 
implications for 
males with BD than 
females with BD.  
Self-report 
measure of BD and 
migraine.  
 
Doctor diagnosis of 
migraine (did not 
adhere to IHS 
criteria for 
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Study Aims Sample size and 
study design 
Main results Conclusions Limitations 
functional 
outcome, and 
medical service 
utilization. 
migraine in BD was 14.9% for 
males and 34.7% for females.  
Bipolar males with migraine had 
greater psychosocial 
impairment, reported an earlier 
age of onset of bipolar disorder, 
and had a higher lifetime 
prevalence of comorbid anxiety 
disorders. Bipolar females with 
comorbid migraine had more 
comorbid medical disorders and 
were more likely to require help 
with daily living compared to 
BD females without migraine.  
 
 
migraine 
diagnosis).   
 
Assessed 
individuals with 
bipolar I disorder 
only.  
 
Analysis was 
conducted post-
hoc 
Low et al. 
(2003) 
To investigate the 
prevalence, clinical 
correlates and 
treatment of 
migraine in BD.  
Cross-sectional 
survey employing a 
face-to-face 
interview involving 
the completion of a 
questionnaire based 
on diagnostic criteria 
of the IHS to 108 
patients within an 
outpatient 
psychiatric facility.  
39% (n=43) BD patients met 
criteria for migraine (43.5% of 
women and 31.4% of men). 
Prevalence of migraine in the 
bipolar II disorder (BDII) group 
was 64.7%.  
 
23 BD patients 53.5% of those 
with migraine) met criteria for 
migraine with aura.  
 
BD with migraine is 
associated with a 
distinct set of clinical 
characteristics and 
may represent a 
subtype of BD. BD 
patients with 
migraine may suffer 
more from the 
‘depressions’ of 
bipolarity as 
indicated by the 
Unrepresentative 
nature of the 
clinical sample.  
 
Relatively small 
sample size.  
 
Overrepresentation 
of women in the 
sample (67.6%).  
 
39 | P a g e  
 
Study Aims Sample size and 
study design 
Main results Conclusions Limitations 
BD patients with migraine were: 
younger; more likely to be 
educated and employed; more 
likely to have an index episode 
of depression and to be treated 
with antidepressants; and had 
fewer psychiatric admissions.  
higher rate of BDII 
and the high 
proportion of 
patients initially 
presenting with 
depression.  
Potential for recall 
bias.  
Brietzke et al. 
(2012b) 
To evaluate the 
difference in 
severity of clinical 
course between 
BD subjects with 
and without 
migraine.  
 
Cross-sectional study 
of 339 individuals 
with BD.  
 
Data was collected 
from baseline 
assessments 
of individuals with 
BD, enrolled in a 
standardized 
programme of 
naturalistic BD 
follow-up, from 3 
outpatient specialist 
treatment centers in 
Brazil.  
 
Presence of migraine 
was defined 
33.9% (n=115) BD subjects had 
received a diagnosis of migraine 
from a doctor. Significantly 
higher rate of women in the BD 
with comorbid migraine group. 
  
BD subjects with comorbid 
migraine experienced more 
mood episodes, particularly 
those of a depressive polarity.  
 
More severe illness course in BD 
subjects with comorbid 
migraine defined by: presence 
of a rapid cycling illness course, 
number of overall mood 
episodes, number of depressive 
episodes, and lifetime number 
of psychiatric hospitalizations. 
Comorbid migraine 
alters the clinical 
course of the bipolar 
illness and is a 
correlate of BD 
severity. 
 
The adequate 
treatment of 
migraine may have a 
beneficial long-term 
impact for patients 
who have both 
conditions. 
Doctor diagnosis of 
migraine 
determined by self-
report.  
 
Analysis was 
conducted post-
hoc.  
 
Findings based on 
an 
unrepresentative 
clinical sample.  
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Study Aims Sample size and 
study design 
Main results Conclusions Limitations 
according to whether 
the subject had a 
previous diagnosis 
from a doctor.   
However, these differences 
were not observed after 
correction for multiple 
comparisons.  
 
Saunders et 
al. (2014) 
To examine gender 
differences in the 
impact of migraine 
on the clinical 
course and 
outcomes in BD.  
 
 
A retrospective study 
of 412 patients with 
BD (bipolar I and II 
disorder, 
schizoaffective 
bipolar type) and 157 
healthy controls 
from the Pretcher 
Longitudinal Study 
of Bipolar Disorder 
2005-2009.  
 
Presence of migraine 
was determined 
according to a self-
reported diagnosis of 
migraine from a 
doctor.  
Migraine was significantly more 
likely in subjects with BD 
compared to controls (31% vs. 
6%).  
 
Female sex increased odds of 
migraine (OR 3.5, 95% CI 2.1-
5.8), as did a bipolar II diagnosis 
(OR 2.1, 95% CI 1.2-3.6), and a 
history of mixed symptoms (OR 
2.0, 95% CI 1.3-3.0). Comorbid 
migraine was correlated with a 
greater number of episodes of 
depression reported at baseline 
and psychosocial factors 
including emotional, and sexual 
abuse.  
 
In bipolar men, comorbid 
migraine was associated with; 
bipolar II disorder (OR 4.2, 95% 
Migraine is highly 
prevalent in BD, 
particularly in 
females with BD and 
particularly in those 
with BDII.  
 
Clinicians should be 
encouraged to 
recognise migraine 
in BD in an attempt 
to improve the long-
term prognosis of 
the disorder.  
Self-report doctor 
diagnosis of 
migraine.  
 
Subjects were part 
of a longitudinal 
study and thus may 
not represent more 
severe forms of the 
disorder.  
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Study Aims Sample size and 
study design 
Main results Conclusions Limitations 
CI 1.4-12.4), rapid cycling (OR 
3.5, 95% CI 1.4-8.8), and more 
depressive symptoms (r=0.29, 
p=.02). These associations were 
not observed in bipolar women 
with comorbid migraine.  
Gordon-
Smith et al. 
(2015) 
To determine 
clinical 
characteristics 
associated with 
comorbid migraine 
in a large, 
representative, UK 
sample of 
individuals with 
clinically well-
characterised BD.  
Cross-sectional study 
of 1488 individuals 
with BD; n=1120 with 
BDI and n=368 with 
BDII  
 
History of migraine 
was assessed via two 
different methods: a) 
doctor diagnosis of 
migraine and b) self-
report questionnaire 
designed to 
incorporate IHS 
criteria for migraine 
diagnosis.  
25.2% (n=375) BD subjects had a 
diagnosis of migraine (n=118 
according to the self-report 
questionnaire, and n=257 
according to a self-reported 
doctor diagnosis.  
 
A multivariate model revealed 
that BD subjects with comorbid 
migraine were significantly 
more likely to be female 
(OR=2.099, p=0.005), have 
comorbid panic attacks 
(OR=1.842, p=0.004), and have 
a rapid cycling illness course 
(OR=1.888, p=0.002). 
Comorbid migraine 
in BD may delineate 
a more homogenous 
subtype of BD with 
an unstable rapid 
cycling course.  
 
Identifying 
individuals with BD 
and comorbid 
migraine may be of 
use in a clinical 
setting and this 
subgroup could be 
the focus of future 
aetiological studies.    
Migraine was 
assessed using self-
report methods 
and the 
measurement of 
migraine was not 
consistent, with the 
study employing 
two different 
measures of 
migraine.  
 
Overrepresentation 
of BDI cases.  
Ortiz et al. 
(2010) 
To evaluate the 
relationship 
between migraine 
and psychiatric 
Community-based, 
cross-sectional 
studies: 
 
Study 1: 24.5% of the BD 
sample had comorbid migraine 
and this was significantly 
greater in those with BDII 
There exists a 
bidirectional 
relationship between 
migraine and BD.  
Diagnosis of 
migraine in study 1 
was made via 
means of a self-
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Study Aims Sample size and 
study design 
Main results Conclusions Limitations 
disorders by 
conducting two 
related studies.  
 
The first looked to 
explore clinical and 
demographic 
characteristics of 
BD patients with 
respect to their 
migraine status.  
 
The second study 
examined 
psychiatric 
correlates in a 
sample of migraine 
patients. 
Study 1: 323 subjects 
with BD (n=204 with 
bipolar I disorder; 
n=92 with bipolar II 
disorder; and n=27 
with bipolar 
spectrum disorders; 
bipolar not otherwise 
specified, or 
schizoaffective 
disorder bipolar 
type). Diagnosis of 
migraine was made 
via a self-report 
standardized 
questionnaire 
following guidelines 
of the IHS.  
 
Study 2: 102 
individuals with 
migraine interviewed 
at a specialty 
migraine clinic where 
the migraine 
compared to BDI (34.8% vs. 
19.1%, respectively). 73% of 
migraine subjects (n=58, 17.9% 
of total sample had migraine 
with aura).  
Migraine comorbidity within BD 
was associated with higher 
rates of; suicidal behavior, 
social phobia, panic disorder 
and generalized anxiety 
disorder. 
 
Study 2: 34.4% of the migraine 
sample had a current 
psychiatric diagnosis, with 
73.5% having a lifetime 
psychiatric diagnosis. A wide 
range of psychopathology was 
reported, particularly for mood 
and anxiety disorders.  
 
There was an increased rate of 
lifetime BD migraine subjects 
compared to that reported in 
the general population (7.8% for 
 
Migraine 
comorbidity in BD is 
associated with an 
increased risk of 
suicidal behaviour 
and comorbid 
anxiety disorders 
report 
questionnaire.  
 
Study 2 was 
conducted in a 
clinical setting and 
therefore may 
represent more 
chronic and severe 
forms of migraine.   
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Study Aims Sample size and 
study design 
Main results Conclusions Limitations 
diagnosis is based on 
the IHS criteria.  
bipolar II disorder, and 4.9% for 
bipolar I disorder). 
Nguyen and 
Low (2012) 
To examine the 
lifetime 
comorbidity and 
clinical correlates 
of migraine with 
different 
combinations of 
mood episodes: (1) 
manic episodes 
alone; (2) 
depressive 
episodes alone; (3) 
manic and 
depressive 
episodes; (4) 
controls with no 
lifetime history of 
mood episodes.  
Cross-sectional, 
population-based 
sample from the 
Canadian 
Community Health 
Survey 1.2 
(n = 36,984).  
 
BD was diagnosed 
according to DSM-IV 
criteria using the 
World Mental Health 
Composite 
International 
Diagnostic Interview 
(CIDI). 
 
Presence of migraine 
was indicated by the 
presence of a self-
reported prior 
diagnosis from a 
health professional.  
 
The lifetime prevalence of 
migraine in BD (groups 1 and 3 
combined) was 24.3%.  
 
Compared with controls (groups 
4), the odds of having migraine 
were 2.0 (95% CI = 1.4–2.8) for 
manic episodes alone, 1.9 (95% 
CI = 1.6–2.1) for depressive 
episodes alone, and 3.0 (95% CI 
= 2.3–3.9) for subjects with both 
manic and depressive episodes.  
 
When compared with those 
with; manic episodes alone, and 
depressive episodes alone, the 
odds of having migraine were 
significantly increased in 
subjects with both manic and 
depressive episodes (OR 1.5 vs. 
manic episodes alone; 1.8 vs. 
depressive episodes alone).  
 
Migraine 
comorbidity in BD 
identifies a subset of 
individuals with 
earlier onset of 
affective illness and 
more psychiatric 
comorbidity and 
suggests that 
migraine may be 
used as an indicator 
of illness severity.  
 
Differences were 
found in the clinical 
correlates of 
migraine 
comorbidity 
depending on the 
specific combination 
of mood episodes 
experienced.  
Migraine status 
was not assessed 
according to IHS 
criteria.  
 
Post-hoc 
retrospective 
design. 
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Study Aims Sample size and 
study design 
Main results Conclusions Limitations 
Migraine comorbidity was 
associated with an earlier onset 
of psychiatric illness in subjects 
with both manic and depressive 
episodes (group 3), whereas in 
those with either manic or 
depressive episodes alone 
9groups 1 and 2), migraine 
comorbidity was associated 
with increased suicidality and 
anxiety 
BD=bipolar disorder; BDI=bipolar I disorder; BDII=bipolar II disorder; IHS=International Headache Society; MA=migraine with aura.  
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To summarise, it can be seen from the above studies that varying rates of 
migraine have been reported within individuals with BD (not specifying bipolar 
subtype), ranging from approximately 24% to 44% (Ortiz et al., 2010; McIntyre 
et al., 2006b; Mahmood et al., 1999; Gordon-Smith et al., 2015; Low et al., 2003; 
Fasmer, 2001). A recent meta-analysis reported a pooled prevalence of migraine 
of 34.8% based on 14 studies and accounting for 3976 individuals with BD 
(Fornaro and Stubbs, 2015). A more consistent finding is the increased 
prevalence of migraine in individuals with BDII compared to those with BDI 
(Fasmer, 2001; Ortiz et al., 2010; Saunders et al., 2014), a finding supported by 
the recent meta-analysis reported by Fornaro and Stubbs (2015). A number of 
studies have also identified differences in the clinical profile of bipolar patients 
according to their history of migraine. The reported clinical characteristics 
associated with migraine comorbidity within BD include: an earlier onset of the 
bipolar illness (McIntyre et al., 2006b; Mahmood et al., 1999); an increased 
number of mood episodes (Brietzke et al., 2012b; Saunders et al., 2014); a 
history of comorbid anxiety disorder (Ortiz et al., 2010; Gordon-Smith et al., 
2015; McIntyre et al., 2006b); and a rapid cycling course of illness (Gordon-Smith 
et al., 2015; Saunders et al., 2014).  
Interestingly, previous studies have identified differences in the psychiatric 
comorbidity of the migraine subtypes, migraine with aura (MA) and migraine 
without aura (MoA), where it has been suggested that MA may have a stronger 
association with psychiatric disorders than MoA (Breslau et al., 1991; Samaan et 
al., 2009).  For example, in a prospective study, MA was reported to have a 
stronger association with major depression than MoA (OR 4.9; 95% CI 3.34-7.19 
vs. OR 3, 95% CI 2.23-4.14, respectively) (Breslau et al., 2000). Similarly, 
Oedegaard et al. (2005a) found that depression alone, and depression with 
comorbid anxiety were more likely in women having MA than MoA, however 
there was no difference in the prevalence of depression and anxiety disorders 
between MA and MoA in men. In addition, Breslau et al. (1991) observed 
significantly increased rates of BD and panic disorder in patients with MA when 
compared to migraine free individuals; however, this was not the case for the 
MoA group. Of particular concern is the association of MA with suicide attempt. 
In 1991, Breslau et al. reported an association of MA and MoA with suicide 
attempt when associated with major depressive disorder (MDD). However, after 
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adjusting for the presence of MDD and other psychiatric and substance use 
disorders, the association remained significant for the MA group only. In a later 
study, Breslau (1992) observed an increased risk for both suicidal ideation and 
suicide attempt in patients with MA alone and patients with MA with coexisting 
MDD, compared to those with neither MDD nor migraine. Thus, it appears that 
there are important differences in the comorbid expression of migraine and 
psychopathology, particularly for affective pathology, dependent on migraine 
subtype. 
To date, much of the research exploring the clinical characteristics of BD 
associated with migraine (described above) has not distinguished between 
migraine with (MA) and without aura (MoA). In 2005, Oedegaard and colleagues 
looked to further characterise the relationship of migraine with affective 
disorders (including unipolar, BDI and BDII subjects) by exploring the clinical 
correlates of MA, migraine aura without subsequent headache, MoA, and no 
migraine (Oedegaard et al., 2005b). Whilst the authors reported overall group 
differences across the four migraine subtypes, the main focus of the paper was 
to make comparisons between individuals with MA vs. migraine aura without 
headache. When comparing the four groups of migraine sufferers, significant 
differences were found for gender distribution, the distribution of unipolar, 
bipolar I and II disorders, rate of affective temperaments, suicide attempt and 
frequencies of reported irritability during depression. When differentiating MA 
from migraine aura without headache, significant differences were found for 
age of migraine onset, affective temperament and suicide attempt, with 
multivariate analysis revealing a significant association between age of 
migraine onset and affective temperament.  
 
1.2.1.2 Pathophysiology and genetics 
One potential explanation for the association between bipolar disorder (BD) and 
migraine could be a shared underlying pathophysiology. The possibility of 
common neurobiological pathways between BD and migraine are suggested by 
the overlap in the pharmacological treatment used to treat both disorders. For 
example, valproate, an anti-epileptic drug well-established for the maintenance 
treatment in BD, has also been shown to have a prophylactic effect in migraine, 
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reducing the number of attacks, duration of headache and intensity of pain 
(Silberstein, 1996). The neurobiological mechanisms underlying the association 
between these disorders remain unknown, however both have been linked to 
disturbances in the serotonergic (Hamel, 2007; Mahmood and Silverstone, 2001; 
Silberstein, 1994), dopaminergic (Emilien et al., 1999; Peroutka, 1997), and 
glutaminergic systems (Vaccaro et al., 2007). Moreover, Brietzke et al. (2012a) 
reviewed evidence implicating disturbances in inflammatory cytokines within 
both disorders.  
Further evidence of common biological mechanisms has come from research 
demonstrating the involvement of ion channels within both BD, and migraine.  
The aetiology of migraine is not fully understood, however, like BD it is 
considered to be a complex polygenic multifactorial disorder, with estimates of 
heritability ranging between 40%-65% (Larsson et al., 1995; Ziegler et al., 1998). 
Much of the progress in identifying genetic susceptibility to migraine has come 
from findings from the genetic architecture of the autosomal dominantly 
inherited migraine subtype, familial hemiplegic migraine (FHM). As previously 
described, hemiplegic migraine (HM) is a subtype of migraine with aura, in 
which migraine attacks are associated with motor weakness and may present in 
isolation (sporadic; SHM) or with a family history (at least one first or second-
degree relative) of similar attacks (familial; FHM). Hemiplegic migraine is rare, 
with a Danish population-based epidemiological survey indicating the 
prevalence of sporadic hemiplegic migraine to be approximately 0.002% and 
familial hemiplegic migraine 0.003% (Thomsen et al., 2002). FHM is genetically 
heterogeneous, and variants in at least three genes have so far been implicated. 
FHM1 is caused by mutations in the calcium channel gene CACNA1A (Ophoff et 
al., 1996), and is estimated to account for approximately 50% of all FHM families 
(Ducros et al., 2001). In 2003, a second locus was discovered with the 
identification of more than 30 mutations identified in the sodium/potassium 
pump gene ATP1A2 (FHM2) (DeFusco et al., 2003). Finally, mutations on 
chromosome 2q24 within the neuronal voltage-gates sodium channel gene 
SCN1A were identified in 2005 (FHM3) (Dichgans et al., 2005). All three FHM 
genes either encode ion channels or are involved in ion transportation, thus 
highlighting the importance of ion channels in the molecular mechanism of 
migraine and supporting the hypothesis of migraine as a ‘channelopathy’. 
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Whilst these specific FHM genes have not been implicated in studies of BD, as 
already described within this chapter, two of the strongest associations to come 
out of genome-wide association studies of BD have been for two genes involved 
in ion transportation (ANK3 and CACNA1C), suggesting that disturbances in ion 
channel function are relevant for both migraine and BD.  
It has been discovered that individuals with hemiplegic migraine (HM) are found 
within the same families as those with non-hemiplegic forms of migraine 
(Launer et al., 1999), and that HM patients can also experience non-HM attacks 
(Carrera et al., 2001). It is therefore plausible to postulate that hemiplegic and 
common migraine subtypes share pathogenic mechanisms, making the 
Mendelian model of FHM useful in the study of non-hemiplegic migraine. Whilst 
the known FHM genes have been studied in the more common forms of 
migraine, with (MA) and without aura (MoA), their role is debated, and strong 
evidence is currently lacking to implicate them in common migraine subtypes 
(Wessman et al., 2007).  
A small number of studies have been conducted to explore potential genetic 
susceptibility regions for the combined migraine-bipolar phenotype. For 
example, a genome-wide linkage study on 31 families (n=202) identified an 
overlapping locus on chromosome 20p11 for both BD and migraine, a region 
harbouring a gene involved in calcium homeostasis (SLC24A3) (Oedegaard et al. 
2010b). To date, two genome-wide association studies (GWAS) have been 
published using the BD-migraine phenotype. The first found evidence of 
association for several single-nucleotide polymorphisms approaching the 
threshold for genome-wide significance (p=5 x 10-8) on chromosome 13q14.1, in 
a region containing the uncharacterised gene KIAA0564 (Oedegaard et al. 
2010a), suggesting that the BD-migraine combined phenotype has the potential 
to reclassify individuals into a more homogeneous genetic subgroup. However, 
these findings must be treated with caution given that they are based on a very 
small sample of 56 bipolar subjects with a doctor diagnosis of migraine. A 
second GWAS involved 460 bipolar subjects with self-reported migraine (cases) 
and 914 bipolar subjects without migraine (controls) (Jacobsen et al., 2015). This 
study identified a genome-wide significant association for rs1160720 in the 
NBEA gene (p= 2.97×10-8). This variant failed to show association with migraine 
or BD individually, leading authors to speculate the aetiological specificity of 
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this gene to the combined phenotype and to hypothesize that BD with comorbid 
migraine may be a distinct syndrome with different genetic risk factors than for 
either migraine, or BD alone.  
 
1.2.2 Summary 
The evidence reviewed above suggests that migraine is frequently comorbid 
with bipolar disorder (BD), and that migraine comorbidity may delineate a 
subset of BD patients with a distinct set of clinical outcomes. Recognition and 
targeted treatment for migraine in bipolar patients may improve course of 
illness and prognosis in BD. Further research unravelling the complex 
relationship between migraine and BD, with a particular focus on the individual 
subtypes of migraine, will help us to better understand and characterise the 
clinical features of this comorbidity and to identify subpopulations of individuals 
with BD that could benefit clinically from more effective, targeted diagnostic 
and treatment strategies. Current evidence also provides support for the use of 
a refined bipolar phenotype including comorbid migraine, pointing to common 
biological mechanisms between the two disorders. However, given the caveats 
of small samples and the lack of standardised criteria for migraine diagnosis 
involved in these studies, it is clear that more work in this area is needed. 
 
1.3    Introduction to epilepsy 
Epilepsy is a chronic disorder of the brain, where there is a tendency for the 
occurrence of unprovoked epileptic seizures. Epilepsy is one of the most 
common neurological conditions in the world, affecting approximately 50 
million people worldwide (WHO, 2016, fact sheet updated February 2016). Eight 
percent of those affected by epilepsy are in developing countries and within 
these countries approximately 75% of people with epilepsy are not receiving 
appropriate treatment (WHO, 2016; fact sheet updated February 2016). In the 
UK, approximately 600,000 people have a diagnosis of epilepsy and take anti-
epileptic drugs, which is equivalent to approximately 1 in 103 people. The 
prevalence rate of epilepsy in the UK is approximately 9.7 per 1000 or 0.97% 
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(Joint Epilepsy Council, 2011). Using a meta-analytic approach, (Ngugi et al., 
2010) estimated the median prevalence of active epilepsy within developed 
countries to be 4.9 per 1000, and the median lifetime prevalence to be 5.8 per 
1000.  The lifetime prevalence of seizures (i.e. the risk of having a non-febrile 
epileptic seizure at some point in an individual’s lifetime) is higher, and is noted 
to be between 2 and 5% (Neligan and Saunder, 2009). The incidence of epilepsy 
is consistently reported to be higher in males than in females, however this 
difference is rarely found to reach statistical significance (Banerjee and Hauser, 
2008). A systematic review of incidence studies reported the median annual 
incidence of epilepsy to be 50.7 per 100,000 for males and 46.2 per 100,000 for 
females (Kotsopoulos et al., 2002). Although epilepsy is found in all age groups, 
it is said to more frequently affect people within the first two decades of life, and 
people over the age of 60 years (Sander, 2003). Figure 1.1 illustrates the UK 
incidence of epilepsy by age, for males and females. 
 
 
Figure 1.1 Incidence of epilepsy by age for males and females. (Image taken 
from: Joint Epilepsy Council. 2011. Epilepsy prevalence, incidence and other 
statistics [online]. http://www.epilepsyscotland.org.uk/pdf/Joint_Epilepsy_
Council_Prevalence_and_Incidence_September_11_(3).pdf). 
 
There is no test for epilepsy; consequently, a diagnosis of epilepsy relies largely 
on history taking, and patient and eyewitness accounts of the seizure. 
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Investigations conducted at the time of examination such as, neuroimaging 
techniques including magnetic resonance imaging (MRI) and computerised 
tomography (CT) scans, and electroencephalogram (EEG), can be helpful in 
establishing epilepsy as the likely cause of the seizure, or for the localization of 
the epileptogenic zone. However, the results of these tests can often be normal 
despite certainty in the diagnosis of epilepsy. For example, within a prospective 
study of 158 patients attending a neurology outpatients (referred following a 
loss of consciousness, or on the basis of having possible epilepsy), neuroimaging 
revealed a relevant abnormality in 12/43 (27.9%) patients, and the yield from 
EEG was 7/25 (28%) of those with epilepsy (although EEG result changed the 
diagnosis in only one case) (Angus-Leppan, 2008). Such findings emphasize the 
invaluable clinical contribution in the diagnosis of epilepsy. Given the lack of any 
form of diagnostic test, it is unsurprising that diagnostic accuracy is a problem. 
Within a population-based study of 214 individuals with a primary diagnosis of 
epilepsy, misdiagnosis rates of 23% were reported (Scheepers et al., 1998). 
Moreover, within a retrospective study of n=184 adults referred with ‘refractory 
epilepsy’ to a UK specialist clinic, Smith et al. (1999) estimated the rate of 
misdiagnosis to be 26.1%. Psychogenic non-epileptic attacks, and syncope are 
two of the most common conditions misdiagnosed as epilepsy. Other 
differential diagnoses of epilepsy include: hypoglycemia; panic attacks; 
paroxysmal movement disorders; paroxysmal sleep disorders; transient 
ischemic attacks (TIA); migraines; and transient global amnesia (TGA) 
(Benbadis, 2009).  
 
Epilepsy is not a single condition, but rather a large and diverse group of 
disorders, having in common an abnormally increased predisposition to 
seizures, and as such many people prefer to use the term ‘the epilepsies’. Whilst 
recognising the diversity of the disorder, the singular term ‘epilepsy’ will 
continue to be used throughout this thesis. The International League against 
Epilepsy (ILAE) made a major contribution to the field when it first introduced 
standardized classifications and terminology for seizures (Commission on 
Classification and Terminology of the International League Against Epilepsy, 
1981) and epilepsy (Commission on Classification and Terminology of the 
International League Against Epilepsy, 1989), which were largely based on 
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seizure manifestations and EEG findings. Since their introduction, advances in 
neuroimaging and genetics have had a substantial impact on our understanding 
of epilepsy and as such, facilitated the need for a revision of the original 
classification systems. In 2010, the first radical overhaul of the organization of 
epilepsy was published, focusing on updating terminology in line with current 
understanding (Berg et al., 2010). Moreover, in 2005, the ILAE commissioned a 
Task Force to formulate conceptual definitions of “seizure” and “epilepsy” 
recognising the need for purposes of clinical diagnosis (Fisher et al., 2005). 
These definitions can be found in Table 1.5.   
 
Table 1.5 International League Against Epilepsy conceptual definition of a 
seizure and epilepsy (Fisher et al., 2005) 
Epileptic seizure A transient occurrence of signs 
and/or symptoms due to abnormal 
excessive or synchronous neuronal 
activity in the brain. 
Epilepsy  A disorder of the brain characterized 
by an enduring predisposition to 
generate epileptic seizures, and by 
the neurobiological, cognitive, 
psychological, and social 
consequences of this condition. 
 
The above definition of epilepsy was traditionally applied as having two 
unprovoked seizures occurring at least 24 hours apart (Hauser et al., 1991). 
However, this operational definition was considered too restrictive and the ILAE 
Task Force were encouraged to consider altering the definition to include 
circumstances that do not meet the two unprovoked seizures criteria. In 
response to this, the task force proposed that epilepsy should be considered 
under any of the following conditions: 1. At least two unprovoked seizures 
occurring more than 24 hours apart; 2. One unprovoked seizure and a 
probability of further seizures similar to the general recurrence risk after two 
unprovoked seizures (approximately 75% or more) (circumstances occurring 
with remote structural lesions, such as stroke, central nervous system infection 
and certain types of traumatic brain injury) and; 3. At least two seizures in a 
setting of reflex epilepsy (for example photosensitive seizures). The new 
definition was introduced in order to encourage clinicians to give greater 
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consideration to recurrence risk following a single unprovoked seizure, making 
it more acceptable to begin treatment in the special circumstances outlined 
above. However, the task force did acknowledge that whilst the revised 
operational definition may be useful for clinical purposes, it may not be suitable 
for all research studies that may lack sufficient evidence or knowledge of risk of 
recurrence. Therefore, it is recognised that within any scientific study or 
publication most diagnoses of epilepsy are likely to still be made using the 
traditional ‘two unprovoked seizure’ criterion.  
According to the 2010 organisation of epilepsy (Berg et al., 2010), seizures are 
broadly categorised into two main groups; focal and generalised (support for 
which has been provided from ictal and inter-ictal EEG). Generalised seizures are 
described as “originating at some point within, and rapidly engage, bilaterally 
distributed networks. Such bilateral networks can include cortical and 
subcortical structures, but do not necessarily include the entire cortex” (Berg et 
al., 2010). Focal seizures are described as “originating within networks limited 
to one hemisphere, which may be discretely localized or more widely 
distributed” (Berg et al., 2010). Focal seizures can spread within the same 
hemisphere, and to areas in the contralateral hemisphere, evolving into a 
generalized seizure. The initial presenting symptomatology of focal seizures 
depends on where in the brain the seizure activity originates, and will often 
reflect the functional role of that part of the cortex. For example, a patient 
experiencing a seizure originating from the temporal lobe may experience 
sensory changes including, amnestic sensations (for example, déjà vu or jamais 
vu), hallucinations (including visual, auditory and olfactory), and emotional 
disturbance (for example intense feelings of euphoria, fear or anger). Within the 
1989 classification, focal seizures were further classified into ‘simple’ or 
‘complex’, depending on the impairment of consciousness. However, in Berg et 
al.’s (2010) reorganization, these terms were abandoned due to the difficulty in 
the judgment of awareness during a seizure. The distinction between focal and 
generalised seizures was first introduced within the original 1989 classification, 
and whilst Berg et al. (2010) considered it useful to maintain this terminology, 
they acknowledged its restrictions and accepted that there are many cases 
where this dichotomy is not meaningful (Berg and Scheffer, 2011). Figure 1.2 
depicts the ILAE 2010 classification of seizures (Berg et al., 2010).  
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The 2010 classification also looked to update the aetiological categories 
proposed by the original classification, to reflect our increased understanding of 
epilepsy. Berg et al. (2010) introduced the aetiological categories of; genetic, 
structural/metabolic, and unknown, replacing the outdated ‘idiopathic’, 
‘symptomatic’ and ‘cryptogenic’ categories.  A comparison of these aetiological 
categories is outlined in Table 1.6. Within the 2010 classification, Berg et al. 
(2010) also re-established the concept of ‘electroclinical syndromes’ defined as 
a complex set of clinical features, signs, and symptoms that together constitute 
a distinctive, recognizable clinical disorder. Electroclinical syndromes are 
characterized on the basis of a typical age at onset, seizure types, and EEG 
characteristics, permitting this specific diagnosis which has implications for 
treatment and management.  
  
 
 
 
  
Figure 1.2 International League Against Epilepsy classification of seizures (Berg et al., 
2010) 
Unprovoked recurring seizures 
Generalised 
Absence Myoclonic Tonic-clonic Clonic Atonic 
Focal Unknown 
Epileptic spasms 
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Table 1.6 Comparison of aetiological categories proposed by the 1989 
Classification and Terminology, and the newly proposed Terminology and 
Concepts (Commission on Classification and Terminology of the International 
League Against Epilepsy, 1989; Berg et al., 2010) 
 
ILAE 1989 Classification ILAE 2010 Classification 
Idiopathic No underlying cause 
other than a 
possible hereditary 
predisposition. 
Genetic A direct result of a 
known or presumed 
genetic defect(s) in 
which seizures are the 
core symptom of the 
disorder. 
Symptomatic A consequence of a 
known/suspected 
disorder of the 
central nervous 
system 
Structural/ 
metabolic 
A distinct other 
structural or metabolic 
condition or disease 
that has been 
demonstrated to be 
associated with a 
substantially increased 
risk of developing 
epilepsy. These 
disorders may be of 
acquired or genetic 
origin. When of 
genetic origin, there is 
a separate disorder 
interposed between 
the gene defect and 
the epilepsy. 
Cryptogenic A disorder whose 
cause is hidden. 
Cryptogenic 
epilepsies are 
presumed to be 
symptomatic 
Unknown The nature of the 
underlying cause is as 
yet unknown; it may 
have a fundamental 
genetic defect at its 
core or it may be the 
consequence of a 
separate 
metabolic/structural 
disorder not yet 
identified.  
 
 
Epilepsy is a chronic but treatable condition. Although some epilepsies remit at 
puberty (for example childhood absence and benign rolandic epilepsy), most are 
long-term, meaning that treatment is often lifelong. The goal of treatment is to 
achieve a seizure-free status without adverse effects and the mainstay of 
treatment is the use of antiepileptic drugs (AEDs). In the UK, up to 70% of people 
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developing epilepsy should expect to become seizure free with optimum 
antiepileptic drug (AED) treatment (Sander, 2004). However, a population-
based community study by Moran et al. (2004) revealed that of 1652 people with 
epilepsy in the UK, only 52% had been seizure-free in the preceding year, with 
seizures remaining uncontrolled in 48%, and these individuals reporting 
significant impact on their work, family and social life. These figures suggest 
that approximately 18% of epilepsy patients who could potentially be seizure-
free may be receiving suboptimal treatment. Within this same study, Moran et 
al. (2004) assessed the pattern of utilization of AEDs for epilepsy in the 
community sample, revealing that the most commonly used AEDs were: 
carbamazepine (37.4%); valproate (35.7%); phenytoin (29.4%); phenobarbitone 
(14.2%); and lamotrigine (10.3%). Moreover, monotherapy was used in 68% of 
patients. Within an earlier study by Hart and Shorvon (1995) that described AED 
utilization in 1051 patients with epilepsy from UK primary care services, the 
most frequently used drugs were: phenytoin (33%); carbamazepine (30%), 
valproate (25%); and phenobarbital (9%). Sixty-five percent of epilepsy patients 
were on monotherapy in this study, a figure very similar to that reported by 
Moran and colleagues 20 years later. However, it does appear that there was 
considerable difference in the particular agents used within monotherapy. 
Moran et al. (2004) noted that valproate (33%) and carbamazepine (31%) were 
the most commonly used drugs in monotherapy, followed by phenytoin (24%) 
and phenobarbital (5%), and that these accounted for 93% of all AEDs used for 
monotherapy. In Hart and Shorvon’s (1995) study, these four AEDs accounted 
for 97%, suggesting that the introduction of newer AEDs such as, topiramate 
and gabapentin, had only a modest impact.  
 
As described above, not all of those treated with AEDs will achieve seizure 
freedom. The International League Against Epilepsy (ILAE) defines drug-
resistant epilepsy as ‘‘failure of adequate trials of two tolerated, appropriately 
chosen and used antiepileptic drug schedules (whether as monotherapies or in 
combination) to achieve sustained seizure freedom’’ (Kwan et al., 2010). One 
option for those that do not respond to AED therapy is epilepsy surgery, which 
aims to eliminate or reduce the frequency of epileptic seizures by removing the 
epileptogenic zone.  
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Epilepsy imposes a substantial burden on both the individual and wider society. 
For example, Begley et al. (2000) estimated the total cost of epilepsy in the 
United States to be $12.5 billion, with the majority of the expenditure 
attributable to indirect costs; such as those related to other disabilities and 
socioeconomic losses. Research also suggests that people with epilepsy are high 
users of healthcare services (Wiebe et al., 1999) contributing to the high 
economic burden associated with the disorder. In addition to the measurable 
impact of these disorders on society, it is also essential to consider the intangible 
costs and devastating consequences on the individual and their family. The 
impact of epilepsy extends far further than the clear adverse implications on 
health. Seizures, and importantly the potential for recurrence of seizures have 
considerable cognitive, psychological, and social effects. Seizure control, or 
ideally, freedom from seizures has been shown to be vital in improving the 
quality of life of patients. For example, (Leidy et al., 1999) demonstrated that 
patients with well-controlled epilepsy had a similar health-related quality of life 
(HRQOL) to the general population; however those whose seizures were 
uncontrolled showed a significantly impaired HRQOL. Moreover, epilepsy has a 
long history of being a stigmatizing disorder; one that is often associated with 
fear and exclusion. Sadly, such misconceptions and negative stereotypes still 
remain today, placing considerable burden on the quality of life of those 
affected by the disorder (Jacoby, 2002).  
 
Comorbidity is common in epilepsy and research indicates higher rates of both 
somatic and psychiatric conditions in individuals with epilepsy compared to the 
general population (Gaitatzis et al., 2004). Mood disorders have long been 
considered frequent psychiatric comorbid conditions in people with epilepsy, 
occurring at much greater rates in those with epilepsy compared to the general 
population; estimates vary due to sampling strategies, between 20-50% 
(Kanner, 2003). Depression is often noted as the most frequent psychiatric 
disorder in people with epilepsy, with incidences ranging from 20-30% in 
community-based epilepsy samples, and 20-55% in specialist epilepsy clinics 
(Baker et al., 1996; Kanner and Balabanov, 2002; Blum et al., 2003; Eden and 
Toone, 1987; Robertson et al., 1994; Ottman et al., 2011). Depression is often 
regarded as an understandable consequence of the epileptic disorder, given the 
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socially disadvantageous nature of epilepsy. However, a more complex, 
bidirectional relationship between the two disorders has also been proposed, in 
light of evidence suggesting an increased risk for developing epilepsy in 
individuals with depression. For example, a population-based case-control 
study of patients with late onset epilepsy (first seizure after the age of 54 years), 
found that major depression was associated with a six-fold increased risk for 
unprovoked seizures (Hesdorffer et al., 2000). Authors also reported that this 
increased risk remained even when controlling for age, sex, length of medical 
follow-up and treatment for depression. Moreover, in a large (n=11,741) Danish 
population-based study using hospital registry data, (Nilsson, 2003), reported a 
relative risk for epilepsy among patients with depression of 1.32, compared with 
controls (patients with diabetes or osteoarthritis). However, this observed 
increased risk seemed to be due to the effect of comorbid alcohol abuse within 
depressed patients, given that the relative risk was 9.9 in patients with 
depression plus alcohol abuse, but only 0.9 in patients with depression without 
alcohol abuse.  
 
To date, much of the neuropsychiatric literature has focused on the study of 
unipolar depression, with investigation into bipolar disorder (BD) remaining 
limited. The following section will review the evidence for overlap between 
epilepsy and BD.  
 
1.3.1 Evidence of overlap between epilepsy and bipolar disorder 
1.3.1.1 Clinical studies 
Traditionally, it was stated that symptoms of bipolar disorder (BD) within 
epilepsy were less common than symptoms of depression and certainly classic 
BD was thought to be rare (Wolf, 1982). It has previously been said that “Classic 
BD type I is rarely seen in epilepsy, and manic episodes occur almost exclusively in 
the setting of postictal psychosis or after epilepsy surgery” (Mazza et al., 2007). 
This notion has since been challenged, with authors now more likely to support 
a putative bidirectional relationship.  
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One of the first systematic assessments of BD symptomatology within epilepsy 
revealed bipolar symptoms to be evident in a sixth of epilepsy patients (Ettinger 
et al., 2005). Within this study, Ettinger et al. (2005) utilized the Mood Disorder 
Questionnaire (MDQ) (Hirschfeld et al., 2000) (a validated screening instrument 
for symptoms of bipolar I and II disorder) with a sample of 127,800 people 
selected to represent the US adult population. Of the 85,358 subjects (67%) who 
returned the survey, 12% of those with epilepsy reported bipolar symptoms (not 
bipolar disorder per se). Bipolar symptoms were reported 1.6 to 2.2 times more 
often in subjects with epilepsy than in those groups with other chronic disorders. 
People with migraine were the second largest group, in terms of their reporting 
of bipolar symptomatology (7%), with rates of bipolar symptomatology also 
higher in those with asthma (6%) and diabetes (3%). A further population-based 
survey conducted more recently, focusing specifically on epilepsy and a 
spectrum of potential neuropsychiatric and pain disorder comorbidities 
demonstrated significant comorbidity for a number of psychiatric disorders 
(including BD), with epilepsy. Specifically, BD was found to be more than twice 
as prevalent among individuals with self-reported epilepsy as those without 
(prevalence ratio = 2.11, 95% CI 1.82-2.45) (Ottman et al., 2011).  
 
In a case-control study to identify epilepsy-related characteristics associated 
with the presence of mood disorders in epilepsy, Jagadheesan et al. (2003) 
compared 44 patients with epilepsy with a history of mood disorder, and 44 
epilepsy patients with no such history.  They identified 5 (11.4%) of those with a 
comorbid mood disorder as having bipolar disorder, whilst the rest (88.6%) had 
major depressive disorder. Epileptic patients with a history of mood disorders: 
were more likely to be educated (88.6% vs. 65.9% p<.05); had a later onset of 
epilepsy (21.44 vs. 12.19 years, p<.01); had a higher frequency of cluster attacks 
54.5% vs. 31.8%, p<.05); and a longer duration of epilepsy illness (7.58 vs. 4.76 
years, p<.05). However, epileptic patients with and without a history of mood 
disorders were found to be similar in terms of seizure frequency, seizure type, 
EEG abnormalities and family history of affective disorder.  
 
An important distinction to consider in the evaluation of BD within epilepsy is 
whether it is ‘true’ BD that is found to be more frequent in people with epilepsy, 
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or whether the symptoms observed are in fact related to phenotypic mimics, 
misdiagnosed as BD. For example, Ettinger et al. (2005), above, suggested that 
the mood disorder questionnaire used in their study may in fact be identifying 
individuals with the controversial interictal dysphoric disorder (IDD). Blumer et 
al. (2004) coined this term to refer to a presentation of chronic depression or 
dysthymia that tends to run an intermittent course and fails to meet criteria for 
a DSM based diagnosis. Blumer and colleagues (2004) described this proposed 
pleomorphic disorder as being characterized by eight key symptoms: 
fluctuating dysthymia, irritability, alternation with occasional euphoric periods, 
fear, anxiety, anergia, pain and insomnia. This frequently observed atypical 
presentation of depressive disorders in patients with epilepsy led clinicians to 
believe that such disorders were clinically different to those seen in non-
epileptic patients (Kanner and Barry, 2001).   
 
Mula et al. (2008) identified major depressive disorder as being the most 
strongly correlated DSM-IV Axis 1 disorder with IDD. However, in their efforts to 
investigate the psychopathological features of IDD using clinical instruments 
designed to measure manic (MDQ: Mood Disorder Questionnaire) and 
depressive (BDI: Beck Depression Inventory) symptomology, Mula et al. (2008) 
noted a higher specificity for IDD diagnosis by the MDQ compared to that of the 
BDI (86% vs. 65.9%, respectively), adding support to the hypothesised close 
relationship between IDD and the bipolar spectrum. Moreover, features of IDD 
relating to mood instability and irritability are symptoms traditionally belonging 
to the spectrum of bipolar disorders, rather than unipolar depression (Moller and 
Curtis, 2004). Others have speculated a relationship with BD, suggesting that 
IDD represents a form of cyclothymic disorder that sometimes exacerbates and 
meets criteria for major depression. IDD remains a controversial concept (Mula, 
2013) with some authors arguing that the definitions are too broad and the 
psychometric tools not specific enough to differentiate from anxiety and 
depressive symptoms (Amiri and Hansen, 2015). While an overlap with this 
proposed syndrome may have explained the symptomatology in some cases, it 
is notable that nearly half of Ettinger et al’s. (2005) respondents with positive 
MDQ scores in fact had a formal diagnosis of BD.   
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In addition, in the evaluation of BD in people with epilepsy, it is essential to take 
into account the number of behavioural changes that can occur around the ictus 
and the features of postictal or prodromal phases associated with seizures, as 
well as the occurrence of manic symptoms as a side effect of antiepileptic 
pharmacology (Mula and Monaco, 2006). Figure 1.3 displays the number of 
behavioural and affective psychiatric disturbances that can occur throughout 
the ictal, postictal and interictal phases of seizure activity. Mula et al. (2008), 
looked to address this distinction, aiming to describe prevalence of both BD and 
bipolar symptoms in adult outpatients with epilepsy, whilst also considering the 
role of potential confounding variables, such as relation to seizures and drug 
therapy. They identified 12% (n=17) of epilepsy patients as having a DSM-based 
diagnosis of BD and 15% (n=21) screening positive for bipolar symptoms with 
the MDQ. However, following consideration of potential confounders, 
prevalence of ‘true’ BD and bipolar symptoms were found to be 1.4% and 2%, 
respectively. In the remaining cases, symptoms were found to be related to 
phenotypic copies such as IDD or related to behavioural manifestations 
occurring around the ictus.  
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It is well known that temporal lobe epilepsy (TLE) plays an important role in the 
genesis of ictal and post-ictal mania and moreover, that manic episodes can 
develop following injury to the temporal or frontal lobes (Starkstein et al., 1988). 
Seizure activity associated with the temporal and frontal epileptogenic zones is 
often referred to as ‘secondary mania’, thought to be caused by a disturbance in 
the limbic system. Due to the role of the limbic system in regulating emotion, 
mood and behaviour, patients with TLE are noted as having a high propensity 
to develop psychiatric disorders (particularly affective disorders) and can 
present a diagnostic challenge as they blur the interface between psychiatry and 
neurology. In this instance, patients with TLE and those with focal seizures more 
generally, may represent a diagnostic challenge given their overlap of 
symptoms such as: olfactory, auditory and gustatory illusions and 
hallucinations; feelings of depersonalisation or detachment; and panic, fear and 
anxiety. Psychiatric classification manuals, such as the DSM-IV (American 
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Figure 1.3 Examples of behavioural and affective changes during seizure phases. 
(Figure reproduced from Knott et al., 2015) 
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Psychiatric Association, 2000), define this as ‘mood disorder due to general 
medical condition’, and in such cases psychiatric disorder is not considered to be 
comorbid with the medical disorder, but rather an expression of it. However, it 
has been argued that such classification systems are superficial and perhaps 
overlook the neuropsychiatric diversity found in epilepsy. For example, De 
Oliveira et al's. (2010) observation of the neuropsychiatric profile of patients 
with TLE revealed high rates of BD (10%) and any mood disorder (49%), even 
when considering clinical variables related to epilepsy. 
Following consideration of phenotypic copies of BD and potential 
manifestations of epilepsy, an important question remaining is whether the 
interictal manic episode within epilepsy is comparable to the manic episode of 
BD patients. A case-control study exploring this question compared the clinical 
features of interictal manic episodes with those of bipolar I disorder (BDI) (Kudo 
et al., 2001). It was reported that compared to BD controls, epilepsy patients 
with interictal manic episodes experienced less severe manic and depressive 
episodes and 62% experienced a rapid cycling course of the bipolar illness. 
However, the study did not control for confounding factors, such as medication 
use, which may have influenced the bipolar illness given the known anti-manic 
properties of epileptic pharmacotherapy.  
 
A fundamental issue needing further exploration is whether it is bipolar 
symptomology or a clinical picture meeting full diagnostic criteria for BD that is 
found at increased rates in people with epilepsy. In an effort to assess rates of 
bipolar symptoms versus BD in epilepsy, Lau et al. (2012) found that of ten 
individuals who met criteria for bipolar symptomology assessed by the MDQ, 
only one had a diagnosis of BD, suggesting that symptomology is not 
synonymous to formal disorder. This appears to be in stark contrast to the 50% 
of positive screens for bipolar symptomology confirmed to have a diagnosis of 
BD in Ettinger et al.’s (2005) study. It is important to emphasize that the MDQ 
(the main tool used to formally assess bipolar symptomology in epilepsy 
cohorts) has not been validated for use within an epilepsy population and so its 
sensitivity within this population is unknown.  
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To date, there has been a distinct lack of studies exploring the systematic 
assessment of well-characterized epilepsy within a bipolar population. Rather, 
much of the research to date has focused on the assessment of multiple physical 
health disorders concurrently, with studies often grouping disorders together by 
organ system (i.e. neurologic disorders). Such studies have identified an 
increased prevalence of neurologic disorders within BD, compared to controls 
subjects (Carney and Jones, 2006; Evans-Lacko et al., 2009). However, whilst 
this has acted to increase our knowledge of medical burden, and broadly defined 
neurologic disorders within BD, it has not allowed for comprehensive 
investigation of epilepsy within BD.  
 
Moreira et al. (2011) aimed to describe the prevalence of nine general medical 
conditions, including epilepsy in a Brazilian sample of outpatients with bipolar I 
disorder. Nearly 69% of subjects were reported to have at least one general 
medical condition, with epilepsy prevalence estimated at 8%. An additional 
study that specifically included epilepsy in their assessment of general medical 
comorbidities used a nationally representative data set to review comorbid 
conditions in hospital discharge records that noted BD. Epilepsy was not stated 
as one of the fifteen most prevalent comorbid conditions in discharge records of 
those with a primary diagnosis of BD. However, they did report an increased 
prevalence of epilepsy among the discharges with a primary diagnosis of BD, 
compared to discharges with a different primary diagnosis (Weber et al., 2011). 
A further study to utilize hospital medical records examined rates of comorbid 
medical disorders in patients with BD and schizophrenia (Oreški et al., 2012). 
Within BD patients, the prevalence of general neurological disorders was 8% 
and an epilepsy prevalence of 1%. These rates were not found to be significantly 
different to those reported in the schizophrenia patient group, although 
neurological disorders were found to be the most prevalent somatic condition 
in schizophrenia patients (11%). Finally, Forty et al. (2014) looked to examine 
rates of a number of medical illnesses, including epilepsy, in a large, well-defined 
sample of patients with BD, and to make comparisons with a control group and 
with a sample of patients with recurrent depression. They found a significantly 
increased rate of self-reported epilepsy in the bipolar group when compared to 
both the control (3.4% vs. 0.5%, p<.001) and the recurrent depression group 
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(3.4% vs. 2.0%, p<.05). They also explored the rate of self-reported epilepsy 
across bipolar subtypes, finding no significant difference between bipolar I 
disorder and bipolar II disorder groups (2.1% vs. 2.2%). 
 
In a clinical sample of 40 first degree relatives of bipolar probands, 60 first 
degree relatives of epilepsy probands and 50 control subjects, Jidda et al., (2014) 
found an increased rate of epilepsy among relatives of individuals with BD 
compared to controls (15.2% vs. 2.0%, p<.001), providing evidence for the 
familial clustering of BD and epilepsy. However, an association between BD and 
parental epilepsy was not reported in a large Finnish study of national registry 
data (Sucksdorff et al., 2015). The authors did, however, observe an association 
between BD and comorbid epilepsy even after adjusting for parental 
psychopathology (OR: 2.53, 95% CI: 1.73-3.70).  
 
Given that very few studies have explicitly assessed epilepsy within a bipolar 
sample, it is clear that this is an area in need of further investigation. It is 
important for future work to focus on the assessment of well-defined epilepsy 
within bipolar subjects, not reliant on self-report measures; as well as exploring 
the temporal relationship of the two disorders, to uncover the true nature and 
direction of their association.  
 
1.3.1.2 Pathophysiology and genetics  
Several converging lines of research suggest a relationship between bipolar 
disorder (BD) and epilepsy. Both conditions are substantially heritable, follow 
an episodic course, can be chronic, and respond to anticonvulsant medications, 
all of which point to a common underlying pathophysiology.  
One of the pathophysiological mechanisms hypothesized to underpin both 
epilepsy and BD, is the kindling phenomenon. Kindling was first described in an 
experimental animal model of epileptogenesis (Goddard et al., 1969) as a means 
of describing the evolution of seizure development and progression. Kindling is 
a process whereby repetitive stimulation involving sub-threshold stimuli 
induces seizures until they start to occur spontaneously. The kindling 
phenomenon results in lasting (and potentially permanent) functional and 
structural changes in the brain and can be modified by pharmacological 
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treatment. Many anti-epileptic drugs (which are also known to have mood-
stabilizing properties), such as carbamazepine, lamotrigine and phenytoin 
successfully block completed kindled seizures, however are unable to block their 
development (Post, 2004). The kindling phenomenon has also been applied to 
explain the episodic nature of BD (Post and Wiess, 1996). Post and Weiss (1996) 
postulated that in a genetically susceptible individual, particular repeated 
(psychosocial) stressors experienced within a vulnerable period and 
environment can lead to the development of mood symptoms occurring with 
increasing intensity and duration, until the occurrence of a full-blown depressive 
or manic episode. It is also proposed that each episode leaves a ‘trace’ and 
increases vulnerability for subsequent episodes, a mechanism referred to as 
‘episode sensitization’ (Huber et al., 2001).  
A further possible common pathogenic mechanism between epilepsy and BD 
involves abnormalities of common neurotransmitter systems (for which their 
role in BD has already been discussed) including; serotonin (5HT), 
norepinephrine (NE), dopamine (DA), glutamate, and gamma-amino-butyric 
acid (GABA). The hypothesis for the involvement of neurotransmitter systems 
has largely been derived from the fact that many antiepileptic drugs (AEDs) are 
known to act on these systems. For example, in the case of GABA: 
carbamazepine is known to modulate the GABAA receptor (Granger et al., 1995); 
valproate increases the release of GABA through the upregulation of GABAB 
receptors (Laeng et al., 2004); and phenytoin has been found to increase 
GABAergic transmission (Cunningham et al., 2000). However, it has also been 
observed that although the AEDs topiramate and retigabine show strong effects 
on GABAergic transmission, they do not demonstrate any anti-manic properties 
(Amann and Grunze, 2005). Moreover, glutamate; the main excitatory 
transmitter in epileptogenesis, is known to be the target of a number of AEDs. 
For example, carbamazepine, valproate and lamotrigine, have all been shown 
to exhibit anti-glutamatergic actions (Lampe and Bigalke, 1990; Löscherr, 1993; 
Teoh et al., 1995; Waldmeier et al., 1995).  
 
The roles of 5HT and NE have been established through the use of animal 
models and humans with temporal lobe epilepsy. Jobe et al. (1999) noted the 
involvement of 5HT and NE in genetically prone rat strains (GEPR-3 and GEPR-
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9), who have a predisposition to sound-induced generalized tonic-clonic 
seizures and were shown to have deficits in serotonergic and noradrenergic pre 
and postsynaptic transmission. Moreover, an increase of extracellular serotonin 
has been identified with valproate (Whitton et al., 1985), lamotrigine (Southam 
et al., 1998) and carbamazepine (Dailey et al., 1997). Finally, evidence for the 
involvement of 5HT and DA in epilepsy is reflected by the finding that low doses 
of these are protective against limbic seizures, and conversely, high 
concentrations demonstrate pro-convulsive properties in some animal models, 
whereby receptor blockades significantly aggravate seizures (Clinckers et al., 
2004).  
 
Detailed twin studies and familial aggregation analysis have made a compelling 
case that both generalized and focal epilepsies have a sizable genetic 
contribution (Thomas and Berkovic, 2014). Similarly, and as already discussed, 
the heredity of bipolar disorder has been estimated to be between 60-85%, for 
which a complex polygenic genetic basis is postulated. Two of the strongest 
associations to come out of genome-wide association studies of BD are for the 
involvement of CACNA1C and ANK3, leading to the hypothesis that BD may be, 
at least in part, an ion channelopathy. Some of the most convincing evidence for 
the involvement of ion channels in epilepsy has come from the identification of 
mutations within voltage-gated sodium channel genes leading to rare 
monogenic epileptic syndromes (Harkin et al., 2007; Meisler and Kearney, 2005; 
Mulley et al., 2005). For example, over 80% of cases with severe myoclonic 
epilepsy of infancy (SMEI), also known as Dravet’s syndrome, have mutations 
within the voltage-gated sodium channel gene SCN1A (Claes et al., 2001; Harkin 
et al., 2007). The SCN1A gene has also been implicated in generalized epilepsy 
with febrile seizures plus (GEFS+) (Escayg et al., 2000; Wallace et al., 1998), 
intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTCS) 
(Fujiwara et al., 2003), and was most recently implicated within a large meta-
analysis of genome-wide associations studies in focal and generalized epilepsies 
including 8696 cases and 26157 controls (International League Against Epilepsy 
Consortium on Complex Epilepsies, 2014). In addition, in 1998, mutations of the 
two potassium channel subunit genes, KCNQ2 and KCNQ3, were identified as 
the underlying genetic abnormality in benign familial neonatal convulsions 
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(BFNC), a condition characterized by recurrent seizures in newborn babies 
(Biervert et al., 1998; Charlier et al., 1998; Singh et al., 1998).  
Whilst the association between mutations in sodium and potassium channel 
genes and both epileptic encephalopathies and adult epilepsies is well-
established, the role of the calcium channel in the aetiology of human epilepsy 
is less clear (Thomas and Berkovic, 2014). Mutations in CACNA1H (neuronal 
voltage-gated T-type calcium channel subunit) have not been proven to cause 
epilepsy independently, but are better considered to be susceptibility variants 
(Heinzen et al., 2012). Nineteen single nucleotide polymorphisms (SNPs) 
identified in 240 cases identified in CACNA1H have been linked to the genetic 
generalized epilepsies and childhood absence epilepsy in particular (Heron et 
al., 2007). Like many candidate gene analyses, the findings from parallel 
sequencing studies did not support a major role for CACNA1H in the genetic 
generalized epilepsies (Heinzen et al., 2012). In contrast, there is a much more 
supportive literature for the role of calcium channel dysfunction in the rodent 
literature. Mouse models where serendipitous mutation produces seizures 
include stargazer (CACNG2), lethargic (CACNB4) and ducky (CACNA2D2) (Cain 
and Snutch, 2012). There is a wealth of literature on the epileptic 
encephalopathies, however, again the relevance of calcium channel gene 
mutation is unknown. De novo mutagenesis is the important mechanism in this 
devastating childhood epilepsy (Epi4K Consortium, 2013). Of the other bipolar 
disorder associated genes only ANK3 has been linked to epilepsy. A de novo 
missense mutation in ANK3 was shown in a child with Lennox-Gastaut 
syndrome and autism spectrum disorder in the Epi4K series (Epi4K Consortium, 
2013). ANK3 has an important regulatory function at the AMPA receptor (Smith 
et al., 2014). Finally, ion channels are pharmacologically related to epilepsy, in 
that several AEDs are known to exert action on sodium, calcium and potassium 
channels (Löscher, 2002; Rogawski and Löscher, 2004).   
 
 
1.3.2 Summary  
There exists a wealth of both clinical and aetiological-based research suggesting 
a link between bipolar disorder (BD) and epilepsy. However, this relationship is 
far from clear and further research is necessary to clarify the nature, impact and 
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mechanism of the co-occurrence of these disorders. A number of studies 
suggest that it is no longer appropriate to consider bipolar symptoms or bipolar 
spectrum disorders to be rare in epilepsy. Whether or not the bipolar 
symptomology identified within epilepsy should be considered to be in a 
spectrum with a disorder fulfilling diagnostic criteria, is currently unknown. 
However, it is important to stress the value of recognising all forms of bipolar 
symptomology, regardless of aetiology and whether or not they meet strict 
diagnostic criteria for classic BD, given their potential for profound negative 
impact on the individual (particularly given the known association between 
bipolar symptoms and suicidality). Variation in the epidemiological data 
available, in terms of the methodology employed, case definition of BD and 
bipolar symptomology, heterogeneous patient populations and scientific 
rigour, means that currently it remains difficult to make any robust statements 
regarding the risk and comorbidity of bipolar spectrum disorders in epilepsy. 
Although the assessment of psychiatric symptoms within epilepsy is a 
complicated endeavour, it appears there is a clear need to screen for bipolar 
symptomology within people with epilepsy and ensure appropriate integrated 
psychiatric care.  
 
Conversely, there is a distinct lack of studies examining the reverse association; 
comorbid epilepsy within a sample of individuals with BD. As such, there is a 
clear need to assess whether epilepsy is overrepresented in BD, as well as to 
explore the potential clinical impact of epilepsy in BD. These lines of research 
will help us to clarify the potential bidirectional relationship between these two 
disorders and will shed some light on the true nature and direction of their 
association. 
 
Whilst it is clear that more research is needed to unravel the clinical relationship 
between epilepsy and BD, there are a number of undeniable similarities 
between the two disorders. These include, their episodic nature, potential to run 
a chronic course, high heritability, and the efficacy of some anti-epileptic 
medications in the prophylaxis of both disorders. These lines of research are 
often cited as evidence of potential common underlying pathophysiology 
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between BD and epilepsy and ignite interest in the mechanisms surrounding this 
relationship.  
 
The final section of this chapter will discuss the general aims and outline of the 
current thesis.  
 
1.4    Aims and outline of the current thesis  
The overall aim of this thesis is to further explore the relationship between 
bipolar disorder (BD) and the neurological conditions of migraine, and epilepsy, 
within a large, well-characterised sample of individuals with BD. The specific 
aims of this thesis are summarised below.  
 
Given the caveats discussed in this introductory chapter of many existing studies 
examining the relationship between migraine and BD, the first aim of this thesis 
is to explore the rate of migraine (as defined by standardised International 
Headache Society criteria) within a large sample of bipolar subjects and to 
assess this rate across the bipolar diagnostic subtypes; bipolar I disorder (BDI), 
bipolar II disorder (BDII) and schizoaffective, bipolar type (SABP) (Chapter 3). 
It is hypothesized that the rate of migraine within the bipolar cohort will be 
higher than the approximate 12% rate reported in the general population 
(Breslau et al., 1991). In line with current literature (Fornaro, 2015), it is also 
hypothesised that the rate of migraine will be higher among those with bipolar 
II disorder (BPII) compared to those with bipolar I disorder (BPII). The current 
chapter presented evidence suggesting that the psychiatric comorbidity of 
migraine is dependent on migraine subtype, with migraine with aura (MA) 
suggested to have a stronger association with psychiatric disorders than 
migraine without aura (MoA) (Breslau et al., 1991; Samaan et al., 2009). 
Therefore, the second aim of this thesis is to extend existing literature by 
exploring the association between the migraine subtypes; migraine with aura 
(MA) and migraine without aura (MoA), and BD (Chapter 3). In addition, the 
current thesis employed various definitions of classifying migraine diagnosis 
(which will be described in detail in Chapter 2). Therefore, the third aim of this 
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thesis is to assess the concurrent validity of these methods in deriving a 
diagnosis of migraine within individuals with BD.  
Previous small-scale research has revealed differences in the clinical course of 
the bipolar illness according to the presence or absence of migraine (Mahmood 
et al., 1999; Low et al., 2003; Brietzke et al., 2012b; Saunders et al., 2014; Ortiz 
et al., 2010). Therefore, the fourth aim of this thesis looks to explore the impact 
of migraine comorbidity on course of illness in BD, by establishing whether the 
presence of migraine defines a clinical subtype of bipolar subjects who 
experience a distinct set of lifetime clinical characteristics (Chapter 4). It is 
hypothesized that the clinical presentation of the bipolar illness will differ 
according to the presence of comorbid migraine. Despite the proposal that MA 
may have a stronger association with psychiatric disorder than MoA, to date no 
studies exploring the relationship of migraine with the clinical features of BD 
have differentiated between these subtypes. Therefore, the second part of 
Chapter 4, and the fifth aim of this thesis, will examine whether there exist 
differences in the lifetime bipolar clinical characteristics associated with MA 
and MoA, separately.  
As discussed within the current chapter, a potential explanation for the 
association between BD and migraine could be a shared underlying 
pathophysiology. Previous research suggesting that migraine comorbidity is 
associated with a distinct clinical profile within BD provides further support for 
the proposal that migraine may provide a useful tool for stratifying individuals 
with BD, potentially identifying subgroups of patients for which there may be 
shared genetic variation. Therefore, the sixth aim of this thesis is to examine 
genetic susceptibility to BD with comorbid migraine, through a genome-wide 
association study (GWAS) (Chapter 5). 
Whilst mood disorders have long been considered frequent psychiatric 
comorbid conditions in people with epilepsy, to date much of the 
neuropsychiatric literature has focused on the study of unipolar depression, with 
investigation in to BD remaining limited (Baker et al., 1996; Kanner and 
Balabanov, 2002; Blum et al., 2003; Eden and Toone, 1987; Robertson et al., 
1994; Ottman et al., 2011). This is particularly surprising given the 
phenotypically similar symptom profile between epilepsy and BD, and the 
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efficacy of some anti-epileptic medications in the prophylaxis of both disorders. 
Therefore, within Chapter 6, I look to further explore the comorbid relationship 
between bipolar disorder and epilepsy. Firstly, Chapter 6 will assess the rate of 
self-reported epilepsy within a large, well-characterised sample of UK 
participants with a diagnosis of BD, which will constitute the 7th aim of this 
thesis. It is hypothesized that the rate of self-reported epilepsy identified in the 
bipolar sample will exceed the 1% rate reported in the general population 
(Ottman et al., 2011; Rai et al., 2012). The chapter will then describe a process 
for identifying a cohort of bipolar individuals with well-defined, expert-
confirmed epilepsy. Using these two definitions of epilepsy (self-report and 
expert-confirmed), the 8th and final aim of this thesis will explore the 
relationship between epilepsy and the clinical features and course of illness 
within BD, by examining lifetime clinical characteristics of illness in individuals 
with bipolar disorder according to their lifetime history of epilepsy. It is 
hypothesized that the clinical features of illness experienced will differ between 
bipolar subjects with and without comorbid epilepsy.  
Chapter 2 will describe the methodological approach for studying each of the 
above aims.  
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Chapter 2 
Methodology 
 
2.1 Summary  
This chapter describes the sample used throughout this thesis, including details 
of recruitment and clinical assessment procedures, and describes the main 
measures used within subsequent chapters.  Details regarding specific 
methodology, sample characteristics and statistical analyses will be outlined 
within the appropriate chapters.  
The sample and data utilized throughout this thesis originated from the Bipolar 
Disorder Research Network (BDRN; www.bdrn.org). I have been a member of 
BDRN since 2012, when, prior to my postgraduate studies, I joined the team as 
a Research Officer where I was responsible for the identification and recruitment 
of NHS patients into the research network.   
 
2.2 Bipolar Disorder Research Network (BDRN) 
The Bipolar Disorder Research Network (BDRN) is a large, ongoing programme 
of molecular genetic and clinical studies of affective disorders, with the overall 
aim of investigating biological, psychological and social determinants of mood 
disorders, including bipolar disorder (BD). BDRN was established in 2008 and is 
led by Principal Investigators Professor Ian Jones, Professor Lisa Jones and 
Professor Nick Craddock. BDRN was originally based both at Cardiff University 
and the University of Birmingham. In 2015, the research group based at the 
University of Birmingham moved to the University of Worcester, where the 
group continue to work in close collaboration with Cardiff University. The 
research programme is funded by the Wellcome Trust and the Stanley Medical 
Research Institute and has UK National Health Service (NHS) Research Ethics 
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Committee approval and Local Research and Development approval in all 
participating NHS trusts/health boards.  
 
2.3 Sample recruitment 
The Bipolar Disorder Research Network (BDRN) uses a number of methods to 
recruit research participants, including both systematic and non-systematic 
methods. At the time of writing, BDRN had recruited approximately 6150 
participants to its network.   
2.3.1 Systematic  
Systematic recruitment methods involve screening for eligible participants 
through NHS services (e.g. Community Mental Health Teams and lithium 
clinics). With the approval of the treating Consultant, suitable patients are 
invited to participate in the study. Patients are not approached when acutely 
psychiatrically ill.  
2.3.2 Non-systematic 
Non-systematic recruitment methods involve promotion of the research within 
local and national media (including television, radio, press and internet 
coverage), advertisements on the research team’s website (www.bdrn.org), and 
through patient support organisations, such as Bipolar UK 
(www.bipolaruk.org.uk). 
 
2.4 Inclusion/exclusion criteria 
Inclusion criteria of the research programme stipulate that individuals must be: 
18 years or over; meet DSM-IV criteria for major affective disorder; and be able 
to provide written informed consent. Individuals are excluded from the study if 
they: have a lifetime diagnosis of intravenous drug dependency; have only 
experienced mood episodes as a result of alcohol/substance dependence, or 
medical illness; or are biologically related to another study participant. 
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2.5 Clinical assessment of the Bipolar Disorder Research 
Network  
Participating subjects are interviewed in person by a trained psychiatrist or 
research psychologist. Following a complete description of the study, voluntary 
consent is obtained. Subjects then undergo a structured clinical assessment 
lasting approximately an hour and a half (described below), and provide a 30ml 
venous blood sample. Subjects are interviewed using the Schedules for Clinical 
Assessment in Neuropsychiatry (SCAN) (Wing JK et al., 1990). The SCAN was 
developed by the World Health Organisation as a set of instruments and 
manuals designed to assess, measure and classify psychopathology and 
behaviour across adult life that is associated with major psychiatric disorders. 
The SCAN sections assessing symptoms of mania, depression and psychosis 
were included within the BDRN interview. The SCAN assessment is 
supplemented by the OPCRIT (OPerational CRITeria) symptom checklist 
(Craddock et al., 1996; McGuffin et al., 1991); which is used to rate the presence 
or absence of manic, depressive and psychotic symptomatology, along with 
some other clinical features. Symptom items are rated on both a lifetime ever 
and worst-episode basis. Where possible, subjects’ psychiatric and general 
practice case notes are reviewed and all available information is combined and 
best-estimate lifetime diagnoses are made according to the Diagnostic and 
Statistical Manual of mental Disorders, Fourth Edition (DSM-IV; American 
Psychiatric Association, 2000), and International Classification of Diseases, 
Tenth Revision (ICD-10; World Health Organisation, 1992). As discussed within 
the introduction of this thesis, the most recent edition of the DSM was 
introduced in 2013 (DSM-5; American Psychiatric Association, 2013). All of the 
cases involved in this thesis were rated prior to the publication of the most 
recent edition, and so were rated according to DSM-IV criteria (American 
Psychiatric Association, 2000).  
Both the Global Assessment Scale (GAS) (Endicott et al., 1976) and Bipolar 
Affective Disorder Dimension Scale (BADDS) (Craddock et al., 2004) are rated 
using all available participant information, including information obtained from 
the SCAN interview and available case notes. GAS is a rating scale to measuring 
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overall severity of psychiatric disturbance and evaluates a subject’s functioning 
during a specified time period on a continuum from 1 to 100, where 1 represents 
the hypothetically most unwell individual and 100 represents the hypothetically 
healthiest.  GAS is rated according to three timeframes; i) lifetime worst in a 
depressive episode; ii) lifetime worst in a manic episode; and iii) functioning over 
the past week. BADDS is a rating system comprised of four dimensions 
measuring lifetime experience of psychopathology in each of these dimensions 
(Mania, Depression, Psychosis and Incongruence). Both the Mania and 
Depression dimensions are composite measures that take into account both the 
severity and frequency of episodes. Both dimensions are rated on a scale of 0 to 
100, where 0 represents no evidence of manic/depressive symptoms and 100 
represents evidence of more than ten incapacitating episodes of 
mania/depression. The Psychosis dimension rates the prominence of lifetime 
psychotic symptoms throughout illness, where ‘illness’ refers to both affective 
and non-affective periods of psychopathology. The final Incongruence 
dimension is a measure of the congruence of psychotic symptoms with affective 
state, where zero represents complete mood congruence (i.e. psychotic 
symptoms occur only during affective episodes) and 100 represents complete 
incongruence (i.e. psychotic symptoms have predominated the illness course 
and occur chronically outside, or in the absence of, affective episodes). The 
quantitative measure offered by the BADDS offers a dimensional system that 
complements traditional diagnostic classification systems.  
 
2.5.1 Inter-rater reliability of lifetime psychiatric ratings 
Consistency in diagnostic and rating procedures is assessed regularly by the 
BDRN research team through inter-rater reliability meetings. Inter-rater 
reliability was formally assessed for 20 randomly selected cases with a range of 
mood disorder diagnoses. Mean overall Cohen’s kappa of 0.85 and 0.83 were 
obtained for DSM-IV and ICD10 diagnoses, respectively. Consistency in the 
rating of other key psychiatric clinical variables, including suicidal ideation, age 
of onset of psychiatric disorder and the number of episodes of mania and 
depression was also assessed. Inter-rater reliability for these key variables was 
high with mean kappa statistics (categorical variables) and intra-class 
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correlation coefficients (continuous variables) ranging from 0.81-0.99, and 0.85-
0.97, respectively (Jones et al., 2005).  
 
2.5.2 Questionnaire measures  
Following interview, participants are left with a set of self-report questionnaires 
to complete. Written instructions request that participants complete all of the 
questionnaires at the same time and return them within one week in the 
stamped, addressed enveloped provided. Participants who do not return the 
questionnaire pack within one month receive a reminder letter which includes 
another copy of the questionnaire pack and a return envelope. Participants who 
do not return the questionnaire pack following a further two weeks receive a 
reminder telephone call.  
The questionnaire pack left with participants includes the following measures:  
▪ Beck Depression Inventory (BDI) (Beck et al., 1961). 
▪ Altman Self-Rating Mania Scale (AMS) (Altman et al., 1997).  
▪ Eysenck Personality Questionnaire (EPQ) (Eysenck and Eysenck, 1975).  
▪ Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego  
Autoquestionnaire (TEMPS-A) (Akiskal et al., 2005). 
▪ Brief Life Events Questionnaire (BLEQ) (Brugha and Cragg, 1990). 
 
Both the BDI and AMS were included to provide a measure of current mood 
state as residual affective symptoms have been shown to have a confounding 
effect on measures of underlying cognitive style and neuropsychological 
functioning (Ferrier et al., 1999; Jones et al., 2005). The questionnaire pack also 
asks participants about both their psychiatric and medical history. In order to 
establish the lifetime prevalence of physical health and psychiatric disorders, 
participants are asked the following question: 
“Has a doctor or health professional ever told you that you have any of the 
following?” 
Twenty physical health disorders are included in the questionnaire. These are: 
asthma, cancer, diabetes type 1, diabetes type 2, elevated lipids/high 
cholesterol, epilepsy, gastric ulcers, heart disease, hypertension, kidney 
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disease, liver disease, memory loss/dementia, migraine headaches, multiple 
sclerosis, osteoarthritis, osteoporosis, Parkinson’s disease, rheumatoid arthritis, 
stroke, thyroid disease. The questionnaire also asks about the presence of 14 
psychiatric disorders: attention deficit disorder (ADHD), autism, depression, 
bipolar disorder, obsessive compulsive disorder (OCD), agoraphobia, 
schizophrenia, panic disorder, phobias, anxiety, alcohol abuse, other substance 
abuse, anorexia and bulimia. For each disorder, participants can choose from 
three responses; ‘yes’, ‘no’, or ‘not sure’.  
 
2.6 BDRN newsletter and questionnaire follow-up assessment  
As a means of keeping in contact with participants, BDRN produce an annual 
newsletter, enabling the group to share recent work and update participants on 
the progress of the research. The newsletter also allows participants to let us 
know of any changes to their contact details, thus keeping the contact details 
for the sample up to date. This newsletter is disseminated to all participants that 
have consented to future contact from BDRN. The newsletter also provides an 
opportunity to gather further information from participants and as such, at 
regular intervals (yearly to two yearly), BDRN send a questionnaire pack with 
the newsletter for participants to complete and return in a stamped, addressed 
envelope.  
 
2.7 Assessment of migraine in the Bipolar Disorder Research 
Network 
In 2011, Bipolar Disorder Research Network (BDRN) participants were sent a 
pack of 9 self-report questionnaires along with an annual newsletter, which 
included a ‘headache’ questionnaire to assess the lifetime history of migraine 
(Appendix A). The headache questionnaire included in the pack was a modified 
version of the Structured Migraine Interview (Samaan et al., 2009). The SMI was 
designed according to International Headache Society criteria (ICHD-II; 
Headache Classification Subcommittee of the International Headache Society, 
79 | P a g e  
 
2004) to assess the lifetime presence of migraine. The SMI consists of 10 
questions to assess each of the individual items outlined in the criteria and 
evaluates; the presence of headache, severity, frequency, distribution, site, 
character and visual aura. When compared with consultant neurologists’ 
diagnosis in 41 patients attending the London Migraine Clinic, face-to-face 
administration of the SMI was found to be highly sensitive (0.87) and moderately 
specific (0.58). In addition, the misclassification rate was reported to be 0.15, 
positive predictive value was 0.97, and negative predictive value was 0.26 
(Samaan et al., 2010). The authors suggested that an explanation for the 
measure achieving only a moderate specificity may be that all subjects in the 
validation study had been referred to the London Migraine Clinical for 
headache, and so the sample was unbalanced by the lack of subjects without 
headache.  
BDRN administered a modified version of the SMI self-report questionnaire to 
the research cohort. BDRN included seven additional questions to the original 
10-item questionnaire to assess: headache frequency; additional aura 
symptoms; aura progression; aura succession; medical explanation for 
headaches; medical investigation; and family history of migraine. Not only did 
these additional questions provide further clinical information, but they also 
allowed for the assessment of sensory and speech-related aura symptoms, and 
for the diagnosis of both familial and sporadic hemiplegic migraine.  
Responses from the headache questionnaire were scored to generate the 
following migraine diagnoses: migraine without aura (MoA); migraine with aura 
(MA) (including hemiplegic migraine); and probable migraine. The criteria used 
for deriving migraine diagnoses within the current thesis and are defined below:  
1. Migraine without aura (MoA): Recurrent headache attacks fulfilling 
a-c:  
a)  lasting between 4-72 hours; b) at least two of: pulsating/one-
sided/moderate to severe pain intensity/aggravated by physical 
activity; c) associated with either nausea and/or vomiting, and/or 
hypersensitivity to sound or light.  
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2. Migraine with aura (MA): At least 2 episodes of aura symptoms 
including visual, sensory or speech disturbances accompanied by 
or followed by (within 60 minutes) a headache fulfilling criteria for 
migraine without aura (below). Aura symptoms must also meet at 
least two of the following:  
a) homonymous visual symptoms and/or unilateral sensory 
symptoms; b) at least one aura symptom develops gradually over 
≥5 minutes and/or different aura symptoms occur in succession 
over ≥5 minutes; or c) each symptom lasts ≥5 and ≤60 minutes.  
 
3. Probable Migraine (PM): Recurrent headache meeting only 2 of 
criteria A-C for migraine without aura.    
 
4. No migraine: Does not meet criteria for the above migraine 
diagnoses.  
 
The criteria outlined above for diagnosing migraine within this thesis are based 
on those of the International Headache Society, however due to the design of 
the SMI, there do exist some minor discrepancies. Firstly, question 3 of the SMI 
asks about hypersensitivity to sound ‘or’ light, whereas International Headache 
Society Criteria (IHS) requires both photophobia ‘and’ phonophobia, for this 
feature to be scored as present. Within the original SMI, it has been argued that 
the change of wording of this question is unlikely to over-diagnose cases of 
migraine given that it has been shown that a quarter of patients with migraine 
tend to under report these symptoms during routine questioning (Evans et al., 
2008). Secondly, IHS criteria stipulate that the headache should not be 
attributed to any of the following: head and/or neck trauma; cranial or cervical 
vascular disorder; non-vascular intracranial disorder; a substance or its 
withdrawal; infection; disorder of homeostasis; disorder of cranium, neck, eyes, 
ears, nose, sinuses, teeth, mouth or other facial cranial structures; or psychiatric 
disorder. Psychiatric disorder was not used as an exclusion factor for the 
diagnosis of migraine in the current thesis, given that an overall aim of the thesis 
was to explore the relationship between migraine and BD. Moreover, given the 
difficulty of attributing secondary effects and that the certainty of diagnosis of 
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secondary headache could not be guaranteed using the questionnaire methods 
employed, this criterion was omitted from the derivation of migraine diagnosis 
within the current thesis.  
The headache questionnaire used by BDRN was designed and disseminated to 
the research cohort prior to my joining of the group and commencement of 
postgraduate studies. However, the coding of responses, derivation of migraine 
diagnoses and all subsequent analyses were all conducted by myself.  
Chapter 3 of this thesis focuses on assessing the validity of the self-report 
headache questionnaire in screening for lifetime presence of migraine within a 
bipolar population. In order to achieve this, a random sub-sample of subjects 
were selected to complete a follow-up telephone interview.  The telephone 
interview used within this thesis is a modified version of that employed by the 
Epilepsy Phenome Genome Project (EPGP) (Winawer and Connors, 2013). The 
EPGP is an international consortium of 27 clinical centers worldwide with the 
objective of collecting detailed phenotypic and genetic data on a large number 
of epilepsy participants. Within their clinical interview, the EPGP also gather 
information regarding migraine headaches. The migraine instrument used by 
the EPGP is a revision of a standardised and validated interview (Lipton et al., 
2001), as recommended in the National Institute of Neurological Disorders and 
Stroke (NINDS) Common Data Elements Project. The NINDS Common Data 
Elements Project set about developing data standards for clinical research and 
the first set of Common Data Elements (CDEs) for headache were developed in 
2011. Validation of this tool in a population sample of 112 migraineurs and 62 
control subjects with other types of headache (mostly tension type headache), 
revealed a sensitivity of 1 and specificity of .82 (Lipton et al., 2001).  
The modified migraine interview used within this thesis can be found within 
Appendix B. One of the primary modifications made to this interview 
concerned the assessment of aura symptoms. The original interview included 
questions for the assessment of visual aura only. When I contacted the authors, 
they explained that this decision was justified by the finding that visual 
symptoms appear to be the most frequent (occurring in 99% of individuals with 
migraine with aura) and that those with several types of aura symptoms have 
been found to experience visual aura in virtually every attack (Russell and 
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Olesen, 1996). Within the BDRN sample we wanted a measure that assessed the 
full range of possible aura symptoms, and so included additional questions for 
the assessment of sensory, speech and motor-based aura symptoms. Moreover, 
it was not possible to map the questions included in the original interview 
regarding aura symptoms to criteria of the IHS, regarding its development and 
duration. Therefore, I included further questions to assess these detailed 
characteristics of the aura. Further additions to the interview included questions 
to assess: medical explanation for headaches, investigation and treatment for 
migraine; frequency of headaches; and family history of migraine. Finally, as 
telephone interviews were completed approximately three years following 
completion of the initial screening questionnaire (in the eight-month period 
between April-November, 2014), it was possible that participants could have 
experienced migraine headaches for the first time after completion of the initial 
questionnaire. Therefore, when participants were asked the age at which they 
first experienced severe headaches (question 2, Appendix B), the interviewer 
also noted whether this was before or after completion of the original migraine 
questionnaire in 2011, to account for such circumstances that could have acted 
to skew validation of the questionnaire tool.  
All subjects were interviewed by myself. I was blind to the subject’s original 
migraine diagnosis derived from the self-report questionnaire at the time of 
telephone interview. 
 
2.8 Assessment of epilepsy in the Bipolar Disorder Research 
Network 
Lifetime history of epilepsy was assessed in the Bipolar Disorder Research 
Network (BDRN) cohort via a staged screening strategy. Within stage 1 of this 
screening strategy, a self-report questionnaire measure was disseminated to 
BDRN participants as part of a larger questionnaire pack, in the summer of 2013, 
by myself and the rest of the BDRN research team during the second year of my 
PhD study (Appendix C).  
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The self-report epilepsy questionnaire utilized by BDRN was a modified version 
of a brief screening instrument to identify individuals with epilepsy, designed by 
Ottman et al. (2010). The original instrument consisted of 9 questions and 
included items that targeted recognised seizures, as well as symptom-based 
questions targeting possible unrecognised seizures (figure 2.1).  
 
 
 
 
Each question within the screening instrument could be answered ‘no’, ‘yes’, 
‘possible’, or ‘don’t know’, where a response was classified as positive if the 
subject answered ‘yes’ or ‘possible’. Ottman et al. (2010) validated their 
screening instrument by administering it through a telephone interview to 
individuals with medical record–documented epilepsy (n=168) or isolated 
unprovoked seizure (n=54), and individuals who were seizure-free on medical 
record review (n=120), from the Rochester Epidemiology Project population-
1. Did anyone ever tell you that you had a seizure or convulsion caused by a 
high fever when you were a child?  
2. [Other than the seizure[s] you had because of a high fever] Have you ever 
had, or has anyone ever told you that you had, a seizure disorder or epilepsy? 
 
Ask the following questions only if subject said ‘‘no’’ to epilepsy or a seizure 
disorder in q2. Otherwise go to next part of interview. 
 
3. [Other than the seizure[s] you had because of a high fever] Have you ever 
had, or as anyone ever told you that you had, any of the following… 
A. A seizure, convulsion, ﬁt or spell under any circumstances?  
B. Uncontrolled movements of part or all of your body such as 
twitching, jerking, shaking or going limp?  
C. An unexplained change in your mental state or level of awareness; 
or an episode of ‘‘spacing out’’ that you could not control?  
D. Did anyone ever tell you that when you were a small child, you 
would daydream or stare into space more than other children?  
E. Have you ever noticed any unusual body movements or feelings 
when exposed to strobe lights, video games, ﬂickering lights, or sun 
glare?  
F. Shortly after waking up, either in the morning or after a nap, have 
you ever noticed uncontrollable jerking or clumsiness, such as 
dropping things or things suddenly ‘‘ﬂying’’ from your hands?  
G. Have you ever had any other type of repeated unusual spells? 
 
Figure 2.1 Nine question screening instrument for the ascertainment of epilepsy 
(Ottman et al., 2010). 
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based study. Within their validation study, Ottman et al. (2010) considered four 
definitions of a positive screen which consisted of a positive response to: (1) any 
question in the screening instrument (any positive); (2) any of Q2 through Q3G 
(any positive excluding febrile seizure); (3) Q2 or Q3A (epilepsy or any seizure); 
and (4) Q2 only (epilepsy only).  For each screen definition, sensitivity was 
defined as the proportion of subjects with medical record–documented 
unprovoked seizures who screened positive, and the false-positive rate (1-
specificity) was defined as the proportion of subjects who screened positive 
among subjects found to be seizure-free on record review. Of those individuals 
identified as having epilepsy on record review, 76% responded positively to the 
‘epilepsy’ screening question (Q2), compared to only 46% of those with isolated 
unprovoked seizure on record review. Among those who did not respond 
positively to Q2, 15% of those with epilepsy and 35% of those with isolated 
unprovoked seizure responded positively to the ‘any seizure’ question (Q3A). 
Only a small number of subjects responded positively to the symptom-based 
questions (Q3B-G). The only possible exception was Q3C which asked about ‘‘a 
change in mental state or level of awareness’’, in which both subjects with and 
without unprovoked seizures were equally likely to respond positively.  
Sensitivity was highest for the broadest screen definition (positive response to 
any screen question) among both those with medical record documented 
epilepsy (96%) and isolated unprovoked seizure (87%). However, it is important 
to note that 7% of seizure-free subjects also screened positive according to this 
definition. Sensitivity declined when the febrile seizure question was excluded, 
both for subjects with epilepsy (94%) and those with an isolated unprovoked 
seizure (85%). Next, when the screen definition of ‘‘epilepsy or any seizure’’ (Q2 
or Q3A) was employed, sensitivity was slightly lower and the false-positive rate 
declined to 3%.  Finally, using the ‘‘epilepsy only’’ screen definition (Q2), 
sensitivity declined to 76% among epilepsy patients however the false positive 
rate also declined considerably to 0.8%. Ottman et al. (2010) also calculated the 
positive predictive value (PPV; the proportion of screen-positive individuals 
subsequently confirmed to be affected), based on an epilepsy prevalence of 2%. 
They revealed PPV to be the lowest for the broadest screen definition. 
Therefore, although this group yielded the highest sensitivity, an expected PPV 
of 23% suggests that approximately only one in four positive screens would be 
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confirmed as having epilepsy within subsequent stages of screening, using this 
broad screen definition of epilepsy. In contrast, Ottman et al. (2010) reported 
that use of the epilepsy question alone produced the highest PPV, estimating 
that 66% of screen-positive individuals would be confirmed to have epilepsy 
using this question. Ottman et al. (2010) argue that the optimal choice for 
screening depends on the resources available and the purpose of a particular 
study. For example, if the objective is to estimate the prevalence of epilepsy, 
then it is essential that sensitivity is maximised to avoid underestimation. 
However, it must also be acknowledged that the rate of false positives will be 
high and positive screens will need to be evaluated in a second stage of 
screening to confirm true epilepsy cases. Conversely, if the objective of a study 
is to identify individuals likely to have epilepsy for further analysis (for example, 
comorbidity studies; Kobau et al., 2006; Ottman et al., 2011) it is suggested that 
the use of the epilepsy question alone (Q2) may be sufficient at minimal cost 
(i.e. lowest false positive rate).  
Within Chapter 6 of this thesis, the objective was to identify individuals with 
epilepsy within a cohort of individuals with bipolar disorder to examine potential 
differences in lifetime bipolar clinical characteristics according to presence of 
epilepsy. Therefore, it was decided that a screening definition of epilepsy with 
the highest specificity (lowest false positive rates) was required. Consequently, 
for the purposes this thesis, self-reported epilepsy/seizures was defined as 
anyone who screened positively (answering either ‘yes’ or ‘possible’) to the main 
seizure disorder/epilepsy question: 
‘Other than the seizure[s] you had because of a high fever (so other than febrile 
seizures), have you ever had, or has anyone ever told you that you had, a seizure 
disorder or epilepsy?’ 
Although it was anticipated that use of the above screening question to identify 
epilepsy cases within the bipolar sample would provide a low false positive rate, 
this thesis looks to more definitely define epilepsy within the cohort through the 
use of a detailed telephone interview, in order to separate true from false 
positives. Details of this process are described fully in Chapter 6. The telephone 
interview utilised within this thesis was an adaptation of a standardised, 
structured diagnostic inventory employed by the Epilepsy Phenome Genome 
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Project (EPGP) and can be found in Appendix D. The interview used by the 
EPGP was modified from a previously validated instrument; the Seizure 
Classification Interview (SCI) which was originally developed as part of the 
Epilepsy Family Study Proband Interview Form (Ottman et al., 1993, 1990). The 
SCI contains both structured questions in discrete categories (e.g. ‘yes’, ‘no’, or 
‘don’t know’), as well as open-ended free verbatim questions. The SCI contains 
separate sections to assess four categories of seizures: 1) ‘big seizures’ or grand 
mal seizures; 2) ‘small seizures’ or partial seizures; 3) ‘sudden jerking of part or 
all of your body’; and 4) ‘episodes in which part or all of your body suddenly goes 
limp, causing you to fall or drop things’. The section on grand mal seizures is 
designed to distinguish between primary and secondary generalization, and 
includes questions on age at onset, history of aura, unilateral onset of 
convulsions, postictal unilateral weakness and numbness, and postictal aphasia. 
A verbatim section asks participants to describe what happens before, during, 
and after the seizure. Loss of consciousness is assessed with questions asking 
about history of postictal confusion and drowsiness, and inability to recall 
events during the seizure.  
The next section on ‘small seizures’ includes questions on age at onset, seizure 
duration, changes in awareness and ability to communicate with surroundings, 
focal motor activity, automatisms, eye-fluttering, postictal confusion, and 
postictal drowsiness. A verbatim description of what happens before, during, 
and after a small seizure is also requested. If the patient has had more than one 
type of small seizure, they are asked to name these in the order of most to least 
frequent and the questions included in this section of the interview are repeated 
for each type. The primary aim of the section on episodes of sudden jerking is to 
confirm history of myoclonic seizures, and includes questions on age at onset, 
extent of body involvement (i.e., part or all), unilateral or bilateral involvement, 
restriction of episodes to the same side, and usual timing (i.e., only before sleep, 
only before a big seizure, only on awakening).  
The final section on episodes of going limp aims to ascertain history of atonic 
seizures and includes questions on age at onset, loss of consciousness, and 
postictal confusion. A validation study of the SCI based on 50 patients confirmed 
to have a lifetime history of epilepsy (defined as the lifetime history of two or 
more unprovoked seizures, in line with the International League Against 
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Epilepsy; ILAE), compared interview-based diagnoses with independent 
diagnoses made by neurologists (also using the ILAE system for seizure 
classification) (Ottman et al., 1990). The study revealed that interview 
diagnoses agreed with those of the neurologist for broad seizure-type 
classifications (i.e., partial vs. generalized onset) in 88% of patients, and for the 
diagnosis of specific seizure type in 64% of patients. Sensitivity ranged from 
0.60 to 1.0 for partial onset seizures, and from 0.43 to 0.67 for generalized onset 
seizures. Specificity ranged from 0.60 to 0.87 for partial onset seizures, and was 
1.0 for generalized onset seizures. Positive predictive value was 0.95 for any 
partial onset and 1.0 for any generalized onset seizure. These results suggest 
that the SCI can be used to produce accurate diagnoses of major seizure 
categories. 
Within their assessment, the EPGP employed a modified version of the SCI 
which no longer included separate sections for the third and fourth seizure 
categories of ‘sudden jerking’ and ‘going limp’, and rather incorporated these 
within a ‘small seizures’ section. The semi-structured interview used by the 
EPGP was designed to ascertain seizure type, symptomatology, seizure 
frequency, age at onset, history of status epilepticus, epilepsy syndrome, 
anticonvulsant response, and additional medical conditions including migraine. 
The interview comprised of the following sections: grand mal seizure overview 
(which mirrored the ‘big seizures’ section in the SCI); a small seizure overview; a 
section asking about seizure triggers; a screen for status epilepticus, prolonged 
seizures and recurrent seizures; a section to assess the lifetime history of 
migraine headaches (described in Section 2.7 of this chapter); and a final section 
asking about alcohol intake and its relation to seizures.   
The telephone interview employed within this thesis was an adapted version of 
that used by the EPGP. One of the main differences between these two 
interviews involved the structure of sections to ascertain an overview of seizure 
types. As outlined above, the EPGP employed separate sections to assess ‘big 
seizures’ and ‘small seizures’. The modified interview used within the current 
thesis did not separately assess these. Rather, in line with the structure of the 
EPGP interview section for ‘small’ seizures, we asked participants to name each 
different seizure type they had experienced (where a different ‘type’ was 
described as one where they feel different during the event, or if what happens 
88 | P a g e  
 
before, during or after the event is different from other types). We then asked 
participants to list these in the order from most to least frequent, and 
participants were asked about each of their seizure types in turn. As per the 
EPGP interview, we asked participants questions to assess age at onset, seizure 
duration, changes in awareness and ability to communicate with surroundings, 
postictal confusion, and postictal drowsiness, as well as a verbatim description 
of what happens before, during, and after the seizure. We did not, however, ask 
participants the specific symptom questions included in the EPGP interview. 
This decision was made as it was thought that the purpose of these questions 
were to determine the type of epilepsy experienced, whereas the aim of the 
study reported in the current thesis was to identify the presence of epilepsy (of 
any kind).  
Further differences between the EPGP interview and modified interview used 
within this thesis include the omission of sections assessing status epilepticus, 
as well as other medical conditions (migraine). Moreover, within the section 
relating to alcohol intake, the interview used within this thesis asked 
participants more generally about their intake and its relation to their seizures, 
rather than asking about alcohol intake prior to and following the onset of their 
epilepsy/seizures as per EPGP interview. Finally, the interview employed within 
this thesis included additional sections that were not included in the original 
interview. These included sections to assess; any medical 
examinations/investigations the participant had received in relation to their 
seizures, medication prescribed, and family history of seizures and epilepsy.  
In order to determine a diagnosis of epilepsy, all interviews were reviewed 
together by myself and Consultant Epileptologist, Professor Mike Kerr. In the 
instance of complex cases, these were blind reviewed by a second 
Epileptologist, Dr Rhys Thomas, and a consensus diagnosis was reached.  
 
2.9 Data capture – Formic 
The BDRN interview and questionnaire measures described above are designed 
using the data capture system Formic Fusion (Formic Ltd: Middlesex, UK). This 
system allows completed forms to be scanned so that the data are electronically 
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recorded. The scanning procedure also allows data verification checks to be 
performed. Following data capture, the data can then be viewed and exported 
for further use.  
Whilst the headache questionnaire used by BDRN was designed and 
disseminated to the research cohort prior to my joining of the group, the 
questionnaire pack including the epilepsy questionnaire, as well as both 
migraine and epilepsy telephone interviews were designed by myself using the 
formic system. Completed questionnaire packs of the entire BDRN cohort were 
also scanned and validated by myself.  
 
2.10 Statistical analysis 
Details regarding specific analyses employed will be described within each 
chapter. Analyses were performed using SPSS version 20 (IBM Corp, 2011) 
unless stated otherwise. Normality of the data was assessed using the 
Kolmogorov-Smirnov test. The majority of the data analysed were not normally 
distributed and so non-parametric tests were employed. Statistical tests were 
considered significant at the p<0.05 level (two tailed) unless stated otherwise.  
 
2.11 Overview of samples used within the present thesis  
Figure 2.2 shows the derivation of the samples used within each chapter of this 
thesis. 
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Figure 2.2 Diagram to show the derivation of the samples used within each chapter of this 
thesis.  
Consented to Bipolar Disorder Research 
Network and undergo clinical assessment 
(Section 2.5) 
Non-systematic recruitment 
(Section 2.3.2) 
Systematic recruitment 
(Section 2.3.1) 
2011 questionnaire pack 
(n=3957)  
(Section 2.7) 
2013 questionnaire pack 
(n=5216) 
(Section 2.8) 
Completion of migraine 
questionnaire a,b,c  
(n=1569, 39.6%) 
Completion of epilepsy 
questionnaire d 
(n=2082, 40%) 
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Chapter 3 
Examination of migraine in a bipolar disorder 
sample 
 
 
3.1 Introduction 
The introductory chapter of this thesis explored evidence for overlap between 
the neurological disorder of migraine, and bipolar disorder (BD), and outlined a 
number of clinical and population studies reporting an increased prevalence of 
migraine among BD sufferers (Mahmood et al., 1999; McIntyre et al., 2006b; 
Ortiz et al., 2010; Gordon-Smith et al., 2015). It was also reported that 
individuals with bipolar II disorder (BDII) may be disproportionately affected by 
migraine (Fasmer, 2001; Ortiz et al., 2010; Saunders et al., 2014); a finding 
supported by a recent meta-analysis exploring the prevalence and moderators 
of migraine in BD (Fornaro and Stubbs, 2015). Chapter 1 also outlined 
differences in the psychiatric comorbidity of migraine that were dependent on 
migraine subtype, with migraine with aura (MA) observed to have a stronger 
association with psychiatric disorders than migraine without aura (MoA) (Ball et 
al., 2009; Breslau et al., 1991).  Taken together, this evidence suggests that 
migraine is frequently comorbid with BD and that the strength of this 
association varies according to the particular subtype of migraine, and of BD, 
under study. Further evidence identifying differences in the clinical course of the 
bipolar illness in those with comorbid migraine, and the possibility of common 
pathophysiological mechanisms between the two disorders, suggest that 
migraine may delineate a distinct subset of individuals with BD. However, given 
the caveats of a number of existing studies regarding: small sample sizes; lack 
of standardised criteria for migraine; unrepresentative clinical samples; and 
inconsistency across studies in their definition of bipolar subtypes (in particular 
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BDII), further research is required to examine the complex relationship between 
migraine and BD. 
The current chapter looks to extend existing literature by identifying the rate of 
migraine within a large, well-defined UK sample of individuals with a Diagnostic 
and Statistical Manual of Mental Disorders (4th edition) (DSM-IV; American 
Psychiatric Association 2000) diagnosis of BD. This study will also assess the rate 
of migraine across the bipolar diagnostic subtypes; bipolar I disorder (BDI), 
bipolar II disorder (BDII) and schizoaffective, bipolar type (SABP). A further 
focus of this study is to explore the association between the migraine subtypes; 
migraine with aura (MA) and migraine without aura (MoA), and BD. Chapter 2 
described the different methods employed by the Bipolar Disorder Research 
Network (BDRN) for the case definition of migraine, and so the final aim of this 
chapter will assess the concurrent validity of these methods for the 
measurement of migraine within the bipolar sample.  
 
3.2 Methods 
3.2.1 Subjects 
Participants were drawn from the Bipolar Disorder Research Network (BDRN), 
a clinical and genetic study of individuals across the United Kingdom with mood 
disorders, described in detail within Chapter 2.  
A questionnaire pack including a self-report questionnaire assessing lifetime 
history of migraine (detailed within Chapter 2; Appendix A) was disseminated 
to 3957 BDRN participants. Of these, 1583 individuals completed and returned 
the questionnaire pack (response rate of 40%). Of these, 1569 (99%) individuals 
had completed the migraine questionnaire. Individuals were included in the 
current study if they met DSM-IV (American Psychiatric Association, 2000) 
diagnostic criteria for bipolar I disorder (BDI), bipolar II disorder (BDII), or 
schizoaffective, bipolar type (SABP), leaving 1428 participants in the current 
study.  
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3.2.2 Assessment of migraine 
3.2.2.1 Self-report questionnaire 
The lifetime history of migraine within the bipolar sample was primarily 
assessed using the self-report questionnaire. The questionnaire was a modified 
version of The Structured Migraine Interview (SMI) (Samaan et al., 2009) and is 
outlined within Chapter 2. Using this measure, a diagnosis of migraine was 
assigned according to criteria of the International Headache Society (IHS) 
(ICHD-II; Headache Classification Subcommittee of the International Headache 
Society, 2004) for migraine without aura (MoA), migraine with aura (MA) 
(including hemiplegic migraine, HM), and probable migraine.  
3.2.2.2 Telephone interview 
In order to assess the concurrent validity of the self-report questionnaire in 
screening for the lifetime presence of migraine within a bipolar population, a 
random sub-sample of subjects were selected to complete a follow-up 
telephone interview. This sub-sample was chosen to comprise of 100 subjects; 
20 individuals identified as having no history of migraine according to the self-
report questionnaire, 60 individuals identified as having probable migraine, and 
20 individuals identified as having a lifetime history of migraine. The majority of 
cases were selected from the ‘probable migraine’ group because this was the 
group where it was expected there was likely to be less concordance between 
actual diagnosis and that derived from the screening measure compared to 
those identified as definitely having or not having migraine. Individuals with 
probable migraine are missing just one criterion for a full migraine diagnosis and 
so it is likely that a number of these represent true migraine cases. Thus, the 
proportion of individuals to be contacted within each diagnostic group was 
chosen to allow for further investigation into the probable migraine group, to 
explore the appropriateness of adopting a broader definition of migraine, 
incorporating those with probable migraine. Participants from each diagnostic 
group (migraine, probable migraine and no migraine) were randomly selected 
to be contacted for telephone interview.  
In order to be considered for selection for telephone interview, participants were 
required to have address and contact number details recorded on the study 
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database. Once these participants had been identified, their unique study 
identifier was listed in ascending order in an excel spreadsheet (participants 
from each migraine group; migraine, probable migraine, no migraine, were 
listed in separate spreadsheets). In order to assign random numbers to each 
participant, the excel command “=RAND()” was used. Participants were then 
ordered according to their assigned random number.  From the ordered and 
randomised list for each migraine group, the top 20 were selected to be 
contacted for telephone interview from the migraine and no migraine groups, 
and the top 60 were selected from the probable migraine group, as discussed 
above. Once telephone interviews had commenced, it was decided that a 
further 10 individuals would be randomly selected to be contacted for telephone 
interview to allow for the likelihood that a 100% response rate would not be 
achieved. These 10 individuals were selected in line with the process and group 
proportions detailed above; 2 from the no migraine group, 6 from the probable 
migraine group and 2 from the migraine group.  
Individuals selected for telephone interview were sent an initial contact letter, 
which provided brief details about the research and informed individuals that a 
researcher would be in contact over the next few weeks.  Individuals were also 
given the opportunity to refuse any further contact regarding this research, by 
contacting the study team by telephone or email. If the individual did not 
contact the team, I called the participant to answer any questions they may have 
had regarding the research and to discuss whether they would be interested in 
taking part. 
The telephone interview employed was an adaptation of a standardized and 
validated interview, developed by (Lipton et al., 2001) (Appendix B) and is 
described in detail in Chapter 2. All subjects were interviewed by myself and I 
was blind to the subject’s original migraine diagnosis derived from the self-
report questionnaire at the time of telephone interview.  
3.2.2.3 Single item checklist 
As described in Chapter 2, as part of the BDRN clinical assessment, individuals 
were asked about their history of a variety of medical illnesses on a brief self-
report medical history checklist. Specifically, information regarding lifetime 
history of medical illness was assessed by asking participants if a doctor or 
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health professional had ever told them that they had ever had any of twenty 
medical disorders, including migraine headaches.  
 
3.2.3 Statistical analysis 
3.2.3.1 Migraine prevalence according to BD diagnostic subtype  
Lifetime prevalence of migraine was compared across bipolar I disorder (BDI), 
bipolar II disorder (BDII), and schizoaffective bipolar type (SABP) diagnostic 
groups, with chi-square tests, to determine whether rates significantly differed 
between groups. To assess the association of each bipolar diagnostic subtype 
(BDI, BDII and SABP) with migraine, binary logistic regression analysis was 
conducted for each bipolar subtype (against other diagnoses combined as a 
reference group) with migraine status as the outcome variable. Due to the 
known increased rate of migraine among women, sex was also entered in to the 
logistic regression models as a covariate.  In addition, a significant difference in 
age at interview was found between bipolar diagnostic groups (p=.027) with the 
median age at interview being highest within the BPI group (49 years), followed 
by the BPII group (47 years), followed by the SABP group (44 years). Migraine 
prevalence is known to peak in mid-life and decline thereafter, therefore given 
the age range observed across bipolar diagnostic groups, age was also included 
as a covariate.   
 
3.2.3.2 Association of migraine subtypes across BD diagnostic subtypes 
To assess the association of each migraine subtype; migraine with aura (MA) 
and migraine without aura (MoA), with bipolar diagnostic groups (BDI, BDII, and 
SABP), a binary logistic regression was conducted for each BD diagnostic group; 
firstly with MoA vs. no migraine, and secondly with MA vs. no migraine, as the 
outcome variable. As above, age and sex were entered into the logistic 
regression models as covariates.  
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3.2.3.3 Comparison of BDRN methods for determining a migraine 
diagnosis 
The primary method used to determine migraine diagnosis within the current 
study was the interpretation of responses to the self-report migraine 
questionnaire, according to IHS criteria. However, in order to clarify symptoms 
of migraine and to provide an extra degree of certainty about the diagnosis, 
telephone interviews were conducted on a sub-sample individuals (described in 
Section 3.2.2.2). As described in the ‘Assessments’ section (Section 3.2.2), 
BDRN also have data available from a single item checklist asking whether 
individuals had ever been told by a doctor or health professional whether they 
had a variety of medical illnesses, including migraine. This study will compare 
the performance of these methods in establishing a diagnosis of migraine within 
subjects with BD.   
Firstly, the study aims to assess concurrent validity of the single item checklist 
measure of migraine diagnosis, using the diagnosis established with the self-
report questionnaire as the reference diagnosis. Secondly, the study aims to 
assess validity of the self-report questionnaire, using the diagnosis derived from 
telephone interviews as the reference diagnosis.  
For both of the above comparisons, validity was assessed by calculating 
sensitivity, specificity, positive and negative predictive value. Sensitivity of an 
instrument refers to the ability of the tool to correctly identify individuals with a 
particular disease and is calculated as follows: 
 
Sensitivity =            true positive 
               true positive + false negative) 
 
 
 
Specificity refers to an instrument’s ability to correctly identify those without 
the disease in question: 
 
 
Specificity=          true negative 
                                        (true negative  + false positive)  
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Measures of sensitivity and specificity are computed in order to evaluate the 
ability of a test to discriminate between individuals with and without a particular 
disease. Both parameters are population measures and so summarise 
characteristics of a test over a particular population. Consequently, they have 
limited clinical usefulness in determining an individual patients’ probability of 
having the disease in question. Alternatively, when we know a patient’s test 
result and want to interpret that to assess the likelihood of them having the 
disease, predictive values are considered to be more appropriate. Positive 
predictive value (PPV) is defined as the probability that the disease is present 
when the test is positive:  
 
     PPV =                true positive 
                                   (true positive + false positive)  
 
 
 
Conversely, negative predictive value (NPV) is the probability that the disease 
is not present when the test is negative: 
 
 
    NPV =     true negative 
                                (true negative  + false negative) 
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3.3 Results 
3.3.1 Completion of BDRN questionnaire pack  
Of the 3957 questionnaire packs disseminated to BDRN participants, 1583 were 
completed and returned, providing a response rate of 40%. Of those who 
returned their questionnaires, 1569 (99.1%, 39.6% of total) had completed the 
migraine questionnaire and of these, 1428 met DSM-IV diagnostic criteria for 
bipolar disorder, with 993 (69.5%) having a diagnosis of bipolar I disorder (BDI), 
380 (26.6%) of bipolar II disorder (BDII), and 55 (3.9%) of schizoaffective, bipolar 
type (SABP). Of the 1428 subjects included in the current study, 1049 (73.5%) 
were female. The mean age of participants at interview was 48.03 ± 11.7 years 
(range 18-83 years).  
Given that the self-report migraine questionnaire was disseminated to BDRN 
participants as part of a larger questionnaire pack, it is possible that participants 
with a history of migraine may have been more likely to complete the migraine 
questionnaire, potentially biasing the sample. To further explore this, I 
examined completion rates of the additional eight questionnaires included in 
the questionnaire pack, by those who completed the migraine questionnaire 
(Table 3.1).  
Table 3.1 Completion rates of additional questionnaires by participants 
completing the migraine questionnaire 
Number of additional questionnaires 
completed by participants completing the 
migraine questionnaire  
N (%) 
All 8 additional questionnaires 1137 (72.5%) 
7 additional questionnaires 415 (26.4%) 
6 additional questionnaires 15 (1%) 
5 additional questionnaires 1 (0.05%) 
4 additional questionnaires 1 (0.05%) 
3 additional questionnaires 0  
2 additional questionnaires 0 
1 additional questionnaires 0 
Migraine questionnaire only 0 
 
Of the 1569 subjects who completed the migraine questionnaire: 1137 
individuals (72.5%) completed the additional 8 questionnaires included within 
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the pack, and a further 415 individuals (26.4%) completed 7 questionnaires. No 
individuals completed the migraine questionnaire only.  
As mentioned above, 99.1% of the 1583 BDRN subjects who returned the 
questionnaire pack completed the migraine questionnaire. Examination of the 
14 subjects (0.9%) who returned their questionnaire pack but did not complete 
the migraine questionnaire revealed that: 28.6% (n=4) completed all of the 
further 8 questionnaires included in the pack; 42.9% (n=6) completed 7 other 
questionnaires; 14.3% (n=2) completed 6 other questionnaires; 7.1% (n=1) 
completed 5 other questionnaires; and finally, 7.1% (n=1) completed 4 other 
questionnaires included in the pack.  
 
3.3.2 Migraine prevalence within the BD sample 
According to the self-report questionnaire, a total of 277 (19.4%) individuals 
were identified as having comorbid migraine according to IHS criteria (21.7% 
among women and 12.9% among men). A further 304 (21.3%) met criteria for 
probable migraine, which as stated previously, is an attack or headache missing 
one of the features needed to fulfil all IHS criteria for a migraine disorder.  65 
(4.5%) individuals were found to have typical aura with non-migraine headache, 
and 4 (0.3%) were classified as having typical aura without headache. Finally, 778 
(54.5%) individuals were found to have no migraine. Figure 3.1 depicts the 
breakdown of these categories within the total sample. 
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Figure 3.1 Migraine prevalence within the bipolar sample (N=1428).  
Note: ‘Other’ consists of typical aura with non-migraine headache n=65        
(4.5%) and typical aura without headache n=4 (0.3%) 
 
 
Figure 3.2 shows the breakdown of migraine diagnoses within the 277 
individuals meeting IHS criteria for migraine.  
 
 
    
 
 
 
 
 
 
 
Of the 277 (19.4%) individuals meeting IHS criteria for migraine; 153 (55.2%; 
10.7% of total sample) met criteria for migraine with aura (MA); 46.9% in males 
and 57% in females. Forty-five individuals with MA met criteria for hemiplegic 
778, 54.5%
277, 19.4%
304, 21.3%
69, 4.8%
No migraine
Migraine
Probable migraine
Other
Migraine (n=277) 
Migraine without aura (n=124) Migraine with aura (n=153) 
Hemiplegic migraine (n=45) 
Figure 3.2 Breakdown of International Headache Society (IHS) migraine 
diagnoses of the 277 individuals identified as having migraine according to the 
self-report questionnaire. 
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migraine (HM) (16.2%; 3.1% of total sample). One-hundred and twenty-four 
individuals (44.8%; 8.7% total sample) met criteria for migraine without aura 
(MoA); 53.1% in males and 43% in females.  
 
3.3.2.1 Migraine prevalence according to bipolar diagnostic subtypes 
Figure 3.3 displays the rate of migraine across bipolar diagnostic subtypes (BDI, 
BDII and SABP).  
 
Figure 3.3 Rate of migraine (%) across bipolar diagnostic subtypes, bipolar I 
disorder (BDI) (n=993), bipolar II disorder (BDII) (n=380), and schizoaffective 
bipolar type (SABP) (n=55).  
 
 
Figure 3.3 reveals that migraine prevalence was found to be highest among 
individuals with SABP (25.5%) and those with BDII (25%). Individual chi-square 
tests revealed that the rate of migraine was statistically significantly higher in 
those with BDII when compared to those with BDI (p=.000004).  
To assess the association of migraine with each bipolar diagnostic subtype 
(against other diagnoses combined) individual logistic regression models were 
constructed with presence or absence of migraine as the outcome variable 
(Table 3.2). Analyses included age and gender as covariates as described in the 
methods section (Section 3.2.3). 
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Table3.2 Association of migraine with bipolar diagnostic subtypes 
Bipolar 
subtype 
Adjusted 
odds Ratio 
(OR) 
95% CI P-value 
Lower Upper 
BDI .487 .361 .657 .000002* 
BDII 2.027 1.486 2.765 .000008* 
SABP 1.439 .730 2.836 .293 
*p<.01. AOR=adjusted odds ratio controlling for age and sex; CI=confidence interval; 
BDI=bipolar I disorder; BDII=bipolar II disorder; SABP=schizoaffective bipolar type  
 
A significant negative association was found to exist between migraine and BDI 
(OR: .487; 95% CI: .361-.657), and a significant positive association was found 
between migraine and BDII (OR: 2.765; 95% CI: 1.486-2.765). A positive 
association was also found between migraine and the SABP patient group; 
however this association failed to reach statistical significance, which may be 
due to the small number of cases in this group (n=55).  
 
3.3.3 Migraine subtypes and their association with BD 
Figure 3.4 displays the rate of migraine without aura (MoA), and migraine with 
aura (MA) across bipolar diagnostic subtypes. Rates of MA were higher than 
MoA in each of the bipolar diagnostic subtypes and were highest in the 
schizoaffective bipolar (SABP) group (64.3%), followed by the bipolar II disorder 
(BDII) group (57.9%), followed by the bipolar I disorder (BDI) group (53%).  
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Figure 3.4 Rate of migraine with aura and migraine without aura across bipolar 
diagnostic subtypes, bipolar I disorder (BDI), bipolar II disorder (BDII), and 
schizoaffective bipolar type (SABP) 
 
 
It was also of interest to determine the association of each migraine subtype 
(MA and MoA) with individual bipolar diagnostic subgroups (BDI, BDII and 
SABP). To explore this, individual logistic regressions were computed to 
examine the specific association of each of the bipolar diagnostic subtypes 
(compared with all other diagnoses combined) with; i) migraine with aura (MA) 
vs. no migraine, and ii) migraine without aura (MoA) vs. no migraine. Table 3.3 
displays adjusted odds ratios (OR) including age and gender as covariates, 95% 
confidence intervals (95% CI), and p-values for each migraine subtype 
(compared to no migraine) across bipolar diagnostic groups. 
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Table 3.3 Association of bipolar disorder subtypes in individuals with aura (MA) 
and without aura (MoA) compared with individuals with no migraine 
Bipolar 
subtype 
Migraine without aura (MoA), n 
(%) 
Migraine with aura (MA),  
n (%) 
AOR 
(95% CI) 
P-value 
(95% CI) 
AOR  
(95% CI) 
P-value 
BDI .555  
(.369-.834)* 
.005* .436  
(.302-.631)* 
.00001* 
BDII 1.875  
(1.231-2.858)* 
.003* 2.183  
(1.491-3.194)* 
.000059* 
SABP 1.066  
(.397-2.867) 
.899 1.740  
(.784-3.863) 
.174 
* p<.01. AOR=adjusted odds ratio controlling for age and sex; 95% CI=95% confidence 
interval; BDI=bipolar I disorder; BDII=bipolar II disorder; SABP=schizoaffective bipolar type  
 
 
Table 3.3 shows that the same direction of effects that were observed with any 
migraine vs no migraine are seen with both migraine subtypes, in terms of a 
significant negative association of MoA and MA with BDI, and a significant 
positive association with BDII. Moreover, it can be seen that the strength of the 
association with BDII is larger for MA than for MoA, and is also larger than the 
association with any migraine (Table 3.2).  
 
3.3.4 Validation of measures for migraine diagnosis  
3.3.4.1 Single item checklist vs. self-report questionnaire for migraine 
diagnosis 
Table 3.4 shows the breakdown of migraine and no migraine diagnoses 
according to the single item checklist measure of migraine and the self-report 
migraine questionnaire. This table also shows calculated values for sensitivity, 
specificity, positive predictive value and negative predictive value for the single 
item checklist measure compared to the self-report questionnaire measure as 
the reference diagnosis.   
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Table 3.4 Relationship between the single item checklist measure and self-
report questionnaire for the diagnosis of migraine 
Single item 
checklist 
 
Self-report questionnaire  
Migraine No migraine Total 
Migraine 125 (56.6%) 35 (6.2%) 160 (20.3%) 
No migraine 96 (43.3%) 532 (93.8%) 628 (79.7%) 
Total 221 (100%) 567 (100%) 788 (100%) 
 
Sensitivity = true+ (true+ + false-) = 125/(125+96) = 0.566 = 56.6% 
 
Specificity = true - (true- + false+) = 532/(532+35) = 0.938 = 93.8% 
 
Positive predictive value = true+/(true+ + false+) = 125/(125+35) = 0.78 = 78% 
 
Negative predictive value = true-/(true- + false-) = 532/(532+96) = 0.85 = 85% 
 
 
A moderate sensitivity (56.6%) and high specificity (93.8%) was found for the 
single-item measure of ‘doctor diagnosed’ migraine, when compared to a 
diagnosis derived from the self-report questionnaire. Such a combination 
suggests that although the measure was very effective in correctly identifying 
those without the disorder, this came at a cost in sensitivity, with 43.3% of those 
identified as having migraine according to the self-report questionnaire, going 
undetected.  Thus, the high specificity implies that one is unlikely to obtain a 
positive screen for a patient who does not truly have the disease; however a 
negative screen is likely to include false negatives, given the relatively modest 
sensitivity. Moreover, the positive predictive value (PPV) was 0.78 and negative 
predictive value (NPV) 0.85, indicating that 78% of those who screened positive 
for migraine with the single item measure actually had migraine (according to 
the self-report questionnaire) and 85% of individuals who screened negatively 
for migraine with the measure, were found not to have migraine with the self-
report questionnaire. Thus, it seems that the single item measure may be better 
at ruling out migraine (NPV 0.85) than it is as ruling in migraine (PPV 0.78).  
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3.3.4.2 Self-report questionnaire vs. telephone interview for migraine 
diagnosis 
As described within the methods section of this chapter, a total sub-sample of 
110 individuals were selected from the 1428 that had completed the self-report 
migraine questionnaire, to be contacted to complete a follow-up telephone 
interview. Of the 110 maximum possible interviews, I completed a total of 80 
(72.7%). The number of individuals successfully contacted and the number of 
interviews completed throughout the telephone interview process are 
summarised in Figure 3.5. 
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Participants selected for telephone interview (n=110) 
(no migraine, n=22; migraine, n=22; probable migraine, n=66) 
Number not in use when contacted, 
sent letter requesting updated 
details, n=24 
(no migraine, n=5 ; probable migraine, 
n=15; migraine, n=4) 
 
No response, n=13 
(no migraine, n=2; 
probable migraine, 
n=10; migraine, 
n=1) 
 
Response, n=11 
(no migraine, n=3;  
probable migraine, 
n=5; migraine, n=3) 
 
Successful contact made, 
n=82 
(no migraine, n=20; probable 
migraine, n=45; migraine, 
n=17) 
 
Unable to contact following 
multiple attempts, n=15 
(no migraine, n=1; probable 
migraine, n=12; migraine, 
n=2) 
 
Interview declined, n=1 
(no migraine, n=1) 
Interview completed, n=80 
(no migraine, n=19;  
probable migraine, n=45; 
migraine, n=16) 
 
Unable to re-contact for 
interview, n=1 
(migraine, n=1) 
Figure 3.5 Flow chart of participants selected and contacted for telephone interview 
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Of the individuals selected for telephone interview (n=110), 22% (n=24) were 
found not to have working numbers when contacted. These individuals were 
sent a follow-up letter asking them to complete a form updating the research 
team with their contact details if they were interested in hearing more about the 
research and to return this form in the stamped addressed envelope provided. 
Thirteen individuals (54.2%) responded to this letter and provided the research 
team with their up to date contact details. A total of 82 individuals (including the 
13 that replied to the request for updated details) were successfully contacted 
to discuss details regarding the research and to enquire whether they would like 
to complete the telephone interview. Of these, 80 (73% of the total possible 
number of participants, n=110) individuals completed the telephone interview. 
One individual declined the interview and one individual was unable to be 
contacted at the arranged time to complete the telephone interview (nor were 
they available on multiple subsequent attempts). Table 3.5 shows the total 
number of interviews completed across the migraine groups. The proportion of 
interviews completed across migraine groups is similar to those we were 
originally aiming for (i.e. 20% from the migraine group, 60% from the probable 
migraine group, and 20% from the no migraine group).  
Table 3.5 Number and percentage of telephone interviews completed across 
migraine groups 
Migraine group N (%) 
No migraine  19 (23.7%) 
Probable migraine  45 (56.3%) 
Migraine 16 (20%) 
Total  80 (100%) 
 
Table 3.6 shows the breakdown of migraine and no migraine diagnoses 
according to the self-report migraine questionnaire and the telephone 
interview. This table also shows calculated values for sensitivity, specificity, 
positive predictive value and negative predictive value for the self-report 
questionnaire compared to diagnoses derived from the telephone interview as 
the reference diagnosis. 
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Table 3.6 Relationship between self-report questionnaire and interview 
diagnosis of migraine 
Self-report 
questionnaire  
Telephone interview 
Migraine No migraine Total 
Migraine 12 (92.3%) 1 (6.7%) 13 (46.4%) 
No migraine 1 (7.7%) 14 (93.3%) 15 (53.6%) 
Total 12 (100%) 15 (100%) 28 (100%) 
 
Sensitivity = true + (true+ + false-) = 12/ (12+1) = 0.923 = 92.3% 
 
Specificity = true - (true- + false+) = 14/ (14+1) = 0.933 = 93.3% 
 
Positive predictive value = true + / (true+ + false+) = 12/ (12+1) =0. 92= 92% 
 
Negative predictive value = true - / (true- + false-) = 14/ (14+1) = 0.93 = 93% 
 
 
The self-report questionnaire was found to have high sensitivity (92.3%) and 
high specificity (93.3%), when compared to migraine status derived from the 
telephone interview. Moreover, positive predictive value (PPV) was 0.92 and 
negative predictive value (NPV) 0.93, indicating that the questionnaire is equally 
effective in ruling in migraine (PPV 0.92) as it is ruling out migraine (NPV 0.93). 
As described in Chapter 2, the telephone interviews were completed 
approximately three years following completion of the initial screening 
questionnaire, making it possible for participants to have experienced migraine 
headaches for the first time after completion of the initial questionnaire, thus 
potentially skewing validation figures. It is important to note, however, that no 
participants during the telephone interview stage reported an onset of severe 
headaches after completion of the original migraine questionnaire in 2011.  
Validity of the self-report questionnaire shown above is for a definition of 
strictly-defined migraine; however within the questionnaire and telephone 
interview a number of individuals meeting criteria for probable migraine were 
also identified. Table 3.7 shows the breakdown of probable migraine and no 
migraine diagnoses according to the self-report migraine questionnaire and the 
telephone interview. This table also shows calculated values for sensitivity, 
specificity, positive predictive value and negative predictive value for the self-
report questionnaire compared to diagnoses derived from the telephone 
interview as the reference diagnosis. 
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Table 3.7 Relationship between the self-report questionnaire and telephone 
interview for the diagnosis of probable migraine 
Self-report 
questionnaire 
Telephone interview 
Probable 
migraine 
No migraine Total 
Probable 
migraine 
9 (75%) 4 (22.2%) 13 (43.3%) 
No migraine 3 (25%) 14 (77.8%) 17 (56.7%) 
Total 12 (100%) 18 (100%) 30 (100%) 
 
Sensitivity = true + (true+ + false-) = 9/ (9+3) = 0.75 = 75% 
 
Specificity = true - (true- + false+) = 14/ (14+4) =0.778 = 77.8% 
 
Positive predictive value = true + / (true+ + false+) = 9/ (9+4) = 0.69 = 69% 
 
Negative predictive value = true - / (true- + false-) = 14/ (14+3) = 0.82  82% 
 
The self-report questionnaire was found to be much less sensitive (75%) and 
specific (77.8%) for the diagnosis of probable migraine, compared to that of 
strictly-defined migraine (92.3% and 93.3%, respectively). The reason for the 
lowered sensitivity and specificity of the questionnaire for the diagnosis of 
probable migraine is likely due to the fact that 29 of the 45 (64.4%) individuals 
identified as having probable migraine according to the questionnaire were in 
fact found to meet full criteria for migraine diagnosis following telephone 
interview. Table 3.8 shows the breakdown of all migraine diagnoses across the 
self-report questionnaire and telephone interview.  
Table 3.8 Breakdown of migraine diagnoses according to the self-report 
questionnaire and telephone interview measures 
Self-report 
questionnaire 
Telephone interview 
Migraine Probable 
migraine 
No 
migraine 
Other* Total 
Migraine 12 3 1 0 16 
Probable 
migraine 
29 9 4 3 45 
No migraine 1 3 14 1 19 
Total 42 15 19 4 80 
*’Other’ represents individuals meeting criteria for typical aura with a non-migraine 
headache 
 
Table 3.8 shows that 75% (n=12) of those initially identified as having migraine 
according to the self-report questionnaire, were confirmed to have migraine 
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following telephone interview; and 19% (n=3) were subsequently reclassified as 
having probable migraine. Only one individual originally identified as having 
migraine according to the self-report questionnaire was found not to have 
migraine following telephone interview. In addition, whilst 4 individuals (8.8%) 
originally identified as having probable migraine according to the self-report 
questionnaire were later found to not have migraine following telephone 
interview, the majority (n=29, 64.4%) were actually reclassified as meeting full 
IHS criteria for migraine. Finally, of those who did not meet criteria for migraine 
according to the self-report questionnaire, this was confirmed in n=14 cases 
(74%) following telephone interview, 3 cases (16%) were reclassified as having 
probable migraine, 1 case (5%) now met full criteria for migraine, and the 
remaining case (5%) met criteria for typical aura with a non-migraine headache.  
When considering a broad diagnosis of migraine (including both strictly-defined 
and probable migraine cases) derived from the self-report questionnaire 
compared to a reference diagnosis derived from the telephone interview, a 
sensitivity and specificity of 93% and 74%, respectively, were observed. In 
addition, a positive predictive value of 0.91 and negative predictive value of 0.78, 
indicated that 91% of those who screened positive for broadly-defined migraine 
with the self-report questionnaire were confirmed to have broad migraine, and 
78% of individuals who screened negatively for broadly-defined migraine were 
found not to have migraine at the telephone interview stage.  
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3.4  Discussion 
Results from this study are consistent with a number of population-based 
studies that demonstrate an increased prevalence of migraine in bipolar 
disorder (BD), compared to that reported within the general population 
(Fasmer, 2001; Mahmood et al., 1999; Ortiz et al., 2010). Using a similar 
questionnaire-based method for identifying migraine within the general 
population, Breslau et al. (1991) reported a lifetime prevalence of migraine of 
12.8%. Within the current study, I report a migraine prevalence of 19.4% based 
on a self-report questionnaire measure diagnosed in line with International 
Headache Society (IHS) criteria. It is important to note that migraine prevalence 
described here is slightly lower than the approximate 25% prevalence stated in 
a number of previous studies investigating migraine within a sample of 
individuals with BD (McIntyre et al., 2006b; Low et al., 2003). Reasons for such 
discrepancy could be explained by methodological differences between studies 
in terms of sample population, study definitions of migraine and BD, and 
differences in the proportion of bipolar I (BDI) and bipolar II (BDII) disorder 
subjects included.  
For example, McIntyre et al. (2006b) studied a community sample and reported 
a migraine prevalence of 24.8%. However presence of migraine was determined 
by physician-diagnosed migraine rather than being based on standardised 
criteria of the IHS. Low et al. (2003) reported one of the highest rates of migraine 
prevalence (39%) within individuals with BD. This finding was based on a clinical 
sample, where subjects were currently receiving treatment in an outpatient 
psychiatric unit. Furthermore, the mean age of their sample matched the peak 
age of migraine noted within the general population (approximately 40 years). 
A final key difference is that the migraine questionnaire used to assess IHS-
defined criteria by Low et al. (2003) was administered through a face-to-face 
semi-structured interview.  
Given the slightly reduced migraine prevalence reported here compared with 
previous studies, it is important to note the high rate of probable migraine 
observed. In addition to the 277 (19.4%) individuals identified as having 
migraine, a further 304 (21.3%) were found to have probable migraine (PM); a 
headache fulfilling all but one criterion for migraine with or without aura. Within 
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the general population, estimates of the 1-year prevalence of PM vary widely, 
from 2.6%-9.1% (Henry et al., 2002; Lipton et al., 2002; Rains et al., 2001; Russell 
and Olesen, 1996). In 2004, Patel et al. reported similar 1-year prevalence rates 
of strict and probable migraine (14.7% and 14.6%, respectively) and revealed an 
overlap in symptom profiles between strict and probable migraine, supporting 
the concept that PM is a form of migraine. Moreover, within a French population 
study of 10,585 subjects aged 15 years and older, Henry et al. (2002) revealed 
PM to be more prevalent than strict migraine (9.1% vs. 7.9%, respectively).  
 
Recognising and diagnosing PM is important within clinical practice. Given the 
overlap in profiles of features and treatment response it is likely that PM involves 
the same pathophysiological processes as strictly defined migraine. 
Consequently, if PM is indeed a prevalent form of migraine, population studies 
that focus solely on narrow definitions of migraine may be underestimating 
both the prevalence and impact of migraine. If this study was to incorporate a 
broad definition of migraine (including both strict and probable migraine), 
prevalence would increase to 40.7%. In support of a broader or more inclusive 
definition of migraine, the current study found that a large proportion (64.4%) 
of interviewed probable migraine cases that were interviewed (n=45), were in 
fact reclassified as meeting criteria for strict migraine following telephone 
interview. If these findings generalised so that 64.4% of all of those identified as 
having probable migraine according to the self-report questionnaire (n=304) 
were to be confirmed to meet criteria for strictly-defined migraine, rates of 
migraine within the current sample would increase to 30% (n=473).  
 
Consistent with previous studies (Fasmer, 2001; Ortiz et al., 2010), I found a 
higher prevalence of migraine among subjects with BDII compared to BDI (25% 
vs. 16.9%, respectively); a difference that was found to be statistically significant 
(OR: 2.054, 95% CI 1.508-2.798, p = .000004). A similarly high prevalence of 
migraine was also observed within the schizoaffective, bipolar type group 
(SABP) (25.5%). This was not found to be significantly different compared to 
those with BDI, however, the small sample size of this group (n=55) may mean 
that there was not sufficient power to detect a significant difference. The only 
study to report rates of migraine within SABP is Baptista et al. (2012), who found 
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higher rates of migraine among this group (20.6%), when compared to either 
BDI (16.7%), BDII (6.3%), or with a bipolar non-specified group (17.1%). 
Interestingly, Baptista et al. (2012) report a higher rate of migraine among those 
with BDI compared to BDII, which is in contrast to existing literature. The finding 
of this chapter of an increased prevalence of migraine among BDII subjects 
provides support for the hypothesis that bipolar I and II may be distinct 
nosological conditions, and that the mechanisms involved in the aetiology of 
BDII may also be involved in the aetiology of migraine. As both BDII and 
migraine are found to be more common in women, it could be argued that the 
increase in migraine prevalence within BDII is possibly due an effect of gender. 
The current study included sex as a covariate in analysis, therefore controlling 
for any effect of gender. Moreover, within the current study, male subjects with 
BDII were also found to have elevated rates of migraine.   
Within our bipolar cohort of migraine sufferers, we identified a greater number 
of patients with migraine with aura (MA) than those without aura (MoA). One-
hundred and fifty-three migraine sufferers (55.2%; 10.7% of total sample) had 
experienced MA, compared to the 124 (44.8%; 8.7% of total sample) subjects 
that had suffered with MoA. This becomes even more prominent if the 69 
subjects identified as having typical migraine with non-migraine headache 
(n=65) and typical aura with no headache (n=4) are included within the former 
group. This finding is in contrast to the third of migraine patients generally 
reported to experience aura symptoms (Silberstein and Lipton, 1993). However, 
this is not the only study to report such a finding. For example, in their cross-
sectional study of 62 Norwegian outpatients with affective disorders, Fasmer, 
(2001) observed a greater number of patients with MA (n=12, 43% of migraine 
group, 19% of total sample) compared to MoA (n=10, 35.7% of migraine group, 
16% of total sample). Similarly, in their community-based study of 323 
individuals with BD, Ortiz et al. (2010) reported a two-fold prevalence of MA 
compared to that reported in the general population (Russell and Olesen, 1996). 
The larger proportion of those with MA compared to MoA in this study is not 
surprising given the statistically significant association found between MA and 
BD, particularly for BDII subjects. Such a finding is in line with previous research 
indicating a stronger association between affective disorders and MA, 
compared to MoA (Breslau et al., 1991; Oedegaard et al., 2005a).  
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Forty-five individuals within the MA group met criteria for hemiplegic migraine 
(HM) (16.2%; 3.1% of total sample). Within the general population, the 
occurrence of HM is said to be rare, however only one population-based 
epidemiological survey of sporadic and familial HM has been conducted to date. 
In 2002, Thomsen et al. (2002) estimated the prevalence of HM to be 0.01%, 
with the familial and sporadic forms being equally prevalent. This estimate is 
much lower than the 3.1% rate of HM observed reported in the current study. As 
introduced within Chapter 1 of this thesis, FHM is an autosomal dominantly 
inherited subtype of migraine, for which polymorphisms in at least three genes 
have been implicated; CACNA1A (Ophoff et al., 1996), ATP1A2 (DeFusco et al., 
2003), and SCN1A (Dichgans et al., 2005). All three FHM genes either encode ion 
channels or are involved in ion transportation, and therefore support the 
hypothesis of migraine as a ‘channelopathy’. Disturbances in ion channel 
function are also implicated in BD, with two of the strongest associations to 
come out of genome-wide association studies of bipolar disorder (BD) being for 
two genes involved in ion transportation; ANK3 and CACNA1C (Ferreira et al., 
2008; Lee et al., 2011; Schulze et al., 2009; Scott et al., 2009; Sklar et al., 2008; 
Smith et al., 2009). Given the proposed similarity in the underlying mechanisms 
of FHM and BD, this may suggest a greater likelihood of genetic overlap 
between the two disorders, which may in turn explain the high rate of HM 
observed in the current bipolar sample.  
 
Evaluation of the different methods utilised by the BDRN to ascertain a migraine 
diagnosis, revealed a moderate level of agreement between the single item 
checklist measure of migraine and the self-report questionnaire. Sensitivity of 
the single-item ‘doctor diagnosed’ migraine was found to be 56.6%, suggesting 
that 43.3% of those identified as having migraine with the questionnaire, were 
undetected. Therefore, although the questionnaire disseminated within this 
study is also based on self-report methods, it appears that asking about 
migraine symptomology in more detail in self-report measures, rather than 
asking a single question about the lifetime presence of migraine (as diagnosed 
by a health professional), is advantageous for increasing sensitivity. The 
combination of high specificity and modest sensitivity observed for the single 
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item measure implies that a positive screen is unlikely in a patient who does not 
truly have the disease, however false negatives are likely in the event of a 
negative screen, suggesting the measure will lead to an under-reporting of true 
migraine cases.  
Results of the validity testing of the self-report migraine questionnaire revealed 
that compared to diagnoses derived from the telephone interview, the measure 
showed both high sensitivity (92.3%) and high specificity (93.3%) for diagnosis 
of strictly-defined migraine. However, for the diagnosis of probable migraine, 
the questionnaire was found to be much less sensitive (75%) and specific 
(77.8%). Lowered sensitivity and specificity of the questionnaire for detecting 
probable migraine may be explained through the large proportion (64.4%) of 
subjects with probable migraine that were reclassified as migraine cases 
following telephone interview. Thus, it could be proposed that compared to the 
questionnaire measure, the telephone interview is more adept at classifying 
borderline cases, given its potential to allow further scope for interaction and 
clarification of questions and answers. Moreover, as previously discussed, the 
fact that over half of the probable migraine cases are found to be true migraine 
cases following the telephone interview supports the notion of acknowledging 
a broader definition of migraine.  
A strength of this study is the large, clinically well-defined sample. Previous 
studies measuring migraine prevalence in BD have generally been conducted 
with much smaller sample sizes, making this study a valuable contribution to 
current literature. Furthermore, subjects were sampled from a community 
population, recruited through both systematic and non-systematic methods, 
thereby increasing its representative nature and generalizability. Moreover, 
studying comorbidities within a community-based sample means that they are 
less likely to be subjected Berkson’s bias, where individuals reporting a diagnosis 
of one disorder are more likely to report a diagnosis of (or be diagnosed with) 
other disorders because of their more frequent contact with health 
professionals in the context of a clinical population (Berkson, 1946). This study 
also benefits from the use of International Headache Society (IHS) criteria and 
so is in line with current standardised criteria for migraine diagnosis.  
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It is important to interpret the findings in the context of certain limitations. 
Firstly, the cross-sectional nature of the study methodology does not allow for 
the determination of causality in the relationship between BD and migraine. In 
order to gain a better understanding of the temporal relationship between BD 
and migraine, a prospective study is necessary. Moreover, the retrospective 
assessment of migraine introduces the possibility of recall bias, limited by the 
subject’s ability to clearly recall detailed aspects of their headaches, particularly 
relating to aura symptoms. Secondly, the lifetime history of migraine was 
ascertained through self-report measures, and so any under or over reporting of 
migraine cannot be ruled out. Migraine is often underdiagnosed in the first 
instance, as many sufferers do not seek medical attention (Lipton and Goadsby, 
1999). However, an advantage of this study is that the self-report questionnaire 
asked symptom-based questions, from which a diagnosis was made based on 
IHS criteria, rather than simply asking about a lifetime diagnosis of migraine. 
Moreover, although an acceptable response rate of 40% was achieved, it is 
possible that a response bias exists, whereby those who experienced migraine 
may have been more likely to complete the questionnaire. This was considered 
less likely to be the case as the migraine questionnaire was part of a larger pack 
of 8 additional questionnaires, with the migraine being the last questionnaire in 
the pack. Examination of questionnaire pack completion rates revealed that of 
those who completed the migraine questionnaire (n=1569), 99.9% completed 
at least 6 of the remaining 8 questionnaires included in the pack. There were 
only 8 individuals (0.6%) who completed either part or all of the additional 
questionnaires but did not complete the migraine questionnaire; where 75% 
completed at least 6 of the remaining 8 questionnaires. Given the 40% response 
rate of the questionnaire packs, it is also important to be cautious in any claims 
regarding overall migraine rates within the BD cohort. Finally, analysis did not 
consider medication use. As noted in the introduction of this thesis, some 
pharmacological treatments are successful within both disorders, in particular 
valproate, which could have acted to dampen migraine symptomatology and 
therefore influence disease prevalence.   
In summary, the nearly two-fold increased prevalence of migraine suggests that 
individuals with BD are at a higher risk of migraine than those without the 
disorder. As discussed within the background section of this thesis, there are 
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many possible reasons for this increased prevalence, including potential shared 
underlying pathophysiological mechanisms. Findings indicate that the presence 
of migraine may be used to delineate a more homogeneous subgroup of BD, 
which could prove useful for future studies assessing the aetiology of both 
disorders. In order to further evaluate the relationship of these comorbid 
phenomena, the next chapter of this thesis will focus on examining the impact 
of comorbid migraine on the course of the affective illness, to determine 
whether those with comorbid migraine experience different clinical 
characteristics to those without comorbid migraine. The next chapter will also 
look to explore the migraine phenotype in more detail by assessing the specific 
association of bipolar clinical variables with migraine subtypes, with and without 
aura.  
  
119 | P a g e  
 
Chapter 4 
Clinical characteristics of bipolar disorder  
according to migraine status 
 
 
4.1 Introduction 
The introduction chapter of this thesis outlined evidence to suggest that 
migraine comorbidity may be associated with a distinct clinical course of the 
bipolar illness. Such studies have indicated that presence of migraine within 
bipolar disorder (BD) is associated with an earlier age of BD onset (Mahmood et 
al., 1999; McIntyre et al., 2006b), increased rate of attempted suicide (Ortiz et 
al., 2010), a higher prevalence of bipolar II disorder subtype (Fasmer, 2001; Ortiz 
et al., 2010), and an increased rate of a rapid cycling illness course (Gordon-
Smith et al., 2015).  
Moreover, there is some evidence to suggest that the relationship between 
affective disorders and migraine may differ depending on the type of migraine 
that is studied. For example, previous studies have identified differences in the 
psychiatric comorbidity of the migraine subtypes, migraine with aura (MA) and 
migraine without aura (MoA), where it has been suggested that MA may have a 
stronger association with psychiatric disorders than MoA. For example, Breslau 
et al. (1991) observed significantly increased rates of BD and panic disorder in 
patients with MA when compared to migraine free individuals. However this was 
not the case for the MoA group. More recently, Oedegaard et al. (2005a) 
reported that depression alone, and depression with comorbid anxiety, were 
more likely in women having MA than MoA, however this difference between 
MA and MoA was not observed in male subjects. An association has also been 
reported between MA and suicide attempt. For example, Breslau et al. (1991) 
observed an association of both MA and MoA with suicide attempt, however 
after controlling for the presence of psychiatric and substance use disorders, an 
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independent association remained for MA only. Despite these findings, much of 
the research exploring the clinical characteristics of BD associated with migraine 
comorbidity to date has not distinguished between the subtypes of migraine. 
The present chapter looks to evaluate the relationship of migraine with the 
clinical course of the bipolar illness. Firstly, the chapter describes the clinical 
features of migraine experienced within the bipolar cohort. The chapter will 
then explore the impact of a migraine diagnosis on the lifetime clinical 
characteristics of the bipolar illness, by identifying characteristics that 
differentiate individuals with BD, according to the presence or absence of 
migraine.  The final part of this chapter looks to examine whether the migraine 
subtypes, migraine with (MA) and without aura (MoA), are associated with 
specific lifetime bipolar clinical characteristics, in order to identify whether MA 
within individuals with BD represents a clinically useful subgroup that is 
characterised by specific clinical features or course of illness.  
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4.2 Methods 
4.2.1 Subjects 
Data were utilised from the Bipolar Disorder Research Network (BDRN). Further 
detail on the sample is provided in Chapter 2.  
As detailed in Chapter 3 of this thesis, 1569 BDRN participants completed and 
returned a self-report questionnaire assessing lifetime history of migraine. Of 
these, 1428 met DSM diagnostic criteria for bipolar disorder type I (BDI), bipolar 
disorder type II (BDII) and schizoaffective, bipolar type (SABP), and so were 
included in the present study.  
4.2.2 Assessments 
Ascertainment of migraine symptomology, from which a migraine diagnosis 
was determined, was made via a self-report questionnaire assessing lifetime 
history of migraine. Further detail on this questionnaire measure is given in 
Chapter 2. Using this measure, a diagnosis of migraine was assigned in line with 
IHS criteria (ICHD-II; Headache Classification Subcommittee of the International 
Headache Society, 2004) for a diagnosis of migraine with (MA) and without aura 
(MoA), hemiplegic migraine (HM) and probable migraine (PM).   
4.2.3 Statistical analysis 
Data were analysed using the statistical package SPSS version 20. Normality of 
the data was assessed using the Kolmogorov-Smirnov test. The majority of the 
data analysed were not normally distributed and so non-parametric tests were 
employed. Statistical tests were considered significant at the p<0.05 level (two 
tailed) unless stated otherwise.  
4.2.3.1 Impact of migraine on the course of the bipolar illness: 
Univariate analysis 
Initially, data were explored with univariate tests in order to gain a better 
understanding of the data and to highlight potentially important variables to be 
included within multivariate analysis. Specifically, demographic and lifetime 
clinical characteristics of BD patients, with and without migraine, were 
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compared using Mann Whitney-U tests for continuous variables and categorical 
variables were assessed using 2x2 and 2x3 chi square tests. In instances where 
20% or more of the cells in a chi-square table had an expected count of less than 
five, Fisher’s exact tests (2x2 tables) and exact significance tests for Pearson’s 
chi-square (2x3 tables and greater) were used. For 2x3 chi-square tables, a 
statistically significant finding was followed-up with post hoc comparisons on 
each pair using 2x2 chi-square tests. 
 
Multivariate analysis 
Variables found to be significant within univariate analysis at the p<.05 level 
were entered into a binary logistic regression model as explanatory variables 
(using the enter method), with presence or absence of migraine as the 
outcome/dependent variable. The presence of collinearity within the logistic 
regression model was assessed with the variance inflation factor (VIF) diagnostic 
(Hamilton, 2006).  If necessary to drop a variable due to collinearity, the decision 
would be made based on order of clinical importance. 
A second logistic regression was then performed, changing the criteria by which 
variables were selected from univariate analysis for inclusion into the logistic 
regression model. For this analysis, only those variables withstanding correction 
for multiple testing, using the conservative Bonferroni correction, were entered 
into the regression model. The Bonferroni procedure to control for multiple 
testing divides the test-wise significance level by the number of tests being 
performed. This method reduces the probability of making a type I error 
(inappropriately rejecting the null hypothesis), however is often criticised for 
being overly conservative, and is particularly troublesome if the number of 
comparisons is large (Bland and Altman, 1995). As 22 independent univariate 
tests were performed, a p-value threshold indicating significance was set at 
p<0.00227.  
4.2.3.2 Analysis of migraine subtypes and bipolar disorder: 
Demographic and lifetime clinical characteristics of BD patients were compared 
between i) migraine with aura (MA) vs. no migraine and ii) migraine without aura 
(MoA) vs. no migraine groups, in order to explore the relationship of each 
migraine subtype, separately, with the clinical features and course of the bipolar 
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illness. Comparisons were made using Mann Whitney-U tests for continuous 
variables and categorical variables were assessed using 2x2 chi square tests. 
Within each group comparison (MA vs. no migraine; and MoA vs. no migraine), 
variables significant within univariate analyses at the p<.05 level were entered 
into a binary logistic regression model as explanatory variables, with migraine 
group status as the dependent variable.  
 
To examine potential clinical differences between BD subjects with migraine, 
with (MA) and without aura (MoA), demographic and lifetime bipolar clinical 
characteristics were compared between the two groups. Characteristics of 
migraine were also compared between MA and MoA groups. Continuous 
variables were assessed with Mann Whitney-U tests and 2x2 chi square tests for 
categorical variables. Demographic, lifetime bipolar clinical characteristics and 
migraine characteristics found to significantly differentiate MA and MoA groups 
(at the p<.05 level) were included as exploratory variables within a binary logistic 
regression model, with presence of aura (MA vs. MoA) as the dependent 
variable.  
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4.3 Results 
4.3.1 Clinical features of migraine 
As detailed within Chapter 3, 19.4% (N=277) of the bipolar sample were classed 
as having migraine according to the self-report questionnaire, diagnosed 
according to International Headache Society criteria (ICHD-II; Headache 
Classification Subcommittee of the International Headache Society 2004). As 
previously described, 153 (55.2%) met criteria for migraine with aura (MA); 45 
(16.2%) of which met criteria for hemiplegic migraine, and 124 (44.8%) received 
a diagnosis of migraine without aura (MO). The current section details the 
clinical features of migraine within the bipolar sample.  
4.3.1.1 Migraine symptomology 
Frequency of migraine symptomology experienced by individuals with migraine 
is summarised in Table 4.1. One-hundred and fifteen (41.5%) individuals 
meeting criteria for migraine experienced nausea and/or vomiting; 139 (50.2%) 
reported hypersensitivity to light or sound; 179 (64.6%) experienced pulsating 
headaches; 204 (73.6%) had unilateral headaches; 119 (43.1%) described the 
pain intensity of their headaches as moderate; 152 (55.1%) described this pain 
as severe; and 93 (33.6%) individuals reported that their headaches were made 
worse by physical activity. 
 
Table 4.1 Frequency of symptoms experienced by bipolar subjects with 
migraine 
Migraine symptom Frequency (%) 
Moderate or severe pain intensity 271 (98%) 
One-sided headache 204 (73.6%) 
Pulsating headache  179 (64.6%) 
Hypersensitivity to light or sound 139 (50.2%) 
Nausea and/or vomiting 115 (41.5%) 
Aggravated by physical activity 93 (33.6%) 
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4.3.1.2 Age of onset of migraine 
Age of onset of migraine was known for n=195 individuals (70.4%). The median 
age of onset of migraine was 17 years, which was found to be younger than the 
median age of onset for BD illness impairment (19 years). The distribution of age 
of migraine and BD onset is displayed in Figure 4.1. For 110 (56.4%) individuals 
with migraine, onset of migraine preceded onset of BD illness impairment, 
whereas onset of BD impairment preceded migraine onset in 72 (36.9%) 
subjects. For 13 (6.7%) individuals, onset of migraine and BD impairment 
occurred within the same year.   
 
 
Figure 4.1 Distribution of age of onset of migraine, and age of onset of 
impairment of bipolar disorder. 
 
4.3.1.3 Medication and other methods of headache relief 
Figure 4.2 summarises the methods used by bipolar subjects with migraine to 
relieve their headache. One-hundred and ninety-four (70%) individuals stated 
that they had taken migraine medication to relieve their headache. One 
hundred and ninety-four (70%) individuals also reported taking non-migraine 
specific painkillers; with 136 of these being the same individuals who utilised 
migraine medication. One-hundred and sixty-two (58.5%) individuals used rest 
as a means of relieving their headache; 183 (66.1%) lay in a dark room; and 136 
(49%) stated that they used sleep as a means of relieving their headache. 
0
10
20
30
40
50
60
0-10 11-20 21-30 31-40 41-50 51-70
P
er
ce
n
ta
ge
Age of onset (years)
Migraine onset Bipolar onset
126 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Methods of headache relief utilised by bipolar subjects with 
migraine 
 
Forty-four (15.9%) individuals utilised all five methods of headache relief; 74 
(26.7%) utilised four of the above methods; 77 (27.8%) utilised three methods; 
40 (14.4%) utilised two methods; and 42 (15.2%) individuals utilised only one of 
the above methods for headache relief.  
 
4.3.1.4 Frequency of recurrent headache 
The frequency at which individuals with migraine experienced their recurrent 
headache was known for 260 individuals (94%) and is summarised in Figure 4.3. 
One-hundred (36.1%) individuals with migraine reported suffering daily 
headache at a time when their headaches were at their most frequent. A further 
76 (27.4%) suffered with weekly headaches; 51 individuals (18.4%) suffered with 
monthly headaches; 27 individuals suffered (9.7%) with headaches every 1-3 
months; 4 individuals (1.4%) suffered with headaches every 3-6 months; 1 
individual (0.5%) suffered annually; and 1 (0.5%) individual suffered with 
headaches less than once a year.  
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Figure 4.3 Frequency of recurrent headache of bipolar subjects with migraine 
 
Although the self-report questionnaire assessed the occurrence of daily 
headache, the time period for which daily suffering was experienced was not 
assessed and so I was unable to identify and differentiate chronic migraine from 
episodic migraine. According to the ICHD-II, chronic migraine is defined as 
headache on least 15 days per month for a minimum of three months, either 
meeting criteria for migraine without aura or responding to migraine-specific 
medication (Headache Classification Subcommittee of the International 
Headache Society 2004).  
 
4.3.1.5 Family history of migraine  
Within the migraine group, 163 (76.2%) individuals had a family history of 
migraine (at least one biological first or second degree relative with a history of 
migraine headaches) and this was found to be significantly higher compared to 
the no migraine group (76.2% vs. 43.6%, p=.000001). There were, however, no 
significant differences found in the rate of family history of affective disorders 
between BD subjects with and without migraine when using both a broad 
definition of affective disorder (including bipolar II disorder, schizoaffective 
disorder and major depressive disorder); 89.7% vs. 85.2%, p=.089, or a narrow 
definition including only those with a diagnosis of bipolar I disorder; 45.5% vs. 
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40.1%, p=.524. Hence, there was no significant association found between 
migraine in bipolar probands and affective disorders in their relatives.  
4.3.1.6 Migraine with aura (MA) 
A summary of the frequency of MA individuals experiencing each aura type and 
the number of aura types experienced by individuals are outlined in Tables 4.2-
4.3. 121 (79.1%) individuals with MA experienced visual disturbances (e.g. 
flickering lights, spots or lines, blurred vision or loss of vision), 68 (44.4%) had 
experienced sensory symptoms (such as pins and needles or numbness) and 29 
(19%) reported speech disturbance. 104 (68%) individuals with MA had 
experienced one aura type, 34 (22.2%) experienced two aura types and 15 (9.8%) 
had experienced all three (visual, sensory and speech) aura types.  
Table 4.2 Frequency of each aura type experienced by individuals with 
migraine with aura (MA) 
Aura type Frequency (%) 
Visual aura  121 (79.1%) 
Sensory aura 68 (44.4%) 
Speech disturbance 29 (19%) 
 
Table 4.3 Number of aura types experienced by individuals with migraine with 
aura (MA) 
Number of aura types experienced Frequency (%) 
1 104 (68%) 
2 34 (22.2%) 
3 15 (9.8%) 
 
Presence of aura was associated with a younger age of migraine onset (median: 
15 vs 18.5 years, p=.004) and a significantly lower proportion of the MA group 
had taken migraine medication to relieve their headache compared to the 
migraine without aura (MO) group (62.7% vs. 79%, p=.003). Compared to those 
without aura (MoA), the MA group did not significantly differ in their rate of 
family history of migraine (MA: 70.8% vs. MoA: 80.5%, p=.098), however the MA 
group did have a significantly higher rate of family history of migraine with aura 
(92.1% vs. 68.4%, p=.002). 
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4.3.1.7 Hemiplegic migraine 
Forty-five individuals from the migraine with aura (MA) group (29.4%; 3.2% of 
total sample) experienced motor weakness that met further development and 
duration criteria outlined by the IHS, and so were defined as having hemiplegic 
migraine. There was no significant difference in the age of onset of migraine 
between individuals with HM and MA (median: 14.5 vs. 15, p=.511), nor in the 
rate of migraine medication use (71.1% vs. 59.3%, p=.167). There was however, 
a significantly higher rate of family history of migraine with aura and additional 
motor weakness in the HM group compared to MA (72.7% vs. 21.2%, p=.003).  
4.3.1.8 Probable migraine 
As detailed within Chapter 3, 304 (21.3%) individuals met criteria for probable 
migraine (PM), according to the self-report questionnaire. The International 
Headache Society (IHS) define PM as an attack or headache missing one of the 
features needed to fulfil all IHS criteria for a migraine disorder. The migraine 
diagnostic criterion most frequently not fulfilled by these subjects was the 
duration criteria of between 4-72 hours, which was not met by 75.3% (n=229) 
subjects meeting criteria for PM.   
4.3.1.9 Summary 
This section has described the clinical features of individuals with migraine 
within the bipolar sample. The following section of this chapter will explore the 
impact of a migraine diagnosis on the lifetime clinical characteristics of the 
bipolar illness, by identifying characteristics that differentiate individuals with 
bipolar disorder, according to the presence or absence of migraine. 
 
4.3.2 Characteristics associated with migraine in the bipolar 
sample: Univariate analysis 
4.3.2.1 Demographic characteristics  
A comparison of demographic variables between bipolar subjects with and 
without migraine is outlined in Table 4.4. Analysis revealed the migraine group 
to be significantly younger at interview than the no migraine group (45 vs. 50 
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years, p=.000001). There was also a significantly greater proportion of females 
in the migraine group (82.3% vs. 69%, p=.000021).  
 
Table 4.4 Demographic characteristics of the bipolar sample according to 
migraine status 
 BD + migraine  
(n=277) 
BD - migraine 
(n=778) 
P-value 
Age at interview 
(years) 
     Median     
     IQR 
     Range 
 
 
45 
16 
20-74 
 
 
50 
18 
18-83 
 
 
.000001 
Sex, n (%)    
     Female  
 
228 (82.3%) 
 
537 (69%) 
 
.000021 
Recruitment, n (%) 
     Systematic 
 
58 (21.7%) 
 
166 (22.3%) 
 
.842 
Family history of 
affective disorder, n 
(%) 
 
209 (89.7%) 
 
561 (85.3%) 
 
.089 
BD=bipolar disorder; IQR= inter-quartile range. Figures in bold indicate variables 
significant at the p<.05 level.  
 
4.3.2.2 Bipolar clinical characteristics 
A comparison of lifetime bipolar clinical characteristics between individuals with 
and without migraine is displayed in Table 4.5. Examination of such 
characteristics revealed that when compared to those with no history of 
migraine, bipolar individuals with migraine: were significantly younger at the 
onset of their bipolar illness (defined as the age at which symptoms of their 
affective disorder first caused significant impairment) (19 vs. 22 years, 
p=.000028); experienced more depressive episodes (10.1 vs. 6.1, p=.000001) and 
more episodes of mania (7 vs. 5.1, p=.002); had a lower rate of psychiatric 
admission (71.3 vs. 81.6%, p=.003); had higher rates of rapid cycling (28.4% vs. 
18.3%, p=.000421); had higher rates of panic disorder (21.1% vs. 13%, p=.005) 
and anxiety disorder (67.6% vs. 52.8%, p=.000195); and a higher rate of suicide 
attempt (60.7% vs. 45.6%, p=.000024). Higher rates of regular cannabinoid use 
(23.3% vs. 15%, p=.002225) and regular use of other unspecified drugs (15.7% vs. 
8.7%, p=.001547) were also found in the migraine group. Finally, migraine was 
found to be significantly associated with BD diagnostic subtype (p=.00004). 2x2 
post hoc comparisons revealed a statistically significant difference between BDI 
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and BDII groups in migraine prevalence, with migraine found to be positively 
associated with a BDII diagnosis (p = .000004).  
 
Table 4.5 Clinical characteristics of the bipolar sample according to migraine 
status 
 BD + migraine 
(N=277) 
BD - migraine 
(N=778) 
P-value 
DSM-IV diagnosis 
       BDI 
       BDII 
       SABP 
 
168 (22.1%) 
95 (37.7%) 
14 (33.3%) 
 
593 (77.9%) 
157 (62.3%) 
28 (66.7%) 
 
.000004 
 
Age at illness onset (years) 
       Median 
       IQR 
       Range 
 
19 
11 
6-51 
 
22 
12 
5-68 
 
.000028 
Lifetime number episodes of 
depression 
       Median 
       IQR 
       Range 
 
 
10.1 
15.1 
0-100.1 
 
 
6.1 
12 
0-100.1 
 
 
.000001 
Lifetime number episodes of 
mania  
       Median 
       IQR 
       Range 
 
 
7 
16 
1-100.1 
 
 
5.1 
7.1 
1-100.1 
 
 
.002348 
History of psychotic 
features, n (%) 
 
158 (57%) 
 
459 (59.2%) 
 
.947 
History of psychiatric 
admission, n (%) 
 
191 (71.3%) 
 
614 (81.6%) 
 
.000347 
History of suicide attempt, n 
(%) 
 
162 (60.7%) 
 
336 (45.6%) 
 
.000024 
History of rapid cycling, n 
(%) 
 
78 (28.4%) 
 
140 (18.3%) 
 
.000421 
History of panic disorder, n 
(%) 
 
45 (21.1%) 
 
71 (13%) 
 
.005 
History of anxiety disorder, 
n (%) 
 
148 (67.6%) 
 
289 (52.8%) 
 
.000195 
Ever been a regular smoker, 
n (%) 
 
126 (54.3%) 
 
371 (51.3%) 
 
.377 
Alcohol dependence, n (%) 47 (18.4%) 139 (19.7%) .663 
Lifetime regular use of 
cannabinoids, n (%) 
 
61 (23.3%) 
 
109 (15%) 
 
.002225 
Lifetime regular use of other 
unspecified drugs, n (%) 
 
41 (15.7%) 
 
63 (8.7%) 
 
.001547 
IQR= inter-quartile range; BDI= bipolar I disorder; BDII= bipolar II disorder; SABP= 
schizoaffective-bipolar type. Figures in bold indicate variables significant at the p<.05 
level.  
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4.3.3 Multivariate model – Predictors of migraine within bipolar 
disorder 
4.3.3.1 Model a) including variables significant at the p<.05 level: 
Variables that were significant within univariate analysis at the p<.05 level 
(Tables 4.4 and 4.5), were entered into a binary logistic regression as 
explanatory variables. Logistic regression analysis indicated the characteristics 
that best predicted the presence of migraine within BD were: a younger age at 
interview (OR .976, 95% CI: .958-.994, p=.008); being female (OR 1.751, 95% CI: 
1.074-2.855, p=.025); history of suicide attempt (OR 1.651, 95% CI: 1.092-2.497, 
p=.017); and a history of anxiety (OR 1.564, 95% CI: 1.036-2.359, p=.033). A 
summary of the significant predictors of BD and comorbid migraine is displayed 
in Table 4.6. 
Table 4.6 Summary of significant predictors of migraine in the bipolar sample 
 Wald X2 df P-value OR (95% CI) 
Age at interview 7.051 1 .008 .976 (.958-.994) 
Sex (female) 5.046 1 .025 1.751 (1.074-2.855) 
History of suicide 
attempt 
5.648 1 .017 1.651 (1.092-2.497) 
History of anxiety 4.536 1 .033 1.564 (1.036-2.359) 
OR= odds ratio; 95% CI= 95% confidence interval; df= degrees of freedom. 
 
 
Model validation  
Power 
Logistic regression uses the maximum likelihood estimation (ML) to derive its 
parameters. Such a method relies on large-sample asymptotic normality, and so 
as the number of cases for each independent variable declines, so does the 
reliability of parameter estimates. A useful rule of thumb suggests at least ten 
cases per independent variable for the smaller classes of the dependent variable 
(Peduzzi et al., 1996). The model reported above includes 587 cases, with 168 of 
these belonging to the (smaller) migraine group. A total of 13 variables were 
entered into the model; therefore surpassing the minimum requirement of ten 
cases per predictor variable for the smaller outcome group.  
 
133 | P a g e  
 
Goodness-of-fit 
Cases correctly classified 
The accuracy of the model in predicting whether or not an individual has a 
diagnosis of migraine, is calculated by comparing predicted scores (individual 
having migraine or not) based on the independent variables within the model, 
with actual group. Within this model, 72.1% of individuals were correctly 
classified as having comorbid migraine or not.  
Hosmer-Lemeshow 
Indication of how well the model fits the data was evaluated using the Hosmer-
Lemeshow goodness-of-fit measure. This measure indicates the extent to which 
the model provides a better fit than the null model. The H-L goodness-of-fit test 
statistic computed for the model was greater than p=.05 (χ² (8) =4.612, p =.798), 
indicating the model predicts values not significantly different from what we 
observed, signifying a good fit of the model to the data. A limitation of this 
goodness of fit measure is that it is simply a significance test and thus is only 
able to inform us of whether the model fits the data or not, rather than providing 
information on the extent of the fit.  
Pseudo R2 
Within logistic regression analyses, there is no analogous statistic to the 
coefficient of determination R2 that acts as an indicator of the percentage of 
variance in the dependent variable explained by the model. However, there are 
a number of approximations, known as Pseudo R2 measures. Two of the main 
Pseudo R-square measures reported are Cox and Snell’s, and Nagelkerke. A 
major limitation of Cox and Snell’s R-square is that its maximum can be less than 
1, thus making it difficult to interpret. Nagelkerke’s modification divides Cox and 
Snell’s R-square by its maximum, allowing it to vary from 0 to 1, providing a 
more reliable measure of the relationship. In the case of the model reported 
above, the Nagelkerke R 2 is 0.133, indicating that the model explains 13.3% of 
the variance within the dependent variable; presence of migraine. 
 
Diagnostic analyses: Multicollinearity  
Logistic regression is sensitive to high correlations between predictor variables, 
resulting in multicollinearity. To identify potential multicollinearity among the 
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13 predictor variables, a multiple linear regression was conducted with 
collinearity diagnostics requested.  Tolerance is an indication of the percent of 
variance in the predictor that cannot be accounted for by the other predictors, 
and values less than .10 may merit further investigation. The VIF (variance 
inflation factor), is denoted as; 1 / tolerance, and as a rule of thumb a VIF value 
greater than 10 may merit further investigation. None of the predictor variables 
had a tolerance value below .10, or a VIF value greater than 10, thus indicating 
that multicollinearity is not apparent within the model.   
Presence of multicollinearity among predictor variables was also examined by 
considering the standard errors for the b coefficient, with a standard error larger 
than 2.0 indicative of numerical problems, such as multicollinearity. None of the 
independent variables in this analysis had standard errors larger than 2, 
reinforcing that multicollinearity is not apparent within the model.  
 
4.3.3.2 Model b) including variables surpassing Bonferroni correction: 
A second logistic regression was computed, including only those variables 
surviving correction for multiple testing using the Bonferroni method. The total 
number of independent univariate tests performed was 22. This included the 21 
comparisons displayed in Tables 4.4 and 4.5 (including post-hoc tests) and an 
earlier comparison made between migraine and no migraine groups regarding 
the family history of migraine. Thus, the p-value threshold indicating 
significance was set at p<0.00227. Employing this more conservative criterion 
for variable selection meant the removal of two clinical variables; ‘number of 
episodes of mania’, and ‘history of panic disorder’, from entry in to the 
regression model. A summary of significant predictors of migraine using this 
method of variable entry is displayed in Table 4.7.   
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Table 4.7 Summary of significant predictors of migraine - Model b 
 Wald X2 df P-value OR (95% CI) 
Age at 
interview 
8.363 1 .004 .974 (.957-.992) 
Sex (female) 5.935 1 .015 1.807 (1.124-2.908) 
Episodes of 
depression 
4.615 1 .032 1.014 (1.001-1.028) 
History of 
suicide attempt 
5.543 1 .019 1.619 (1.084-2.419) 
History of 
anxiety 
4.788 1 .029 1.538 (1.046-2.262) 
OR=odds ratio; 95% CI=95% confidence interval; df=degrees of freedom. 
 
As can be seen from the above summary, all variables that were found to best 
predict migraine within the bipolar sample using a more conservative criterion 
for determining entry into the model are the same as those found when using a 
threshold of p<.05. An additional variable found to independently predict 
migraine within model b was an increased number of episodes of depression. 
This model correctly classified 71.6% of individuals as having comorbid migraine 
or not. The H-L goodness-of-fit test statistic computed for the model was 
greater than .05 (χ² (8) =4.483, p =.811), signifying a good fit of the model to the 
data. According to the Nagelkerke pseudo R2 measure, the model explained 
13.2% of the variance in the dependent variable.  
4.3.3.3 Summary  
This section has made comparisons between bipolar subjects with and without 
a diagnosis of migraine on a number of demographic and bipolar clinical 
variables, as a means of exploring the impact of migraine on the bipolar illness. 
The next section will explore the migraine phenotype in more detail by assessing 
the specific association of bipolar clinical variables with migraine subtypes, 
migraine with and without aura.  
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4.3.4 Characteristics of bipolar disorder according to migraine 
subtypes compared to migraine-free subjects 
 
Univariate comparisons of demographic and bipolar clinical characteristics 
between individuals with i) migraine with aura (MA) vs. no migraine and ii) 
migraine without aura (MoA) vs. no migraine are displayed in Table 4.8.  
Table 4.8 Comparison of demographic and lifetime bipolar clinical variables in 
the migraine groups (migraine with aura and migraine without aura) and the 
no migraine group.  
 MA (1) 
(n=153) 
MoA (2) 
(n=124) 
No migraine 
(3)  
(n=778) 
P-value 
1 vs 3 
P-value 
2 vs 3 
Age at interview 
(years) 
     Median (IQR) 
     Range 
 
 
46 (16) 
20-70 
 
 
44.5 (17) 
23-74 
 
 
50 (18) 
18-83 
 
 
.000290 
 
 
.000043 
Sex, n (%) 
    Female 
 
130 (85%) 
 
98 (79%) 
 
537 (69%) 
 
.000063 
 
.023 
Systematic 
recruitment, 
n (%) 
 
39 (26.4%) 
 
19 (16%) 
 
166 (22.3%) 
 
.286 
 
.117 
Family history of 
affective 
disorders, n (%) 
 
122 
(90.4%) 
 
87  
(88.8%) 
 
561  
(85.3%) 
 
.118 
 
.353 
DSM-IV 
diagnosis, n (%) 
       BDI 
       BDII 
       SABP 
 
 
89 (68.2%) 
55 (35.9%) 
9 (5.9%) 
 
 
79 (63.7%) 
40 (32.3%) 
5 (4%) 
 
 
593 (88.2%) 
157 (20.2%) 
28 (3.6%) 
 
 
.000023 
 
 
 
.009 
 
Age at illness 
onset (years) 
       Median (IQR) 
       Range 
 
 
19 (11) 
6-51 
 
 
20 (10) 
6-51 
 
 
22 (12) 
5-68 
 
 
.000071 
 
 
.023 
No. episodes of 
depression 
       Median (IQR) 
       Range 
 
 
12.1 (14) 
0-100.1 
 
 
9.5 (16) 
0-100.1 
 
 
6.1 (12) 
0-100.1 
 
 
.000001 
 
 
.009 
No. episodes of 
mania 
       Median (IQR) 
       Range 
 
 
7.5 (16.1) 
1-100.1 
 
 
5.1 (12) 
1-100.1 
 
 
5.1 (7.1) 
1-100.1 
 
 
.000090 
 
 
.598 
History of 
psychotic 
features, n (%) 
 
85 (55.6%) 
 
73 (58.9%) 
 
459 (59.2%) 
 
.400 
 
.940 
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Examination of demographic and clinical characteristics between the migraine 
with aura (MA) and no migraine groups revealed statistically significant 
differences (p<0.05) between the two groups, in that the MA group: were 
younger at interview (46 vs. 50 years, p=.000043); were more likely to be female 
(85% vs. 69%, p=.000063); had a younger age of BD onset (19 vs. 22 years, 
p=.000071), experienced more episodes of both depression (12.1 vs. 6.1, 
p=.000001) and mania (7.5 vs.5.1, p=.000090); had a lower rate of psychiatric 
admission (69.9% vs. 81.6%, p=.001); had higher rates of suicide attempt (66.7% 
vs. 45.6%, p=.000003) and rapid cycling of illness (34.5% vs. 18.3%, p=.000006); 
had a higher rate of panic (26.8% vs. 13%, p=.000132) and anxiety disorder 
(68.8% vs. 52.8%, p=.001). Lifetime-ever regular use of cannabinoids (24.5% vs. 
15%, p=.005), and other unspecified drugs (15.4% vs. 8.7%, p=.014) were also 
found to be significantly associated with MA compared to BD subjects with no 
migraine. MA was significantly associated with BD diagnostic subtype 
History of 
psychiatric 
admission, n (%) 
 
102 
(69.9%) 
 
89  
(73%) 
 
614  
(81.6%) 
 
  .001 
 
.025 
History of 
suicide attempt, 
n (%) 
 
98 (66.7%) 
 
64 (53.3%) 
 
336 (45.6%) 
 
.000003 
 
.115 
History of rapid 
cycling, n (%) 
 
53 (34.6%) 
 
25 (20.5%) 
 
140 (18.3%) 
 
.000006 
 
.559 
History of panic 
disorder, n (%) 
 
33 (26.8%) 
 
17 (13.3%) 
 
71 (13%) 
 
.000132 
 
.931 
History of 
anxiety disorder, 
n (%) 
 
86 (68.8%) 
 
62 (66%) 
 
289 (52.8%) 
 
.001 
 
.018 
Alcohol 
dependence, n 
(%) 
 
26 (18.7%) 
 
21 (18.1%) 
 
139 (19.7%) 
 
.789 
 
.689 
Lifetime history 
regular use of 
cannabinoids, n 
(%) 
 
35 (24.5%) 
 
26 (21.8%) 
 
109 (15%) 
 
.005 
 
.057 
Lifetime history 
regular use of 
other 
unspecified 
drugs, n (%) 
 
22 (15.4%) 
 
19 (16.1%) 
 
63 (8.7%) 
 
.014 
 
.012 
MA=migraine with aura; MoA=migraine without aura; BDI=bipolar I disorder; BDI=bipolar II 
disorder; SABP=schizoaffective bipolar type. Figures in bold indicate variables significant at the 
p<.05 level.  
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(p=.000023). 2x2 post hoc comparisons revealed a statistically significant 
difference between BDI and BDII groups, with MA being positively associated 
with a BDII diagnosis (p=.000008).  
 
Variables that were significant within univariate analysis at the p<.05 level 
between MA and no migraine groups (Table 4.8) were entered into a binary 
logistic regression as explanatory variables. Logistic regression analysis 
indicated the characteristics associated with migraine with aura (MA) compared 
to no migraine within BD subjects were: being female (OR: 2.424; 95% CI: 1.209-
4.859); being younger (OR: .975; 95% CI: .952-.999); having a bipolar II diagnosis 
(OR: 1.772; 95% CI: 1.003-3.132); and a history of suicide attempt (OR: 2.017; 95% 
CI: 1.184-3.435). A summary of the significant predictors of BD with comorbid 
migraine with aura (MA) is displayed in Table 4.9. 
 
Table 4.9 Summary of significant predictors of migraine with aura (MA) 
compared with bipolar subjects with no migraine 
 Wald X2 df P value OR (95% CI) 
Female 6.225 1 .013 2.424 (1.209-4.859) 
Age at interview 4.338 1 .037 .975 (.952-.999) 
Bipolar II disorder 
diagnosis  
3.876 1 .049 1.772 (1.003-3.132) 
History of suicide 
attempt 
6.672 1 .010 2.017 (1.184-3.435) 
BDII=bipolar II disorder; df=degrees of freedom; OR=odds ratio; 95% CI=95% 
confidence interval. 
 
 
This model correctly classified 82.3% of individuals as having comorbid migraine 
or not and according to the Nagelkerke pseudo R2 measure, the model explained 
19.2% of the variance in the dependent variable. A Hosmer-Lemeshow (H-L) fit 
statistic indicated a good fit of the model to the data (p=.05: χ² (8) = 
7.794, p =.426). The clinical variables that best predicted migraine with aura, 
when compared to migraine-free individuals did not differ when only variables 
that surpassed Bonferroni correction for multiple comparisons (p-value 
threshold of (0.05/20) p<.0025) were entered into the logistic model as predictor 
variables (see Appendix E).  
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Univariate analysis (Table 4.8) revealed statistically significant differences 
(p<0.05) between the BD subjects with no history of migraine and individuals 
with migraine without aura (MoA), in that the MoA group: were younger (44.5 
vs. 50 years, p=.000043); more likely to be female (79% vs. 69%, p=.023); had a 
higher rate of BDII (32.3% vs. 20.2%, p=.009); had an earlier onset of the bipolar 
illness (20 vs. 22 years, p=.023); experienced more episodes of depression (9.5 
vs. 6.1, p=.009);  had a lower rate of psychiatric admission (73% vs. 81.6%, 
p=.025); had a higher rate of anxiety disorders (66% vs. 52.8%, p=.018); and had 
a higher rate of lifetime-ever regular drug use (16.1% vs. 8.7%, p=.012). A logistic 
regression model entering variables that were significant within univariate 
analysis at the p<.05 level as explanatory variables, revealed that the only 
variable associated with MoA was age at interview (OR: .974, 95% CI: .952-.997, 
p=.024, Wald = 5.071). No clinical bipolar variables were found to be associated 
with MoA when compared to those with no history of migraine.  
 
4.3.5   Comparison of bipolar clinical features and migraine 
characteristics between bipolar subjects with migraine with 
and without aura 
 
A comparison of demographic and bipolar clinical characteristics between 
individuals with migraine with aura (MA) and migraine without aura (MoA) 
(Table 4.10) indicated that the MA group: were more likely to have been 
recruited systematically (p=.041); had more episodes of depression (p=.009), 
and mania (p=.018); and experienced higher rates of rapid cycling illness 
(p=.010), and panic disorder (p=.017).   
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Table 4.10 Comparison of demographic and bipolar clinical characteristics 
between bipolar patients with comorbid migraine, with and without aura. 
 MA 
(n=153) 
MoA 
 (n=124) 
P-Value 
Age at interview (years) 
     Median (IQR) 
     Range 
 
46 (16) 
20-70 
 
44.5 (17) 
23-74 
 
.357 
Sex, n (%) 
    Female 
 
130 (85%) 
 
98 (79%) 
 
.198 
Recruitment, n (%) 
    Systematic 
 
39 (26.4%) 
 
19 (16%) 
 
.041 
Family history of affective 
disorders, n (%) 
 
122 (90.4%) 
 
87 (88.8%) 
 
.693 
DSM-IV diagnosis, n (%) 
       BDI 
       BDII 
       SABP 
 
89 (53%) 
55 (57.9%) 
9 (64.3%) 
 
79 (47%) 
40 (42.1%) 
5 (35.7%) 
 
.582 
 
Age at illness onset (years) 
       Median (IQR) 
       Range 
 
19 (11) 
6-51 
 
20 (10) 
6-51 
 
.221 
Number of episodes of 
depression 
       Median (IQR) 
       Range 
 
 
12.1 (14) 
0-100.1 
 
 
9.5 (16) 
0-100.1 
 
 
.009 
Number of episodes of mania 
       Median (IQR) 
       Range 
 
7.5 (16.1) 
1-100.1 
 
5.1 (12) 
1-100.1 
 
.018 
History of psychotic features, 
N (%) 
 
85 (55.6%) 
 
73 (58.9%) 
 
.579 
History of psychiatric 
admission, n (%) 
 
102 (69.9%) 
 
89 (73%) 
 
.578 
History of suicide attempt, n 
(%) 
 
98 (66.7%) 
 
64 (53.3%) 
 
.027 
History of rapid cycling, n (%) 53 (34.6%) 25 (20.5%) .010 
History of panic disorder, n 
(%) 
33 (26.8%) 17 (13.3%) .017 
History of anxiety disorder, n 
(%) 
86 (68.8%) 62 (66%) .656 
Alcohol dependence, n (%) 26 (18.7%) 12 (18.1%) .990 
Lifetime history regular use of 
cannabinoids, n (%) 
35 (24.5%) 26 (21.8%) .616 
Lifetime history regular use of 
other unspecified drugs, n (%) 
22 (15.4%) 19 (16.1%) .874 
MA=Migraine with aura; MoA=migraine without aura; BDI=bipolar I disorder; BDI= 
bipolar II disorder; SABP=schizoaffective bipolar type. Figures in bold indicate variables 
significant at the p<.05 level.  
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The characteristics of migraine across MA and MoA groups are displayed in 
Table 4.11. Presence of aura was associated with a younger age of migraine 
onset (median: 15 vs. 18.5 years; p=.004). Within the MA group, age of onset for 
migraine and BD was known for 116 individuals (76%). The median age of onset 
of migraine (15 years) was found to be younger than the median age of onset of 
BD within this group (19 years). For 69 (59.5%) individuals onset of migraine 
preceded onset of BD illness impairment, whereas onset of BD impairment 
preceded migraine onset in 38 (32.8%) individuals. For 9 (7.7%) individuals onset 
of migraine and BD impairment occurred within the same year. For the MoA 
group, age of onset of both migraine and BD illness impairment was known for 
79 (64%) individuals. Within this group, median age of migraine onset (18.5 
years) was also younger than the median age of onset of BD illness impairment 
(20 years). Thirty-nine individuals (49.4%) experienced migraine prior to onset 
of BD illness impairment, whereas BD impairment preceded migraine onset for 
37 (46.8%) individuals. Lastly, within the MoA group, migraine and BD 
impairment onset occurred within the same year for 3 individuals (3.8%).   
A significantly lower proportion of the MA group had taken migraine medication 
to relieve their headache compared to the MoA group (p=.003) and this was not 
related to the younger age of onset of migraine of the MA group. The 
distribution of migraine frequency was significantly different between MA and 
MoA groups (p=.004), with post hoc analysis revealing more frequent migraine 
among those with MA. The MA group had a higher rate of family history of 
migraine, however this was not found to be statistically significant (p=.098). 
Interestingly, there were no significant differences found in the rate of family 
history of affective disorders between BD subjects with MA and MoA (Table 
4.10) (90.4% vs. 88.8%, p=.693).  
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Table 4.11 Comparison of migraine characteristics between bipolar patients 
with migraine subtypes, with and without aura. 
 MA 
(n=153) 
MoA 
(n=124) 
P-value 
Age of migraine onset 
(years) 
      Median  
      IQR 
      Range 
 
15 
9 
1-70 
 
18.5 
17 
6-50 
 
.004 
Migraine frequency, n (%) 
      More than once a week 
      More than once a month 
      Less than once a month   
 
69 (47.3%) 
40 (27.4%) 
37 (25.3%) 
 
31 (27.2%) 
36 (31.6%) 
47 (41.2%) 
.002 
1 vs 2, p=.002 
1 vs 3, p=.015 
2 vs 3, p=.730 
Migraine medication, n (%) 96 (62.7%) 98 (79%) .003 
Family history of migraine, n 
(%) 
95 (80.5%) 68 (70.8%) .098 
MA=Migraine with aura; MoA=migraine without aura. Figures in bold indicate variables 
significant at the p<.05 level.  
 
A logistic regression was computed entering demographic, bipolar clinical 
characteristics, and migraine characteristics that were found to significantly 
differentiate MA and MoA groups (at the p<.05 level) as explanatory variables, 
with presence of aura (MA vs. MoA) as the dependent variable. The regression 
model revealed that a history of panic disorder (OR: 8.481, 95% CI: 1.665-43.196, 
p=.010) and a younger age of migraine onset (OR: .955, 95% CI: .922-.988, 
p=.009) were predictive of aura status. However, with a total of 134 cases 
included in the model, and only 55 cases belonging to the smaller migraine 
without aura (MoA) group, this violates our earlier requirement of at least ten 
cases per independent variable for the smaller classes of the dependent variable 
(Peduzzi et al., 1996). We should therefore be very cautious in our interpretation 
of the above results.  
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4.4 Discussion 
Analysis revealed that when compared to bipolar subjects with no history of 
migraine, those with comorbid migraine experienced a different clinical course 
of the bipolar illness. Moreover, the comorbid expression of the relationship 
between bipolar disorder (BD) and migraine was dependent on migraine 
subtype. Specifically, the observed differences in the clinical presentation of BD 
associated with migraine comorbidity were largely driven by the migraine with 
aura subtype.   
When other significant differences were controlled for, subjects with comorbid 
migraine were more likely to; be younger, be female, have an increased rate of 
anxiety disorder and an increased rate of suicide attempt. Migraine prevalence 
is found to vary with age, increasing throughout adolescence and early adult life, 
peaking in the fourth and fifth decades and declining thereafter. Therefore, the 
significantly younger age of the migraine group (45 vs. 50 years) is compatible 
with this peak age distribution. The higher percentage of women in the migraine 
group is in line with the gender distribution of migraine in the general 
population, in which a female preponderance is observed (Breslau et al., 1991; 
Jette et al., 2008), and is in agreement with previous studies conducted within 
bipolar samples (Baptista et al., 2012; Saunders et al., 2014). The observed 
female preponderance of migraine has previously been explained, by hormonal 
changes, and more specifically, with falling levels or withdrawal of oestrogen 
(Lichten et al., 1996; Whitty et al., 1966).  
Consistent with a number of studies, migraine was associated with a lifetime 
history of anxiety disorder in individuals with BD (McIntyre et al., 2006b; Ortiz 
et al., 2010). The association between migraine and anxiety disorder is well 
established. For example, a large, population-based study in the US reported 
that 9.1% of subjects with migraine, had comorbid generalised anxiety disorder, 
compared with 2.5% of those without migraine (OR 3.9, 95% CI 2.5 to 6.0). This 
association remained significant even after adjusting for demographic variables 
including other common pain conditions (arthritis and back pain) (McWilliams 
et al., 2004). Moreover, a prospective study by Merikangas et al. (1990) revealed 
that the association between migraine and anxiety disorders was even stronger 
than that for the affective disorders. Merkingas and colleagues reported 
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generalised anxiety disorder (OR 5.3, 95%CI 1.8 to 15.8) and social phobia (OR 
3.4, 95% CI 1.1 to 10.9) as being the types of anxiety disorder exhibiting the 
strongest association with migraine. The combined effects of depression and 
anxiety in migraine have also been reported on. Breslau et al. (1991) revealed 
that the comorbidity of migraine and major depression occurred frequently in 
the presence of coexisting anxiety. They also reported that migraine onset was 
often preceded by onset of anxiety disorder and was followed by the onset of 
major depression. In the same paper, Breslau et al. (1991) revealed that whilst 
the presence of migraine alone increased the odds of major depression nearly 
threefold (odds ratio: 2.7), migraine together with co-occurring anxiety (vs. 
those with neither disorder) increased the odds of major depression by 22.8 
times. This increase in odds exceeded what would have been expected by 
summing the individual effects of migraine and anxiety on the likelihood of 
major depression. In this analysis the category of major depression included all 
of those with such a history, including those with mania or hypomania.  
Research suggests that anxiety disorders may be the most prevalent psychiatric 
comorbidity among BD. Epidemiological studies show that as many as 74.9% of 
individuals with BD have at least one anxiety disorder at some point in their life 
(Merikangas and Kalaydjian, 2007). Findings from the current chapter indicate 
that this relationship may be even higher among bipolar patients with migraine. 
Psychiatric comorbidity can further complicate the bipolar illness and may 
influence the course of illness leading to poorer outcomes and prognosis. 
Therefore, identifying, and treating comorbid psychiatric disorders is very 
important in the clinical management of the disorder. In particular, comorbid 
anxiety disorders have been associated with more affective relapses, increased 
suicidality, decreased social functioning, and sleep disturbances (Freeman et al., 
2002; Hawke et al., 2013). They have also been shown to complicate the 
pharmacologic treatment of BD, by reducing the effectiveness of mood 
stabilisers (Keller, 2006), and increasing non-adherence to pharmacotherapy 
(Perlis et al., 2010).  
Comorbid migraine was also found to be independently associated with a past 
history of suicide attempt.  Such a finding is in line with Ortiz et al. (2010) who 
found that almost 40% of bipolar subjects with migraine had a history of suicide 
attempt, which was significantly greater than that seen within bipolar subjects 
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without migraine (27%). Moreover, Nguyen and Low (2012) reported that 
migraine comorbidity with mood episodes was associated with both suicidal 
ideation and suicidal attempt within their large Canadian nationally 
representative (n=26,984) population-based study. It is important to note the 
particularly high rate (60%) of suicide attempt observed within bipolar subjects 
with comorbid migraine within the current study. This figure surpasses that 
reported by Ortiz et al. (2010) and exceeds the commonly reported statistic that 
25-50% of bipolar patients will attempt suicide at least once in their lifetime 
(Goodwin and Jamison, 1990; Hawton et al., 2005; Jamison, 2000; Valtonen et 
al., 2006). The link between migraine and suicidality is not fully understood. 
Whilst suicidal thinking and behaviour in migraine is often attributed to 
psychiatric disorders that can accompany migraine, evidence suggests that this 
association may be independent of psychiatric comorbidity, particularly for 
migraine with aura (Breslau et al., 1991). I will discuss this proposal in more detail 
when summarising the main findings of the migraine subtype analysis.  
Within univariate analysis, bipolar subjects with migraine reported a greater 
number of episodes of depression compared to those without migraine. An 
increased number of episodes of depression was also found to be an 
independent predictor of migraine in the second multivariate model, entering 
variables that survived adjustment for multiple testing. This finding is in line with 
Brietzke et al. (2012b), who noted that migraine comorbidity within BD was 
associated with more mood episodes, especially those of depressive polarity. 
Such a finding has important clinical implications given the potential for an 
individual being inappropriately treated with anti-depressant monotherapy, 
increasing the risk of a pharmacologically-induced manic episode.  
In addition to exploring the impact migraine comorbidity has on the bipolar 
illness, it is also important to determine whether migraine experienced within 
bipolar disorder is similar to that experienced within the general population. 
Within the current study, of those individuals for whom age of onset of migraine 
was known (n=195, 70.4%), 67% reported onset before the age of 20 years. This 
is in accordance with a number of studies stating that at least half of all migraine 
onsets begin before the age of 20 (Lipton et al., 2001; Silberstein and Lipton, 
1993; Stewart et al., 1991). Regarding the characteristics of migraine, the most 
frequent migraine symptoms were:  moderate or severe pain intensity (98%), 
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unilateral pain (73.6%), pulsatile pain (64.6%), hypersensitivity to light or sound 
(50.2%), nausea/vomiting (41.5%), with aggravation by physical activity being 
the least frequently endorsed symptom (33.6%). The only study to detail 
symptom frequencies of migraine within the general population, was Lipton et 
al. (2001) in their large US population-based American Migraine Study II. 
However, differences between the studies in the assessment of symptoms make 
them difficult to compare. Specifically, Lipton et al. (2001) did not assess the 
International Headache Society (IHS) criterion of ‘aggravation by physical 
activity’, and chose to report the symptoms of ‘nausea’ and ‘vomiting’ 
separately. In the current study and in line with IHS criteria, I report a combined 
figure assessing the presence of nausea and/or vomiting. Moreover, as 
discussed within the methods chapter of this thesis, the current study asked 
subjects about hypersensitivity to sound ‘or’ light, in contrast to Lipton et al. 
(2001) who asked about hypersensitivity to light ‘and’ sound, separately. Lipton 
et al. (2001) did report the frequencies for pulsatile and unilateral pain, of which 
pulsatile pain was found to be more prevalent; 85% vs. 59% for unilateral pain. 
This is in contrast to the current study where bipolar subjects more frequently 
endorsed unilateral pain.  
Within the bipolar cohort of migraine sufferers, I identified a greater number of 
patients with migraine with aura (MA) than without aura (MoA). One-hundred 
and fifty-three individuals with migraine (55.2%; 10.7% of total sample) had 
experienced MA, compared to the 124 (44.8%; 8.7% of total sample) subjects 
that had suffered with MoA. This becomes even more prominent if the 69 
subjects identified as having typical aura with non-migraine headache (n=65) 
and typical aura with no headache (n=4) are included within the former group. 
As discussed in Chapter 3, this finding is in contrast to the third of migraine 
patients reported to experience aura symptoms within the general population 
(Silberstein and Lipton, 1993). Fasmer (2001) also observed a greater number of 
patients with MA (n=12, 43% of migraine group; 19% of total sample) compared 
to MoA (n=10, 35.7% of migraine group; 16% of total sample) within their sample 
of inpatients with major affective disorders. Similarly, Ortiz et al. (2010) 
reported a two-fold prevalence of MA in a sample of subjects with bipolar 
spectrum disorders, compared to that reported in the general population 
(Russell and Olesen, 1996). Such a finding is in line with previous research 
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indicating a stronger association between affective disorders and MA, 
compared to MoA (Breslau et al., 1991; Oedegaard et al., 2005a; Ball et al., 
2009).  
 
Of the 153 individuals identified as having migraine with aura, visual aura was 
found to be the most frequent of aura symptoms (79.1%), followed by sensory 
(44.4%) and aphasic (19%). A similar pattern is observed within the general 
population (Russell and Olesen, 1996), although with a higher proportion of 
individuals experiencing visual aura (99%) and a lower proportion reporting 
sensory aura (31%), than observed within our BD sample of MA individuals. In 
line with existing literature, we revealed an earlier age of migraine onset for the 
MA group compared with MoA (15 vs. 18.5, p=.004). Age of onset of both MA 
and MoA were younger than the onset of BD in either group (19 and 22 years, 
respectively), suggesting that migraine may precede BD. Specifically, for the 
MA group, onset of migraine preceded BD onset in nearly 60% of individuals, 
whereas in the MoA group, migraine preceded BD in approximately equal 
proportions to those where BD onset preceded migraine onset (49.4% vs. 
46.8%, respectively). Thus, MA may constitute a first hallmark of BD for some 
patients and raise clinicians’ suspicion for the presence of affective pathology.   
 
To our knowledge, this is the first study to differentiate between the subtypes 
of MA and MoA when exploring the relationship of migraine with the clinical 
features and course of BD. Multivariate analysis revealed that when compared 
to BD subjects with no history of migraine, those with migraine with aura (MA): 
were more likely to; be younger, be female, have a diagnosis of bipolar II 
disorder (BDII) and have a higher lifetime rate of attempted suicide. In Chapter 
3, I observed a higher prevalence of both migraine with (MA) and without aura 
(MoA) among individuals with BDII compared to bipolar I disorder (BDI). When 
compared with bipolar subjects without migraine, there was a significant 
negative association with BDI and a significant positive association with BDII 
with both subtypes of migraine. Moreover, the strength of the association with 
BDII was observed to be larger for MA than that for MoA. In the current study, 
BDII was found to be an independent predictor of MA when compared with 
bipolar subjects without migraine, however was not found to be associated with 
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MoA within multivariate analysis, suggesting the association of BDII with 
migraine is perhaps driven by the MA subtype.  
 
Given this independent association of MA with BDII, together with the proposal 
that a rapid cycling illness course is associated with the BDII subtype (Kupka et 
al., 2003), it could be suggested that association between MA and BDII may be 
explained by the association of a rapid cycling course of illness with BDII. 
Interestingly, a rapid cycling illness course was not found to be associated with 
MoA when compared to bipolar subjects without migraine. A significantly 
increased rate of rapid cycling illness was found in bipolar subjects with MA 
when compared to those with MoA, suggesting that the association with rapid 
cycling may be specific to migraine with aura. 
 
MA was also associated with past history of suicide attempt. When focusing on 
all forms of migraine, evidence has suggested an increased rate of suicide 
attempt within BD patients. In addition, as outlined within the introduction of 
this thesis, an association has also been noted between suicide attempt and MA, 
even after adjusting for presence of major depressive disorder (MDD) and other 
psychiatric comorbid conditions (Breslau, 1992; Breslau et al., 1991). Within the 
current study, a history of suicide attempt was not found to differentiate BD 
subjects with MoA compared to those with no migraine. A comparison between 
bipolar subjects with MA and MoA revealed an increased rate of suicide attempt 
in the MA group, suggesting that the relationship between suicide attempt and 
any migraine within BD is specific to the MA subtype. Thus, identifying the 
presence of MA in bipolar patients may help clinicians to identify those at 
increased risk for suicide, therefore enabling appropriate management and 
intervention.  
 
No bipolar clinical characteristics were found to be associated with MoA when 
compared to bipolar subjects without migraine in the multivariate model, 
suggesting that the migraine-BD comorbidity may have more serious 
implications for those with MA and that the relationship between BD and 
migraine is perhaps driven by the MA subtype. When differentiating MA from 
MoA, significant differences were found in the clinical characteristics of BD and 
149 | P a g e  
 
migraine. A multivariate model revealed history of panic disorder and a younger 
age of migraine onset to be associated with aura status. Our group previously 
reported an independent association of panic attacks with comorbid migraine 
(not distinguishing between subtypes) in BD, even after controlling for other 
significant differences (Gordon-Smith et al., 2015). Results of the current study 
suggest that a history of panic attacks and an early onset of migraine in bipolar 
patients with MA may be indicative of a subgroup of individuals at increased risk 
for a number of important clinical outcomes, including suicidality.  
This study benefits from a large, clinically well-defined, sample of subjects with 
bipolar disorder. Furthermore, subjects were sampled from a UK community 
population, recruited through both systematic and non-systematic methods. 
This representative sample therefore increases the generalisability of the study 
findings. A further strength of this study is the use of IHS criteria (Headache 
Classification Subcommittee of the International Headache Society, 2004) for 
determining migraine diagnosis. It is, however, important to interpret findings 
in the context of certain limitations. Firstly, as mentioned within the previous 
chapter, the cross-sectional nature of the study methodology does not allow for 
the determination of causality in the relationship between BD and migraine and 
therefore future prospective studies would be useful. Secondly, lifetime history 
of migraine was ascertained through retrospective self-report measures and is 
therefore subject to recall bias and may have resulted in either an under or over 
reporting of migraine. Moreover, although an acceptable questionnaire 
response rate of 40% was achieved, it is possible that a response bias may exist. 
However, as described in Chapter 3, the migraine questionnaire was part of a 
larger pack of 13 questionnaires and so it is unlikely that individuals completed 
this questionnaire based on their migraine status. Finally, analysis did not 
consider medication use, which will inevitably modify the bipolar illness. 
Moreover, some pharmacological treatments are successful within both 
disorders, most notably valproate, and so it is unknown to what extent such 
treatment options influenced the prevalence and course of both disorders.  
The results in this chapter suggest that comorbid migraine may represent a 
subtype of BD that is associated with a distinct set of lifetime clinical 
characteristics. Moreover, differences identified in the comorbid expression of 
this relationship suggest that the relationship between migraine and BD may be 
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driven by the migraine with aura subtype. This finding emphasizes the 
importance of not only recognising migraine within individuals with bipolar 
disorder, but also the value of identifying subtypes of migraine among this 
patient group. This could help to predict the course of the bipolar illness and 
identify those at increased risk for important illness outcomes and hence, offer 
appropriate management sooner. Further research aimed at unravelling the 
complex relationship between migraine subtypes and BD will help us to better 
understand and characterise the clinical features of the migraine-BD 
comorbidity and identify sub-populations of individuals with BD that could 
benefit clinically from more effective, targeted diagnostic and treatment 
strategies, and may provide a useful focus for future aetiological studies, 
potentially revealing common pathophysiology underlying both disorders.  
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Chapter 5 
Exploring the genetic susceptibility of bipolar 
disorder and comorbid migraine: a genome-wide 
association study 
 
5.1 Introduction 
As has already been discussed in earlier chapters of this thesis, migraine is a 
common comorbid condition within bipolar disorder (BD), with studies 
consistently showing an increased prevalence of migraine among those with BD 
(Mahmood et al., 1999; McIntyre et al., 2006b; Ortiz et al., 2010; Gordon-Smith 
et al., 2015). Moreover, studies have suggested that migraine comorbidity may 
influence course of illness in BD. For example, presence of migraine has been 
associated with: an earlier age of onset of BD (Mahmood et al., 1999; McIntyre 
et al., 2006b); attempted suicide (Ortiz et al., 2010); a rapid cycling course of 
illness (Gordon-Smith et al., 2015); and a bipolar II diagnosis (Fasmer, 2001; 
Ortiz et al., 2010). Such findings suggest that recognition of migraine may be a 
meaningful way of refining the bipolar phenotype to identify more 
homogeneous patient populations. 
As outlined within the introduction of this thesis, a number of possible shared 
underlying mechanisms influencing susceptibility to migraine and BD have been 
suggested. For example, both migraine and BD have been linked to 
disturbances in the serotonergic (Hamel, 2007; Mahmood and Silverstone, 2001; 
Silberstein, 1994), dopaminergic (Emilien et al., 1999; Peroutka, 1997), and 
glutamatergic systems (Vaccaro et al., 2007). Disturbances in inflammatory 
cytokines (Brietzke et al., 2012a) and alterations in ion channels (Di Lorenzo et 
al., 2012; Fasmer et al., 2009) have also been implicated in the pathophysiology 
of both disorders. In addition, some pharmacological treatments are common 
to migraine and BD. For example, valproate is a treatment for BD but can also 
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be used in the prophylactic treatment of migraine, reducing the number of 
attacks, duration of headache and intensity of pain (Silberstein, 1996).  
As discussed within the introduction of this thesis, previous studies have 
suggested that migraine may provide a useful tool for stratifying individuals 
with BD, potentially identifying subgroups of patients for which there may be 
shared genetic variation. For example, using the migraine-bipolar phenotype, a 
genome-wide linkage study on 31 families (n=202) identified an overlapping 
locus on chromosome 20p11 for both BD and migraine (Oedegaard et al. 2010b). 
Regions of genetic susceptibility have also been identified for the migraine-
bipolar phenotype through genome-wide association studies (GWAS). Based on 
a sample of 56 bipolar cases with comorbid migraine compared with 699 
controls (bipolar subjects without any headache), Oedegaard et al., (2010a) 
found evidence of association for several single-nucleotide polymorphisms 
(SNPs) approaching genome-wide significance (5 x 10-8) on chromosome 
13q14.1 (e.g. rs9566845, p=7.7 × 10−8; and rs9566867, p=8.2 × 10−8), in a region 
containing the uncharacterised gene KIAA0564. Whilst little is known about the 
gene, a Dutch genome-wide linkage study supported the involvement of this 
genomic region in migraine by reporting linkage to a region in close proximity 
to that harbouring KIAA0564 (Ligthart et al., 2008).  
In a second GWAS involving 460 bipolar subjects with self-reported migraine 
(cases) and 914 bipolar subjects without migraine (controls), Jacobsen et al., 
(2015) identified a genome-wide significant association for rs1160720 in the 
NBEA gene (chromosome 13q13). The NBEA gene encodes neurobeachin, a 
scaffolding protein primarily expressed in the brain (Lauks et al., 2012). NBEA 
has also been shown to be involved in trafficking vesicles containing GABA and 
glutamate receptors (Lauks et al., 2012; Nair et al., 2013), thus implicating the 
glutamatergic system as a potential pathway leading to the development of the 
combined migraine-bipolar phenotype (Cherlyn et al., 2010; Ligthart et al., 
2011). Interestingly, this variant failed to show association with migraine or BD 
individually, leading the authors to speculate the etiological specificity of this 
gene to the combined phenotype and to hypothesize that BD with comorbid 
migraine may be a distinct syndrome with different genetic risk factors than for 
either migraine, or BD alone.  
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The above studies support the proposal that the BD-migraine combined 
phenotype has the potential to reclassify individuals into a more homogeneous 
genetic subgroup. However, neither of the above published GWAS of migraine 
and BD used standardised, International Headache Society (IHS) criteria, which 
may have resulted in phenotypic heterogeneity, potentially limiting the power 
of these studies to identify susceptibility genes for the combined BD-migraine 
phenotype.  
So far, the current thesis has identified a group of bipolar subjects with 
comorbid migraine as defined by IHS criteria (Chapter 3) and has revealed 
differences in the clinical course of the bipolar illness according to the presence 
of migraine (Chapter 4). These findings add support to the proposal that 
migraine comorbidity may be used to delineate subgroups among individuals 
with BD for which there may be common genetic variation. The current study 
looked to extend previous work by examining genetic susceptibility to BD with 
comorbid migraine (defined according to IHS criteria), through a genome-wide 
association study.  
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5.2 Methods 
5.2.1 Subjects 
Chapter 3 of this thesis identified 277 bipolar subjects meeting International 
Headache Society (Headache Classification Subcommittee of the International 
Headache Society, 2004) criteria for migraine, according to a self-report 
questionnaire based on The Structured Migraine Interview (SMI; Samaan et al., 
2009). 778 bipolar subjects were identified as being free from migraine 
comorbidity. Out of the combined total of 1,055 subjects, genotype data was 
available for 712 subjects (of which n=526, 74% were female). Thus, the case-
control study reported here included 210 bipolar subjects with migraine and 502 
bipolar subjects without migraine. Of the 210 bipolar subjects identified as 
having migraine, 119 (57%) met IHS criteria for migraine with aura (MA).   
All subjects were derived from the Bipolar Disorder Research Network (BDRN). 
Please see Chapter 2 for a description of the sample and assessment 
information. Of the 712 subjects included in the current study; 486 (68.3%) 
subjects met criteria for bipolar I disorder (BPI), 199 (27.9%) met criteria for 
bipolar II disorder (BPII), and the remaining 27 (3.8%) subjects met criteria for 
schizoaffective, bipolar type (SABP). All participants were: above 18 years of 
age; unrelated; and of white European descent (according to both self-report 
and principal component analysis of GWAS data – see Section 5.2.3).  
5.2.2 Genotyping and quality control 
Genotype data for the current study was provided by Professor Elaine Green 
(Professor of Genomics, Plymouth University), via the Broad Institute. DNA 
extraction was performed by Kbiosciencs (now known as LGC; 
http://www.lgcgroup.com/our-science/genomics-solutions/#.V17Cm_krK70). 
Samples were genotyped at the Broad Institute on either the Illumina 
HumanOmniExpress-12v1, or the Illumina HumanOmniExpressExome-8v1. 
Specifically, of the 712 subjects included in the current study, 217 individuals 
were genotyped on the HumanOmniExpressExome-8v1, and 495 on the 
HumanOmniExpress-12v1. The proportion of cases (bipolar subjects with 
migraine) genotyped on each array was comparable, with 28.9% of those 
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genotyped on HumanOmniExpressExome-12v1, and 30.9% of those genotyped 
on HumanOmniExpressExome-8v1, being cases (bipolar subjects with 
migraine). 
Data was provided by EG in the following binary files; a ‘.bed’ file (containing 
genotype data for individuals), a ‘.bim’ file (a mapping file, providing 
information on each genetic marker), and a ‘.fam’ file (providing participant 
identification information). As part of the data pre-processing stage, I created a 
new binary data file (using the ‘--make-bed’ command in PLINK) to keep only 
those individuals to be used within the analysis (i.e. bipolar cases with migraine, 
and bipolar cases without migraine). This was performed using the ‘--keep’ 
command in PLINK followed by a ‘.txt’ file listing the individual identifier of the 
712 individuals to be included in the study. In order to allocate disease status to 
included participants (1=unaffected-no migraine; 2=affected- migraine), I read 
in information from an alternative phenotype file using the ‘--pheno’ command. 
This phenotype file included the family identifier, individual identify and 
phenotype for each individual. As above, I then created a new binary data file 
including updated disease status using the ‘--make-bed’ command, which, by 
default created a ‘.bed’, ‘.bim’ and ‘.fam’ file. Once the genotype and phenotype 
information had been read into PLINK, it was possible to conduct the next stage 
of data pre-processing; sample-level and single nucleotide polymorphism 
(SNP)-level filtering. This is explained in more detail below.  
Initial quality control (QC) was performed at the Broad Institute. I checked QC 
parameters within the current analysis and all passed the thresholds in line with 
those followed by the Psychiatric Genetics Consortium (see Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014).  Within the 
current analysis, QC thresholds for the dataset were set so that single nucleotide 
polymorphisms (SNPs) were excluded if: they had a minor allele frequency 
(MAF) below 5%; had less than 97% genotyping call rate; and if they significantly 
deviated from Hardy-Weinberg Equilibrium (P-value < 0.0001). In addition, 
thresholds were set so that samples with more than 3% failed genotypes were 
excluded. I also tested for relatedness using IBD estimation (-- genome –0.2), 
and autosomal heterozygosity deviation (| Fhet | < 0.2), in PLINK, which did not 
identify any individuals to be excluded.   
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5.2.3 Genome-wide association analysis 
Principal component estimation was performed by Dr Sophie Legge using 
EIGENSTRAT (Price et al. 2006) to identify potential outliers and explore 
potential effects of population stratification (differences in allele frequency 
between cases and controls due to systematic ancestry differences) in the 
sample. Using EIGENSTRAT, principal components analysis is used to infer 
continuous axes of genetic variation (eigenvectors) that reduce the data to a 
small number of dimensions, whilst describing as much variability between 
individuals as possible. Next, gen0types and phenotypes are continuously 
adjusted by amounts attributable to ancestry along each axis, creating a virtual 
set of matched cases and controls. Finally, association statistics are computed 
using ancestry-adjusted genotypes and phenotypes (Price et al., 2006).  
 
I included the first three principal components as covariates to account for 
population structure. Association analysis was performed using logistic 
regression in PLINK (Purcell et al. 2007), using the ‘--logistic’ command. In 
addition, I used the ‘--ci 95’ command to output the standard error and 95% 
confidence intervals of the odds ratio. Manhattan and quantile-quantile (QQ) 
plots were generated in R (http://www.R-project.org). SNPs were functionally 
annotated using the UCSC Genome Browser (Kent et al., 2002; 
https://www.genome.ucsc.edu/), and Ensembl Genome Browser (Flicek et al., 
2014; http://www.ensembl.org/index.html). Following the association analysis, 
PLINK was used to identify independent (in relative linkage disequilibrium) 
SNPs (--clump-p1 0.0001 --clump-p2 0.0001 --clump-r2 0.1 --clump-kb 3000), 
where the SNP with the highest association was selected as the index SNP. I 
employed a genome-wide significance level of P < 5 x 10-8, which is commonly 
used in GWAS and corresponds to a Bonferroni multiple testing correction of a 
0.05 Type 1 error level for 1 million independent tests (Johnson et al., 2010).  
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Figure 5.1 Principal component analysis plot displaying principal component 1 
and 2. Points represent individual samples; black points represent bipolar 
subjects without migraine (controls) and red points represent bipolar subjects 
with migraine (cases). Cases and controls appear to overlap considerably, 
therefore it can be presumed that they originate from similar populations.
 
Figure 5.2 Principal component analysis plot displaying principal components 1 
and 3. Points represent individual samples; black points represent bipolar 
subjects without migraine (controls) and red points represent bipolar subjects 
with migraine (cases). Cases and controls appear to overlap considerably, 
therefore it can be presumed that they originate from similar populations. 
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Figure 5.3 Principal component analysis plot displaying principal component 2 
and 3. Points represent individual samples; black points represent bipolar 
subjects without migraine (controls) and red points represent bipolar subjects 
with migraine (cases). Cases and controls appear to overlap considerably, 
therefore it can be presumed that they originate from similar populations. 
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5.3 Results 
Association was tested in a total of 210 bipolar subjects with migraine (cases) 
and 502 bipolar subjects without migraine (controls).  1,325 SNPs were excluded 
due to a MAF below 5%, and 1 SNP was excluded for failing HWE, leaving 
377,465 SNPs available for analysis. Figure 5.4 shows a quantile-quantile (QQ) 
plot displaying the relationship between observed p-values (y axis) and 
expected p-values (x axis). Both the QQ plot (Figure 5.4) and estimated genomic 
inflation factor show no evidence of inflation (λ=1) and so this was not corrected 
for in the association analysis. Figure 5.5 shows a Manhattan plot of all SNPs in 
the analyses, displaying the p-values of the comparisons between the bipolar 
subjects with migraine (cases), and without migraine (controls).            
     
Figure 5.4 QQ plot of –log10 observed logistic regression p-values (y-axis) 
against expected p-values (x-axis). λGC = 1. 
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Figure 5.5 Manhattan plot of -log10 p-values for each SNP (y-axis), plotted by 
chromosomal position (x axis). Red line represents genome wide significance 
level (P < 5 x 10-8). 
 
As seen within Figure 5.5, no SNP surpassed the genome wide significance level 
of p < 5 x 10-8. Table 5.1 lists the ten most strongly associated SNPs in relative 
linkage equilibrium. The strongest signal associated with comorbid migraine 
within bipolar disorder (BD) was found for a locus on chromosome 19p13.3, 
marked by rs4375794 and located within the Protease Serine 57 (PRSS57) gene. 
The minor allele of rs4375794 (T) was more frequent in bipolar subjects with 
migraine compared to those migraine-free controls (OR = 1.921, 95% CI = 1.454-
2.537, p=3.45 x 10-6) (Table 5.1; Figure 5.5). A further 6 of the top independent 
SNPs were significant at the p< 5 x 10-5 level (Table 5.1) with three of these being 
located in known genes; IQ Motif Containing G (IQCG), Long Intergenic Non-
Protein Coding RNA 683 (LINC00683); and SP3 Transcription Factor (SP3). 
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SNP CHR Position A1/A2 MAF A MAF U OR 95% CI P-value Gene Location Predicted  
function 
rs4375794 19 691909 T/C 0.2571 0.1527 1.921 1.454- 2.537 3.45x10-6 PRSS57 Exonic Synonymous 
rs13175238 5 68058660 A/G 0.1476 0.07186 2.237 1.559-3.209 1.22x10-5  Intergenic  
rs3898584 17 68800128 C/T 0.1024 0.2006 0.4545 0.3199-0.6459 2.08x10-5  Intergenic  
rs9880989 3 197665599 T/G 0.2238 0.1347 1.852 1.382- 2.481 2.17x10-5 IQCG Exonic Missense 
rs17059667 18 74337641 T/C 0.1357 0.06786 2.157 1.486- 3.13 4.20x10-5 LINC00683 Downstream 
gene variant  
 
rs2376070 2 104646414 T/C 0.2619 0.164 1.809 1.375-  2.38 3.49x10-5  Intergenic  
rs4972618 2 174769344 T/C 0.3714 0.479 0.6426 0.5088- 0.8117 4.75x10-5 SP3 Downstream 
gene variant 
 
rs7583046 2 42468471 G/A 0.3952 0.506 0.6381 0.5062-0.8043 5.93x10-5 EML4 Intronic  
rs870713 9 84227158 C/A 0.3881 0.508 0.6143 0.4871- 0.7748 6.14x10-5 TLE1 Intronic  
rs4978770 9 111887219 T/G 0.1627 0.08982 1.969 1.404- 2.761 6.33x10-5 TMEM245 Upstream 
gene variant 
 
Columns are: variant ID (SNP); chromosome (CHR); chromosomal position (Position); minor reference allele (A1); major allele (A2); minor allele frequency in cases (MAF A); and 
minor allele frequency in controls (MAF U); odds ratio (OR); 95% confidence interval (95% CI); p-value; gene; location to/in gene; and predicted function. 
 
Table 5.1 Top 10 independent single nucleotide polymorphisms (SNPs) from GWAS analysis.  
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5.4 Discussion 
The current chapter describes a genome-wide association study (GWAS) in 
which 210 bipolar subjects with comorbid migraine (cases) and 502 bipolar 
subjects without migraine (controls) were analysed. No single SNP met the 
threshold for genome-wide association with migraine in bipolar disorder (BD). 
The strongest evidence for association was for rs4375794, an exonic SNP found 
within Protease Serine 57 (PRSS57) on chromosome 19p13.3 (OR = 1.921, 95% CI 
= 1.454-2.537, p=3.45 x 10-6). In addition, a further 6 of the top 10 independent 
SNPs showed moderate significance at the p< 5 x 10-5 level: rs13175238 
(chromosome 5), rs3898584 (chromosome 17), rs9880989 (chromosome 3), 
rs17059667 (chromosome 18), rs2376070 (chromosome 2), and rs4972618 
(chromosome 2). Three of these SNPs were located in known genes; IQ Motif 
Containing G (IQCG) (rs9880989), Long Intergenic Non-protein Coding RNA 683 
(LINC00683) (rs17059667); and SP3 Transcription Factor (SP3) (rs4972618). 
A description of the possible candidate genes in regions implicated by the top 
10 independent SNPs is included in Appendix F. Review of gene ontology 
databases for these genes did not reveal any obvious implications for current 
theories of BD or migraine pathophysiology. Moreover, variants within these 
genes have not been previously implicated in BD, migraine, nor with the 
combined migraine-BD phenotype. Below, I briefly summarise any known 
function of the genes associated with the migraine-BD phenotype in this study 
up to a significance level of p< 5 x 10-5 (PRSS57, IQCG, LINC00683, SP3): 
PRSS57 (Protease, Serine, 57) 
PRSS57 is involved in serine-type endopeptidase activity. Serine proteases are 
proteolytic enzymes that break the peptide bond that joins amino acids 
together in proteins. In mammals, serine proteases are involved in a number of 
biological processes, such as; digestion, blood clotting, reproduction and the 
complement system.  
IQCG (IQ Motif containing G) 
IQCG is one of several IQ motif–containing genes of unknown function. IQ 
motifs are present in several hundred proteins, most notably myosins, but also 
in a variety of nonmyosin proteins such as neuronal growth proteins, voltage-
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gated channels, phosphatases, spindle-associated proteins, and sperm surface 
proteins (Bähler and Rhoads, 2002). Harris et al. (2014) recently reported a male-
specific infertility mutant in which the genetic lesion was traced to IQCG. These 
mice exhibited spermiogenesis defects. 
LINC00683 (Long Intergenic Non-Protein Coding RNA 683) 
LINC00683 is a non-annotated RNA gene, affiliated with the non-coding RNA 
class.  
SP3 (Sp3 Transcription Factor) 
SP3 is a protein coding gene, belonging to a family of Sp1 related genes that 
encode transcription factors that regulate transcription. This protein contains a 
zinc finger DNA-binding domain and several transactivation domains, and 
functions as a bifunctional transcription factor, both activating and repressing 
transcription (Suske, 1999).  
 
Whilst it is possible to identify risk variants for complex disease in a small sample 
(Klein et al., 2005), it is generally accepted that the GWAS approach requires 
very large samples, with numbers typically reaching the tens of thousands 
(Craddock et al., 2008). Therefore, a lack of statistical power, given the limited 
number of cases and controls may be a potential explanation for the current 
study not finding any genome-wide significant effects. GWAS rely on the 
‘common disease-common variant’ (CDCV) model, in which several common 
variants are thought to confer a small risk and interact to give rise to the disorder 
(Barnett and Smoller, 2009). Therefore, GWAS require large numbers of cases 
and controls in order to detect such small effects with statistical confidence. 
Moreover, considering the stringent significance threshold enforced by GWAS 
(because of the requirement to adjust for the large number of statistical tests 
performed), power is likely to be inadequate to detect small effect sizes unless 
large numbers of cases and controls are studied. One way of increasing the 
number of samples in the current study could be to include cases identified as 
having probable migraine. In Chapter 3, an additional 304 subjects were 
identified to have probable migraine, defined as an attack or headache missing 
one of the features needed to fulfil all International Headache Society (IHS) 
criteria for a migraine disorder (ICHD, 2004). Chapter 3 demonstrated that of the 
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45 probable migraine cases selected for a follow-up telephone interview, 64.4% 
were in fact found to meet full criteria for migraine, thus supporting the proposal 
of including probable migraine cases within a replication of the current study.  
An alternative to the ‘common disease-common variant’ model is the ‘common 
disease-multiple rare variants’ model in which a proportion of disease is said to 
be caused by highly penetrant rare genetic variants, each with large effect 
(Pritchard, 2001). GWAS are not designed to detect the effects of such variants 
that are often suggested to account for much of the ‘missing heritability’ 
problem associated with GWAS (Maher, 2008). It is therefore possible that 
susceptibility to the migraine-BD phenotype may be explained by rare variants 
that could not be detected by the current GWAS approach.  
 
Moreover, there has been much debate concerning whether the migraine 
subtypes, migraine with (MA) and without aura (MoA) are distinct subtypes or 
whether they are part of the same disease spectrum (Ligthart et al., 2006; 
Nyholt et al., 2004; Russell et al., 2002, 1996). The observation that both types 
of attack can occur within the same individual (Launer et al., 1999), and that MA 
and MoA are frequently found within the same family (Carlsson et al., 2002) is 
often cited as evidence of a shared aetiology between the subtypes. In contrast, 
MA has been identified as having a higher genetic component than MoA, with 
Russell and Olesen (1995) revealing a considerably higher heritability estimate 
and sibling recurrence risk compared to MoA (3.8 vs. 1.9). Such a finding 
suggests that MA and MoA may have different aetiologies and therefore 
different modes of inheritance. Furthermore, results from a recent meta-
analysis of 23,285 migraine cases and 95, 425 controls of European ancestry 
identifying 142 SNPs surpassing genome-wide significance at 12 loci, revealed 
important differences between subjects with MA and MoA (Anttila et al., 2013). 
When analyzing MoA and MA separately, Antilla et al. (2013) revealed a larger 
number of significant loci associated with MoA compared to MA (despite similar 
sample sizes). In addition, subgroup comparisons for the 12 implicated loci 
indicated that the effect sizes were larger in MoA compared to MA cases.  Whilst 
this was unexpected given the suggested higher heritability of MA compared to 
MoA, one possible explanation for the observed difference is that MA may be 
less influenced by common variants than MoA, and mediated more by rare 
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variants with larger effect. Given that over half (57%) of the migraine subjects 
within the current study were identified as having MA, this provides further 
support for the possibility that causal variants of large effect, not picked up by 
GWAS, may be contributing to the migraine and BD phenotype.  
 
In addition, future research investigating the potential shared aetiological 
underpinnings between migraine and BD, may benefit from focusing on the rare 
subtype of MA, hemiplegic migraine (HM). As described in the introduction of 
this thesis, the familial subtype of HM (FHM) is genetically heterogeneous, with 
polymorphisms in at least three genes being implicated; CACNA1A (Ophoff et 
al., 1996), ATP1A2 (DeFusco et al., 2003), and SCN1A (Dichgans et al., 2005). All 
three FHM genes either encode ion channels or are involved in ion 
transportation, thus implicating ion channels within the molecular 
pathophysiology of both migraine and BD. Chapter 3 of this thesis identified 45 
individuals meeting criteria for hemiplegic migraine (HM) (3.1% of total sample). 
This greatly exceeds the 0.01% rate of HM reported by Thomsen et al. (2002) in 
a Danish population-based epidemiological survey. Whilst the number of 
individuals identified within the current thesis would likely be underpowered to 
conduct a GWAS, it is important that future research focus on this migraine 
subtype when searching for potential shared susceptibility genes for the 
migraine-BD phenotype.   
 
Whilst there have been two previously published GWAS using the bipolar 
disorder (BD)-migraine combined phenotype (Oedegaard et al., 2010a; 
Jacobsen et al., 2015), neither employed the gold-standard criteria for the 
diagnosis for migraine established by the International Headache Society 
(Headache Classification Subcommittee of the International Headache Society, 
2004). It is therefore possible that these studies were subject to phenotypic 
heterogeneity, and that the methods used to identify cases may have resulted 
in false positive migraine identification. Therefore, the associations observed in 
these studies, may not be replicated in samples employing these criteria. 
Introduction and adoption of IHS classification for migraine has helped to clarify 
our understanding of the scope of the public health problem posed by migraine. 
For example, a meta-analysis of 24 studies, only five of which employed IHS 
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classification criteria (ICHD-I; Headache Classification Committee of the 
International Headache Society, 1988), revealed that case definition accounted 
for the largest portion of variation in migraine prevalence among studies (36%) 
(Stewart et al., 1995). A second meta-analysis including 18 population-based 
studies, all of which had utilised IHS criteria, revealed that following 
standardisation of case definition, a substantial proportion of variation in 
prevalence was explained for by very few factors, such as age and geographic 
location of the study population (Scher et al., 1999). Therefore, in searching for 
genes predisposing individuals to migraine and BD, studies should endeavor to 
reduce the degree of genetic heterogeneity by reducing the clinical 
heterogeneity in study samples.  
Identifying risk variants associated with the combined migraine-BD phenotype, 
and understanding the mechanisms through which they confer susceptibility, 
could improve our knowledge of the pathogenesis of both disorders, potentially 
leading to novel approaches to treat and prevent these disorders. Given the lack 
of statistical power of the current study, it is essential for future studies to ensure 
large samples, to increase the likelihood of identifying shared genetic variation. 
Moreover, given the proposed differences between the migraine subtypes, 
migraine with (MA) and without aura (MoA), it is important for future studies 
examining the genetic susceptibility to migraine and BD to differentiate 
between these subtypes. This is particularly important given the findings of the 
current thesis suggesting that the clinical expression of the migraine-BD 
phenotype may be particularly associated with the MA subtype (Chapter 4). 
Finally, it is possible that the shared genetic component between migraine and 
BD is explained by rare variation that is not detected through the GWAS 
approach. Therefore, future studies would benefit from adopting more powerful 
methods able to detect such variation, such as next generation sequencing.  
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Chapter 6 
Epilepsy in bipolar disorder: impact on clinical 
features, course and outcome 
 
6.1 Introduction 
It is well recognized that mood disorders and epilepsy commonly co-occur. The 
psychiatric comorbidity of epilepsy has been well described, with mood 
disorders reported to occur at much greater rates than the background 
prevalence; estimates vary due to sampling strategies, between 20-50% 
(Kanner, 2003). However, to date, much of the neuropsychiatric literature has 
focused on the study of unipolar depression with investigation into bipolar 
disorder (BD) remaining limited. 
 
In addition, there has been a distinct lack of studies exploring the systematic 
assessment of well-characterized epilepsy within a bipolar population. Rather, 
much of the research to date has focused on the assessment of multiple physical 
health disorders concurrently, with studies often grouping disorders together by 
organ system (i.e. neurologic disorders). Such studies have identified an 
increased prevalence of neurologic disorders within BD, compared to controls 
subjects (Carney and Jones, 2006; Evans-Lacko et al., 2009). However, whilst 
this has acted to increase our knowledge of medical burden, and broadly defined 
neurologic disorders within BD, it has not allowed for comprehensive 
investigation of epilepsy within BD.  
 
Several converging lines of research suggest a relationship between bipolar 
disorder and epilepsy. Both conditions are substantially heritable, follow an 
episodic course (for which a kindling paradigm has been suggested), can be 
associated with a brain that has a superficially normal structure, and respond to 
anticonvulsant medications. Such shared features between the two disorders 
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are often cited as evidence of possible shared underlying pathophysiology and 
ignite interest in the mechanisms surrounding this relationship.    
 
The current chapter looks to explore the comorbid relationship between BD and 
epilepsy. Firstly, the chapter will assess the rate of self-reported epilepsy within 
a large, well-characterised sample of UK participants with a DSM-IV (American 
Psychiatric Association, 2000) diagnosis of BD. The chapter will then describe 
the process for identifying a cohort of bipolar individuals with well-defined, 
expert-confirmed epilepsy. Using these two definitions of epilepsy (self-report 
and expert-confirmed), the chapter will then explore lifetime clinical 
characteristics of illness in individuals with bipolar disorder according to their 
lifetime history of epilepsy, in order to explore whether the co-occurrence of 
epilepsy within individuals with BD alters the clinical course of the bipolar illness.  
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6.2 Methods 
6.2.1 Participants 
Participants were drawn from the Bipolar Disorder Research Network (BDRN), 
a clinical and genetic study of individuals across the United Kingdom with mood 
disorders, described in detail within Chapter 2. Individuals with a lifetime DSM-
IV diagnosis of bipolar I disorder (BDI), bipolar II disorder (BDII) or 
schizoaffective, bipolar type (SABP), were included in the current study.   
6.2.2 Assessment of epilepsy  
As described in Chapter 2 of this thesis, lifetime history of epilepsy and seizures 
within the BDRN bipolar cohort was identified through the use of a staged 
screening strategy.  
6.2.2.1 Screening stage 1: Self-report questionnaire assessment of 
epilepsy/seizures 
Participants were initially screened for a lifetime history of epilepsy/seizure 
disorder via a self-report questionnaire. The self-report questionnaire was a 
modified version of a brief screening instrument to identify individuals with 
epilepsy, designed by (Ottman et al., 2010) (Appendix C). The original 
instrument and revision employed by BDRN are both described in detail within 
Chapter 2. For the purposes of the current study, self-reported epilepsy/seizures 
was defined as anyone who screened positively (answering either ‘yes’ or 
‘possible’) to the main seizure disorder/epilepsy question: 
‘Other than the seizure[s] you had because of a high fever (so other than febrile 
seizures), have you ever had, or has anyone ever told you that you had, a seizure 
disorder or epilepsy?’ 
The self-report epilepsy questionnaire was included as part of a larger 
questionnaire pack and sent to 5216 individuals who had originally taken part in 
BDRN, in June 2013. Of these, 2169 individuals completed and returned the 
questionnaire pack (response rate of 42%) and of these, 2082 (96%, 40% of the 
total sample) had completed the epilepsy questionnaire. Given that the self-
report epilepsy questionnaire was disseminated to BDRN participants as part of 
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a larger questionnaire pack, it was possible that those participants with a history 
of epilepsy may have been more likely to complete the epilepsy questionnaire, 
potentially biasing the sample. To further explore this, I examined completion 
rates of the additional 6 questionnaires included in the questionnaire pack, by 
those who completed the epilepsy questionnaire. This is summarised in Table 
6.1.  
Table 6.1 Completion rates of additional questionnaires by participants 
completing the epilepsy questionnaire 
Number of additional questionnaires 
completed by participants completing the 
epilepsy questionnaire  
N (%) 
All 6 additional questionnaires 1955 (93.9%) 
5 additional questionnaires 111 (5.3%) 
4 additional questionnaires 15 (0.7%) 
3 additional questionnaires 1 (0.1%) 
2 additional questionnaires 0 (0%) 
1 additional questionnaire 0 (0%) 
0 additional questionnaires 0 (0%) 
 
Of the 2082 subjects who completed the epilepsy questionnaire: 1955 
individuals (93.9%) completed the additional 6 questionnaires included within 
the pack; and a further 111 individuals (5.3%) completed 5 questionnaires. No 
individuals completed the epilepsy questionnaire only.  
As mentioned above, 96% of the 2169 BDRN subjects who returned the 
questionnaire pack completed the epilepsy questionnaire. Examination of the 
87 subjects (4%) who returned their questionnaire pack but did not complete the 
epilepsy questionnaire revealed that: 42 (48.3%%) completed all of the further 
6 questionnaires included in the pack; 22 (25.3%) completed 5 other 
questionnaires; 11 (12.6%) completed 4 other questionnaires; 6 (7%) completed 
3 other questionnaires; 5 (5.7%) completed 2 other questionnaires; and finally 1 
(1.1%) completed only 1 other questionnaire included in the pack.  
A total of 486 individuals were excluded from the study. The reasons for 
exclusion are summarised in Table 6.2. A number of individuals were excluded 
as they did not meet original BDRN study criteria (reasons 1-3 in Table 6.2) and 
so clinical data was not available for these individuals (described within Chapter 
2). The current study aimed to examine epilepsy within individuals with bipolar 
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spectrum disorders, which included bipolar I disorder (BDI), bipolar II disorder 
(BDII), and schizoaffective, bipolar type (SABP). Therefore, individuals not 
meeting DSM-IV diagnostic criteria for these disorders were excluded from the 
study (n=169). Finally, a large number of individuals (n=270) could not be 
included in the current study as their original BDRN study data (interview, case-
notes and questionnaires) were yet to be reviewed by the research team and 
therefore diagnostic and clinical ratings were not available for these individuals. 
Following these exclusions, 1596 participants remained in the current study.  
Table 6.2 Reasons for exclusion from the study 
Reason for exclusion N 
1. Relative in the study 6 
2. Age of onset of bipolar disorder was 
after 65 years 
1 
3. Ethnicity other than Caucasian 40 
4. Excluded for diagnosis 169 
5. Interview awaiting rating 270 
Total 486 
  
6.2.2.2 Screening stage 2: Identifying individuals for telephone interview 
Individuals who screened positively for epilepsy/seizures via the main screening 
question underwent a second stage of screening, in an attempt to separate true 
from false positives and identify individuals to be contacted for a more detailed 
assessment via a telephone interview. During this process, individuals had the 
remainder of their questionnaire responses (questions 3-5; Appendix C) 
reviewed by a Research Psychologist (Sarah Knott: SK) and Consultant 
Epileptologist (Professor Mike Kerr: MK), separately. Additionally, individuals 
who had answered ‘don’t know’ to the main screening question also underwent 
this second stage of screening. This was to allow for any potential confusion or 
misinterpretation by the participants between the symptomatology of BD and 
epilepsy and was considered an important group to further explore.  
During stage two of the screening process individuals were classified in to one 
of three groups based on their questionnaire responses: ‘definite epilepsy’, 
‘possible epilepsy’ and ‘no epilepsy’. An individual was categorised as having: 
‘definite epilepsy’ if within the rest of the individual’s questionnaire responses, 
there was clear evidence of well-described seizures; ‘possible epilepsy’ if the 
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responses were suggestive of a story in-keeping with epilepsy but further 
information was not available to confirm; and ‘no epilepsy’ if the further 
information provided in the questionnaire responses was not supportive of an 
epilepsy diagnosis. This stage of screening was considered necessary as time 
constraints meant that it was not possible to follow up all of those who had 
initially screened positive for self-reported epilepsy/seizures (i.e. all those who 
answered either ‘yes’ or ‘possible’ to the main screening question) with a more 
detailed assessment in the form of a telephone interview (screening stage 3). 
Caveats of this method are discussed at the end of this chapter.  
6.2.2.3 Screening Stage 3: Telephone interview 
Individuals identified as ‘definite’ or ‘possible’ epilepsy cases from the second 
stage of screening were selected for the follow-up telephone interview. In 
addition, a random sample of 20 individuals from those identified as ‘no 
epilepsy’ from the second stage of screening were also selected for telephone 
interview. A diagram to illustrate the staged screening process to identify 
lifetime history of epilepsy within the bipolar sample is shown in Figure 6.1.  The 
telephone interview utilised within this study was an adaptation of a 
standardised, structured diagnostic inventory employed by the Epilepsy 
Phenome Genome Project (EPGP) and is described in detail within Chapter 2. 
All completed interviews were assessed together by MK and SK, in order to 
determine epilepsy status.  
Those BDRN participants chosen for a follow-up telephone interview were sent 
an initial contact letter providing brief details about the research. The letter 
informed individuals that a BDRN researcher would contact them, by telephone, 
over the next few weeks to answer any questions they may have regarding the 
research and to discuss whether they would be interested in taking part. 
Individuals were also given the opportunity to refuse any further contact 
regarding this research, by contacting the study team by telephone or email. 
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Screening Stage 1: 
Self-report questionnaire 
Screening Stage 2: 
Identifying Individuals for 
telephone interview 
Screening Stage 3: 
Telephone interview 
Main screening question response 
Yes Possible Don’t know No 
Questionnaire responses screened to create following groups 
Definite epilepsy 
Contacted for telephone interview 
Random 
sample of 20 
Possible epilepsy No epilepsy 
Figure 6.1 Three stage screening process for identifying lifetime history of epilepsy within the Bipolar Disorder Research 
Network (BDRN) sample 
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6.2.3 Statistical analysis 
Data were analysed using the statistical package SPSS version 20. Normality of 
the data was assessed using the Kolmogorov-Smirnov test. The majority of the 
data analysed were not normally distributed and so non-parametric tests were 
employed. Statistical tests were considered significant at the p<0.05 level (two 
tailed) unless stated otherwise.  
6.2.3.1 Comparison of clinical characteristics according to the presence 
of comorbid epilepsy - univariate analysis  
Demographic and lifetime clinical characteristics of bipolar subjects were 
compared between: i) self-reported epilepsy vs. no epilepsy; and ii) expert-
confirmed epilepsy vs. no epilepsy, in order to explore the relationship between 
epilepsy and the clinical features and course of the bipolar illness, using both a 
broad and narrow definition of epilepsy. Comparisons were made using Mann 
Whitney-U tests for continuous variables and categorical variables were 
assessed using 2x2 and 2x3 chi square tests. In instances where 20% or more of 
the cells in a chi-square table had an expected count of less than five, Fisher’s 
exact tests (2x2 tables) and exact significance tests for Pearson’s chi-square (2x3 
tables and greater) were used.  
6.2.3.2 Comparison of clinical characteristics according to the presence 
of comorbid epilepsy - multivariate analysis  
To identify independent predictors of comorbid epilepsy within individuals with 
bipolar disorder, variables significant at the 5% level in univariate analyses were 
included as explanatory variables in a logistic regression model (using the enter 
method) with presence or absence of epilepsy as the dependent variable.  
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6.3 Results 
6.3.1 Identifying lifetime history of epilepsy within a sample of 
individuals with bipolar disorder 
6.3.1.1 Screening stage 1: Self-reported epilepsy/seizures 
One-hundred and twenty-seven individuals (8%) screened positively (i.e. 
answered either ‘yes’ or ‘possible’) to the main screening question; ‘Other than 
the seizure(s) you had because of a high fever, described above, have you ever had, 
or has anyone ever told you that you had, a seizure disorder or epilepsy?’ hence 
were identified as having self-reported epilepsy/seizure disorder. A breakdown 
of responses to the main screening question is shown in Table 6.3.  
 
Table 6.3 Participant responses to the initial screening question on the self-
report epilepsy questionnaire in the bipolar sample. 
  
Response to the initial screening question      
“Have you ever had, or has anyone ever 
told you that you had, a seizure disorder or 
epilepsy’ 
N (%) 
Yes 82 (5.1%) 
Possible 45 (2.8%) 
No 1386 (87.0%) 
Don’t know 64 (4.0%) 
Missing/did not respond 19 (1.1%) 
Total 1596 (100.0%) 
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6.3.1.2 Screening stage 2: Identifying individuals for telephone interview  
As described in the methods section, the 127 individuals who screened positively 
for self-reported epilepsy underwent a second stage of screening, whereby the 
remainder of their questionnaire responses were reviewed. In addition, those 
who answered ‘don’t know’ (n=64) to this question also went through the 
second screening process in order to allow for any potential confusion in the 
symptomatology of bipolar disorder (BD) and epilepsy. Thus, in total 191 
individuals had their questionnaire responses further reviewed within the 
second stage of screening. Stage two of the screening process was completed 
by both SK and MK, separately. A kappa statistic (Cohen, 1960) of 0.8 revealed 
an excellent level of agreement (Fleiss, 1981). In instances where there was 
disagreement between raters, the case was further discussed and a consensus 
was reached.  
Following this screening process, individuals were classified into one of three 
diagnostic groups; ‘definite epilepsy’, ‘possible epilepsy’ and ‘no epilepsy’. Table 
6.4 displays a summary of the diagnostic groups following stage two of 
screening, as well as a breakdown of how each diagnostic group responded to 
the main seizure question during the first stage of screening. 
 
Table 6.4 Breakdown of responses to the main seizure question (screening 
stage 1) for each stage 2 diagnostic group 
Diagnostic group following 
screening stage 2 (n) 
Response to the main screening 
question in screening stage 1 
Definite epilepsy (n=13) Yes, n=13 (100%) 
Possible epilepsy (n=66) Yes, n=38 (57.6%) 
Possible, n=21 (32%) 
Unsure, n=7 (10.4%) 
No epilepsy (n=112) Yes, n=31 (27.7%) 
Possible, n=24 (21.4%) 
No, n=57 (50.9%) 
 
6.3.1.3 Screening stage 3: Telephone interview 
As described previously, all those identified as ‘definite’ (n=13) and ‘possible’ 
(n=66) epilepsy cases within the second stage of screening were selected for the 
third stage follow-up telephone interview in order to more definitely define 
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epilepsy within the cohort. A random sub-sample of 20 ‘no epilepsy’ cases 
identified within stage two of screening were also selected to be contacted for 
the third stage telephone interview. Thus, in total, 99 individuals were selected 
to complete the detailed telephone interview within the third and final stage of 
the screening process.   
I conducted all telephone interviews over an eight-month period, between April-
November 2014. As described within the methods section of this chapter, 
individuals were sent an initial contact letter briefly detailing the research before 
first contact by telephone was made. This was the case for 83 individuals, 
however there was no contact number available for 15 individuals. For these 
cases an initial letter was sent requesting that interested individuals complete 
an attached contact form updating the study team of their contact details and 
return it to the study team in an enclosed stamped addressed envelope. If there 
was no response to this letter after a period of one month, a reminder letter was 
sent. Finally, one individual had an invalid address and contact number and so 
contact could not be made by either letter or telephone. Individuals were 
contacted a maximum of 5 times by telephone, on different days and at different 
times of the day if successful contact had not been made on the previous 
attempts.   
The process from initial contact letter to completed interviews is summarised 
in Figure 6.2. 
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Participants selected for telephone interview (n=99) 
Initial contact letter requesting updated details (n=15) Invalid address (n=1) Initial contact letter (n=83) 
Successful telephone contact with 
participant (n=78) 
Unable to successfully contact 
participant after multiple attempts 
(n=6) 
Interview declined 
(n=4) 
Contact number not in 
use, request letter sent 
(n=13) 
No response from 
number request letter 
(n=8) 
Response 
(n=4) 
Response 
(n=5) 
Interview completed 
(n=74) 
No response from 
initial or reminder 
letters (n=6) 
Response from 
participant updating 
contact details (n=5) 
No response, reminder 
letter sent (n=10) 
No contact made 
(n=1) 
Figure 6.2 Screening stage 3 process from initial contact letter to completed telephone interview 
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Of the maximum 99 possible interviews, I successfully completed 74 (75%) 
within the eight-month period. A breakdown of the number of interviews 
completed within each of the screening stage 2 epilepsy diagnostic group is 
shown in Table 6.5.  
 
Table 6.5 Number of interviews completed within stage 2 epilepsy diagnostic 
groups 
Number of interviews conducted within…. N (%) 
Definite epilepsy (n=13) 11 (84.6%) 
Possible epilepsy (n=66)  48 (72.7%) 
No epilepsy (n=20 randomly selected cases) 15 (75%) 
Total (n=99) 74 (75%) 
 
The largest proportion of completed interviews were conducted within the 
‘definite epilepsy’ group (84.6%), with similar rates within both the ‘possible’ 
and ‘no epilepsy’ groups (72.7% and 75%, respectively). Only four individuals 
declined the interview, two from those classified as ‘possible epilepsy’ cases and 
two classified as ‘no epilepsy’.  I was unable to contact the remaining 21 
individuals despite multiple attempts. There were two cases that could not be 
contacted for interview within the ‘definite epilepsy’ group. The first did not 
have a contact number available and did not respond to letters requesting 
updated contact details. The second could not be reached despite multiple 
attempts. Within the ‘possible epilepsy’ group, 16 individuals could not be 
reached following multiple attempts and two declined the interview. Of the 20 
randomly selected ‘no epilepsy’ cases, three were unable to be contacted and 
two declined the telephone interview.  
For those individuals who could not be contacted for telephone interview 
(n=25), I attempted to gather information to help establish the presence of 
epilepsy through the use of medical records. As part of the initial BDRN consent 
process, all participants had consented for their medical records to be requested 
and reviewed in strict confidence by members of the research group. However, 
as 88% of the 25 individuals who could not be successfully contacted for 
telephone interview were originally interviewed for BDRN three or more years 
(range 2-7 years) prior to the time telephone interviews were conducted in 2014, 
it was deemed inappropriate to request general practice medical records for 
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these individuals. Alternatively, for these individuals, existing psychiatric case 
notes (obtained at the time of original BDRN interview) were reviewed.  
Psychiatric case notes were available for 15 (60%) of the individuals that I was 
unable to contact for telephone interview. For this group, there was no mention 
of epilepsy or seizures for 11 individuals. For two individuals, seizures/fits were 
discussed; one individual was noted as having a seizure following a high 
temperature, and another was noted as having several fits in 2010, with 
inconclusive MRI and EEG results and an entry from a neurologist in 2010 
documenting that they were optimistic there would be no further events. For a 
further two individuals, a ‘possible epilepsy’ diagnosis had been recorded within 
their medical records. The first of these had a brief mention of 
‘absences/concentration lapses’, with no further information available, and the 
second had a reference to a possible diagnosis of temporal lobe epilepsy (TLE). 
This individual was described as having a seizure in 2001 following a drug 
overdose. There was no further mention of seizures until 2009 when TLE was 
raised as a possibility, however it was noted that this was complicated by heavy 
alcohol use. There was no further mention of seizures or investigations for TLE. 
When the above four cases were reviewed by myself and Professor Mike Kerr, 
we concluded that there was not enough information to robustly establish the 
presence of epilepsy, and so without a supplementary telephone interview, 
these cases could not be included in the ‘expert-confirmed epilepsy’ group.  
As described in the methods section of this thesis (Chapter 2) the telephone 
interview employed within this study was an adaptation of a standardised, 
structured diagnostic inventory employed by the Epilepsy Phenome Genome 
Project (EPGP). Within the interview, participants provided a detailed 
description of each of their seizure ‘types’, a description of seizure triggers, 
information regarding any investigations and medication the participant had 
undertaken, and finally information regarding alcohol intake and any potential 
relationship with seizures. All interviews were reviewed by SK and MK, in order 
to determine a diagnosis of epilepsy. 
Of the 74 completed telephone interviews, 19 cases were identified as having a 
lifetime diagnosis of epilepsy and 40 cases were not considered to have a 
lifetime diagnosis of epilepsy, following expert review. Ten cases were identified 
as being either borderland or complex cases and were blind reviewed by a 
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second Consultant Epileptologist, Dr Rhys Thomas (RT), and a consensus 
diagnosis was reached. Following this process, a further 7 cases were confirmed 
to have a lifetime diagnosis of epilepsy. General practice case notes were 
requested for all 26 expert-confirmed epilepsy cases. If no response was made 
to this request, a second letter was sent to the participant’s GP surgery. In 
instances where there was no response to the requests for medical records, 
existing psychiatric case notes (obtained at the time of original BDRN interview) 
were reviewed. General practice medical records were obtained for 8 of 26 
cases; 7 of which documented a history of seizures and/or epilepsy. For the 
remaining 18 cases, psychiatric case notes were reviewed and evidence 
suggestive of a history of seizures and/or epilepsy was noted for 10 cases. Thus, 
a history of seizures and/or epilepsy was corroborated by medical records for 17 
of 26 cases (65%).  
For the remaining 5 completed interviews, there was not enough information to 
confidently confirm or refute a diagnosis of epilepsy until further evidence had 
been sought. Medical case notes were available for all 5 cases; either following 
a request from the participant’s GP (n=3) or from existing case notes requested 
following original BDRN interview (n=2). Subsequent re-review of these cases 
identified a further 3 cases as having a lifetime diagnosis of epilepsy. And so, 
within the sample of 1596 individuals with bipolar disorder, 29 were identified 
as having expert-confirmed epilepsy (1.8%), of which 20 (70%) cases were found 
to have evidence corroborating a history of seizures and/or epilepsy within their 
medical records. Tables 6.6 summarises the breakdown of expert-confirmed 
epilepsy cases (n=29) within each diagnostic group identified within the second 
stage of screening.  
  
Page | 182  
 
Table 6.6 Breakdown of cases identified as having expert confirmed epilepsy 
within screening stage 2 diagnostic groups 
Intermediate diagnosis following 
screening stage 2 
Number of expert-confirmed 
epilepsy cases identified 
following telephone interview (%) 
Definite epilepsy  
(of n=11 interviewed) 
 
n=10 (91%) 
Possible Epilepsy  
(of n=48 interviewed) 
 
n=18 (37.5%) 
No epilepsy  
(of n=15 interviewed) 
 
n=1 (6.7%) 
 
As can be seen from Table 6.6, one individual identified as having ’definite 
epilepsy’ within the second stage of screening was not confirmed by an expert 
as having epilepsy following review of their telephone interview. Within their 
self-report questionnaire, this individual noted having convulsions in their early 
childhood for which they received medication, thus was considered to have a 
past history of epilepsy and was placed within the ‘definite epilepsy’ group. 
Following a description of these events at telephone interview, an epilepsy 
diagnosis was not confirmed, but rather the individual was believed to have had 
a history of febrile convulsions, for which they had received rectal diazepam 
administered as an emergency treatment.  
Interestingly, an individual who was initially placed within the ‘no epilepsy’ 
group within the second stage of screening, was in fact deemed as having an 
expert-confirmed diagnosis of epilepsy following telephone interview. This 
individual screened positively for self-reported epilepsy within the screening 
questionnaire stating that they had experienced three seizures (aged 50) ‘due to 
alcoholism’. This was considered not to be epilepsy but an alcohol-related 
seizure and so the individual was subsequently placed within the ‘no epilepsy’ 
group. Following description of these events, a clinical decision was made in 
agreement by two epilepsy experts (MK and RT) to reclassify the individual as 
having epilepsy that was ‘possibly exacerbated by alcohol’. In this instance, 
there did not appear to be a compelling relationship between the use of alcohol 
and the seizures experienced. In fact it has been suggested that an individual is 
more likely to experience a seizure due to compensatory physiologic changes in 
the context of abrupt cessation of alcohol (rather than from the consumption of 
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alcohol itself), a condition that does not require a diagnosis of epilepsy (Engel, 
2001).   
A diagram to illustrate the number of individuals in each screening stage is 
shown in Figure 6.3. 
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n=18 n=30 
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n=1 
n=10 
n=57 
n=7 
n=24 n=21 
n=31 
n=38 n=13 
Expert-confirmed 
epilepsy, n=29 
Screening Stage 1: 
Response to main screening 
question 
Screening Stage 2: 
Epilepsy diagnostic groups derived 
from further screening 
Screening Stage 3: 
Confirmed to have epilepsy 
following telephone interview 
Yes,  
n=82 
Possible,  
n=45 
Don’t know,  
n=64 
No,  
n=1387 
Definite epilepsy,  
n=13 
Possible epilepsy,  
n=66 
No epilepsy,  
n=112 
Figure 6.3 A summary of the number of individuals involved in each stage of screening for epilepsy within the bipolar sample 
Not confirmed to have 
epilepsy, n=45 
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This section has described the process of identifying a lifetime history of 
epilepsy within the bipolar cohort. Firstly, the section presented the rate of 
individuals with self-reported epilepsy (n=127, 8%), before outlining the 
methods employed to more definitely define epilepsy within the cohort and to 
identify a group of individuals with ‘expert-confirmed-epilepsy’ (n=29, 1.8%). 
The following section of this chapter will utilise these two definitions of epilepsy 
to examine clinical differences in the course of illness for bipolar individuals with 
and without coexisting epilepsy.  
 
6.3.2 Clinical characteristics according to presence of comorbid 
epilepsy – univariate analysis 
6.3.2.1 Demographic Characteristics  
A comparison of demographic characteristics between bipolar subjects with no 
lifetime history of epilepsy and i) self-reported epilepsy, and ii) expert-
confirmed epilepsy is presented in Table 6.7. There were no significant 
differences between bipolar subjects with and without a lifetime history of 
epilepsy, using either definition. There was, however, a trend towards those 
with expert-confirmed epilepsy being older than bipolar subjects with no history 
of epilepsy, and this difference was approaching statistical significance at the 
p<.05 level.  
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Table 6.7 Demographic variables according to the presence of comorbid 
epilepsy 
 
 
No epilepsy  
 
(1) 
N=1386 
Self-reported 
epilepsy  
(2)  
N=127 
Expert-
confirmed 
epilepsy (3) 
N=29 
P-value  
1 vs 2 
P-value  
1 vs 3 
 
Age at 
interview 
    Median (IQR) 
    Range 
 
49 (17) 
20-84 
 
47.50 (15) 
22-69 
 
53 (14) 
31-68 
 
.632 
 
.058 
Female, n (%) 974 (70.3%) 86 (68.3%) 22 (75.9%) .635 .514 
Marital history 
– ever married, 
n (%) 
1146 (85.4%) 112 (89.6%) 26 (89.7%) .198 .789 (F) 
Post-secondary 
education, n 
(%) 
969 (74.6%) 78 (67.8) 19 (70.4%) .112 .618 
Systematic 
recruitment, n 
(%) 
360 (26.8%) 35 (28.1%) 6 (20.7%) .770 .463 
Family history 
of affective 
disorders, n (%) 
991 (86.2%) 92 (83.6%) 19 (79.2%) .464 .365 (F) 
IQR= inter quartile range; F=Fishers exact test.  
 
 
6.3.2.2 Bipolar Disorder Clinical Characteristics  
A comparison of lifetime bipolar clinical characteristics between individuals with 
and without epilepsy (self-report and expert-confirmed) is displayed in Table 
6.8. Examination of illness characteristics revealed that when compared to 
bipolar subjects with no history of epilepsy, those with self-reported epilepsy 
were significantly more likely to have attempted suicide in their lifetime (64.2% 
vs. 47.4%, p=.000367). There was also a trend for bipolar subjects with self-
reported epilepsy to experience more lifetime episodes of depression (10 vs. 8, 
p=.068), however the median number of lifetime manic episodes experienced 
was identical between groups. Bipolar subjects with and without self-reported 
epilepsy were also similar in terms of their: level of functioning in their lifetime 
worst depressive episode (indicated by their identical scores on the GAS 
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depression dimension); rate of rapid cycling of episodes (defined as four or more 
episodes in a one year period); and age of onset of their bipolar illness.  
Focusing on analysis comparing the group of bipolar subjects with better 
defined, expert-confirmed epilepsy to those with no history of epilepsy, the 
epilepsy group was found to experience a significantly greater number of 
lifetime episodes of depression (13.55 vs. 8, p=.043). The expert-confirmed 
epilepsy group also scored significantly higher on the BADDS depression 
dimension, reflecting increased occurrence and severity of depressive episodes 
(83.5 vs. 69.5, p=.007), meeting criteria for ’incapacitating depression’ (referring 
to severe major depression that includes presence of one or more of the 
following features: stupor; mutism; loss of contact with reality, including 
psychotic features). 
A trend was also observed for those with expert-confirmed epilepsy to 
experience a higher rate of suicide attempt compared to those with no history 
of epilepsy (65.5% vs. 47.4%, p=.054) and this was found to be bordering on 
statistical significance. Interestingly, the rate of suicide attempt in those with 
expert-confirmed epilepsy is nearly identical to that observed within those with 
self-reported epilepsy, suggesting that there may be an issue of limited power 
to detect a statistically significant effect, given the small sample size of the 
group. There were also trends for the expert-confirmed epilepsy group to 
experience a better level of functioning in their lifetime worst manic episode, 
reflected in a higher GAS (Global Assessment of Functioning) mania subscale 
score (48 vs. 35, p=.058); and for their manic episodes to be less severe and 
frequent, evidenced by their lower score on the BADDS mania dimension (80.5 
vs. 83, p=.066). Interestingly, these trends were not observed for the broader 
definition, self-report epilepsy group.  
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Table 6.8 Bipolar disorder illness variables according to the presence of 
comorbid epilepsy 
 
 No epilepsy  
 
(1) 
N=1386 
Self-reported 
epilepsy  
(2)  
N=127 
Expert-
confirmed 
epilepsy (3) 
N=29 
P-value  
1 vs 2 
P-value  
1 vs 3 
 
DSM-IV diagnosis, 
n (%) 
    BDI 
    BDII 
    SABP 
 
 
 
940 (67.8%) 
400 (28.9%) 
46 (3.3%) 
 
 
85 (67.7%) 
36 (28.3%) 
5 (3.9%)  
 
 
16 (55.2%) 
13 (44.8%) 
0 (0%) 
 
 
.928 
 
 
.128 
Age of BD onset  
    Median (IQR) 
    Range 
 
21 (12) 
5-64 
 
20 (15) 
9-51 
 
19.50 (17) 
9-63 
 
.528 
 
.834 
No. episodes of 
mania 
    Median (IQR) 
    Range 
 
 
5.1 (8) 
1-300 
 
 
5.1 (7.1) 
1-100.1 
 
 
6 (17.6) 
1-30 
 
 
.884 
 
 
.825 
No. episodes of 
depression 
    Median (IQR) 
    Range 
 
 
8 (16) 
0-150.1 
 
 
10 (15.1) 
0-100.1 
 
 
13.55 (13.1) 
20-40.1 
 
 
.068 
 
 
.043 
Psychotic 
features, n (%) 
733 (61.1%) 60 (64.4%) 14 (58.3%) .471 .784 
Rapid cycling, n 
(%) 
291 (21.1%) 30 (23.8%) 6 (20.7%) .475 .959 
Suicide attempt, n 
(%) 
631 (47.4%) 79 (64.2%) 19 (65.5%) .000367 .054 
History of 
psychiatric 
section, n (%) 
498 (37.6%) 
 
41 (33.9%) 7 (25%) .417 .172 
GAS Mania  
    Median (IQR) 
    Range 
 
35 (30) 
5-65 
 
39.50 (30) 
10-60 
 
48 (27) 
20-60 
 
.652 
 
.058 
GAS Depression 
    Median (IQR) 
    Range 
 
40 (15) 
10-81 
 
40 (14) 
3-80 
 
40 (13) 
20-53 
 
.155 
 
.138 
BADDS Mania 
    Median (IQR) 
    Range 
 
83 (5) 
20-100 
 
83 (5.03) 
40-99 
 
80.5 (42.5) 
40-90 
 
.500 
 
.066 
BADDS 
Depression 
    Median (IQR) 
    Range 
 
 
69.5 (22) 
0-100 
 
 
76 (22.6) 
0-99 
 
 
83.5 (14.1) 
53-90 
 
 
.194 
 
 
.007 
BADDS Psychosis      
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    Median (IQR) 
    Range 
22 (19) 
1-100 
21 (18.25) 
10-99 
21 (4.75) 
20-75 
.876 .498 
BDI= bipolar I disorder; BDII= bipolar II disorder; SABP= schizoaffective bipolar type; IQR= inter quartile 
range. GAS= Global Assessment Scale; BADDS= Bipolar Affective Disorder Dimensional rating Scale. 
Figures in bold indicate statistically significant differences between groups at the p<.05 level.  
6.3.2.3 Psychiatric Comorbidity  
Table 6.9 shows a comparison of co-existing self-reported psychiatric disorders 
between bipolar subjects with and without epilepsy (self-report and expert-
confirmed definitions). When compared to bipolar subjects with no history of 
epilepsy, those with self-reported epilepsy experienced a higher rate of anxiety 
spectrum disorders including; phobias (13.6% vs. 5.7%, .004), in particular 
agoraphobia (10.1% vs. 4.6%, p=.017) and panic disorder (29.6% vs. 16.1%, 
p=.001). The epilepsy group also experienced a greater rate of generalised 
anxiety disorder, however this failed to reach statistical significance (67.7% vs. 
59.1%, p=.096). In addition, a significantly higher rate of alcohol (18.6% vs. 
10.6%, p=.017) and other substance abuse (10.2% vs. 4%, p=.009) was observed 
within the self-reported epilepsy group.   
Similar to those with self-reported epilepsy, when compared to bipolar subjects 
with no history of epilepsy, those with expert-confirmed epilepsy experienced 
higher rates of panic disorder (35% vs. 16.1%, p=.034) and other substance abuse 
(15% vs. 4%, p=.048). Although the associations of increased rates of phobias 
(particularly agoraphobia) and alcohol abuse are no longer observed, the 
reported rates of these conditions within the expert-confirmed group are very 
similar to those seen within the more broadly-defined, self-report group, 
suggesting that this is likely explained by the lack of statistical power given the 
small sample size of the expert-confirmed epilepsy group. Unlike the analysis 
focusing on self-reported epilepsy, there was a significantly higher rate of 
generalised anxiety disorder in those with expert-confirmed epilepsy when 
compared to bipolar subject with no history of epilepsy (81% vs. 59.1%, p=.044).  
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Table 6.9 Psychiatric comorbidity according to the presence of comorbid 
epilepsy 
 No epilepsy  
 
(1) 
N=1386 
Self-reported 
epilepsy  
(2)  
N=127 
Expert-
confirmed 
epilepsy (3) 
N=29 
P-value  
1 vs 2 
P-value  
1 vs 3 
 
Affective and psychotic disorders 
Depression, n (%) 983 (88.2%) 84 (84%) 20 (95.2%) .213 .499 (F) 
Schizophrenia, n 
(%) 
77 (6.9%) 3 (3.1%) 0 (0%) .154 .392 (F) 
Anxiety spectrum disorders  
Agoraphobia, n 
(%) 
51 (4.6%) 10 (10.1%) 2 (9.5%) .017 .259 (F) 
Panic disorder, n 
(%) 
175 (16.1%) 29 (29.6%) 7 (35%) .001 .034 (F) 
Phobias, n (%) 63 (5.7%) 13 (13.6%) 3 (14.3%) .004 .120 (F) 
Generalised 
anxiety disorder, 
n (%) 
648 (59.1%) 67 (67.7%) 17 (81%) .096 .044 
Substance abuse disorders 
Alcohol abuse, n 
(%) 
119 (10.6%) 18 (18.6%) 4 (20%) .017 .260 (F) 
Other substance 
abuse, n (%) 
45 (4%) 10 (10.2%) 3 (15%) .009 (F) .048 (F) 
F=Fishers exact test. Figures in bold indicate variables significant at the p<.05 level. 
 
 
6.3.3 Clinical characteristics according to presence of comorbid 
epilepsy – multivariate analysis 
6.3.3.1 Self-reported epilepsy: 
To identify independent predictors of self-reported epilepsy within individuals 
with bipolar disorder (BD), variables significant at the 5% level in univariate 
analyses were included as explanatory variables in a logistic regression model 
(using the enter method) with absence or presence of epilepsy as the dependent 
variable. Analysis revealed a history of suicide attempt to be a significant 
predictor of self-reported epilepsy (OR: 1.790, 95% CI: 1.130-2.836, p=.013, 
Wald: 6.162, df=1).  
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The model explained 5.1% of the variance (Nagelkerke R2=0.51) within the 
dependent variable (presence of epilepsy) and a Hosmer and Lemeshow 
goodness of fit test statistic of χ² (3) =.912, p =.823, suggested a good fit of the 
model to the data (greater than p=.05). However, as described earlier within this 
thesis, a limitation of this test statistic is its ability to inform us only whether a 
model fits the data or not, rather than indicating the extent of the fit. The 
current model correctly classified 91.9% of individuals as having epilepsy or not. 
As described within Chapter 4, logistic regression analysis is sensitive to high 
correlations between predictor variables, resulting in multicollinearity. To 
identify potential multicollinearity among predictor variables, a multiple linear 
regression was conducted with collinearity diagnostics requested.  As no 
Tolerance values (indication of the proportion of variance in the predictor that 
cannot be accounted for by the other predictors) were less than .10, and no VIF 
values (Variance inflation factor) were greater than 10, this suggests that 
multicollinearity was not apparent among predictor variables.  
 
6.3.3.2 Expert-confirmed epilepsy: 
The small number of cases within the expert-confirmed epilepsy group (n=29) 
creates problems with logistic regression analysis given that the method uses 
the maximum likelihood estimation (ML) to derive its parameters and as such, 
relies on large-sample asymptotic normality. A useful rule of thumb suggests at 
least 10 cases per independent variable for the smaller classes of the dependent 
variable (Peduzzi et al., 1996) (in this instance those with expert-confirmed 
epilepsy, n=29). As a total of five variables were found to be significantly 
associated with expert-confirmed epilepsy within univariate analysis at the 
p<.05 level, this would not meet the minimum requirement of 10 cases per 
predictor variable for the smaller outcome group required for a logistic 
regression model. Thus, the analysis would be underpowered and parameter 
estimates would be unreliable. For this reason, a logistic regression model to 
identify independent predictors of expert-confirmed epilepsy within individuals 
with bipolar disorder was not computed.  
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6.3.3.3 Multivariate model summary 
Logistic regression analysis revealed a history of suicide attempt to be 
significantly associated with self-reported epilepsy within individuals with 
bipolar disorder. The following section of this chapter looks to further explore 
the relationship between epilepsy and suicide attempt within BD.   
 
6.3.4 Explaining the increased rates of suicide attempt in bipolar 
subjects with self-reported epilepsy  
6.3.4.1 Lithium use  
A potential explanation for the increased rate of suicide attempt observed 
within our bipolar subjects with comorbid epilepsy, compared to those without 
comorbid epilepsy, may be related to the possible reduced use of lithium within 
people with epilepsy. Lithium is an effective treatment for reducing the risk of 
suicide in those with mood disorders (Cipriani et al., 2013). However, 
international consensus clinical practice statements for the treatment of 
neuropsychiatric conditions associated with epilepsy, suggest that lithium 
should not be considered in those with BD and epilepsy, as it has been 
associated with increased seizures and neurotoxicity (Kerr et al., 2011). It may 
also be the case that individuals with BD and epilepsy are less likely to be 
prescribed lithium if they are already being treated with alternative mood 
stabilizing anti-epileptic medication. Therefore, it is of interest to assess 
whether the increased rate of suicide attempt in those with BD and epilepsy may 
be related to a lowered rate of lithium use within this group. Comparison of 
lifetime rates of lithium use (Figure 6.4), revealed that bipolar subjects with self-
reported epilepsy were less likely than those without epilepsy to have been 
treated with lithium, however this was not found to be statistically significant 
(62.7% vs. 68.6%, p=.175). Interestingly, the association of lifetime history of 
suicide attempt with self-reported epilepsy within BD remained when 
controlling for the use of lithium treatment (OR: 2.024; 95% CI: 1.376-2.978, 
p=.000346). Conversely, rate of lithium use was found to be higher in the expert-
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confirmed epilepsy group compared to bipolar subjects without epilepsy, 
however, again this was found to be non-significant (75.9% vs. 68.6%, p=.403).  
                    
 
Figure 6.4 Rate of lithium use across bipolar subjects with and without self-
reported epilepsy 
 
6.3.4.2 Anti-depressant medication  
The relationship between the use of anti-depressants and increased suicide risk 
is complex and often disputed. However, evidence from large meta-analyses of 
randomized controlled trials has indicated a trend towards a higher risk of 
suicidal behaviour for patients receiving anti-depressant medication than those 
receiving placebo (Khan et al., 2003; Whittington et al., 2004). Unipolar 
depression is often noted as the most frequent psychiatric disorder in people 
with epilepsy, with incidences ranging from 20-30% in community-based 
epilepsy samples, and 20-55% in specialist epilepsy clinics (Kanner and 
Balabanov, 2002; Blum et al., 2003; Robertson et al., 1994; Ottman et al., 2011). 
Moreover, within the above univariate analyses, bipolar subjects with comorbid 
epilepsy (both self-reported and expert-confirmed) experienced a greater 
number of lifetime episodes of depression. Such a finding suggests that bipolar 
subjects with comorbid epilepsy may experience an illness course predominated 
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by episodes of depression and therefore, may be more likely to be misdiagnosed 
with unipolar depression and treated with anti-depressant monotherapy, 
potentially contributing to their increased risk for suicidal behaviour. However, 
when a comparison between bipolar subjects with and without self-reported 
epilepsy was conducted within the current sample (Figure 6.5), the groups were 
found to be similar regarding their use of anti-depressant medication (90.7% vs. 
92.4%, p=.509).  
                  
 
Figure 6.5 Rates of anti-depressant use across bipolar subjects with and 
without self-reported epilepsy 
 
6.3.4.3 Anti-epileptic medication  
It is also possible that the increased rate of suicide attempt observed in bipolar 
subjects with comorbid epilepsy may be related to the use of anti-epileptic 
medication. In 2008, the Food and Drug Administration (FDA) issued a 
controversial alert regarding a two-fold increased risk of suicidal thoughts and 
behaviour related to the use of anti-epileptic drugs (AEDs). This alert was based 
on a meta-analysis including data from 199 placebo-controlled trials of 11 
anticonvulsant drugs for three indications, including epilepsy. Since its 
publication, the validity of the study and its methodology has been called into 
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question, with Hesdorffer and Kanner (2009) maintaining that; “The relationship 
between suicidality and epilepsy is a complex, multifactorial problem, and AEDs 
probably have little impact.” Within our cohort of bipolar subjects identified as 
having self-reported epilepsy, there was an increased rate of antiepileptic drug 
use in those with a history of suicide attempt against those without such history, 
however this was not found to be statistically significant (Figure 6.6) (46.3% vs. 
34.2%, p=.229). Similarly, within those with expert-confirmed epilepsy, there 
was an increased rate of anti-epileptic drug use within those with a history of 
suicide attempt, however, again this was found to be non-significant (94.4% vs. 
80%, p=.236). It is important to highlight, however, that these were within-
group analyses of already modest sized groups, thus they are limited by their 
small sample size and as a result, statistical power.  
 
 
                                                
Figure 6.6 Rate of anti-epileptic drug use within bipolar subjects with self-
reported epilepsy, with and without a history of suicide attempt 
 
6.3.4.4 Summary 
An association has been observed between a history of suicide attempt and self-
reported epilepsy within individuals with bipolar disorder, and preliminary 
analysis suggests that this increased risk may not be explained through the 
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potential effects of medication. The following section will further explore this 
association by assessing whether comorbid epilepsy remains a risk factor for 
suicide attempt within bipolar disorder, in light of other coexisting disorders and 
known risk factors.  
 
6.3.5 Suicide attempt in bipolar disorder: Epilepsy and other risk 
factors  
It is known that the presence of secondary psychiatric disorders within bipolar 
disorder (BD) is associated with an increased risk of suicide attempt (Chen and 
Dilsaver, 1995; Frank et al., 2002; Goodwin and Hoven, 2002; Nemeroff, 2002). 
Earlier, this chapter identified increased rates of anxiety spectrum disorders as 
well as alcohol and substance abuse in both self-reported and expert-confirmed 
definitions of epilepsy and that these were significantly increased in the larger, 
self-reported epilepsy group. Therefore, in terms of clinical relevance, it is 
important to assess whether having epilepsy increases suicide risk within BD, 
over and above having another neuropsychiatric disorder.  
Moreover, as discussed within the background section of this thesis, medical 
illness and psychiatric disorders are known to co-occur more often than would 
be expected by chance (Stenager and Stenager, 2000), both demonstrating an 
independent association with suicidal behaviour within clinical samples. 
Furthermore, data from community settings have repeatedly observed high 
rates of suicidal ideation among medical patients (Lin et al., 1989; Lish et al., 
1996), particularly for chronic medical illness (Druss and Pincus, 2000). Given 
that epidemiologic studies confirm high rates of medical comorbidity within 
epilepsy (Seidenberg et al., 2009), it is important to assess the association of 
epilepsy with suicide in light of other coexisting chronic medical illness.  
Table 6.10 displays the psychiatric and chronic medical comorbidity of subjects 
with BD, according to their history of suicide attempt. Bipolar subjects with a 
history of suicide attempt experienced a higher rate of: comorbid depression 
(92.3% vs. 84.5%, p=.000014); anxiety spectrum disorders (66% vs. 57.6%, 
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p=.002); alcohol abuse (15% vs. 8.6%, p=.001); migraine (27.4% vs. 22.1%, 
p=.030); asthma (24.8% vs. 19%, p=.014); and diabetes (6.2% vs. 2.6%, p=.002).  
 
Table 6.10 Psychiatric and medical comorbidity within subjects with bipolar 
disorder according to their history of suicide attempt 
 
 
History of 
suicide attempt 
n=764 
No history of 
suicide attempt 
n=770 
P-value 
Psychiatric comorbidity 
Depression, n (%) 591 (92.3%) 506 (84.5%) .000014 
Schizophrenia, n 
(%) 
48 (7.6%) 31 (5.1%) .082 
Anxiety spectrum 
disorders, n (%) 
426 (66%) 352 (57.6%) .002 
Alcohol abuse, n 
(%) 
96 (15%) 52 (8.6%) .001 
Other substance 
abuse, n (%) 
36 (5.6%) 21 (3.5%) .067 
Chronic medical comorbidity 
Epilepsy (self-
reported 
measure), n (%) 
79 (11.1%) 44 (5.9%) .000367 
Migraine, n (%) 175 (27.4%) 143 (22.1%) .030 
Asthma, n (%) 156 (24.8%) 113 (19%) .014 
Multiple sclerosis, 
n (%) 
1 (0.2%) 1 (0.2%) 1.000 (F) 
Arthritis, n (%) 105 (16.3%) 80 (13.1%) .111 
Diabetes, n (%) 40 (6.2%) 16 (2.6%) .002 
Heart disease, n 
(%) 
23 (3.6%) 14 (2.3%) .187 
Figures in bold indicate variables significant at the p<.05 level. 
 
 
Within a logistic regression model, coexisting psychiatric and medical comorbid 
conditions found to differentiate bipolar subjects with and without a history of 
suicide at the p<.05 level (Table 6.10), were entered as predictor variables along 
with self-reported epilepsy, with presence of a history of suicide attempt as the 
dependent variable. The regression model revealed self-reported epilepsy to be 
an independent predictor of suicide attempt when controlling for other 
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significantly associated comorbid conditions. Multivariate analysis revealed 
that comorbid alcohol abuse, depression, and diabetes were also associated 
with a lifetime history of suicide attempt within BD (Table 6.11).  
Table 6.11 Summary of significant comorbidities predicting suicide attempt 
within subjects with bipolar disorder 
 Wald Df P-value OR (95% CI) 
Epilepsy (self-report) 9.521 1 .002 2.080 (1.306-3.311) 
Alcohol abuse 5.294 1 .021 1.588 (1.071-2.354) 
Depression 11.705 1 .001 2.034 (1.354-3.055) 
Diabetes 6.712 1 .010 2.287 (1.223-4.276) 
df=degrees of freedom; OR = odds ratio; 95% CI = 95% confidence interval 
 
 
It was considered important to further understand the relationship between 
epilepsy and suicide in bipolar patients, by considering other demographic, 
epilepsy-related and bipolar-related variables that may be relevant. Table 6.12 
shows a comparison of demographic, epilepsy-related and bipolar clinical 
characteristics between bipolar subjects with and without a history of suicide 
attempt. 
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Table 6.12 Demographic, epilepsy-related and bipolar illness variables within 
subjects with bipolar disorder according to their history of suicide attempt 
 History of 
suicide 
attempt 
n=764 
No history 
of suicide 
attempt 
n=770 
P-value 
Demographic variables 
Age 
    Median (IQR) 
    Range 
 
49 (16) 
21-84 
 
49 (19) 
20-86 
 
.697 
Female, n (%) 577 (75.5%) 509 (66.1%) .000050 
Married/lived as married, n 
(%) 
649 (87%) 635 (85.2%) .325 
Epilepsy-related variables 
Age of epilepsy onset 
    Median (IQR) 
    Range 
 
18.5 (23) 
1-67 
 
13 (29) 
0-58 
 
.853 
Epilepsy illness duration 
    Median (IQR) 
    Range 
 
28 (20) 
0-67 
 
27.5 (42) 
3-71 
 
1.000 
Lifetime AED use 
(specifically for 
epilepsy/seizures), n (%) 
 
44 (10.1%) 
 
30 (6.8%) 
 
.085 
Bipolar illness variables 
Age of onset 
    Median (IQR) 
    Range 
 
19 (10) 
7-63 
 
22 (13) 
5-64 
 
.000001 
 
BD illness duration 
    Median (IQR) 
    Range 
 
27 (17) 
1-59 
 
23 (20) 
0-67 
 
.000001 
History of mixed episodes, 
n (%) 
156 (37.3%) 122 (28.4%) .006 
No. episodes of depression 
    Median (IQR) 
    Range 
 
6.1 (11) 
0-150.1 
 
10.1 (14.1) 
0-100.1 
 
.000001 
IQR= inter quartile range; BD = bipolar disorder; AED=anti-epileptic drugs.  Figures in 
bold indicate variables significant at the p<.05 level. 
 
 
Within a second logistic regression model; sex, age of bipolar onset, bipolar 
disorder illness duration, history of mixed episodes, and the lifetime number of 
episodes of depression were included as predictor variables, along with self-
reported epilepsy and other significantly associated comorbid conditions 
(alcohol abuse, depression and diabetes), with history of suicide attempt as the 
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dependent variable.  Multivariate analysis revealed self-reported epilepsy to be 
an independent predictor of suicide attempt after controlling for significantly 
associated demographic, bipolar illness variables and comorbid conditions. 
Analysis also revealed that bipolar subjects with a history of suicide attempt 
were more likely to have: comorbid depression; diabetes; a younger age of 
bipolar onset; longer bipolar illness duration; more lifetime episodes of 
depression; and a history of mixed episodes (Table 6.13).  
 
Table 6.13 Summary of significant predictors of history of suicide attempt 
within subjects with bipolar disorder 
 Wald df P-value OR (95% CI) 
Epilepsy (self-
reported) 
5.019 1 .025 2.149 (1.100-4.196) 
Comorbid 
depression 
6.186 1 .013 1.929 (1.149-3.237) 
Comorbid diabetes 4.731 1 .030 2.171 (1.104-6.688) 
Age of BD onset 4.769 1 .029 .978 (.958-.998) 
BD illness duration 8.127 1 .004 1.022 (1.007-1.038) 
Number of 
episodes of 
depression 
9.632 1 .002 1.017 (1.006-1.027) 
Presence of mixed 
episodes 
4.364 1 .037 1.47 (1.023-2.047) 
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6.4 Discussion 
6.4.1 Identifying lifetime history of epilepsy within bipolar disorder 
Lifetime history of epilepsy and seizures within the bipolar sample was assessed 
using a staged screening strategy.  The first stage involved a self-report 
questionnaire, where 127 individuals (8%) screened positively for a lifetime 
history of epilepsy, based on the following question; “Have you ever had, or has 
anyone ever told you that you had, a seizure disorder or epilepsy?” This is 
considerably higher than the 2% lifetime prevalence of epilepsy identified 
within (Ottman et al., 2011) US population-based study employing the same 
screening question. It is important to note, however, that the current study 
defined a positive screen for epilepsy as those answering either ‘yes’ or ‘possible’ 
to the above screening question (in line with Ottman et al., 2010), whilst Ottman 
et al. (2011) restricted the definition to a self-reported ‘yes’ to the same 
question. Using this restricted definition within the current study, we still see a 
more than two-fold increased rate of epilepsy within the sample of individuals 
with bipolar disorder compared to that reported by Ottman et al. (2011) (5.1 vs. 
2%).   
As previously outlined within the background section of this thesis, there exists 
a distinct lack of studies exploring rate of epilepsy within a bipolar population, 
with many instead focusing on the assessment of multiple physical health 
disorders concurrently, often grouping disorders together by organ system (i.e. 
neurological disorders). Moreira et al. (2011) is one of very few studies to 
separately assess epilepsy within their evaluation of general medical conditions 
in a Brazilian sample of outpatients with bipolar I disorder. Through the use of a 
self-report questionnaire, Moreira et al. (2011) revealed an epilepsy prevalence 
of 8.2%, consistent with findings reported in the current study. Moreover, the 
8% rate of epilepsy reported within the current study is larger than the 3.4% 
identified by Forty et al. (2014), also based on a sample drawn from the Bipolar 
Disorder Research Network (BDRN). Within their study, Forty et al. (2014) 
examined rates of a number of medical illnesses, including epilepsy, by asking 
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subjects whether they had ever been told by a health professional that they have 
any of 20 listed health problems. The lowered rate of epilepsy observed by Forty 
et al. (2014), utilising subjects drawn from the same sample as that reported in 
the present thesis, may be explained by the requirement of health conditions to 
have been diagnosed by a health professional. It could be argued that the rate 
of epilepsy within the current study may be inflated or overestimated due to a 
potential response bias, with individuals with epilepsy being more likely to 
complete and return the self-report questionnaire. However, this is unlikely 
given that the epilepsy questionnaire was part of a larger pack and 96% of those 
who returned the pack had completed the epilepsy questionnaire. Moreover, 
validation of the original screening question within individuals with medical 
record-documented epilepsy, isolated unprovoked seizures and those who were 
seizure free on medical record review (Ottman et al., 2010), revealed a 
sensitivity of 76%, suggesting that the rate of self-reported epilepsy observed 
within the current study, may in fact be underestimated. However, as the 
screening question had not been validated within a psychiatric population, this 
can be speculated only.  
The next stage was to identify a group of individuals with well-defined epilepsy 
for further analysis concerning clinical characteristics associated with BD and 
comorbid epilepsy. For this reason and because of time constraints, a decision 
was made not to follow up all those who screened positively for epilepsy within 
the first stage of screening with further assessment. Alternatively, I 
implemented a second stage of screening, whereby participants had the 
remainder of their questionnaire responses reviewed in an attempt to separate 
true from false positives and to identify those to be contacted for further 
assessment.  A limitation of this method meant that the study is unable to 
comment on the prevalence of well-defined/expert-confirmed epilepsy within 
bipolar disorder, or to assess the sensitivity of the screening questionnaire 
within a bipolar sample. Throughout the study, an emphasis was placed on 
identifying a group of individuals for whom we were confident in their case 
definition of epilepsy, in order to undergo further clinical analysis and for 
comparison with the broader definition group of self-reported epilepsy.  
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In total, 191 subjects underwent the second stage of screening; 127 individuals 
who screened positively for epilepsy within stage 1 of screening, as well as 64 
individuals who answered ‘don’t know’ to the initial screening question. During 
this process, individuals were classified into one of three diagnostic groups; 
‘definite epilepsy’ (n=13), ‘possible epilepsy’ (n=66), and ‘no epilepsy’ (n=112). 
Individuals classified as either ‘definite’ (n=13) or ‘possible’ (n=66) epilepsy 
within the second stage of screening were selected for further assessment in the 
form of a detailed telephone interview, along with a random sample of 20 
individuals classified as ‘no epilepsy’.  Following telephone interview and review 
by an epilepsy expert, 29 individuals were confirmed to have a lifetime history 
of epilepsy (1.8% of total sample), of which 70%, were corroborated by a review 
of general practice/psychiatric case notes.  As already expressed, the purpose of 
this stage was not to identify everybody within the bipolar sample that had a 
definite history of epilepsy, but rather to confidently identify a group of 
individuals with expert-confirmed epilepsy for further analysis. Nevertheless, it 
should be noted that this very conservative estimate already matches the 2% 
rate of more broadly-defined self-reported epilepsy from Ottman et al.'s (2011) 
survey conducted within the general population. Finally, it should be noted that 
whilst all interviews were interpreted by an epilepsy specialist and case notes 
were successfully sought for a large proportion of ‘expert-confirmed’ cases, 
these participants did not have their clinical history taken by a neurologist, nor 
did they undergo physical examination or further investigation, including EEG, 
MRI or telemetry, for example. 
 
6.4.2 Clinical characteristics according to the presence of comorbid 
epilepsy  
The current study is the first of its kind to assess bipolar illness characteristics 
associated with comorbid epilepsy. Specifically, the study looked to examine 
clinical differences in the course of the bipolar illness according to the presence 
or absence of epilepsy, for both broad ‘self-report’, and narrow ‘expert-
confirmed’ definitions of epilepsy.  
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Multivariate analysis revealed an independent association of a history of suicide 
attempt with self-reported epilepsy within individuals with BD. It is important to 
emphasize that due to the exploratory nature of the analysis and modest size of 
the samples, variables were selected for entry into the logistic regression model 
predicting self-reported epilepsy, if they surpassed a significance threshold of 
p<.05 and many associations identified within univariate analysis would not 
stand up to corrections for multiple testing. It is therefore crucial to treat any 
significant findings with caution and also emphasizes the need for larger 
samples when examining the comorbid relationship between epilepsy and BD. 
However, it is also of note that of the variables found to be significantly 
associated with self-reported epilepsy within univariate analysis, a history of 
suicide attempt, as well as comorbid panic disorder would survive a more 
stringent significance threshold of p<.01 and even a very conservative 
Bonferroni correction (.05/27=.002).  
Suicidal behaviour is a serious consequence of BD and it is known that between 
25-50% of sufferers will attempt suicide at least once in their lifetime (Goodwin 
and Jamison, 1990; Hawton et al., 2005; Jamison, 2000; Valtonen et al., 2006). 
Findings of the current study suggest that these rates may be even higher in 
bipolar patients with comorbid epilepsy. Moreover, although multivariate 
analysis could not be conducted with expert-confirmed epilepsy as an outcome 
(due to the insufficient number of cases), a high rate of suicide attempt was 
observed within univariate analysis when the group was compared to those with 
no history of epilepsy (65.5% vs. 47.4%). Whilst this difference didn’t quite reach 
statistical significance (p=.054), the rate of suicide attempt was nearly identical 
to that observed within those with self-reported epilepsy (64.2%), suggesting 
the lack of statistical significance is likely to result from the reduced sample size 
and reduced statistical power. In addition, when bipolar subjects with expert-
confirmed epilepsy were compared to those with no history of epilepsy, they 
were found to experience a greater frequency and severity of lifetime episodes 
of depression. It has been reported that prolonged exposure to depressive 
episodes increases the risk of suicide attempt in bipolar patients (Valtonen et al., 
2006). Thus, the finding of an increased number and severity of depressive 
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episodes within those with expert-confirmed epilepsy may help explain the 
increased risk of suicide seen within these subjects. Unfortunately, this can only 
be speculated as I was not able to explore this within multivariate analysis. 
Further research with a larger sample of individuals with well-characterised 
epilepsy is required to further elucidate this relationship.  
Lithium is associated with reduced suicidality within individuals with mood 
disorders (Cipriani et al., 2013). However, given its previous association with 
increased seizures and neurotoxicity, the use of lithium is not advised within 
individuals with epilepsy. Exploratory work revealed no significant differences 
in the rates of lithium use in bipolar subjects with and without epilepsy. This 
suggests that the increased rate of suicide attempt observed within comorbid 
epilepsy may not be explained by the lowered rate of lithium use of this group.  
Moreover, although controversial, an increased risk of suicidal thoughts and 
behaviour has been associated with anti-epileptic medication (FDA et al., 2008). 
Within-group analysis of bipolar subjects with comorbid epilepsy (both self-
report and expert-confirmed) revealed an increased rate of anti-epileptic drug 
use in those with a history of suicide attempt against those without such history, 
however these findings were not found to be statistically significant. However, 
it is important to keep in mind the small sample sizes involved in these analysis; 
increasing the chance of a Type II error.  
Within univariate analysis, presence of epilepsy, using both a self-reported or 
expert-confirmed definition, did not appear to influence the age of bipolar 
illness onset, the lifetime number of manic episodes, nor the rate of rapid cycling 
of illness episodes. However, results did suggest differences in the rate of a 
number of coexisting psychiatric conditions. Both, self-report and expert-
confirmed epilepsy groups reported significantly higher rates of panic disorder 
and substance abuse (not including alcohol abuse), when compared to bipolar 
subjects with no epilepsy. Moreover, higher rates of phobias (particularly 
agoraphobia) and alcohol abuse were observed in both epilepsy groups, but 
were only significantly increased in those with self-reported epilepsy. However, 
once again, the rates observed in those with expert-confirmed epilepsy were 
very similar to those reported by the broader self-report epilepsy group, 
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suggesting the lack of association is likely to result from the reduced sample size 
and reduced statistical power. The co-occurrence of anxiety disorders and 
substance abuse disorders is well-documented (Radat and Swendsen, 2005), 
and both are known to be highly comorbid with BD (Keller, 2006; Regier et al., 
1990b). Furthermore, people with epilepsy have a higher prevalence of anxiety 
disorders than controls, in both community and specialist settings (Scicutella 
2001; Tellez-Zenteno et al. 2007). Results suggest that the presence of epilepsy 
within BD may further increase the risk for comorbid anxiety spectrum 
disorders. For example, anxiety experienced by bipolar patients may be further 
exacerbated by individuals’ psychological reactions to comorbid epilepsy that 
may stem from the unpredictable nature of the epileptic illness, restrictions on 
normal living, and stigmatization.  
 
6.4.3 Suicide attempt in bipolar disorder: Epilepsy and other risk 
factors 
Within the general population, people with epilepsy are at an increased risk for 
suicide, with an estimated lifetime prevalence of suicide and suicide attempts 
between 5-14% (Robertson, 1997). Moreover, rates have been reported as being 
6-25 times higher in temporal lobe epilepsy compared with the general 
population and even higher in those who have undergone epilepsy surgery 
(Harris and Barraclough 1997). Psychiatric comorbidity within epilepsy is 
recognised as an important risk factor for suicide attempt (Nilsson et al., 2002). 
For example, Jones et al. (2003) observed that the highest risks for suicide 
attempt in people with epilepsy were associated with a lifetime history of major 
depressive disorder and lifetime manic episode (odds ratio of 5.9 and 12.6, 
respectively). Moreover, Christensen et al. (2007) found an almost 14-fold risk of 
suicide in people with epilepsy when psychiatric comorbidity (in particular mood 
and anxiety disorders) was taken in to account. However, it is important to note, 
that not all the increased risk of suicide associated with epilepsy could be 
explained by psychiatric history.   
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In addition, chronic medical conditions are known to often coexist in people with 
epilepsy (Boro and Haut, 2003; Gaitatzis et al., 2004), and a presence of general 
medical illness is associated with suicidality, with the presence of more than one 
illness conferring a particularly high risk (Druss and Pincus, 2000). Importantly, 
Druss and Pincus (2000) found that the relationship between medical illness and 
suicidality persisted even after adjustment for factors such as depression and 
heavy alcohol use. Within the current study, although a number of coexisting 
psychiatric and medical disorders were associated with suicide attempt within 
the bipolar sample, the relationship between epilepsy and suicide attempt 
persisted, after adjusting for these factors, suggesting that it is not fully 
mediated by these disorders. Moreover, within a multivariate model, having 
epilepsy was associated with a 2.08 times increase in the odds of suicide 
attempt, which was greater than for having comorbid depression or alcohol 
abuse disorder (2.03 and 1.58, respectively). Interestingly, among associated 
comorbidities, having diabetes showed the greatest increase in odds for suicide 
attempt within bipolar disorder (2.29). While diabetes has previously been 
associated with suicidality in youth (Goldston et al., 1997, 1994; Hayes, 1993), 
studies within an adult population have not shown a direct link (Goodwin et al., 
2003; Kyvik et al., 1994).  
When bipolar illness variables were compared between bipolar subjects with 
and without history of suicide attempt, as expected, a younger age of bipolar 
onset, longer illness duration, greater number of episodes of depression, and 
history of mixed episodes were all significantly associated with suicide attempt. 
Age of onset of epilepsy, duration of epileptic illness, and lifetime use of 
antiepileptic medication for epilepsy/seizures were also compared across the 
whole bipolar sample, however did not differ according to the presence of 
suicide attempt. In contrast, within an inpatient setting, Nilsson et al. (2002) 
identified a strong association between risk of suicide and onset of epilepsy at 
an early age (particularly during adolescence). Nilsson and colleagues (2002) did 
not find associations with risk of suicide for severity of epilepsy, as expressed by 
seizure frequency and anti-epileptic drug polytherapy, or with the localization 
or lateralization of epileptogenic focus. Unfortunately, the above epilepsy-
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characteristics were not measured by the self-report questionnaire in the 
current study and so cannot be commented on here.  
Multivariate analysis revealed an independent association of epilepsy with 
suicide attempt even when controlling for significantly associated bipolar-
related variables and comorbid conditions (identified in earlier analysis and 
described above) (OR: 2.149, 95% CI: 1.100-4.196, p=.025). Analysis also 
revealed that having comorbid epilepsy was associated with a greater increase 
in the odds ratio for suicide attempt, than for the number of episodes of 
depression, history of mixed episodes, bipolar illness duration and comorbid 
depression.  
The overall aim of the current study was to examine the relationship between 
epilepsy and BD and to present findings from the first systematic study of 
epilepsy within BD. Strengths of this study include its large, well-characterised 
sample of individuals with bipolar disorder and the staged screening process for 
the identification of epilepsy cases, including evaluation by an epilepsy expert 
and medical case note review. Moreover, to the best of my knowledge, this 
study is the first of its kind to examine clinical characteristics associated with 
comorbid epilepsy within BD. Nonetheless, a number of limitations need to be 
considered, in addition to those already mentioned above. 
 
Firstly, self-reported epilepsy was defined by the response to a single question 
on a questionnaire used to screen for lifetime history of epilepsy within 
epidemiological studies (Ottman et al., 2010). Validation of the single screening 
question within the general population revealed a sensitivity of 76% for epilepsy. 
Within the validation study, sensitivity increased through the use of a broader 
positive screen definition of epilepsy, such that when all questions in the 
screening instrument were included, sensitivity rose to 96%. However, it is 
important to emphasize that the optimal choice for screening depends on both 
available resources and objectives of the study. If the purpose was to examine 
prevalence, maximum sensitivity would need to be ensured to avoid 
underestimation. However, consequently, a large number of false positives 
would need to be evaluated at further stages of screening. As the purpose of this 
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study was to identify individuals with epilepsy within BD for further analysis (as 
per Ottman et al., 2011), it was decided that the use of the main screening 
question alone would be appropriate. It is also worth reiterating that as not all 
of those identified as having comorbid epilepsy from the first stage of screening 
were followed up with a detailed telephone interview, the study is unable to 
comment on the rate of well-defined, expert-confirmed epilepsy within BD. In 
addition, due to exploratory nature of the analysis and the modest size of both 
the self-report and expert-confirmed epilepsy groups, corrections were not 
routinely made for multiple testing. Therefore, any significant findings must be 
treated with caution. In similar vein, due to the insufficient number of cases 
within the expert-confirmed epilepsy group, I was unable to conduct 
multivariate analysis to assess clinical characteristics associated with a narrower 
definition of epilepsy. However, reassuringly, the same direction of effects was 
observed for the majority of variables within univariate analysis for those with 
expert-confirmed epilepsy as the self-report group, when compared to bipolar 
subjects with no history of epilepsy.   
 
In summary, the current study identified high rates of lifetime history of epilepsy 
within a sample of individuals of BD, and identified differences in the clinical 
characteristics of BD according to the presence or absence of epilepsy, including 
history of suicide attempt and coexisting psychiatric disorders. The study also 
revealed an independent association of suicide with self-reported epilepsy that 
did not appear to be explained by medication effects; however more work is 
needed within larger samples to fully explore these effects. Finally, the study 
revealed comorbid epilepsy to be an independent risk factor for suicide attempt 
within individuals with BD, after controlling for other associated risk factors, 
such as number of episodes of depression, bipolar illness duration and coexisting 
medical and psychiatric illness.  
 
The results of this study highlight the importance of recognising and identifying 
comorbid epilepsy within individuals with BD, given the association with 
important illness outcomes, including increased suicidality. Further research 
exploring detailed characteristics of epilepsy within bipolar disorder, in terms of 
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determining the type of epilepsy, and its epileptogenic features are required to 
further unravel their complex comorbid relationship. Ultimately, it is crucial for 
clinicians to recognize the benefit of improved collaboration between the 
practice of neurology and psychiatry as a means of improving the evaluation and 
management of comorbid epilepsy and mood disorders. Equally, recognition of 
epilepsy within BD and further understanding of their comorbid relationship 
may reveal an attractive opportunity for subcategorising for future genetic 
studies, potentially identifying common pathophysiological mechanisms.  
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Chapter 7 
General Discussion 
 
The overall aim of this thesis was to examine the relationship between bipolar 
disorder (BD) and the neurological conditions of migraine, and epilepsy. This 
final chapter will summarise the findings from the four results chapters and 
discuss potential implications of the findings. Next, strengths and limitations of 
the thesis will be discussed, followed by suggestions for future work and final 
conclusions. 
 
7.1  Summary of findings 
7.1.1 Bipolar disorder and migraine  
Evidence from clinical (Fasmer, 2001; Mahmood et al., 1999) and population-
based (McIntyre et al. 2006b) studies suggest that migraine is frequently 
comorbid with bipolar disorder (BD). In addition, it has been reported that 
individuals with bipolar II disorder (BDII) may be disproportionately affected by 
migraine (Fornaro and Stubbs, 2015). Given the caveats of many existing studies 
regarding: small sample sizes; lack of standardised criteria for migraine; 
unrepresentative clinical samples; and inconsistency across studies in their 
definition of bipolar subtypes (in particular BDII), Chapter 3 of this thesis looked 
to examine the relationship between BD and migraine in a large, well-defined 
UK sample of individuals with a diagnosis of BD (Bipolar Disorder Research 
Network; BDRN).  
The first aim of this chapter was to explore the rate of migraine (as defined by 
standardised International Headache Society criteria) within BD and to assess 
this rate across the bipolar diagnostic subtypes; bipolar I disorder (BDI), bipolar 
II disorder (BDII) and schizoaffective, bipolar type (SABP).  Chapter 3 identified 
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a rate of migraine within BD of 19.4%. This is higher than the 12.8% rate of 
migraine reported by Breslau et al. (1991) using a similar questionnaire-based 
method for identifying migraine within the general population. Consistent with 
previous studies (Fasmer, 2001; Ortiz et al., 2010), Chapter 3 also found a 
significantly higher prevalence of migraine among subjects with BDII compared 
to those with BDI (25% vs. 16.9%, respectively). Findings from the first results 
chapter also extend previous literature by showing that individuals with BD also 
experience high rates of probable migraine (21.3%), which is defined by the 
International Headache Society (IHS) as a headache fulfilling all but one criterion 
for migraine with or without aura (Headache Classification Subcommittee of the 
International Headache Society 2004). If Chapter 3 was to incorporate a broader 
definition of migraine; including both strict and probable migraine, the observed 
rate of migraine within BD would increase to 40.7%. This is larger than the 
combined lifetime prevalence of probable and strictly-defined migraine (29.2%) 
within the general population reported by Lantéri-Minet et al. (2005) within 
their French population-based survey.   
The category of ‘probable migraine’ was introduced within the second edition 
of the IHS criteria (ICHD-II; Headache Classification Subcommittee of the 
International Headache Society, 2004), replacing the previously termed 
‘migraneous disorder’ of the first IHS criteria (ICHD; Headache Classification 
Committee of the International Headache Society, 1988). This was largely due 
to criticism from clinicians who believed such patients should be considered as 
genuine migraine sufferers. In addition, it appeared that a large proportion of 
likely migraine patients were falling into this category. For example, Rains et al. 
(2001) reported that of patients presenting to an outpatient headache clinic, 
36% were given a diagnosis of ‘migrainous disorder’. Moreover, Michel et al. 
(1993) revealed that whilst the IHS criteria for migraine had excellent specificity, 
sensitivity was low (<50%), suggesting that that the diagnostic criteria for 
migraine may perhaps be too restrictive. Therefore, in light of such criticism, the 
second edition of the International Classification of Headache Disorders (ICHD-
II; Headache Classification Subcommittee of the International Headache 
Society 2004) acknowledged this category of headache sufferers as being an 
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integral part of migraine, introducing the new subtype of ‘probable migraine’. 
The finding from the current thesis revealing that a large proportion (64.4%) of 
those identified as having probable migraine were reclassified as meeting 
criteria for strict migraine, following telephone interview, adds further support 
to the use of a broader or more inclusive definition of migraine that includes 
probable migraine cases. Research has revealed similarities between probable 
and strictly-defined migraine in terms of their epidemiologic features, 
associated disability, impact on health-related quality of life, and treatment 
profiles (Patel et al., 2004; Silberstein et al., 2007), further supporting the 
proposal that probable and strict migraine may be two phenotypic forms of the 
same entity. However, a population-based study conducted in the US has shown 
that probable migraine is dramatically underdiagnosed and undertreated. For 
example, among 1262 participants in a health plan identified as having probable 
migraine, only 2.7% had received a prescription for an acute migraine specific 
drug (Bigal et al., 2006). This suggests that improvements in the clinical 
recognition of probable migraine as an important migraine subtype are 
required, and that research studies (both within the general population and 
within BD) focusing solely on strictly-defined migraine may be underestimating 
both the prevalence and burden of migraine. 
Previous research has noted that the psychiatric comorbidity of migraine is 
dependent on migraine subtype, with migraine with aura (MA) suggested to 
have a stronger association with psychiatric disorders than migraine without 
aura (MoA) (Breslau et al. 2000; Oedegaard et al. 2005a; Samaan et al. 2009). 
Therefore, the second aim of this chapter was to explore the association 
between the migraine subtypes; migraine with aura (MA) and migraine without 
aura (MoA), and BD. In this chapter, just over half of bipolar individuals with 
migraine were identified as having MA compared to MoA (153, 55.2% vs. 124, 
44.8%), which is in contrast to the third of migraine patients reported to 
experience aura symptoms in the general population (Silberstein and Lipton, 
1993). Moreover, rates of MA were higher than MoA in each of the bipolar 
diagnostic subtypes (BDI, BDII and SABP), and when controlling for sex and age, 
both MA and MoA, had a significant positive association with BDII, with the 
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strength of this association being stronger for the MA subtype. This is in line 
with the finding by Breslau et al. (1991) who revealed that rates of BDI and BDII 
were increased in individuals with MA compared to those with no migraine, a 
finding that was not observed for individuals with MoA.   
The final aim of Chapter 3 was to assess concurrent validity of the differing 
methods used by BDRN for the assessment of migraine. When compared to 
diagnosis derived from the self-report questionnaire measure (the primary 
method used by BDRN to determine a diagnosis of migraine), the single-item 
checklist item asking individuals whether they had ever been told by a doctor 
that they had migraine, was found to have moderate sensitivity (56.6%) and 
high specificity (93.8%). This indicates that a ‘doctor diagnosis’ screen for 
migraine is likely to result in an underestimate of true migraine cases, in that 
whilst a positive screen is unlikely in a patient who does not truly have the 
disease, false negatives are highly likely in the event of a negative screen. A 
positive predictive value of 0.78 and negative predictive value to 0.85, indicate 
that the ‘doctor diagnosis’ screen is better at ruling out migraine than it is at 
ruling in migraine. This finding is consistent with a recent meta-analysis of the 
prevalence and moderators of migraine within BD (Fornaro and Stubbs, 2015) 
that found the prevalence of migraine was substantially higher in studies 
employing standardised IHS criteria, compared to those employing non-
standardised criteria, such as self-report. In the current study, when compared 
to migraine status derived from the detailed telephone interview (based on 
criteria of the IHS), the self-report questionnaire was found to have high 
sensitivity (92.3%) and high specificity (93.3%). Measures of PPV (0.92) and NPV 
(0.93) indicated that the questionnaire was equally effective in ruling in migraine 
as it is ruling out migraine. The self-report questionnaire was found to be much 
less sensitive (75.0%) and specific (77.8%) for diagnosing probable migraine. 
This was explained by the large proportion of individuals with probable migraine 
(64.4%) that were found to meet full criteria for migraine diagnosis following 
telephone interview. Therefore, whilst questionnaire-based methods adhering 
to IHS criteria are sufficient for identifying those with strictly defined migraine, 
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identification of ‘probable’ cases may warrant further investigation to establish 
if these are indeed true migraine cases.  
Identifying migraine as a common comorbid condition within BD is important to 
understand the additional burden faced by patients and adds support to the 
proposal that there may exist shared underlying pathophysiological 
mechanisms between the two disorders. It is possible that such 
pathophysiological homogeneity may reflect clinical homogeneity, and so 
Chapter 4 looked to establish whether the presence of migraine defined a 
clinical subtype of bipolar subjects who experience a distinct course of the 
bipolar illness. Findings from this chapter showed that when other significant 
differences were controlled for migraine comorbidity within BD was associated 
with a history of suicide attempt and anxiety disorder. Moreover, when the 
multivariate model was re-run entering only variables that survived correction 
for multiple testing, migraine comorbidity was also found to be associated with 
an increased number of episodes of depression. These findings build upon 
existing research suggesting that comorbid migraine may represent a clinically 
useful subgroup characterised by specific clinical features.  
As reported above, previous research has noted that the psychiatric comorbidity 
of migraine is dependent on migraine subtype, with MA suggested to have a 
stronger relationship with BD than MoA (Breslau et al., 2000, 1991; Oedegaard 
et al., 2005a; Samaan et al., 2009). However, to date no studies exploring the 
relationship of migraine with the clinical features and course of BD have 
differentiated between these subtypes. Therefore, the second part of Chapter 4 
looked to examine whether there exist differences in the lifetime bipolar clinical 
characteristics associated with MA and MoA. Findings from this chapter 
suggested that the comorbid expression of the relationship between BD and 
migraine was dependent on migraine subtype and that observed differences in 
the clinical presentation of BD associated with migraine comorbidity were 
largely associated the migraine with aura subtype.  Multivariate analysis 
revealed that when compared to BD subjects with no history of migraine; those 
with migraine with aura (MA) were more likely to: be younger; be female; have 
a diagnosis of bipolar II disorder (BDII); and have a higher lifetime rate of 
216 | P a g e  
 
 
 
attempted suicide. The independent association of a BDII diagnosis with MA 
was unsurprising given the already mentioned finding that both migraine 
subtypes were found to be significantly associated with BDII and that this 
association was stronger for MA (Chapter 3). Conversely, no bipolar clinical 
characteristics were found to be associated with MoA when compared to bipolar 
subjects without migraine within a multivariate model. This suggests that the 
migraine-BD comorbidity may have more serious implications for those with 
migraine with aura and that the relationship between BD and migraine is 
perhaps explained by the association with the MA subtype. 
A number of possible mechanisms may explain the increased comorbidity of 
migraine with mood disorder among bipolar patients. Firstly, the association of 
the two disorders may be a result of chance. For example, there may be spurious 
increased rates of migraine in BD due to Berkson’s bias, whereby individuals 
reporting a diagnosis of one disorder are more likely to report a diagnosis of (or 
be diagnosed with) other disorders within clinical samples because of their 
increased contact with health professionals (Berkson, 1946). However, given 
that comorbidity has been demonstrated in population-based, and community 
studies, this is unlikely to be the complete explanation. Secondly, the 
relationship may be causal; with BD directly increasing the risk of migraine 
and/or vice versa. Finally, the association may be explained by potential shared 
environmental and/or biological risk factors that produce an underlying brain 
state that predisposes to both disorders. In the latter case, evidence has 
suggested that there may be shared genetic variation between migraine and BD 
(Oedegaard et al., 2010a; Oedegaard et al., 2010b; Jacobsen et al., 2015). 
Therefore, the aim of Chapter 5 was to examine genetic susceptibility to BD with 
comorbid migraine, through a genome-wide association study (GWAS). Whilst 
Chapter 5 did not identify genetic variation associated with the migraine-BD 
phenotype, this was not surprising, given the limited number of cases and 
controls involved, compared to what is generally required to detect common 
variation of small effect that is identified with the GWAS approach (Craddock et 
al., 2008).  
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7.1.2 Bipolar disorder and epilepsy  
Mood disorders have long been considered frequent psychiatric comorbid 
conditions in people with epilepsy; however, to date much of the 
neuropsychiatric literature has focused on the study of unipolar depression, 
(Baker et al., 1996; Kanner and Balabanov, 2002; Blum et al., 2003; Eden and 
Toone, 1987; Robertson et al., 1994; Ottman et al., 2011; Hesdorffer et al., 2000). 
In addition, the majority of the research assessing the relationship between 
bipolar disorder (BD) and epilepsy has looked to establish the rate of BD and 
bipolar symptomatology in people with epilepsy, with findings suggesting 
higher rates within people with epilepsy compared to the general population 
(Ettinger et al., 2005), and with other chronic disorders (Ottman et al., 2011).  
In contrast, there is a distinct lack of research exploring the occurrence of 
epilepsy within a bipolar population. However, there is some evidence to 
suggest that there may be an increased prevalence of epilepsy within BD 
subjects compared to that observed within the general population (Moreira et 
al., 2011; Weber et al., 2011; Forty et al., 2014). Given that very few studies have 
explicitly assessed epilepsy within a bipolar sample, the final results chapter 
looked to assess whether epilepsy is overrepresented in BD, by identifying the 
rate of self-reported epilepsy within a large, well-characterised sample of UK 
participants with a diagnosis of BD. Using a single screening question developed 
by Ottman et al. (2010), 127 (8%) individuals were identified as having self-
reported epilepsy in the current study. This is higher than the 2% lifetime 
prevalence of epilepsy identified within Ottman et al's. (2011) US population-
based study employing the same screening question, and higher than the 1.2% 
lifetime prevalence of epilepsy in the adult population of England, employing a 
similar ‘doctor diagnosis’ self-report definition of epilepsy (Rai et al., 2012). The 
rate of self-reported epilepsy described in Chapter 6 was consistent with 
Moreira et al. (2011) who reported an 8.2% prevalence of self-reported epilepsy 
in their Brazilian sample of outpatients with bipolar I disorder. Findings 
therefore indicate that epilepsy may be overrepresented in BD and may reflect 
a common comorbid condition of the bipolar illness that requires further 
exploration.   
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Next, Chapter 6 aimed to identify a group of bipolar individuals with well-
defined, ‘expert-confirmed’ epilepsy from those who initially screened positive 
for epilepsy, for further analysis. This process identified 29 individuals as having 
a lifetime history of epilepsy, confirmed by a consultant epileptologist, of which 
70% were corroborated by a review of general practice/psychiatric case notes. 
Using these two definitions of epilepsy (self-report and expert-confirmed), 
Chapter 6 then looked to explore the impact of epilepsy on the clinical course of 
the bipolar illness, to assess, whether comorbid epilepsy constituted a distinct 
subgroup of BD characterised by specific clinical features.  
This was the first study of its kind to assess bipolar illness characteristics 
associated with comorbid epilepsy. Univariate analysis revealed self-reported 
epilepsy to be associated with: a higher rate of suicide attempt; and higher rates 
of additional psychiatric comorbidity including; agoraphobia, phobias, panic 
disorder, and alcohol and other substance abuse. When compared to bipolar 
subjects with no history of epilepsy, expert-confirmed epilepsy was associated 
with: more frequent and severe episodes of depression; and increased rates of 
panic disorder, generalised anxiety disorder and substance abuse. Moreover, 
there were trends for those with expert-confirmed epilepsy to: experience 
higher rates of suicide attempt; have better functioning in their worst episode 
of mania; and experience less frequent and severe manic episodes. Whilst a 
multivariate model could not be computed for the presence of expert-confirmed 
epilepsy due to the limited number of individuals within this group, multivariate 
analysis revealed an independent association of a history of suicide attempt 
with self-reported epilepsy within individuals with BD. Moreover, when bipolar 
subjects were compared on characteristics according to their lifetime history of 
suicide attempt, analysis revealed self-reported epilepsy to be an independent 
predictor of suicide attempt even after controlling for other significantly 
associated risk factors, including; bipolar-related illness characteristics, such as 
number of episodes of depression, history of mixed episodes, and bipolar illness 
duration; as well as coexisting psychiatric and chronic medical and illness. This 
finding is in line with reports in the general population suggesting that people 
with epilepsy are at an increased risk for suicide (Christensen et al., 2007; 
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Pompili et al., 2005; Robertson, 1997). Whilst psychiatric comorbidity (mood 
disorders in particular) within epilepsy is recognised as an important risk factor 
for suicide attempt (Nilsson et al., 2002), not all of the increased risk of suicide 
associated with epilepsy is explained by psychiatric history (Christensen et al., 
2007).   
Overall, the results of this thesis suggest that both migraine and epilepsy may 
disproportionately affect individuals with BD, and that when present they have 
the potential to modify or complicate the course of illness within BD. Individuals 
with bipolar II disorder (BPII) may be particularly likely to have comorbid 
migraine and this may be particularly relevant for the migraine with aura (MA) 
subtype. Comorbidity with both migraine, and epilepsy were associated with 
severe outcomes, characterised by increased psychiatric comorbidity and 
suicide attempt. In addition, expression of the migraine-BD comorbidity 
appears to be dependent on migraine subtype and may have more serious 
implications for those with migraine with aura compared to migraine without 
aura. Recognition and treatment of migraine and epilepsy within individuals 
with BD may therefore have a beneficial impact on the course of illness and 
outcome in people with BD. Further implications of these findings will be 
discussed in the next section (Section 7.2). 
Migraine and epilepsy are often comorbid, and individuals with one of the 
disorders are more than twice as likely to have the other (Lipton et al., 1994; 
Ottman and Lipton, 1994). A review of 13 studies by Andermann and 
Andermann (1987) revealed that the prevalence of epilepsy in individuals with 
migraine ranged from 1-17%, with a median of 5.9%. In addition, the prevalence 
of migraine among individuals with epilepsy is estimated at 8-24% (Ottman and 
Lipton, 1994). Migraine and epilepsy are both chronic disorders characterised by 
recurrent neurologic attacks, and neither should be considered single clinical 
entities. Both disorders are thought to result from hyperexitability in the brain 
and there exist overlaps in the therapeutic agents used to treat each disorder 
(Bianchin et al., 2010). Moreover, there is also some evidence to suggest shared 
genetic effects on migraine and epilepsy (Bianchin et al., 2010; Deprez et al., 
2007; Polvi et al., 2012; Winawer and Connors, 2013).  
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Whilst not an aim or central focus of the current thesis, it was of interest to 
consider whether migraine and epilepsy occurred at an increased rate with each 
other within BD. To explore this, I examined the number of bipolar subjects who 
reported having self-reported epilepsy and also met criteria for migraine 
according to the questionnaire measures. Of the 877 bipolar subjects who 
completed both the migraine and epilepsy questionnaires; n=175 (20%) had 
migraine, n=64 (7.3%) had epilepsy, and n=20 (2.2%) were found to have both 
migraine and epilepsy. If migraine and epilepsy occurred independently with BD 
and did not occur at an increased rate with each other, one would expect 1.46% 
to report both migraine and epilepsy (frequency[migraine] x 
frequency[epilepsy]=0.2x0.073=0.0146). Therefore, if migraine and epilepsy did 
not occur at an increased rate with each other, one would expect 12.8 bipolar 
subjects to have both disorders (1.46% of 877). The 20 individuals observed to 
have comorbid migraine, and epilepsy within the sample suggests an increased 
number to what would be expected. Moreover, a one-tailed chi square test 
would deem this increased rate to be statistically significant at the p<.05 level. 
However, this finding should be interpreted with caution and requires 
replication within larger samples.  
 
7.2 Potential implications 
The findings of this thesis suggest that migraine and epilepsy are common 
comorbid conditions of bipolar disorder (BD). Given that the presence of 
migraine, and epilepsy, were associated with a more severe course of illness, 
including increased suicidality, this highlights the need for effective screening 
and identification of these conditions within individuals with BD, so that they 
can be incorporated into individual risk assessment care plans. Ideally, screening 
for migraine and epilepsy should occur early on in the individual’s psychiatric 
assessment as this may help clinicians to identify those at increased risk for 
important illness outcomes, such as suicidality and further psychiatric 
comorbidity. Whilst I am not suggesting that clinicians should or would not 
already assess for suicide risk as part of a formal risk assessment with the 
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patient, knowing the patient also suffers from migraine and/or epilepsy, should 
alert clinicians to those who are at especially increased risk for such adverse 
outcome and tailor management and treatment plans accordingly.  
Specifically, screening for migraine may be particularly important in individuals 
with bipolar II disorder (BDII) since these individuals were shown to have 
significantly increased rates of migraine compared to those with bipolar I 
disorder (BDI). In addition, findings of this thesis indicate that it is important to 
differentiate between migraine subtypes, such that the presence of aura 
symptoms may alert the clinician to those who may be at increased risk for 
adverse outcome. Moreover, given the large proportion of ‘probable migraine’ 
cases described in this thesis, it may also be important to pay attention to cases 
that just miss the strict classification for full migraine. This may be particularly 
relevant given that probable migraine is known to be a frequent, undertreated 
and disabling condition with an epidemiologic profile similar to that of strict 
migraine (Silberstein et al., 2007). Finally, given that migraine was shown to 
precede BD illness impairment in 57% of cases, migraine may constitute a first-
visit hallmark for some bipolar patients and warrant the screening of affective 
psychopathology.  
The bipolar illness characteristics experienced by bipolar subjects with comorbid 
migraine and epilepsy suggest that these patients may benefit from a tailored 
treatment approach. Specifically, the increased rates of anxiety disorders 
experienced by these groups may benefit from targeted psychological therapy. 
Psychiatric comorbidity within BD can further complicate the bipolar illness and 
may influence the course of illness and lead to poorer outcomes and prognosis 
(Vieta et al., 2001) and in particular, comorbid anxiety itself has been associated 
with increased suicide risk (Simon et al., 2007).  
Chapter 4 identified that presence of migraine within BD was associated with a 
greater number of episodes of depression. Moreover, a trend for an increased 
number of episodes of depression was observed in bipolar subjects with self-
reported epilepsy compared to those with no history of epilepsy. Further 
support was provided from analysis of expert-confirmed epilepsy cases, 
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revealing significantly increased occurrence and severity of depressive episodes. 
Such findings suggest that BD patients with comorbid migraine or epilepsy may 
suffer more from the depressions of bipolarity. Such a finding has important 
clinical implications given the potential for an individual being inappropriately 
treated with anti-depressant monotherapy, increasing the risk of a 
pharmacologically-induced manic episode. Decisions concerning 
pharmacotherapy for an individual with BD should take into consideration 
comorbid conditions such as migraine and epilepsy, and where possible it would 
be advantageous to select such agents that act on both disorders. Once 
migraine and/or epilepsy has been identified within an individual with BD, it is 
essential for the clinician to firstly assess whether they are already being treated 
for the condition and to assess whether there exist any potential drug 
interactions between the agents used to treat these disorders. If we consider the 
long-lasting, chronic course of BD, and the impact of comorbidity on evaluation, 
diagnosis, illness course, and social and economic costs of psychiatric disorders 
(Merikangas and Kalaydjian, 2007), it is essential that the management of 
complex comorbid conditions constitutes an important and fundamental part of 
individualized treatment. Comorbidity within psychiatric disorders affects 
evaluation, diagnosis, illness course as well as social and economic costs of the 
disorder. Therefore, it is crucial for clinicians to recognize the benefit of 
improved collaboration between the practice of neurology and psychiatry as a 
means of improving the evaluation and management of individuals with BD, 
migraine, and epilepsy.  
Aside from the potential clinical implications of recognizing migraine, and 
epilepsy within individuals with BD, the use of these disorders to define more 
clinically homogeneous patient populations may be useful for future 
aetiological investigations. For example, the differences observed regarding the 
clinical characteristics of the bipolar illness according to the presence of 
migraine, and epilepsy support the proposal that these comorbid conditions 
may represent a subtype of individuals with BD who are more biologically 
similar. Thus, a greater understanding of the pathophysiological mechanisms 
that underlie BD with migraine, and BD with epilepsy, and indeed BD with 
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migraine and epilepsy, may contribute to our understanding of the underlying 
aetiology of all three disorders, and have important implications for psychiatric 
nosology.  
 
 
7.3 Strengths and limitations 
Specific strengths and limitations relevant to the individual studies within this 
thesis are discussed within the appropriate chapters. The present section will 
discuss methodological strengths and limitations more generally.  
 
One of the major strengths of this thesis is the large, clinically well-defined 
sample of subjects with bipolar disorder (BD) upon which the findings are based. 
All subjects were assessed using standardized and rigorous clinical assessment 
methods, which where possible were supported by psychiatric and general 
practice case notes. The rich clinical data available through Bipolar Disorder 
Research Network (BDRN) allowed for a thorough assessment of the 
relationship of migraine, and epilepsy with the clinical features and course of 
illness within BD. Moreover, the sample was recruited from throughout the UK 
using a variety of both systematic and non-systematic methods, thus relying on 
both volunteers and NHS services. Therefore, in relation to the assessment of 
comorbidity within BD, the sample is less likely to suffer from Berkson’s bias 
whereby individuals reporting a diagnosis of one disorder are more likely to 
report a diagnosis of (or be diagnosed with) other disorders because of their 
more frequent contact with health professionals in the context of a clinical 
population (Berkson, 1946). The large sample recruited by BDRN over many 
years meant that the current thesis could extend previous small scale research 
evaluating the relationship between migraine and BD and permitted further 
detailed investigation of the migraine phenotype, by differentiating between 
the migraine subtypes, migraine with and without aura when exploring the 
association between migraine and the clinical features of BD.  Moreover, the 
large sample involved in the current thesis also allowed for the exploratory 
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analysis of a small group of individuals with expert-confirmed epilepsy and their 
relationship with the clinical features and course of illness in BD.  
 
However, the findings also need to be considered in the light of several 
limitations. Firstly, a limitation applicable to all studies reported throughout this 
thesis is the cross-sectional nature of the study methodology. Whilst such 
designs are useful to investigate associations between risk factors and an 
outcome of interest and are particularly suitable for estimating the prevalence 
of a behaviour or disease in a population, they do not allow determination of 
causality. Therefore, in order to gain a better understanding of the temporal 
relationship between BD and migraine, and BD and epilepsy, longitudinal 
prospective studies are required. Moreover, due to the cross-sectional study 
design, it is possible that a non-response bias exists, whereby individuals 
choosing to take part in the study differ on important variables from those who 
do not. Thus, individuals recruited into BDRN may not be representative of the 
bipolar population. In addition, completion of the self-report questionnaires to 
initially assess migraine and epilepsy within the BD sample may also be subject 
to non-response bias, such that those with the condition may have been more 
likely to complete the questionnaire. However, given that both of these 
questionnaires were part of a larger questionnaire pack, it is unlikely that 
individuals completed this questionnaire based on their affected status. This is 
further supported by an examination of questionnaire pack completion rates, 
which revealed that 96% of those who completed the migraine questionnaire, 
and 94% of those who completed the epilepsy questionnaire, also completed all 
other questionnaires included within the pack. Moreover, no individuals 
completed the migraine or epilepsy questionnaires only.  
A second limitation of this thesis involves the retrospective assessment 
methods used. Whilst such methods permit evaluation of the lifetime course of 
the bipolar illness, as well as assessment of the lifetime history of migraine and 
epilepsy, once again, it is difficult to establish the temporal precedence of these 
comorbid conditions and BD. Moreover, retrospective studies are prone to recall 
bias and given that the mean age of BDRN subjects at interview is approximately 
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45 years and onset of BD typically occurs during late adolescence, such bias may 
be particularly relevant here. Recall bias may also have limited the subject’s 
ability to clearly recall details regarding their headache, and seizure history, 
potentially leading to an under or overestimate of these disorders. 
A third limitation of the current thesis concerns the overrepresentation of 
females within the bipolar sample (approximately 70%). Such gender bias is 
often observed in research participation, and given that a major research 
interest of BDRN is to examine the experience of affective illness in relation to 
childbirth, this may also help to explain the high proportion of females observed 
within this particular sample.  Whilst rarely found to be significantly different, 
the incidence of epilepsy is reported to be higher among males than in females 
(Banerjee and Hauser, 2008), and so may have resulted in an underestimate of 
epilepsy within the current sample. In contrast, there is a known female 
preponderance of migraine, with a sex ratio for lifetime migraine being two to 
threefold greater among women (Low et al., 2007). A higher rate of migraine 
among women was observed in the current thesis, with 21.7% of women and 
12.9% of men meeting criteria for migraine. It is therefore possible that the 
overrepresentation of females within the current thesis led to an overestimate 
of migraine. There was also a significant gender difference between bipolar 
subjects with and without a history of migraine (82.3% vs. 69%, respectively) 
however this was accounted for within multivariate analysis.  
Fourthly, as all subjects were recruited as part of ongoing molecular genetic 
studies, they were required to be of UK/ Eire white ethnicity in order to reduce 
genetic heterogeneity between subjects. It is important to acknowledge the 
implications of such an inclusion criterion on the generalizability of findings, 
which may not extend to other ethnic groups.  
Finally, a limitation relevant to all studies reported in this thesis is the lack of 
detailed information regarding psychiatric medication. Medication use will 
inevitably modify the bipolar illness and so it would have been useful to control 
for different treatment regimens between BD individuals with and without 
migraine (Chapter 4), and epilepsy (Chapter 6). Moreover, it has already been 
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discussed within this thesis that the pharmacological agents used to treat BD, 
migraine and epilepsy overlap. For example, antiepileptic medications are 
known to be effective mood stabilizers and are often used in the primary 
treatment of BD (Kaufman, 2011; Moreno et al., 2004). Similarly, some of the 
pharmacological agents used within BD (most notably valproate) are known to 
be successful in treating migraine (Silberstein, 1996). Therefore, it is possible 
that the use of these medications for psychiatric purposes may have acted to 
modify migraine symptomatology or seizure activity, potentially influencing the 
prevalence rates and presentation of these disorders within the bipolar sample.  
 
7.4 Suggestions for future work 
The findings of this thesis suggest that comorbid migraine and epilepsy may be 
used to delineate clinical subgroups among individuals with bipolar disorder 
(BD). Moreover, BD, migraine, and epilepsy share several characteristics, for 
example, all three conditions; follow an episodic course, are chronic disorders, 
are heritable, and respond to antiepileptic medication. These lines of evidence 
all point to a common underlying pathophysiology for which potential shared 
environmental and/or biological risk factors may produce an underlying brain 
state precipitating these conditions. However, further research is needed to 
unravel the complex relationship between BD and the neurological 
comorbidities of migraine and epilepsy in order to better understand and 
characterise their relationship, both clinically and aetiologically.  Below I will 
summarise particular research areas that have been identified within this thesis 
as potential important avenues for future research.  
In Chapter 3, I reported that 21.3% of individuals with BD met criteria for 
probable migraine, a figure that was actually found to exceed the proportion of 
individuals meeting full IHS criteria for migraine (19.4%). Given the overlap in 
their epidemiological and symptom profile (Patel et al., 2004), it is likely that 
probable migraine involves the same pathophysiological process as strictly-
defined migraine. Currently, no studies have examined either the clinical or 
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aetiological relationship of probable migraine with BD. If the findings associated 
with comorbidity of strict migraine with BD were to be replicated with probable 
migraine, this would support the proposal of adopting a broader definition of 
migraine when examining the comorbid relationship between migraine and 
affective disorders, which would act to dramatically increase sample sizes of 
future studies. Moreover, if the findings were not found to replicate, this would 
help to identify important differences between probable and strictly-defined 
migraine, which may provide further insight into the biological underpinnings of 
these disorders.  
Chapter 4 found that the comorbid expression of the relationship between BD 
and migraine was dependent on migraine subtype, with the observed 
differences in the clinical presentation of BD associated with migraine 
comorbidity being largely explained by the association with migraine with aura 
(MA). Moreover, when examining the association between migraine and bipolar 
diagnostic subtypes, Chapter 3 reported a significant association between 
migraine and bipolar II disorder and that this association was stronger for those 
with MA. An association between MA and psychiatric disorders has previously 
been shown (Breslau et al., 1991; Oedegaard et al., 2005a; Samaan et al., 2009), 
however this is the first study to differentiate between the migraine subtypes of 
migraine with (MA) and without aura (MoA) when investigating the impact of 
migraine on the clinical course of BD. Therefore, it is important to replicate 
these findings in additional large, well-characterised samples.  
Differentiating between migraine subtypes may also be beneficial for future 
studies examining the genetic susceptibility to BD and migraine. There is much 
debate over whether MA and MoA form part of the same disease spectrum or 
whether they represent distinct subtypes (Ligthart et al., 2006; Nyholt et al., 
2004; Russell et al., 2002, 1996). The finding that MA has a higher genetic 
component than MoA (Russell and Olesen, 1995) suggests potentially distinct 
aetiologies. Given findings of the current thesis demonstrating that the 
association with MA may be explaining the distinct symptom profile associated 
with migraine comorbidity in BD, this suggests it would be beneficial for future 
studies to examine MA and MoA separately when searching for potential shared 
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genetic variation between BD and migraine. In addition, the three studies to 
date that have looked to identify susceptibility regions for the migraine-BD 
phenotype have only used self-reported doctor diagnosis definitions of migraine 
(Oedegaard et al. 2010a; Oedegaard et al. 2010b; Jacobsen et al. 2015). It is 
therefore, essential for future studies adopt recognized, standardized criteria 
(such as that of the International Headache Society) in their assessment of 
migraine.  
Moreover, Chapter 5 argued that a potential explanation for the current thesis 
not finding evidence of genetic variation associated with the migraine-BD 
phenotype may be due to the small number of cases and controls involved. 
Chapter 5 also argued that it was possible that susceptibility to the migraine-BD 
phenotype may be explained by rare variants which were unable to be detected 
by the GWAS approach undertaken. Findings from a recent meta-analysis of 
migraine GWAS revealing larger effect sizes for implicated loci in individuals 
with MoA compared to MA suggest that MA may be mediated more by rare 
variants with larger effect. Taken together these findings suggest that it would 
be useful for future studies to use more powerful approaches to detect both 
common and rare variation when searching for shared variation, such as next 
generation sequencing.  
Moreover, future research looking to explore potential shared aetiological 
underpinnings between migraine and BD, may benefit from focusing on the rare 
subtype of MA, familial hemiplegic migraine (FHM). FHM is genetically 
heterogeneous, and polymorphisms in at least three genes have so far been 
implicated; CACNA1A (Ophoff et al., 1996), ATP1A2 (DeFusco et al., 2003), and 
SCN1A (Dichgans et al., 2005). Mutations in these three FHM genes are reported 
to explain between 50-70% of published families with FHM, thus the existence 
of other genes involved in the pathogenesis of FHM is likely (Thomsen et al., 
2007). All three FHM genes either encode ion channels or are involved in ion 
transportation, therefore highlighting the importance of ion channels in the 
molecular mechanism of migraine. Given that two of the strongest associations 
to come out of genome-wide association studies of BD have been for two genes 
involved in ion transportation (ANK3 and CACNA1C), this suggests that 
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disturbances in ion channel function are relevant for both migraine and BD. This 
proposed similarity in the underlying mechanisms of FHM and BD, may, 
therefore, suggest a greater likelihood of genetic overlap between the two 
disorders. Within the current thesis, 45 individuals within the MA group met 
criteria for hemiplegic migraine (HM) (3.1% of total sample). This is much higher 
than that reported within a Danish population-based epidemiological survey, 
which estimated the prevalence of HM to be 0.01%, with the familial and 
sporadic forms being equally prevalent (Thomsen et al., 2002). A possible 
avenue for future research would be to conduct next generation sequencing on 
these individuals in an attempt to identify potential shared genes that may be 
explaining the high rate of HM observed in the bipolar sample. 
To date, very few studies have examined the rate of epilepsy within individuals 
with BD, with those that have often assessing epilepsy among a larger number 
of other medical conditions in order to assess the medical burden experienced 
within BD (Forty et al., 2014; Moreira et al., 2011; Weber et al., 2011). The wealth 
of aetiological-based research suggesting a link between BD and epilepsy, and 
initial findings suggesting that epilepsy may be overrepresented in individuals 
with BD, suggest that establishing epilepsy prevalence within BD should be a 
priority for future research. Chapter 6 of this thesis employed the use of a single 
screening question to identify the rate of self-reported epilepsy within the 
bipolar sample. This screening question has been previously shown to have a 
sensitivity of 76%, and so it is possible that the rate of self-reported epilepsy 
identified within the current thesis of 8% is an underestimate. Whilst this may 
be appropriate for a study of comorbidity, looking to identify individuals with 
epilepsy for further analysis, estimates of prevalence would require the use of a 
screen with maximum sensitivity to avoid underestimation. Such studies would 
require all positive screens to be followed up within a second stage of screening, 
due to the high number of false positives that often accompany highly sensitive 
screening tools.  Due to time constraints, the current thesis could not follow-up 
all individuals who screened positively for epilepsy within the first assessment 
stage and was therefore unable to comment on the prevalence of confirmed 
epilepsy cases following further review. Rather, the 1.8% of individuals 
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confirmed to have epilepsy following detailed telephone interview and expert 
review could only be considered a conservative estimate. Chapter 6 was the first 
study of its kind to assess bipolar illness characteristics associated with 
comorbid epilepsy. Given its exploratory nature and modest sample size, 
corrections were not made for multiple testing. Therefore, future research using 
larger samples is needed to confirm the bipolar clinical correlates associated 
with BD and epilepsy.  
The mechanisms underlying the comorbid relationship between BD and 
comorbid migraine, and epilepsy are poorly understood. Therefore, future 
prospective research is required in order to better understand their relationship 
and to determine whether migraine and/or epilepsy are risk factors for BD, 
whether BD is a risk factor for the development of migraine and/or epilepsy, or 
both.  Moreover, a focus of future research on treatment response and 
prognosis of BD with comorbid migraine, and epilepsy, may help to elucidate 
the underlying mechanisms of shared pathophysiology between these 
disorders.  
 
7.5 Final conclusions 
This thesis has identified that the neurological disorders of migraine and 
epilepsy are common in individuals with bipolar disorder (BD), and that their 
presence may be associated with a distinct course of the bipolar illness. Such 
findings highlight the need for effective identification of these conditions within 
BD and have implications for the management and treatment of individuals with 
BD. Findings of this thesis suggest that individuals with bipolar II disorder may 
be particularly susceptible to migraine and that the identification of aura 
symptoms within those with comorbid migraine and BD may identify those who 
may be at particular risk for adverse psychiatric outcome. In addition, this thesis 
revealed that suicide risk may be a particular concern for bipolar individuals with 
comorbid migraine, and epilepsy, further emphasizing the need for an 
awareness of comorbidity and its complications in the management of BD as a 
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means of improving patient outcomes. Further research unravelling the 
complex relationship between BD with migraine and epilepsy is needed to help 
elucidate the nature, impact and mechanism of the co-occurrence of these 
disorders. 
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Appendices 
 
 
 
Appendix A – Self-report migraine questionnaire disseminated to the 
Bipolar Disorder Research Network (BDRN) sample (Chapters 3, 4 and 5). 
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Appendix B – Migraine telephone interview employed within the current 
thesis within a sub-sample of bipolar subjects (Chapter 3).  
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Appendix C – Self-report epilepsy questionnaire disseminated to the 
Bipolar Disorder Research Network (BDRN) sample (Chapter 6). 
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Appendix D - Epilepsy telephone interview employed within the current 
thesis within a sub-sample of bipolar subjects (Chapter 6). 
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Note: within original interview, the above section is repeated for all stated 
seizures/events. 
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Appendix E – Summary of significant predictors of migraine with aura 
(MA) compared with bipolar subjects with no migraine entering only 
variables that surpassed Bonferroni correction for multiple comparisons 
into the logistic model as predictor variables. 
 
 Wald X2 df P value OR (95% CI) 
Female 7.259 1 .007 2.582 (1.295-5.149) 
Bipolar II disorder 
diagnosis  
4.458 1 .035 1.817 (1.044-3.164) 
History of suicide 
attempt 
6.630 1 .010 1.974 (1.176-3.312) 
BDII=bipolar II disorder; df=degrees of freedom; OR=odds ratio; 95% CI=95% 
confidence intervals. 
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Appendix F - Description of genes in regions implicated by the top 10 
independent SNPs from genome-wide association analysis.  
 
 
PRSS57 (Protease, Serine, 57) 
PRSS57 is involved in serine-type endopeptidase activity. Proteases are 
enzymes that break the peptide bond that joins amino acids together in 
proteins. Serine proteases are proteolytic enzymes that break the peptide bond 
that joins amino acids together in proteins. In mammals, serine proteases are 
involved in a number of biological processes, such as; digestion, blood clotting, 
reproduction and the complement system.  
IQCG (IQ Motif containing G) 
IQCG is one of several IQ motif–containing genes of unknown function. IQ 
motifs are present in several hundred proteins, most notably myosins, but also 
in a variety of nonmyosin proteins such as neuronal growth proteins, voltage-
gated channels, phosphatases, spindle-associated proteins, and sperm surface 
proteins (Bahler & Rhoads, 2002). Harris, Schimenti, Munroe, and Schimenti 
(2014) recently reported a male-specific infertility mutant in which the genetic 
lesion was traced to IQCG. These mice exhibited spermiogenesis defects. IQ 
motif-containing genes typically regulate calmodulin (CaM) (a multifunctional 
intermediate calcium-binding messenger protein expressed in all eukaryotic 
cells). CaM activation can stimulate actin cytoskeleton changes. Therefore, it is 
possible that the flagellum formation defects in mutants reflect an involvement 
of IQCG in spermatid morphogenesis and suggest a potential role for localized 
calcium signaling in sperm flagellum morphogenesis. 
LINC00683 (Long Intergenic Non-Protein Coding RNA 683) 
LINC00683 is a non-annotated RNA gene, affiliated with the non-coding RNA 
class.  
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SP3 (Sp3 Transcription Factor) 
SP3 is a protein coding gene, belonging to a family of Sp1 related genes that 
encode transcription factors that regulate transcription. This protein contains a 
zinc finger DNA-binding domain and several transactivation domains, and 
functions as a bifunctional transcription factor, both activating and repressing 
transcription (Suske, 1999).  
EML4 (Echinoderm Microtubule Associated Protein Like 4) 
EML4 is a Protein Coding gene and is a microtubule-associated WD-repeat 
protein of the echinoderm microtubule-associated protein family Heidebrecht, 
H.J. et al. (2000) Genomics 68, 348-350. Expression of EML4 is necessary for 
correct intracellular microtubule network formation (Pollmann et al. (2006) Exp. 
Cell Res. 312, 3241-3251.). Abnormal fusion of parts of this gene with portions of 
the anaplastic lymphoma receptor tyrosine kinase gene, which generates 
EML4-ALK fusion transcripts, is one of the primary mutations associated with 
non-small cell lung cancer. Diseases associated with EML4 include congenital 
pulmonary airway malformation and inflammatory myofibroblastic tumor.  
TLE1 (Transducin-like enhancer protein 1) 
TLE1 is one of 4 Transducin-Like Enhancer of split (TLE) genes that encode 
human transcriptional repressors homologous to the Drosophila corepressor, 
Groucho (transcriptional factor that plays a critical role in Drosophila embryotic 
development) (Stifani et al. (1991) Nat Genet. 2, 119-27). The TLE family proteins 
are required for many developmental processes, including lateral inhibition, 
segmentation, sex determination, dorsal/ventral pattern formation, terminal 
pattern formation and eye development (Chen & Courey (2000) Gene. 249 (1–
2): 1–16). TLE1 has been implicated in the pathogenesis of cancer (Chuang et al. 
(2013 Pathol Int. 63 (12), 573-80); Brunquell et al. (2012) Mol Cancer Res. 10 (11), 
1482-95).  
TMEM245 (Transmembrane Protein 245)  
TMEM245 is a non-annotated, protein coding gene.  
